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Obstructive sleep apnoea syndrome (OSAS) is characterised by exposure to chronic 
intermittent hypoxia (CIH) as a consequence of repetitive occlusions of the upper 
airway in patients during sleep. Exposure to CIH evokes redox changes which 
culminate in impaired upper airway and diaphragm muscle function. Excessive 
reactive oxygen species (ROS) are also associated with aberrant respiratory plasticity, 
which manifests as destabilised breathing during sleep. There is a paucity of 
information regarding the molecular mechanisms underlying these effects. We 
sought to investigate the putative role of the superoxide-generating NADPH oxidase-
2 (NOX2) enzyme in CIH-induced respiratory muscle dysfunction and respiratory mal-
adaptation.  
 
A mouse model of CIH was generated by the cycling of gas from normoxia (21% O2) 
for 210 seconds to hypoxia (5% O2 at the nadir) over 90 seconds for 8hr/day for 2 
weeks. Adult male (C57BL/6J) mice were assigned to one of 5 groups: normoxic 
controls, CIH-exposed, CIH + apocynin (NOX2 inhibitor, 2mM) given in the drinking 
water throughout the exposure to CIH, and NOX2 null (B6.129S-Cybbtm1Din/J) assigned 
to a sham or CIH exposure. On day 15, whole body plethysmography (WBP) was used 
to measure breathing parameters on a breath-by-breath basis in room air and in 
response to chemostimulation. An apnoea was defined as ≥ 2 missed breaths. 
Sternohyoid and diaphragm muscle contractile function was examined ex vivo. Gene 
expression was examined by quantitative reverse transcription polymerase chain 
reaction (qRT-PCR). Western blot was used to measure protein expression. NOX 
enzyme activity and indices of oxidative stress were determined using 
spectrophotometric assays.   
 
Basal minute ventilation (Vl I) was unchanged following 2 weeks of exposure to CIH, 
however the number of apnoeas per hour was significantly increased compared with 
sham-exposed mice. Apocynin intervention significantly reduced the frequency of 
apnoeas compared with the CIH-exposed group. Apnoea index was increased in 
NOX2 null mice exposed to CIH, reminiscent of that observed in wild-type mice. 
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Exposure to CIH resulted in severe sternohyoid and diaphragm muscle weakness, 
evidenced by a ~45% reduction in the force-generating capacity of these respiratory 
muscles compared with sham. Exposure to CIH increased NOX enzyme activity in the 
sternohyoid, with no alteration to the gene or protein expression of NOX subunits. 
In contrast, exposure to CIH increased the protein and mRNA expression of NOX4 in 
the diaphragm, while NOX activity and expression of all other NOX subunits remained 
unchanged. No indication of overt oxidative stress was observed in the diaphragm or 
sternohyoid muscle following exposure to CIH. Apocynin treatment and NOX2 gene 
knock-out completely prevented CIH-induced diaphragm and sternohyoid muscle 
weakness. Exposure to CIH increased the mRNA expression of genes relating to 
autophagy, atrophy and muscle differentiation in the diaphragm in a NOX2-
dependent manner; these CIH-induced responses were not observed in the 
sternohyoid.  
 
Mice show signs of profound respiratory muscle dysfunction following exposure to a 
mild-to-moderate paradigm of CIH. The putative NOX inhibitor, apocynin, prevents 
CIH-induced respiratory muscle weakness. Moreover, studies in NOX2 null mice 
reveal that NOX2 is obligatory for CIH-induced respiratory muscle weakness. The 
mechanisms underpinning CIH-induced muscle weakness likely differ between 
sternohyoid and diaphragm muscle, evidenced by varied molecular responses to CIH, 
which may relate to differences in fibre-type expression. CIH-induced respiratory 
muscle weakness may contribute to upper airway obstruction and impaired swallow 
and cough, relevant to OSAS. The reduction in apnoea frequency following treatment 
with apocynin, but not NOX2 knock-out, implicates ROS (that are not NOX2-derived) 
in the manifestation of CIH-induced respiratory disturbances. CIH-induced increase 
in the propensity for apnoea may be of clinical relevance as it may underpin 
progression in the severity of OSAS pathology (i.e. mild-to-moderate-to-severe 
OSAS). Our results have implications for human OSAS and point to antioxidant 
intervention, potentially targeting NOX2 blockade, as a potential therapeutic 
strategy.
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1.1 The respiratory control system 
1.1.1 The control of breathing  
Breathing represents a complex neuro-mechanical process that relies on the 
coordinated activity of the muscles of respiration and control centres in the brain. 
Adequate ventilation is pivotal in the maintenance of blood gas homeostasis to 
support the metabolic demands of the body. The respiratory system is an integrated 
system involving a multiplicity of components including the central nervous system 
(CNS), motor nerves, skeletal musculature and the lungs and conducting airways. An 
important characteristic of the respiratory control system lies in its ability to adjust 
breathing patterns in response to physiological perturbations in situations of both 
health and disease.  
 
Control of the respiratory system is maintained by a central respiratory oscillatory 
network located within the medulla of the brainstem, from which neural output 
travels through cranial and spinal motoneurons to the muscles of respiration. 
Changes are effected through two groups of muscles, inspiratory and expiratory, 
whose coordinated activity serves to meet physiological demands. Breathing is a 
state-dependent process with the automatic control of breathing originating from 
distinct sites of the brainstem, the central pattern generators (CPGs), which comprise 
rhythm-generating sites including the Pre-Bötzinger complex (Pre-BötzC) and the 
parafacial respiratory group (PRG) (Feldman and Del Negro, 2006, Smith et al., 2009).  
 
The respiratory control system responds to various perturbations by altering its 
output in order to maintain respiratory homeostasis. Sensory cues from receptors 
located throughout the upper airway (irritant, temperature and pressure-sensitive 
receptors), the respiratory muscles (muscle spindles) and the lungs (e.g. pulmonary 
stretch receptors) are relayed to the respiratory centres of the brain. In addition to 
this, the respiratory control system alters its output based on sensory cues from 
chemoreceptors, which relay information regarding the gas composition and pH of 
the blood. These chemoreceptors are located in the peripheral and central nervous 
systems. The aortic and carotid bodies are the principal peripheral chemoreceptors 
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(Prabhakar and Peng, 2004). The carotid body is the primary oxygen (O2) sensor, 
comprised of a collection of O2-sensitive glomus cells, located at the bifurcations of 
the common carotid arteries. The carotid body is pivotal for eliciting the ventilatory 
and cardiovascular responses to periods of hypoxaemia. Central chemoreceptors 
respond to alterations in the hydrogen ion content in the surrounding environment 
of the brain, such as changes in brain extracellular fluid (ECF) carbon dioxide (CO2) 
and pH. The central chemoreceptors are located in diffuse sites throughout the 
brainstem  including: the ventrolateral medulla (Okada et al., 2002), within the raphé 
serotonergic system (Corcoran et al., 2009), the retrotrapezoid nucleus (Guyenet et 
al., 2009) and the locus coeruleus (Gargaglioni et al., 2010). Collectively, the 
respiratory control system maintains respiratory homeostasis, that is, the 
maintenance of appropriate levels of arterial O2, CO2 and pH. 
 
1.1.2 Respiratory plasticity  
Respiratory plasticity has been described as a persistent change in the neural control 
system, which manifests as structural and/or functional alterations, based on prior 
experience (Mitchell and Johnson, 2003). The respiratory control system has the 
ability to induce adaptive plastic changes to accommodate short-term perturbations, 
such as walking, exercising, vocalization, or may relate to environmental stressors, 
such as ascent to and descent from high altitude. The control system also exhibits 
the capacity to adapt over longer periods, for example during pregnancy, as well as 
throughout growth, development and ageing (Mitchell and Johnson, 2003). These 
alterations in respiratory output are considered beneficial, adaptive changes to 
maintain respiratory homeostasis in the face of increased demand.  
 
Sleep poses a significant challenge for the respiratory control system. Although sleep 
is a natural and essential process, this state results in a reduction in eupnoeic 
ventilation (Douglas et al., 1982a) and diminished hypoxic and hypercapnic 
responsiveness (Douglas et al., 1982a, Douglas et al., 1982b). During wakefulness, an 
increase in upper airway (UA) resistance leads to mechanical loading of the airway 
and a concomitant increase in pharyngeal dilator muscle activity, serving to prevent 
the occurrence of apnoea (respiratory pause) and hypopnoea (inadequate 
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ventilation) (Fogel et al., 2001). However, a loss of the ‘wakefulness stimulus’ during 
sleep leaves ventilation under metabolic control. This, coupled with a reduction in 
respiratory muscular tone during sleep, renders the respiratory control system 
sensitive to a reduction in the partial pressure of CO2 (PaCO2), thus predisposing 
those with low CO2 reserve or high upper airway collapsibility to apnoeic events 
(Skatrud and Dempsey, 1983, Dempsey et al., 2010).  
 
The phenotypical response of the respiratory system to a perturbation is largely 
based on the pattern, duration and intensity of the stimulus (Baker and Mitchell, 
2000, Peng and Prabhakar, 2004) as well as the timing of the perturbation 
throughout the life cycle (Reeves and Gozal, 2006). Hypoxia-induced respiratory 
plasticity, which has a wide scope for clinical relevance, is one of the best-studied 
forms of plasticity. Hypoxia refers to the condition wherein tissues are inadequately 
oxygenated to meet the demand necessary to carry out physiological functions. A 
reduced level of O2 appears in many situations, including exposure to high altitude 
(West, 1987), physical exercise (Richardson et al., 1995) and multiple disease states  
(Semenza, 2014). While hypoxia initiates rapid and robust increases in respiratory 
motor output to defend against hypoxaemia, it also triggers persistent changes in 
chemosensory neurons and integrative pathways that transmit brainstem 
respiratory activity to respiratory motor neurons (MacFarlane et al., 2008). The 
ventilatory response to sustained hypoxia is a well characterised mechanism known 
as ventilatory acclimatization to hypoxia (VAH) (Powell et al., 1998). The classic 
example of VAH is the prototypical response upon ascent to high altitude, exhibited 
as a progressive increase in ventilation, sustained beyond the initial hypoxic 
exposure. However, when hypoxia is experienced intermittently, unique forms of 
respiratory plasticity occur. Intermittent hypoxia (IH) is a feature of many respiratory 
disorders, notably obstructive sleep apnoea syndrome (OSAS), as a result of 
repetitive upper airway collapse. Of interest, both adaptive and mal-adaptive forms 
of respiratory plasticity have been reported following IH exposure (Bradford et al., 
2005, Mahamed and Mitchell, 2008).  
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IH-induced plasticity occurs at multiple levels of the respiratory control system and 
has been shown to manifest impaired motor control of the upper airway (O'Halloran 
et al., 2002, Veasey et al., 2004, Ray et al., 2007), discordant respiratory rhythm and 
pattern generation culminating in increased apnoea index (Edge et al., 2012, 
Donovan et al., 2014, Zanella et al., 2014, Souza et al., 2015, Elliot-Portal et al., 2018), 
facilitation of breathing or altered chemoreflex control of breathing (Reeves and 
Gozal, 2006, Skelly et al., 2012b, Morgan et al., 2016b, Elliot-Portal et al., 2018) and 
respiratory muscle weakness (McGuire et al., 2002a, McGuire et al., 2002b, Liu et al., 
2005, Pae et al., 2005, Dunleavy et al., 2008, Liu et al., 2009, Jia and Liu, 2010, Skelly 
et al., 2012b, Wang et al., 2013b, Zhou and Liu, 2013, McDonald et al., 2015). Thus, 
the mechanisms underlying IH-induced plasticity are of great interest in the context 
of diseases characterised by IH, such as OSAS.  
 
1.2 Respiratory musculature  
Respiratory muscles are striated skeletal muscles made up of many bundles of cells 
from the fusion of developmental myoblasts to produce long, cylindrical, multi-
nucleated structures called fibres (Frontera and Ochala, 2015). The functional unit of 
skeletal muscle, the motor unit, constitutes a single motor neuron and the bundle of 
muscle fibres it innervates, all of which have similar structural and functional 
properties (Hoppeler, 2014). Upon firing, a motor neuron stimulates all fibres within 
that motor unit to contract simultaneously, thus creating the appropriate muscle 
response. The size of motor units varies depending on their role, with motor units in 
the eye containing a small number of target fibres producing precise movements, 
whereas motor units containing a large number of fibres, for example in the leg, yield 
more powerful movements (Sherwood, 2001). 
 
1.2.1 Respiratory muscle structure  
Respiratory muscle structure encompasses a high degree of sophistication as it 
comprises a variety of fibre types, enabling different functional properties. The 
myosin heavy chain (MHC) is the motor protein of muscle thick filaments after which 
a classification system subdividing skeletal muscle fibres into 4 major groups is 
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named. Fibres are classed as type 1, type 2a, type 2x or type 2b determined by the 
isoform of MHC they express (Schiaffino et al., 1989). Type 1 muscle fibres are red in 
colour due to a high myoglobin composition. They are slow contractile fibres, 
specialised for continuous low-level contractions and resemble a fatigue-resistant 
phenotype. These fibres are endowed with a high mitochondrial content and a 
resultant large oxidative capacity. Type 2a fibres are fast oxidative fibres that also 
appear red due to large myoglobin content. They too are rich in mitochondrial 
density and yield fast, medium-powered contractions with good resistance to 
fatigue, albeit less than that of type1 fibres. Type 2a fibres hold the capacity for both 
oxidative and glycolytic metabolism. Type 2x fibres are fast contractile fibres, with 
high power production and intermediate resistance to fatigue. They possess low 
myoglobin content, medium mitochondrial density and oxidative capacity, and high 
glycolytic capacity. Type 2b fibres are white in colour due to low myoglobin 
concentration and mitochondria density. These fibres are very fast contracting with 
the greatest power production of the 4 subtypes; however, they have a low 
resistance to fatigue. They constitute the most glycolytic fibre, with a low oxidative 
capacity. The functional capacity of a respiratory muscle is determined by its MHC 
composition, which essentially regulates the metabolic make up and thus, force 
generation and fatigability of that muscle (Torgan and Daniels, 2001). Alterations to 
MHC composition can have diverse consequences for muscle physiology, as 
evidenced in a range of different rodent models of disease (Mathur et al., 2014, 
Talbot and Maves, 2016, Chaillou, 2018). 
 
1.2.2 Respiratory muscle function  
Skeletal muscle plays a vital role in multiple bodily functions widely categorised into 
mechanical and metabolic roles. It is primarily important for converting chemical 
energy into mechanical energy, thus generating force and power, maintaining 
posture and producing movement. Additionally, it contributes to basal energy 
metabolism, the maintenance of core temperature and the utilisation of large 
amounts of O2 and fuel during physical activity and exercise (Frontera and Ochala, 
2015). Muscle fibres are hugely adaptable and malleable in response to an array of 
stimuli including exercise, injury/disease and environmental stimuli such as hypoxia 
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(Hoppeler and Vogt, 2001). Adaptations can manifest as alterations in the metabolic 
capacity, contractile apparatus and cell signalling-mediated regulation of the muscle 
(Fluck and Hoppeler, 2003). While adaptation is a necessary and appropriate 
response in the face of perturbations, skeletal muscle can also succumb to mal-
adaptive tendencies following persistent stimulation (Cutlip et al., 2006).  
 
The mechanism of excitation–contraction (EC) coupling was first defined by 
Alexander Sandow as the series of events occurring from the generation of an 
action potential in skeletal muscle fibres to the production of force  (Sandow, 
1952). The propagation of an action potential along the sarcolemma of a muscle 
fibre results in a rapid depolarisation. This depolarisation extends into 
invaginations of the sarcolemma called t-tubules inducing a conformational change 
in the L-type calcium (Ca2+) channel, dihydropyridine receptors (DHPRs). By direct 
protein-protein interactions, DHPRs open ryanodine receptors (RyRs) enabling the 
efflux of Ca2+ into the myoplasm. RyRs reside in close proximity to the sarcoplasmic 
reticulum (SR), a pivotal intracellular Ca2+ store. The SR stores Ca2+ at high 
concentrations and so the opening of RyRs produces a favourable concentration 
gradient, promoting the outflow of Ca2+ from the SR into the myoplasm. This increase 
in intracellular Ca2+ encourages the binding of actin and myosin to yield a contractile 
twitch. Ca2+ released from the SR binds to troponin C, causing tropomyosin to move 
away from the active site of actin. Myosin attaches to actin’s now vacant binding site 
forming a cross-bridge. The breakdown of adenosine triphosphate (ATP) releases 
energy which enables the myosin to pull the actin filaments inwards and shorten the 
muscle, generating a power stroke. ATP binding to myosin eventually breaks the 
cross-bridge by detaching it from actin. This process of muscular contraction can 
continue to repeat, as long as there are adequate stores of ATP and Ca2+. Once a 
stimulus has ceased, the muscle relaxes as Ca2+ is taken back into the SR, a process 
facilitated by sarco/endoplasmic reticulum Ca2+-ATPase pumps (SERCAs) (Lamboley 





1.2.3 Respiratory pump muscle  
The diaphragm muscle is a thin, dome-shaped, striated skeletal muscle with fibres 
extending radially from its central tendon to insertion points on the ribcage. The 
diaphragm displays remarkable adaptability and plasticity owing to its mixed fibre-
type composition, which encompasses a mixture of all 4 MHC subtypes. This mixed 
fibre-type composition is essential in befitting the physiological role of the diaphragm 
muscle. Type 1 fibres support the diaphragm’s primary function as an inspiratory 
pump muscle through the preservation of a high degree of endurance, essential for 
providing substantial muscle stamina.  This function is fundamental in supporting 
adequate ventilation on a breath-by-breath basis throughout life. Additionally, the 
diaphragm exhibits a large force reserve capacity owing to type 2a and 2x/2b fibres. 
These fibres generate large amounts of force to facilitate non-respiratory functions 
such as airway clearance manoeuvres (Gransee et al., 2012). During restful breathing, 
the diaphragm contracts increasing volume in the thoracic cavity, generating 
subatmospheric pressure within the thorax, thus allowing the lungs to fill with air 
from the external environment. Expiration is predominantly a passive process, as the 
diaphragm relaxes back to its resting position allowing the thoracic cavity to recover 
to its pre-inspiratory volume. The lungs have a natural tendency to recoil inwardly, 
thus also facilitating a return to their resting volume. Accessory muscles, such as the 
external intercostals, parasternal intercostals, and scalenes are active during quiet 
breathing and as such are considered obligatory muscles of inspiration (De Troyer 
and Estenne, 1984). During active periods of breathing, such as during exercise and 
forced-breathing manoeuvres, accessory muscles of inspiration including the 
sternocleidmastoids, serratus and pectoralis are recruited to aid the diaphragm by 
raising the upper ribs and sternum (De Troyer et al., 1987, Fujiwara et al., 1999). This 
also holds true for the process of expiration during active breathing, as accessory 
expiratory muscles including the internal intercostals, rectus abdominis, external and 
internal obliques and transversus abdominis contract to forcibly expel air from the 
lungs. Impaired diaphragm function is well described in a plethora of disease states 
characterised by respiratory morbidity including OSAS, Duchenne muscular 
dystrophy (DMD), chronic heart failure (CHF), chronic obstructive pulmonary disease 
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(COPD) and amyotrophic lateral sclerosis (ALS)  (Chien et al., 2010a, Ahn et al., 2017, 
Burns et al., 2018, Sharma and Singh, 2019, de Carvalho et al., 2019). 
 
1.2.4 Upper airway musculature  
The UA consists of a complex arrangement of soft tissue, cartilage, bone and skeletal 
muscle subserving a multiplicity of functions. It operates as more than simply a 
conduit for air, food and drink, with vital respiratory and non-respiratory functions, 
such as phonation, also described (Morris, 1988, Fregosi and Ludlow, 2014). The 
pattern of muscle control in the UA must have the ability to rapidly alternate 
between different system requirements for non-respiratory and respiratory 
functions to ensure the maintenance of UA calibre. This requires the co-ordinated 
activity of more than 20 UA muscles, which contract and dilate, stiffen, or constrict 
the airway under voluntary or involuntary control, circumstantially. The paired 
sternohyoid muscles provide an example of a muscle which exhibits low activity 
during basal ventilation, with an increased activation upon airway occlusion, 
highlighting their role in maintaining airway patency as well as re-establishing airway 
patency following collapse (Roberts et al., 1984). The sternohyoid is a thin, narrow 
muscle attaching the hyoid bone to the sternum and is structurally composed of 
mainly type 2b fibres enabling large force generation. The sternohyoid has been the 
focus of a wealth of research regarding upper airway stability in recent years (Skelly 
et al., 2013, O'Connell et al., 2013, Shortt and O'Halloran, 2014, Williams et al., 
2015a) with its ease of accessibility and fibres which run in a uniform direction 
making it a good candidate for ex vivo experimental approaches. These airway 
muscles regulate airway patency and collectively decrease resistance to airflow 
during inspiration, facilitating in concert with the thoracic muscles, the matching of 
ventilation of alveoli to their perfusion (gas exchange), and they prevent aspiration 
of foreign objects or noxious material into the lungs. Respiratory muscles in the 
upper airway exhibit activation patterns that are coordinated with the diaphragm 
muscle in order to effectively couple low airway resistance to air inflow into the lungs 
during periods of reduced intrathoracic pressure (Gransee et al., 2012). When the 
dilating force produced by the upper airway muscles in insufficient to counterbalance 
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the collapsing force produced by the inspiratory pump muscles, UA collapse ensues 
leading to occlusive events and subsequent hypopnoea and apnoea, characteristic of  
OSAS (Brouillette and Thach, 1979b).  
 
1.3 Cell signalling mediated regulation of skeletal muscle 
Skeletal muscle relies on the complex interplay between a multitude of signalling 
pathways in order to function normally and maintain homeostasis in response to 
changes in demand of a muscle. Many of these pathways have reactive oxygen 
species (ROS)-sensitive components (e.g. protein tyrosine phosphatases; PTPs), 
making them viable targets controlling alterations in growth, metabolic activity, 




The balance between protein synthesis and degradation, or hypertrophy and 
atrophy, is pivotal in determining muscle mass, thereby directly affecting its 
contractile performance. Atrophy of skeletal muscle is a major consequence of many 
disease states (Lecker et al., 2006).  Studies examining gene expression in models of 
muscle atrophy has led to the identification of a category of genes that are routinely 
up- or downregulated in atrophying muscle, commonly termed atrogenes  (Sandri et 
al., 2004, Sandri, 2008). The ubiquitin-proteasome system and autophagy-lysosomal 
system are the predominant mechanisms by which the cell breaks down proteins, 
both of which are transcriptionally controlled by the Forkhead box O (FOXO) family 
of transcription factors.  
 
1.3.2 The ubiquitin-proteasome system 
The ubiquitin-proteasome system is a protein degradation system whereby proteins 
are tagged for poly-ubiquitination and subsequent degradation. This regulatory 
system preferentially recognises and degrades oxidised proteins, thus preventing 
their potentially cytotoxic build up which has been implicated in various human 
disease states including  neurodegenerative disorders and cancer (Aiken et al., 2011). 
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Muscle wasting has been associated with an increase in proteolysis through 
increased ubiquitin conjugation to muscle proteins with a concomitant increase in 
the key muscle specific ubiquitin ligases; muscle RING finger protein 1 (MurF1) and 
muscle atrophy Fbox (MAFbx/Atrogin-1) (Lecker et al., 2006). Additionally,  
inflammation has been shown to cause an up-regulation in the mRNA expression of 
MurF1 and/or MAFbx/Atrogin-1 in incidences of muscle wasting in a range of 
conditions including  cancer, COPD, severe head trauma and  ALS  (Narici and Maffulli, 
2010).  
 
1.3.3 The autophagy-lysosomal system 
The autophagy-lysosomal system represents a lysosomally-mediated proteolytic 
process, commonly activated by ROS in periods of oxidative stress. Whether this 
system functions to mediate atrophy or facilitate cell survival remains a highly 
complex subject and appears to be largely stimulus-dependent (Mammucari et al., 
2007). Basal levels of autophagy are necessary for the homeostatic maintenance of 
muscle mass. Knock-out mice for the critical Atg7 gene to block autophagy, 
specifically in skeletal muscle, demonstrate muscle atrophy, weakness and several 
features of myopathy (Masiero et al., 2009). Conversely, autophagy genes (LC3B, 
GABARAPL1 and BNIP3) are among the upregulated atrogenes, which encode for 
proteins that are degraded when autophagosomes fuse with lysosomes (Zhao et al., 
2007). Oxidative stress, induced by expression of mutant SOD1G93A specifically in 
skeletal muscle, results in loss of muscle mass and weakness mainly via autophagy 
activation (Dobrowolny et al., 2008). This muscle atrophy was prevented by the 
inhibition of microtubule-associated proteins 1A/1B light chain 3B (LC3B), 
highlighting the interplay between autophagy and atrophy pathways (Dobrowolny et 
al., 2008).  
 
A specialised form of autophagy, described as mitophagy, functions to remove 
damaged mitochondria and maintain mitochondrial integrity and quality. Receptor-
mediated mitophagy is one of the primary mechanisms of mitochondrial quality 
control essential for cell survival (Wu et al., 2014). Mitophagy receptors are 
commonly found on the outer and inner mitochondrial membrane and certain outer 
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mitochondrial membrane receptors of mitophagy have been identified, including 
BNIP3, Nip3-like protein X (NIX), and the FUN14 domain-containing protein 1 
(FUNDC1) (Lazarou, 2015). These mitophagy receptors contain motifs that indicate 
their direct interaction with LC3B to enable the engulfment of defective 
mitochondria (Gkikas et al., 2018). The expression and activity of BNIP3 on the outer 
mitochondrial membrane was initially shown to be involved in cell death processes 
(Liu et al., 2014a). BNIP3-deficient mammalian cells exhibit PINK1 proteolysis 
activation which resulted in a subsequent inability to induce mitophagy (Zhang et al., 
2016b). Additionally, upon exposure to hypoxia, BNIP3 expression is increased in a 
HIF-1 dependent manner, which subsequently inhibits the cleavage of PINK1 
proteolysis, thus promoting mitophagy (Zhang et al., 2016b). The PTEN-induced 
kinase (PINK1)-Parkin (PARK2)-dependent pathway has emerged as a principal 
regulator of mitochondrial degradation in a range of biological systems (Narendra 
and Youle, 2011). The majority of research into this pathway focuses on mutations in 
PINK1 and PARK2 genes associated with an increase in mitophagy in hereditary early 
onset Parkinson disease (PD) (Ashrafi and Schwarz, 2015). Similar to observations in 
the traditional autophagy pathway, mitophagy holds an essential homeostatic 
function in skeletal muscle as evidenced by the observation that PARK2-deficient 
mice exhibit a mild impairment in muscle contractility and severe impairment in 
mitochondrial function evidenced by a decrease in mitochondrial respiration rates, 
uncoupling and electron transport chain (ETC) complex functioning (Gouspillou et al., 
2018). Additionally, physical inactivity and thus skeletal muscle unloading is known 
to contribute to loss of muscle mass and function. Studies have revealed molecular 
marker patterns indicative of increased mitophagy and decreased regulation of 
mitochondrial biogenesis, preceding a loss in mitochondrial content, which may 
underlie muscle dysfunction (Leermakers et al., 2019).  
 
1.3.4 PI3K/AKT  
Protein kinase B (Akt) is a serine/threonine protein kinase capable of acting as pro-
hypertrophic or pro-atrophic in skeletal muscle, dependent upon its phosphorylation 
state. Akt is a pivotal component in the process of regulating skeletal muscle fibre 
size and promoting hypertrophy through the activation of downstream signalling 
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components involved in protein synthesis including mammalian target of rapamycin 
(mTOR) and glycogen synthase kinase 3 beta (GSK3β). Negative genetic perturbations 
of Akt, mTOR and p70S6 Kinase (p70S6K) (downstream target of mTOR) have resulted 
in a significantly reduced cell size, thus highlighting their importance and central role 
in the integration of a variety of growth signals for protein synthesis to occur (Glass, 
2005). Studies in myotubes have suggested that the pharmacological activation of 
any one of these components may provide a therapeutic intervention in diseases 
characterised by muscle atrophy (Rommel et al., 2001).  
 
GSK3β has been shown to modulate hypertrophy upon its phosphorylation by Akt. 
This inhibits its catabolic activity as the expression of a dominant negative kinase 
inactive form induces dramatic hypertrophy in skeletal muscles (Rommel et al., 
2001). While there are independent atrophy systems, skeletal muscle atrophy 
pathways can also function as the converse of hypertrophy pathways. Indeed, the 
inhibition of Akt has been shown to be pro-atrophic in a burn model of atrophy 
(Sugita et al., 2005). Similarly, the activation of the phosphoinositide 3-kinase (PI3K)-
Akt-FOXO pathway can elicit cell growth, with its inhibition associated with reduced 
cell survival.  
 
Atrophy, associated with a specific increased expression of ubiquitin ligases, MuRF1 
and MAFbx, is antagonised by treatment with insulin-like growth factor-1 (IGF1) 
through the PI3K-Akt pathway in myotubes and in a diabetic model of atrophy (Sandri 
et al., 2004, Lee et al., 2004). This affirms that Akt holds the capacity to inhibit 
atrophy, as well as stimulate hypertrophy. The mechanism underlying this inhibition 
was shown to involve the FOXO family of transcription factors. When phosphorylated 
by Akt, FOXO is excluded from the nucleus, rendering it unable to translocate and 
upregulate the transcription of MuRF1 and MAFbx (Sandri et al., 2004). 
 
1.3.5 FOXO 
The FOXO proteins are a subgroup of the Forkhead family of transcription factors 
characterised by a conserved DNA-binding domain, ‘the forkhead box’. In mammals, 
there are four FOXO genes, FOXO1, 3, 4 and 6, all of which are expressed in skeletal 
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muscle and encompass a central role in skeletal muscle plasticity. FOXO factors are 
evolutionarily conserved mediators of insulin and growth factor signalling, which are 
found at the interface of essential cellular processes including the regulation of gene 
expression that controls apoptosis, cell cycle progression and oxidative resistance. 
FOXO3 and FOXO1 are involved in the modulation of the activity of certain 
components in the ubiquitin-proteasome and the autophagy-lysosome proteolytic 
pathways, culminating in muscle atrophy (Accili and Arden, 2004). FOXO factors can 
initiate apoptosis by activating the transcription of ubiquitin ligases, and also FasL, 
the ligand of the Fas-dependent cell death pathway. However, they are also involved 
in stress resistance by upregulating catalase and MnSOD in periods of oxidative 
stress. While it appears paradoxical that FOXO proteins can regulate both apoptosis 
and cell survival mechanisms, a possible explanation has been suggested in that it is 
stress-resistant under mild conditions and pro-apoptotic when the intensity of a 
stimulus increases beyond that of a certain threshold (Carter and Brunet, 2007). 
 
1.3.6 mTOR 
mTOR is a highly conserved serine/threonine kinase of the phosphatidylinositol 
kinase-related family. A number of signal transduction pathways result in the 
simulation of mTOR, primarily involved in pathways responsible for the upregulation 
of protein synthesis. It plays a key role in the co-ordination of important homeostatic 
mechanisms including cell growth, metabolism and the inhibition of apoptotic 
signalling with its best understood targets including the translation regulators 
ribosomal protein S6 kinase (P70S6K), S6K1 and 4E-BP1 (Marini and Veicsteinas, 
2010). The function of mTOR differs amongst tissues and so while pharmacological 
inhibition may prove beneficial in one, it may have detrimental effects in another, 
making the therapeutic targeting of mTOR a complex issue. mTOR is activated by a 
wide range of stimuli including growth factors, mechanotransduction signals and the 
energetic state of the cell. A decrease in ATP levels inhibits mTOR through the 
activation of 5’AMP-activated protein kinase (AMPK).  Therefore, under hypoxic 
conditions, the downregulation of mTOR facilitates pro-atrophic signalling and 




The mitogen activated protein kinases (MAPKs) are a family of serine/threonine 
protein kinases composed of 3 distinct signalling molecules in skeletal muscle: 
extracellular regulated kinases 1 & 2 (ERK 1/2), p38 MAPK and c-Jun NH2-terminal 
kinases (JNK). These MAPK branches are activated by MEK 1/2, MKK 3/6 and MKK 
4/7 following stimulation by cytokines, growth factors and cellular stress to elicit 
their effects intracellularly to regulate cell proliferation, differentiation, 
inflammation, cell survival and apoptosis. A putative role of stimulated MAPKs 
includes the transcriptional regulation of the cellular redox status. They have been 
suggested to mediate adaptive antioxidant defence systems in skeletal muscle in 
response to oxidative stress. Hydrogen peroxide (H2O2) has been shown to induce a 
strong activation of ERKs, JNKs and p38 in a dose- and time-dependent manner in 
skeletal myoblasts (Kefaloyianni et al., 2006). Whether MAPKs are pro-hypertrophic 
or pro-atrophic remains largely controversial, as the specific activity of these 
individual paths are dependent on the type, duration and intensity of a contractile 
stimulus in skeletal muscle, as well as their interaction with other signalling 
mechanisms. However, ERK 1/2 appears to be largely pro-hypertrophic, and p38 and 
JNK, termed the stress kinases, are predominantly pro-atrophic.  
 
1.3.8 Muscle differentiation/regeneration  
The process of generating muscle, myogenesis, can be divided into several distinct 
phases, which occur during embryonic development (Tajbakhsh, 2009). However, 
adult skeletal muscle can also undergo regenerative myogenesis, which depends on 
the activation of satellite cells that have the potential to differentiate into newly 
functional muscle fibres (Yin et al., 2013). The most extensively studied form of 
regenerative myogenesis takes place when mature muscle undergoes damage, 
which stimulates large cohorts of satellite cells to expand mitotically and 
differentiate to repair the tissue and re-establish homeostasis (Rudnicki et al., 2008). 
It is well documented that skeletal muscle regeneration shares some similarities with 
myogenesis, including several molecular mechanisms including common 
transcription factors and signalling molecules, as well as having encompassing similar 
cellular events such as the activation and proliferation of myogenic cells, and the 
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formation of myotubes (Yusuf and Brand-Saberi, 2012). Skeletal muscle regeneration 
is finely orchestrated by several cellular and molecular events leading to the 
restoration of muscle mass, muscle vascularization,	 innervation, as well as the 
recovery of contractile and metabolic properties of the muscle (Chargé and Rudnicki, 
2004). However, in the face of chronic muscle damage or insult, a progressive process 
of fibrosis may ensue as successive rounds of degeneration and regeneration can 
result in the incomplete remodelling of the extracellular matrix (ECM) and 
consequently, an accumulation of matrix components (Smith and Barton, 2018). 
Thus, the ECM replaces functional muscle with resultant large amount of fibrosis and 
scar tissue rather than contractile tissue yielding a muscle with a lower force-
generating capacity (Smith and Barton, 2018). Two of the principal molecular 
pathways in the regulation of muscle hypertrophy involve myogenic regulatory 
factors (MRFs) and IGF-I (Asfour et al., 2018, Bikle et al., 2015).   
 
Briefly, myoblast determination protein 1 (MyoD) is predominantly upregulated 
during the proliferation of satellite cells, which yields the formation of myoblasts 
(Sharman et al., 2001). The upregulation of the MRF, myogenin, is widely suggested 
to signify the subsequent myoblast differentiation (Smith et al., 1994). The 
contribution of other MRFs to myogenesis is unsettled in the literature, however, the 
deletion of MADS box transcription enhancer factor 2 C (MEF2C) has been shown to 
prevent muscle differentiation in satellite cells, through a failure to differentiate, 
highlighting its importance in the process (Liu et al., 2014b). Silent mating type 
information regulation 2 homologue 1 (SIRT1) is a sensitive modulator of metabolic 
processes and indeed, has been shown to regulate metabolic processes during 
myogenesis (Nedachi et al., 2008). An inhibition of SIRT1 activity yields a reduced 
myofibre size and attendant decrease in gene expression central to muscle 
development (Ryall et al., 2015). Myostatin is a key endogenous, negative regulator 
of muscle growth with a principal function in the determination of both muscle fibre 
number and size with the disruption of the myostatin gene resulting in skeletal 
muscle hypertrophy and hyperplasia with a resultant two-fold increase in muscle 
mass in mouse models (McPherron et al., 1997). Moreover, myostatin inhibitors have 
shown therapeutic potential in disease models characterised by muscle 
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degeneration (Smith and Lin, 2013). The inhibition of myostatin in the mdx mouse 
model of DMD results in greater muscle mass, increased functional strength, and 
decreased fibrosis and fatty infiltration of muscles, culminating in a reduction in the 
severity of muscular dystrophy (Wagner et al., 2002).  
 
In addition to these MRFs, it has been demonstrated that IGF-I is involved in the 
induction of anabolism through the stimulation of satellite cells to proliferate and 
differentiate during the process of compensatory hypertrophy (Adams and McCue, 
1998), while also activating a cascade of signalling pathways via PI3K/Akt/ mTOR/ 
p70S6K, resulting in the downstream activation of targets required for protein 
synthesis (Glass, 2003). Thus, the pivotal role of IGF-1 in the regulation of muscle 
hypertrophy has been demonstrated in numerous animal models, which report an 
increase in IGF-1 expression in concert with increased muscle mass (Phelan and 
Gonyea, 1997, Musarò et al., 2001). Interestingly, an IGF-1-induced increase in 
muscle mass has been shown in both human (Bamman et al., 2001) and animal 
models (DeVol et al., 1990) in response to mechanical load, suggesting that the 
activation of this pathway may have relevance to disorders characterised by load-
induced hypertrophy.  
 
1.3.9 Hypoxia inducible factor  
The hypoxia inducible factor (HIF) family is made up of HIF-1, HIF-2 and HIF-3 and it 
represents the cell’s primary response system to hypoxia, achieved through 
orchestrating an appropriate cellular response during periods of low partial pressure 
of oxygen (PO2). First sequenced and purified in 1995, HIF is a heterodimeric protein 
belonging to the basic helix-loop-helix PAS family of transcription factors (Wang and 
Semenza, 1995). Of the isoforms in this family, HIF-1 is the most ubiquitously 
expressed and best characterised, with it widely recognised as a master regulator of 
hypoxia signaling, due to its general and diverse role in the cell. HIF-1 undergoes 
continuous degradation through its hydroxylation, which enables its recognition by 
E3 ubiquitin ligases (Epstein et al., 2001). However, during periods of hypoxia, this 
degradation is decreased and HIF-1α stabilises, accumulates and complexes with the 
HIF-1β subunit to form a functional transcription complex. This activates a plethora 
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of hypoxia inducible genes through binding at the respective hypoxia response 
element (HRE). The HIF family also comprises HIF-2 and HIF-3. HIF-2 protein is 
regulated in a similar manner to HIF-1 and is also implicated in the hypoxia response, 
as it is suggested to confer muscle resistance to ischaemia (Aragones et al., 2008). 
Very little data exists concerning HIF-3 function, with no studies to date examining 
its expression or role in skeletal muscle.  
 
The HIF α/β heterodimeric transcription factor controls more than 100 genes with 
functions in erythropoiesis/iron metabolism, vascular tone, angiogenesis, matrix 
metabolism, cell proliferation and apoptosis (Ke and Costa, 2006). The stabilisation 
of HIF-1 is largely organ- and stimulus-dependent with evidence that brain tissue 
begins to accumulate HIF-1α when inspired oxygen drops to 18%, whereas organs 
such as the liver and kidneys require a more severe drop in PO2 before the 
accumulation of HIF-1α ensues  (Stroka et al., 2001). Similarly, normoxic HIF-1α 
stability has been demonstrated at higher levels in type 2 fast glycolytic fibres, than 
in type 1 slow oxidative fibres, suggesting that HIF activity is also muscle fibre-type 
specific (Pisani et al., 2005). 
 
1.4 Reactive oxygen species (ROS)  
ROS is the collective term for a variety of reactive entities derived from molecular O2. 
These include oxygen radicals, superoxide (O2-) and hydroxyl (OH-), as well as non-
radical substances such as hydrogen peroxide (H2O2). The structure and function of 
many biomolecules is subject to modification by oxidation-reduction (redox) 
reactions facilitated by these ROS. The univalent reduction of O2 yields the formation 
of O2-, the precursor of most forms of ROS and an imperative mediator of oxidative 
chain events. O2- can spontaneously degrade or be dismutated by superoxide 
dismutase (SOD) to form H2O2. Unlike O2-, H2O2 holds the capacity to cross the cell 
membrane easily, enabling its implication in more widespread effects. O2- and H2O2 
have a relatively low reactivity. However, when H2O2 is not fully reduced to water 
(H2O), its partial reduction yields the strongest and most potent oxidant, the hydroxyl 
radical (OH-), which exerts detrimental effects on a broad range of non-specific 
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targets. ROS react with a large range of biomolecules, albeit to alternating degrees, 
dependent upon the type of ROS present, the source of ROS, the stimulus evoking 
ROS production, the subcellular location and antioxidant defence capacity in a 
particular tissue or organ (Steinbacher and Eckl, 2015). 
 
1.4.1 Physiological role of ROS in skeletal muscle function  
Davies et al., (1982) were the first group to demonstrate that specific ROS, O2- and 
H2O2, are generated in skeletal muscle at rest and at increased levels during 
contraction. It has since been well established that skeletal muscle continuously 
produces ROS, with the contractile apparatus of muscle fibres proving highly 
sensitive to alterations in cellular redox state (Powers, 2011). Skeletal muscle 
experiences varying effects of ROS, with the force generated by muscle largely 
determined by redox balance (Figure 1.1). The application of antioxidants or a 
reducing agent, thus eliminating ROS, yields a muscle force-generating capacity 
significantly below that of its maximum ability (Figure 1.1; Point 1). In a similar 
manner, when the cell is in a highly oxidised state, muscle force is production is 
severely compromised (Figure 1.1; Point 4). In its basal state, muscle force is 
produced at approximately half of its potential capacity (Figure 1.1; Point 2) when 
compared to maximal force production observed at an optimal redox state (Figure 
1.1; Point 3). This suggests that under basal conditions, ROS exert a powerful tonic 
inhibition on skeletal muscle contractile performance. Indeed, it has been 
demonstrated that superoxide scavengers and NOX2 inhibitors are powerful 
inotropic agents in diaphragm and representative UA muscles (Skelly et al., 2010, 
Skelly et al., 2012b, Williams et al., 2015b). By extension, it could be posited that ROS 
associated with stimuli, such as hypoxia, which also reflexly serves to enhance muscle 






Figure 1.1 Redox balance in skeletal muscle. A theoretical model proposed by (Reid 
et al., 1993) displaying the biphasic effects of ROS on skeletal muscle force 
production. Schematic adapted from review by (Powers, 2011). 
 
Studies examining the underlying mechanisms pertaining to ROS-dependent 
alterations to muscle function have largely suggested that ROS elicit complex redox 
alterations to Ca2+ release apparatus and/or increase the sensitivity of myofibrillar 
contractile proteins to Ca2+. ROS have been shown to activate ryanodine 1 receptors 
(RyR1) via s-glutathionylation of cysteine residues producing an increase in calcium-
induced calcium release (CICR) in the t-tubules of skeletal muscle (Hidalgo et al., 
2006). It has also been demonstrated that thiol groups on the sarcoplasmic reticulum 
are a critical target of oxidative modification by O2-, culminating in an increase in Ca2+ 
release, with thiol reducing agents successfully closing the channel (Abramson and 
Salamaz, 1988). In contrast, various studies have reported a down-regulation and 
impaired Ca2+ channel functioning in skeletal muscle upon exposure to ROS  (Guerra 
et al., 1996). This apparent dichotomy may be attributed to varying levels of ROS, 
which are known to have divergent effects in skeletal muscle. Additionally, ROS can 
potentially alter the sensitivity of myofibrillar contractile proteins to Ca2+ or affect 
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muscle at the level of cross-bridge cycling (Powers, 2011). Positive inotropic effects 
observed in a pharyngeal dilator muscle following administration of the superoxide 
scavenger, tempol, were reported to be due to an increased Ca2+ sensitivity of 
myofibrillar contractile apparatus, as contractile kinetics were unaffected (Skelly et 
al., 2010).  
 
1.4.2 ROS reactions with protein  
ROS are well renowned for eliciting their effects through cysteine residues in 
proteins, which act as redox switches. This results in the oxidation of these residues, 
inducing a conformational change that alters a protein’s activity and manifests as a 
change in metabolic processes, homeostasis and contractile performance (Zuo and 
Clanton, 2005, Marin-Corral et al., 2009, Klomsiri et al., 2011). Excessive levels of 
ROS, culminating in oxidative stress, results in tissues exhibiting higher levels of 
carbonylated proteins, ultimately leading to protein loss of function (Moller and 
Kristensen, 2004). Amino acids differ in their susceptibility to ROS with thiol and 
sulphur containing amino acids showing the greatest susceptibility, as the oxidation 
of iron-sulphur centres by O2- is largely irreversible and renders enzymes inactive. 
Excessive ROS results in site-specific modifications of amino acids, fragmentation of 
peptide chains and an increased susceptibility to proteolysis. Studies have suggested 
that oxidised proteins are more likely to be tagged for ubiquitination and subsequent 
proteasomal degradation (Cabiscol et al., 2000). Interestingly, the muscle-specific 
ubiquitin ligase, MuRF1, has been shown to bind the MHC complex in skeletal muscle 
resulting in its degradation, with siRNA blockage of MuRF1 preventing this loss 
(Clarke et al., 2007).  
 
Increased levels of protein oxidation with concomitant alterations to antioxidant 
responses have been reported in poorly functioning respiratory and limb muscles of 
COPD (Barreiro et al., 2017), DMD (Petrillo et al., 2017) and CHF (Ahn et al., 2017) 
patients. The effect of hypoxia on redox alterations, in the form of protein oxidation, 
in murine models of respiratory disease is varied. Models which utilise sustained 
hypoxia, typically report increases in protein oxidation in skeletal muscle, 
exemplified by increased carbonyl and/or decreased free thiol content (Lewis et al., 
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2015, Lewis et al., 2016). In contrast, the effects of intermittent hypoxia on skeletal 
muscle largely depend on the severity of the IH stimulus, which will be discussed in 
more detail below (1.10.3). Indeed, increased levels of protein oxidation and the 
subsequent role this plays in alterations to muscle contractile capacity appears to be 
correlated with disease or stimulus severity.  
 
1.4.3 ROS reactions with DNA 
ROS are a major source of DNA damage that have the potential to affect both nuclear 
and mitochondrial DNA. Oxidative alterations to purine or pyrimidine bases and the 
deoxyribose backbone of DNA generally involve a reaction with OH-. OH- favourably 
oxidises guanine to produce 8-hydroxyguanine, making it a routinely used biomarker 
of DNA oxidative damage (Tsuboi et al., 1998). Unrepaired oxidative modifications of 
DNA bases on a single strand results in a mismatch in nucleotides. This forms the 
basis for ROS-induced DNA mutations with the subsequent translation yielding 
malfunctioning or inactive proteins. Mitochondrial DNA appears to be more 
susceptible to oxidative damage than nuclear DNA, possibly owing to  its low level of 
protective proteins and histones and as well as its significantly closer localisation to 
the main ROS-producing system within the cell (Richter, 1992). An accumulation of 
mitochondrial DNA mutations has been shown to predispose the mitochondria to 
oxidative stress through an increased build-up and leakage of electrons from the ETC. 
This culminates in dysfunctional mitochondria and a resultant shift from oxidative to 
glycolytic metabolism in certain tumorous cancers, a theory first proposed by Otto 
Warburg in the 1920s (Koppenol et al., 2011).  
 
Furthermore, similar ROS-induced metabolic adaptations that may have implications 
for skeletal muscle contractile function have been identified in patients and models 
encompassing hypoxia as a core feature of disease. Slow-to-fast fibre-type 
transitions in patients with COPD and CHF is commonly reported in limb muscle, 
resulting in a more fatigable muscle (Kitzman et al., 2014, Ausín et al., 2017). 
Interestingly, an opposite adaptation in fibre-type composition from fast-to-slow is 
evident in the diaphragm of these patients, culminating in a weaker muscle (Doucet 
et al., 2004, Bowen et al., 2017). While there are a multitude of possible stimuli for 
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these transitions, the former is suggested to be a product of chronic muscle 
inactivity, with the latter explained by the large contractile activity necessary by the 
diaphragm to sustain breathing pattern in these diseases. A shift towards a faster 
fibre-type has also been demonstrated in the UA muscles of patients with OSAS, with 
the mechanism and cause-result relationship in this instance remaining less clear 
(Chen et al., 2016), but probably related to loading due to airway obstruction.   
 
1.4.4 ROS reactions with lipids 
Lipid peroxidation is among the most detrimental processes of ROS-induced stress, 
by enhancing pre-existing oxidative stress, through the production of radicals that 
hold the capacity to further react with proteins and DNA. This initiates a cyclical chain 
of events resulting in a plethora of mal-adaptive effects including loss of membrane 
fluidity and elasticity, impaired cell function and rupture. Direct products of lipid 
peroxidation include malondialdehyde (MDA), isoprostanes and 4-hydroxynoneal (4-
HNE), which harbour mutagenic and carcinogenic properties, rendering them highly 
cytotoxic substances. MDA levels have been shown to be significantly higher in the 
plasma of patients with breast and lung cancer (Gonenc et al., 2001). Similarly, an 
increase in levels of F-2 isoprostane has been observed in the early stages of patients 
with Alzheimer’s disease (Montine et al., 2002) and hepatic cirrhosis (Pratico et al., 
1998). Lipid peroxidation is most well documented in the skeletal muscle of patients 
with diabetes. It has been demonstrated that 4-HNE adducts directly related to the 
severity of insulin resistance through the modification of mitochondrial proteins and 
essential components of the insulin signalling pathway (Ingram et al., 2012). 
Stressors, including sustained and intermittent hypoxia, have also been shown to 
induce lipid peroxidation in weakened skeletal muscle (Shortt et al., 2014, O'Leary et 
al., 2018).  
 
1.4.5 ROS reactions with residues of cell signalling components  
While ROS oxidise a vast array of biomolecules directly, they may also exert their 
effects through the alteration of various elements of cell signalling pathways. PTPs 
have a vital role in dephosphorylating receptor tyrosine kinases (RTKs), thus 
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regulating the downstream signalling cascade they control (Truong and Carroll, 
2013). The reversible oxidation of the catalytic site in the cysteine residue to sulfenic 
acid in these phosphatases results in a sustained activation of the associated pathway 
(Lim et al., 2008). However, when further oxidation to sulfinic or sulfonic acid occurs, 
the process is irreversible (Lim et al., 2008). 
 
ROS have been shown to inhibit PTPs, which regulate pathways associated with 
protein synthesis and degradation, such as the MAPK pathway (Zhang et al., 2016a). 
Sustained activation of ERK 1/2 results in an unregulated proliferation of cells 
associated with tumorigenesis in a range of cancers (Feitelson et al., 2015), while 
sustained activation of p38 and JNK is associated with unregulated cell death and 
neuronal apoptosis in patients with Alzheimer’s and PD (Kim and Choi, 2010). 
Similarly, phosphatase and tensin homolog (PTEN), which regulates the 
PI3K pathway, has also been shown to be subject to redox regulation by H2O2 in 
humans (Lee et al., 2002). Indeed, an inhibition or loss of PTEN activity has been 
described as a central mechanism in an array of cancers and rare syndromes 
(Hollander et al., 2011).  
 
The difficulty in defining the contribution of ROS to signalling lies with the fact that 
they exert their effects at multiple stages of signalling (upstream or downstream) and 
sometimes in opposing fashions (inhibitory or stimulatory). In addition, transcription 
factors have also been shown to be redox-sensitive (Haddad, 2002). Nuclear factor 
kappa B (NF-κB) is a family of transcription factors associated with a wide range of 
functions in inflammation, immunity, cell proliferation, apoptosis and tumorigenesis 
(Oeckinghaus and Ghosh, 2009). ROS can inhibit NF-κB directly by binding at the 
specific p50 cysteine, which inhibits its DNA binding ability (Morgan and Liu, 2011). 
In contrast, ROS can also activate NF-κB by phosphorylating its inhibitor 1-κB, thus 
highlighting the complexity of the role that ROS play in the control of cell signalling 
with their effects like to be circumstantially defined (Morgan and Liu, 2011).  
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1.5 Endogenous antioxidant systems  
Oxidative stress was first described by (Sies, 1991) as “a disturbance in the pro-
oxidant to antioxidant balance, in favour of the former, leading to potential damage”. 
This occurs due to an accumulation of ROS, a depletion of antioxidant defences, or a 
culmination of both. All forms of life maintain a reducing environment in cells with 
the body employing a number of enzymatic and non-enzymatic defence systems in 
order to maintain levels of ROS at an optimal level necessary for a range of 
homeostatic functions. Skeletal muscle is endowed with this sophisticated defence 
system, rendering it remarkably flexible in response to changes in the redox milieu 
that can occur both in health and disease (Kozakowska et al., 2015). A principal 
mechanism essential for cellular defence against redox imbalance is the activation of 
the transcription factor, nuclear factor erythroid 2-related factor 2 (NRF2). The NRF2-
antioxidant response element signalling pathway controls the expression of genes 
whose protein products are responsible for the elimination of reactive oxidants by 
enhancing cellular antioxidant capacity (Nguyen et al., 2009). The most predominant 
antioxidant systems which function in this manner include superoxide dismutase 
(SOD), catalase (CAT), the glutathione (GSH) system and peroxiredoxins (PRDXs).  
 
1.5.1 Superoxide dismutase  
SOD is pivotal in neutralising the primary form of ROS, O2-. Three SOD isoenzymes 
exist which catalyse the conversion of O2- to H2O2, using a transition metal 
incorporated into its active site. Of these isoenzymes, SOD-1 incorporates copper-
zinc and is located in the cytosol and mitochondrial intermembrane, SOD-2 uses 
manganese with its localisation exclusive to the mitochondrial matrix and SOD-3 also 
uses copper-zinc with its highest expression reported in the extracellular space. ALS 
is a neurological disorder resulting in the death of motor neurons in the brain and 
spinal cord leading to muscular paralysis (Bruijn et al., 2004). In humans, SOD-1 
mutations underlie apoptosis of spinal neurons, revealing its central role in the 
pathogenesis of ALS (Fridovich, 1995). The pivotal role of SOD-1 in the pathogenesis 
of ALS has since been exemplified and well examined in a wide range of models 
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harbouring SOD-1 mutations (Nagahisa et al., 2016, Crown et al., 2019, Bakavayev et 
al., 2019).  
 
SOD isoforms have been shown throughout skeletal muscle fibres, with 15%-35% of 
total SOD activity attributed to the mitochondria and the remaining activity in the 
cytosol (Powers et al., 1994). Furthermore, higher SOD activity has been reported in 
oxidative (type 1) fibres, compared to glycolytic (type 2b) muscle fibres in rodent 
models (Criswell et al., 1993). Skeletal muscle from SOD-1 deficient mice exhibit 
muscle atrophy with concomitant oxidative damage, resembling that of an 
accelerated age-related sarcopenia (Muller et al., 2006). This was suggested to be as 
a result of excess O2- and its secondary product, highlighting the pivotal physiological 
role of SOD-1 as a ROS buffer in skeletal muscle. Furthermore, an increase in the 
mRNA of embryonic myosin heavy chain (MyHC-emb), paired box protein-7 (Pax7) 
and myogenin, characteristic of the early phase of muscle regeneration, were 
significantly increased in skeletal muscle of SOD-1 null mice (Nagahisa et al., 2016). 
This reveals the capacity for excessive ROS, due to the absence of SOD-1, to initiate 
skeletal muscle damage and resultant structural alterations that can present as mal-
adaptive to muscle function. Interestingly, the accelerated age-related muscle loss 
and weakness in whole-body SOD1 KO mice (Muller et al., 2006) is considerably less 
severe when SOD1 is specifically deleted in skeletal muscle or neurons of mice 
(Sakellariou et al., 2018). Findings from the latter study demonstrate that 
neuromuscular integrity, redox mechanisms, and pathways are differentially altered 
in nerve and muscle of whole-body and muscle-specific SOD1 deficient mice 
(Sakellariou et al., 2018). These results point to impaired redox signalling, rather than 
oxidative damage, in peripheral nerves as a key contributor to muscle loss in whole-
body SOD1 deficient mice and thus, potentially sarcopenia during aging.  
 
1.5.2 Catalase  
CAT is a heme-dependent enzyme responsible for catalysing the conversion of H2O2 
to H2O and O2 utilising iron as a co-factor attached to its active site. It exhibits a wide 
distribution throughout the cell with an extremely high turnover rate. Mice lacking 
CAT exhibit a diminished rate of removal of H2O2 and increased susceptibility to 
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oxidant tissue injury (Ho et al., 2004). As a result, a deficiency in CAT has been linked 
to ROS-induced accelerated diabetic renal injury (Hwang et al., 2012) and non-
alcoholic fatty liver disease (NAFLD) (Hwang et al., 2020). 
 
CAT is also localised to skeletal muscle and similar to SOD, its activity is reportedly 
highest in oxidative fibres compared to those with a low mitochondrial density 
(Laughlin et al., 1990). Increased levels of H2O2 with an attendant decrease in CAT 
have been demonstrated in a mouse model of sarcopenia (Sullivan-Gunn and 
Lewandowski, 2013). It is suggested that the increased level of ROS and decline in 
CAT-dependent antioxidant capacity may be a contributing factor to the 
development of muscle weakness that is characteristic of sarcopenia.  
 
1.5.3 Glutathione system  
8 isoforms of GPX (GPX 1-8) have been reported in mammals which catalyse the 
reduction of H2O2 to H2O, through the utilisation of reduced glutathione (GSH). GSH 
is readily oxidised to form glutathione disulfide (GSSG) through this reaction. 
Therefore, this demands that cells possess a pathway to continuously replenish GSH 
stores and maintain a reduced environment. Expression of GPX in skeletal muscle 
varies across fibres types, with oxidative fibres exhibiting the highest activity when 
compared with muscle fibres of low oxidative capacity (Lawler et al., 1994). Oxidative 
fibres also incorporate 4-5 times the amount of GSH that glycolytic fibres do 
(Leeuwenburgh et al., 1997). GSH encompasses a range of functions including direct 
reactions with several ROS through acting as a substrate for the elimination of H2O2. 
GSH also participates in the reduction of other antioxidants, thus aiding their activity 
e.g. vitamin E & C. The administration of GSH precursors, such as N-acetylcysteine 
(NAC), have shown efficacy in preventing respiratory muscle weakness in murine 
models which exhibit oxidative stress (O'Leary et al., 2018, Burns et al., 2019). This 
highlights the importance of a balanced GSH/GSSG ratio in ensuring a homeostatic 
redox state to support optimal skeletal muscle function.  
 
SOD, CAT, GPX and GSH display a sensitivity to exercise in rat skeletal muscle, in that 
the alterations to the activity of these antioxidants is largely determined by the 
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intensity and duration of exercise  (Powers et al., 1994, Leeuwenburgh et al., 1997). 
In a similar manner, hypoxia holds the capacity to alter antioxidant capacity 
dependent upon the pattern, duration and intensity of the hypoxia paradigm 
employed. Hypoxia-induced decreases in antioxidant status are believed to 
represent instances of oxidative stress based on an overwhelming depletion of 
antioxidant capacity (Jackson et al., 1996, Williams et al., 2015b, Debevec et al., 
2017). In contrast, hypoxia-induced increases in antioxidant defences has also been 
demonstrated, which may serve as an early protective mechanism to combat an 
increase in ROS levels to maintain redox balance (White et al., 1988). Similarly, the 
administration of antioxidants to boost antioxidant defence systems and prevent 
against deleterious effects of hypoxia-induced ROS have been demonstrated (Ding 
and Liu, 2011, Shortt et al., 2014).  
 
1.5.4 Peroxiredoxins   
Peroxiredoxins (PRDXs) are a highly abundant ubiquitous family of cysteine-
dependent peroxidase enzymes which have a central role in regulating peroxide 
levels within cells, and as such represent an important antioxidant defence 
mechanism (Perkins et al., 2015). In humans, six different isoforms of PRDX are 
present (PRDX 1-6) , four PRDX1 subtypes, one PRDX5 subtype and one PRDX6 
subtype (Dammeyer and Arnér, 2011). PRDX1, PRDX2, PRDX3, PRDX5 and PRDX6 are 
localized in the cytosol, in the mitochondria, in the nuclei and in the peroxisomes 
(Kang et al., 1998, Seo et al., 2000, Rhee et al., 2005), whereas PRDX4 is mainly 
present in the endoplasmic reticulum, or it is secreted (Fujii et al., 2015). This family 
of enzymes represents one of the most important and widespread peroxide and 
peroxynitrite scavenging enzymes (Karplus, 2015), with their role previously 
overshadowed by well-studied antioxidant enzymes such as catalase and GPX, 
considered for a long time to be the major enzymes responsible for protecting cells 
against hydroperoxides. PRDXs have a key role in the control of various physiological 
functions, including cell growth, differentiation, apoptosis, embryonic development, 
lipid metabolism, the immune response, as well as cellular homeostasis (Nicolussi et 
al., 2017).  
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PRDXs are expressed in multiple cellular compartments and have the ability to 
scavenge and react with H2O2 in cells at very low physiological concentrations and 
are several orders of magnitude more reactive with H2O2 than many other proteins 
reported to be redox regulated (Manta et al., 2009). PRDX1, 2 & 3 are rapidly and 
reversibly oxidised following treatment with H2O2 and in response to repeated 
isometric contraction in isolated muscle fibres (Stretton et al., 2020). These findings 
suggest that PRDXs are likely candidates to link contraction-induced H2O2 generation 
in skeletal muscle with activation of redox-regulated signalling proteins and 
transcription factors (Stretton et al., 2020). PRX3 has also been suggested to function 
as a regulator of mitochondrial function, thus having implications in skeletal muscle 
performance (Lee et al., 2014). Mice deficient in PRX3 exhibit deregulated 
mitochondrial networks and membrane potential of myotubes, in which ROS levels 
were significantly increased. A concomitant increase in skeletal muscle fatigability 
was also reported, suggested to be a result of disrupted mitochondrial homeostasis 
(Lee et al., 2014). Interestingly, proteomic screening of EDL muscle from dystrophin 
deficient mdx mice has revealed an 80% reduction in PRDX2, suggested to be due to 
proteolytic degradation following hyperoxidation by NOX2 (Olthoff et al., 2018).  
Muscle force loss due to eccentric contractions was exacerbated by PRDX2 ablation 
and improved by PRDX2 overexpression, highlighting the pivotal role of this 
antioxidant in protection against oxidant induced muscle injury in this model (Olthoff 
et al., 2018).  
 
1.6 Sources of ROS 
1.6.1 Mitochondria  
ATP synthesis is an energetically unfavourable reaction with the energy necessary for 
its occurrence dependent on the oxidation of nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH2). This is achieved by the four 
complexes of the ETC in a process of aerobic metabolism. The differential electrical 
charge established throughout this cycle drives ATP synthesis with ROS produced as 
normal intermediate molecules. Electron leakage occurs as electrons exit the ETC 
prematurely, most commonly at complexes 1 and 3, prior to O2 being terminally 
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reduced at cytochrome C oxidase. This accounts for ~1-2% of O2 consumption as 
these electrons react with molecular O2 to form ROS, which function in their 
homeostatic role under resting conditions (Jastroch et al., 2010). Mitochondria have 
been deemed the primary location of oxygen consumption and ROS production and 
as a result, they are becoming key players in O2 sensing (Taylor, 2008).  
 
Hypoxia has been described as the PO2 where the mitochondrial ETC is more 
reduced, considered a sentinel for insufficient O2 availability at the level of 
mitochondrial flow (Clanton, 2007). Skeletal muscle is an example of a tissue that 
adapts to local reductions in PO2 during hypoxia by inducing a hypometabolic state 
to sustain O2 delivery and ensure adequate tissue oxygenation (Lewis and O'Halloran, 
2016). Adaptations of skeletal muscle to sustained periods of hypoxia include a loss 
of mitochondrial content, thus a reduced oxidative capacity (Gamboa and Andrade, 
2010). This loss of mitochondrial content is proportional to muscle fatigue, 
suggesting a shift to a more glycolytic muscle phenotype.  
 
Given the pivotal role of O2 as an electron acceptor in the ETC, hypoxia induces a 
build-up of electrons in this cycle. This ultimately leads to an increase in electron 
leakage and subsequent ROS formation, serving to exacerbate mitochondrial 
dysfunction (Waypa et al., 2016). It has been suggested that mitochondrial 
membrane potential regulates the production of mitochondrial ROS and that 
uncoupling oxidative phosphorylation from the ETC in mitochondrial membrane may 
decrease mitochondrial superoxide production (O'Leary and O'Halloran, 2016). An 
increase in the mRNA expression of a mitochondrial uncoupling protein, UCP-3, in 
respiratory muscle following sustained hypoxia exposure may represent a protective 
mechanism against ROS overproduction. However, this would also yield an 
associated decrease in ATP synthesis, highlighting the possible implication of ROS-
induced alterations to mitochondrial capacity in diaphragm muscle weakness.  
 
1.6.2 Xanthine Oxidase  
Xanthine Oxidase (XO) is an isoform of xanthine oxidoreductase belonging to the 
molybdenum hydroxylase flavoprotein family. It holds a primary function in 
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catalysing the oxidation of hypoxanthine to xanthine, and further to uric acid in the 
process of purine catabolism. These reactions utilise molecular O2 as an electron 
acceptor resulting in the formation of O2- (Volek et al., 2002). It has been 
demonstrated that XO plays a role in exercise-induced stress in the diaphragm 
muscle of COPD patients. An increase in MDA and GSSG in the diaphragm of patients 
with COPD following strenuous exercise was absent in patients treated with a XO 
inhibitor, allopurinol (Heunks et al., 1999). Treatment with allopurinol has also been 
shown to attenuate endothelial dysfunction in rats following exposure to CIH (Dopp 
et al., 2011). Similarly, allopurinol  prevents IH-induced hypertension, oxidative stress 
and XO activation in the adrenal medulla of rats exposed to CIH, affirming its 
potential role in CIH-induced ROS production (Nanduri et al., 2013a).  
 
1.6.3 Phospholipase A2 
The importance of lipids in cell signalling and tissue physiology can be appreciated by 
the array of pathologies associated with dysregulated lipid metabolism (Bang and 
Dyerberg, 1980, Adibhatla and Hatcher, 2008, Musso et al., 2009). An important 
event in lipid metabolism involves the activation of phospholipase A2 (PLA2) 
enzymes which hydrolyse membrane phospholipids. PLA2 enzymes cleave fatty acids 
at the sn-2 position of glycerophospholipids to yield free fatty acids and 
lysopholipids. This reaction is of particular importance when arachidonic acid (AA) is 
released as it serves as a primary substrate for ROS-generating enzyme systems 
including lipooxygenases (LOXs) and cyclooxygenases (COXs) (Adibhatla and Hatcher, 
2008). Both Ca2+-dependent and independent forms of PLA2 have been identified in 
skeletal muscle, which both exhibit the capacity to produce ROS (Powers, 2011). Of 
interest, hypoxia-induced activation of PLA2 has been observed in the left 
myocardium of male rats, highlighting its possible role as a source of CIH-induced 
ROS (Micova et al., 2016).  
 
1.7 NADPH oxidase (NOX) 
Skeletal muscle fibres produce ROS on a continuous basis throughout different 
subcellular localisations in response to physiological and pathological stimuli 
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(Moldovan and Moldovan, 2004). The mitochondria have long been considered the 
predominant source of ROS in skeletal muscle. Ten years after the discovery of O2- 
superoxide production in isolated skeletal muscle fibres (Reid et al., 1992), the 
presence of the NOX enzyme complex in ventilatory skeletal muscle was described 
(Javeshghani et al., 2002). While ROS are continuously produced, by sources such as 
the mitochondria, the discovery of the NOX enzyme complex demonstrated that ROS 
can also be produced by enzymatic systems in a controlled manner in response to 
various stimuli. The NOX family of enzymes is the only known system whose sole 
purpose is to produce ROS, with their function governed by alterations in gene 
expression as well as acute regulation. There are seven members of the NOX family: 
NOX1-5 and DUOX1-2. These isoforms differ in their level of expression, regulation 
of expression, organ-specific expression, the specific type of ROS they produce and 
in the control of their enzymatic activity (Brandes et al., 2014).  
 
1.7.1 NOX1 
NOX1 is primarily considered to be a colonic NOX system as it is highly expressed in 
epithelial cells of the gastrointestinal (GI) tract. In concert with this, NOX1-derived 
O2- demonstrate their principal function in GI host defence. However, the 
overexpression of NOX1 and subsequent overproduction of ROS has been reported 
in the pathogenesis of inflammation-associated tumour development through an 
increase in the resistance of tumour cells to cell death mechanisms (Rokutan et al., 
2006). NOX1 is expressed at marginal levels in cardiomyocytes, where it is suggested 
to play a protective role against hypoxia-induced bradycardia (Kojima et al., 2015). It 
has been demonstrated that NOX1 expression is upregulated by myostatin in 
differentiating C2C12 muscle cells (Sriram et al., 2011). However, its levels in skeletal 
muscle are relatively low compared with other NOX isoforms and thus, its 
physiological role in this instance has not yet been well discerned.  
 
The majority of NOX isoforms require the association of the catalytic subunit with 
accessory cytosolic subunits for successful enzymatic activation. NOX1 is found 
complexed with the cytosolic subunit, p22phox, with its ROS production dependent 
on its co-expression with regulatory subunits, p47phox and p67phox, as increased 
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superoxide production is abolished in their absence (Bánfi et al., 2003). Additionally, 
in the search for other NOX1 interacting proteins, its preferential activation by NOX 
activator 1 (Noxa1) and NOX organiser 1 (Noxo1) proteins has been reported, leading 
to high stimulus-independent increases in ROS (Schröder et al., 2017). These results 
suggest that NOX1 activity is differentially activated depending upon the stimulus 
present. Like the majority of NOX isoforms, NOX1 is Rac-dependent, with its 
activation pivotal in the assembly of accessory subunits to the catalytic subunit, thus 
enabling their association and subsequent activation (Cheng et al., 2006). 
 
1.7.2 NOX2  
NOX2 (gp91phox) was originally discovered in phagocytes and neutrophils as a 
pivotal component of the ‘respiratory burst’ enabling its specialised function in host 
defence against invading pathogens and microorganisms. While NOX2 is still widely 
considered to have a phagocytic specific tissue expression, studies now suggest that 
it is actually the most widely expressed NOX isoform. NOX2 mRNA has been 
identified in the thymus, small intestine, colon, spleen, pancreas, ovary, placenta, 
prostate, and testis, with this wide tissue distribution thought to be a result of the 
infiltration of phagocytes and/or blood (Cheng et al., 2001). However, an increasing 
body of evidence is emerging which reveals the expression of NOX2 in a large range 
of non-phagocytic tissues including neurons (Serrano et al., 2003), hepatocytes 
(Reinehr et al., 2005), cardiomyocytes (Heymes et al., 2003) and skeletal muscle 
myocytes (Javeshghani et al., 2002). 
 
The NOX2 enzyme complex is composed of the catalytic subunit, gp91phox, and 
p22phox, which together form a mutually stabilising complex, flavocytochromeb558, 
in the plasma membrane. The activity of NOX2 can be induced by specific agonists 
such as angiotensin II (AngII), growth factors and by mechanical stress including that 
of muscle contractions (Loureiro et al., 2016). Upon stimulation, accessory cytosolic 
subunits including p47phox, p67phox, p40phox and Rac assemble the complex in its 
entirety. This enables and regulates its enzymatic activity to initiate the electron 
transfer from NADPH on the cytosolic side to O2 across the cell membrane to 
generate O2-. While all subunits have been shown to be involved in NOX2-derived O2- 
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generation, the relative contribution of each subunit is highly complex and remains 
largely inconclusive. Nevertheless, the phosphorylation of p47phox and activation of 
Rac appear to be among the pivotal regulators of O2- production by NOX2 in skeletal 
muscle. Significantly impaired diaphragm contractile function with an attendant 
increase in p47phox mRNA in a mouse model of CHF are notably absent in p47phox 
null mice (Ahn et al., 2015). The authors suggest that NOX2-dependent ROS 
production was inhibited in the absence of the activator subunit, p47phox. Similarly, 
an increase in Rac activity has been reported in the skeletal muscle of mdx dystrophic 
mice (Pal et al., 2014).  Interestingly, Rac inhibitors result in a decrease in the 
phosphorylation state of p47phox and markers of H2O2 production, suggesting a role 
for Rac in NOX2-induced oxidative stress in mdx skeletal muscle. Additionally, Rac 
associated with microtubules has been shown to activate NOX2 enzymes following 
contraction, with the stretch-induced increase in ROS prevented in skeletal muscle 
fibres lacking NOX2 or Rac (Sylow et al., 2015).  
 
All NOX2-related subunits have been identified in skeletal muscle (Javeshghani et al., 
2002), highlighting the possibility of their role in ROS-dependent alterations to EC 
coupling mechanisms. Skeletal muscle SR has been shown to contain NOX, which 
reduces molecular O2 to generate O2- (Xia et al., 2003). O2- generated by NOX present 
in the SR increases RyR activity, due to an increase in RyR binding and thus Ca2+ 
release (Xia et al., 2003). Additionally, this group have confirmed that the increase in 
NOX activity was associated with increased O2- generation that originated in the SR, 
not in the mitochondria (Xia et al., 2003). The expression of NOX2 subunits including 
gp91phox, p47phox, p22phox and p67phox has also been shown in intact and 
isolated t-tubules and triads of mammalian skeletal muscle (Hidalgo et al., 2006). 
NOX2 increased O2- and H2O2 production and enhanced the activity of RyRs, 
confirmed by their significantly increased s-glutathionylation. NOX2 expression and 
activity are higher in skeletal muscle exhibiting predominantly type-1 fibres, 
encompassing a high oxidative capacity compared to type-2 fast twitch fibres, which 
comprise a more glycolytic phenotype. Therefore, the differences regarding NOX2 
expression among fibre types may have relevance to the contractile characteristics 
of that fibre (Loureiro et al., 2016). Studies in isolated fibres from mouse flexor 
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digitorum have demonstrated that NOX2 is a major contributor of ROS which 
regulates muscle force production at rest and during contractions (Sakellariou et al., 
2013). NOX2 has also been shown to be activated during moderate-intensity exercise 
in mouse and human skeletal muscle, representing the primary source of ROS under 
these conditions (Henríquez-Olguin et al., 2019). Additionally, mice lacking 
regulatory NOX2 subunits showed that lack of ROS generation during exercise 
strongly impaired muscle glucose uptake and GLUT4 translocation during exercise 
(Henríquez-Olguin et al., 2019). These findings suggest that NOX2 is a major source 
of ROS production during exercise and that NOX2-dependent ROS production is an 
important signal for increasing muscle glucose uptake during exercise. As well as the 
respiratory musculature, the expression of NOX2 has been documented throughout 
sites of the respiratory control network, including peripheral chemoreceptors 
(carotid body) (Dinger et al., 2007, Peng et al., 2009), central pattern generating and 
integrative sites (Glass et al., 2007), and motor neurons (MacFarlane et al., 2008). 
Thus, NOX2-dependent ROS may exert their effects at multiple levels of the 
respiratory system, which culminates in alterations to the system’s phenotypic 
response that manifests as adaptive or mal-adaptive.  
 
Hypoxia is a potent activator of NOX2 (Williams et al., 2015b, Nanduri et al., 2015). 
NOX2-derived ROS have been implicated in a wide range of CIH-induced morbidities 
across organs and systems including the brain (Zhan et al., 2005), heart (Hayashi et 
al., 2008) and testes (Zhang et al., 2013). Interestingly, CIH has been shown to 
exacerbate respiratory muscle dysfunction in DMD by reducing diaphragm strength 
by a further 30% (Farkas et al., 2007). Moreover, inhibiting NOX2-dependent ROS 
production increases force and respiratory function in dystrophic diaphragm (Loehr 
et al., 2018). This highlights a potential role for NOX2 blockade in the prevention of 
CIH-induced diaphragm muscle weakness. The role of NOX2 in CIH-induced 
respiratory system dysfunction is discussed in detail below.  
 
1.7.3 NOX3 
The vestibular system of the inner ear is central for the perception of motion and 
gravity with otoconia being the key organs of this system. NOX3 expression is limited 
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to the plasma membrane of vesicles in the inner ear where O2- is thought to trigger a 
conformational change in the binding of otoconin to phospholipids of the vesicle 
membrane, thus promoting its formation. A clear enzymatic function of NOX3 has 
been exhibited in otoconia morphogenesis as mutations affecting otoconia 
formation result in mutations in the gene for NOX3 (Paffenholz et al., 2004). NOX3 
complexes with p22phox, but other subunit regulation differs depending on species. 
Association with Noxo1 alone markedly stimulates ROS production in humans (Cheng 
et al., 2004), whereas mouse models appear to require Noxo1 and Noxa1 (Banfi et 
al., 2004a). However, Noxo1 may be considered the most physiologically relevant 
regulator of NOX3 in the context of our present knowledge, as NOX3-dependent 
ocotonia formation has shown to be impaired following Noxo1 inactivation 
mutations (Kiss et al., 2006). This suggests a constructive developmental role for 
NOX3-derived ROS. Contradictory results exist regarding the involvement of Rac in 
NOX3 activation (Ueyama et al., 2006, Miyano et al., 2006) affirming the complexity 
in the regulation of NOX enzymes.  
 
1.7.4 NOX4 
The NOX4 isoform was first discovered in the kidney and it is the tissue with the 
highest expression, with lower levels reported in skeletal muscle, endocrine tissue 
and lungs (Bedard and Krause, 2007). The catalytic component of NOX4 requires the 
binding of p22phox for successful ROS generation, independent of other 
conventional NOX subunits. NOX4 has been shown to preferentially produce H2O2, 
as approximately 90% of the electron flux through isolated Nox4 produces H₂O₂ and 
only 10% forms O2- (Nisimoto et al., 2014). NOX4 exhibits constitutive activity, 
enabling NOX4-derived ROS to elicit long-lasting and adaptive effects. As a result, it 
has long been thought to be predominantly regulated by transcription, although 
there is evidence to suggest that it may be subject to acute activation by a range of 
stimuli also (Manea et al., 2015). While NOX4 does not rely on conventional NOX 
subunits for its activity, some modulators of NOX4 have been suggested including 




Poldip2 is highly expressed in skeletal muscle and may function to stabilise and 
regulate the NOX4-p22phox complex (Lyle et al., 2009). The interaction of Poldip2 
with p22phox results in a 3-fold increase in NOX4 activity in vascular smooth muscle 
cells (VSMCs) (Lyle et al., 2009). TSK5 has also been suggested to be a regulatory 
protein required for ROS production by NOX4 in certain cells. NOX4 contains a 
p47phox binding domain and TSK5 is structurally similar to p47phox, deducing its 
possible interaction with the enzyme complex (Diaz et al., 2009). The information 
regarding Rac is controversial, however there is potential for its role in NOX4 
activation as an inhibition of Rac by knockdown in mesangial cells prevents a NOX4-
dependent increase in ROS (Gorin et al., 2003). Additionally, reports suggest that 
since there is no Rac binding site on NOX4 it may function through an alternative 
mechanism. An increase in ROS, with a concomitant increase in NOX4 and Rac in 
VSMCs is prevented by knockdown of NOX4 or inactivation of Rac (Meng et al., 2008). 
Additionally, there was no evidence for a direct interaction between NOX4 and Rac, 
suggesting that Rac may function through alterations to the cytoskeleton, which 
change the supply of NADPH to NOX4 or alter its intracellular location.  
 
NOX4 contains a mitochondria localisation sequence and as such, has been identified 
in the mitochondria of cardiac (Ago et al., 2010) and skeletal muscle (Sakellariou et 
al., 2013), more specifically in the SR and t-tubules of the latter (Loureiro et al., 2016). 
The expression and activity of NOX4 have been shown to be induced by cytokines, 
transforming growth factor β (TGFβ), angiotensin and hypoxia. NOX4 plays a pivotal 
role in the response to hypoxia by functioning as an O2 sensor as it possesses an 
unusually high Km for oxygen (∼18%). This is similar to that of known oxygen-sensing 
enzymes which enables it to generate H2O2 as a function of PO2 (Nisimoto et al., 
2014). Hypoxia rapidly enhanced the mRNA and protein expression of NOX4 in 
pulmonary vessels, an effect which was abrogated following mutation of the hypoxic 
response element of NOX4 (Diebold et al., 2010). Hypoxia-induced vascular 
remodelling and pulmonary hypertension have been shown to be associated with 
increased levels of NOX4 and p22phox (Nisbet et al., 2009). NOX4 expression has also 
been shown to be positively regulated by O2 tension. An increase in NOX4-derived 
H2O2 has been shown to be coupled to an increased oxidation of cysteine residues of 
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RyRs in isolated SRs, cultured myofibres and intact muscle. This produced an increase 
in Ca2+ release and enhanced muscle contraction, thus implicating a role for NOX4 in 
muscle performance in response to changes in PO2 (Sun et al., 2011b). Additionally, 
it has recently been demonstrated that NOX4 can be regulated by ATP levels due to 
its ATP-binding motif (Shanmugasundaram et al., 2017). ATP has the capacity to 
directly bind and negatively regulate NOX4 activity, suggesting that NOX4 can serve 
as a metabolic sensor and become activated with decreased mitochondrial ATP 
levels, which may be important in the response to exercise. Indeed, studies in NOX4 
deficient mice demonstrates that H2O2 and NOX4 are necessary to promote the 
immediate response to exercise in skeletal muscle as glucose and fatty acid oxidation 
were notably blunted in NOX4 deficient mice, possibly through the regulation of 
UCP3 (Specht et al., 2021). This study points to NOX4 as a major source of ROS 
responsible for initiating metabolic signalling, pivotal in skeletal muscle adaptation 
to exercise (Specht et al., 2021). 
 
Similar to NOX2, higher NOX4 expression and activity has been identified in slow 
twitch fibres compared to fast twitch fibres (Loureiro et al., 2016). Furthermore, 
higher levels of NOX4 have been observed in the diaphragm compared to limb 
muscles (Frye et al., 2012). NOX4 abundance and activity may therefore be based on 
muscle fibre-type composition or the recruitment pattern of specific muscles. 
However, exercise-induced adaptations of skeletal muscle, including alterations to 
muscle metabolism or muscle fibre-type composition occur independently of NOX4 
(Vogel et al., 2015). Diaphragm muscle dysfunction is a key component of the 
ventilatory abnormalities that are part of the integrative pathophysiology of CHF. An 
increase in NOX4-related subunits and levels of protein carbonyls have been 
implicated in diaphragm muscle weakness in patients with CHF (Ahn et al.). 
Additionally, spinal cord injury (SCI) results in marked atrophied and dysfunctional 
skeletal muscle.  An increase in NOX4 mRNA and protein in limb muscle has been 
shown to be associated with enhanced binding of Nox4 to RyR1, increased oxidation 
and nitrosylation of RyR1, culminating in reduced muscle force in SCI rats (Liu et al., 
2017). Indeed, NOX4 has been reported to increase oxidative stress on skeletal 
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muscle RyRs in metastases, thus inducing skeletal muscle weakness in breast cancer 
(Regan et al., 2017).  
 
1.7.5 NOX5  
NOX5 is a O2- generating enzyme that is structurally unique and deemed distantly 
related to other members of the NOX family, as it contains NH2-terminal EF-hand 
motifs, which possess four Ca2+ binding sites that are essential for its activation. 
Therefore, this isoform of NOX requires no association with additional subunits for 
its activation, but rather is Ca2+-dependent. An increase in Ca2+ binding induces a 
conformational change in the EF-hand motifs, exposing its catalytic site and enabling 
the transfer of electrons from NADPH to O2 to form O2- (Banfi et al., 2004b). It is the 
most recent of the conventional NOX enzymes to be identified and was first located 
in human testes, lymph nodes and spleen (Bánfi et al., 2001). The absence of NOX5 
from the rodent genome has significantly impaired the understanding of its structure 
and mechanism of action and as a result most of the knowledge surrounding this 
isoform comes from human tissues and overexpression studies.  
 
NOX5 expression has been demonstrated in the vasculature, heart and kidneys 
highlighting its possible implication in cardiovascular disease, as renal function is 
impaired and blood pressure elevated in mice expressing human NOX5 (Chatterjee 
et al., 2015). Oxidative stress associated with hypertension can affect vascular 
function through the post-translational oxidative modification of cysteine residues in 
proteins central to vascular redox signalling (Montezano et al., 2015). Therefore, this 
is suggested to influence the cellular response to oxidative stimuli by promoting a 
proliferative rather than contractile phenotype as an example of vascular 
remodelling, eventually predisposing the system to dysfunction. The mechanisms of 
NOX5-derived ROS are only newly emerging, but it is plausible to suggest that it may 
have implications for oxidative stress-induced hypertension commonly observed in a 
range of disease states.  
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1.7.6 DUOX1 and DUOX2  
Dual oxidase 1 (DUOX1) and dual oxidase 2 (DUOX2) both encompass the traditional 
catalytic core subunit associated with NOX enzymes, but also have an intracellular 
domain containing two EF-hand motifs comprising of Ca2+ binding sites. DUOX1 and 
DUOX2 are activated independent of an association with other cytosolic subunits. 
However, they do require the maturation proteins DUOXA1 and DUOXA2 to enable 
their preferential localisation to the plasma membrane from the endoplasmic 
reticulum (Rigutto et al., 2009). Both DUOXs were initially identified as a source of 
H2O2 necessary for thyroid hormone biosynthesis with Ca2+ shown to trigger an 
increased ROS production in human thyroid cells and bronchial epithelial cells (De 
Deken et al., 2000, De Deken et al., 2002).  Bi-allelic inactivating mutations in the 
DUOX2 gene results in a complete disruption of thyroid hormone synthesis 
characterised by severe and permanent hypothyroidism in patients, confirming the 
pivotal contribution of DUOX2 to homeostatic thyroid function (Moreno et al., 2002). 
However, the overexpression of DUOX1 in the thyroid yielded a delayed but 
sustained increase in ROS in response to ionising radiation with evidence of DNA 
damage (Ameziane-El-Hassani et al., 2015), an effect that may promote secondary 
malignancies following radiation treatment. Interestingly, pre-treatment with 
catalase abrogated these effects.  
 
Transfection of skeletal muscle myoblasts with DUOXA1 has been shown to increase 
levels of H2O2 and apoptosis, with siRNA knockdown ameliorating this effect 
(Sandiford et al., 2014).  Additionally, both dual oxidases have been characterised in 
hind leg skeletal muscle of rats, with their physiological function in this instance 
unknown (Sun et al., 2011a). DUOXs have been located at the apical side of the 
airway and digestive tract suggesting that these enzymes also function in the 
traditional NOX role of innate host defence against pathogens (Rigutto et al., 2009). 
While incorporating similar homologies, DUOX1 and DUOX2 appear to function 
differentially, possibly due to a divergence in their regulation. It has been reported 
that DUOX1 is positively regulated by cAMP-dependent protein kinase A (PKA) while 
DUOX2 is highly induced by protein kinase C (PKC) (Rigutto et al., 2009).  
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1.7.7 NOX inhibitors  
The most promising approach in the development of therapeutic strategies against 
oxidative stress is by identifying disease-relevant enzymatic sources of ROS, targeting 
these selectively, while leaving physiological ROS signalling through other sources 
intact.  NOX enzymes have been identified as the main potential drug-target 
candidates in diseases associated with dysfunction in ROS signalling. NOX enzymes 
stand out as their sole function is to produce ROS, whereas the majority of 
enzymatic sources produce ROS as a by-product or upon biochemical uncoupling or 
damage.  
 
A range of small molecules have long been thought to inhibit NOX activity, however, 
the majority have been identified as non-specific due to off-target effects. The most 
traditional and well-studied of these molecules include, diphenyleneiodonium (DPI) 
and apocynin. DPI is a flavoprotein inhibitor and thus inhibits many other enzymes 
besides NOX, which may result in an over-scavenging of ROS. Similarly, while 
apocynin is reported to inhibit the translocation of p47phox to the plasma 
membrane, thus inhibiting NOX2 activity, non-specific ROS scavenging properties 
have also been observed (Altenhöfer et al., 2015). However, even the most advanced 
NOX inhibitors in development, setanaxib and GKT136901, have been shown to 
exhibit ROS scavenging activities (Augsburger et al., 2019, Dao et al., 2020). Thus, it 
has been suggested that a panelled approach may be beneficial in assessing the 
target specificity of NOX inhibitors given the importance of NOX-dependent redox 
signalling in physiological homeostasis across tissues (Dao et al., 2020).  
 
The World Health Organisation (WHO) has recently recognised NOX inhibitors as a 
new therapeutic class, which hold significant potential for the treatment of fibrotic, 
inflammatory, neurodegenerative and oncological disorders. GKT137831 (setanaxib 
or GKT-831), claimed to be a NOX1/4 dual inhibitor and a partial NOX5 inhibitor, was 
the first NOX inhibitor to reach the clinical trial stage (Wiesel et al., 2012).  Phase II 
clinical trials using GKT137831 are ongoing for the treatment of idiopathic pulmonary 
fibrosis and kidney disease in patients with type 1 diabetes. Additionally, Ewha-18278 
(APX-115) has been shown to inhibit NOX1, NOX2, and NOX4 in pre-clinical studies 
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(Cha et al., 2017). Moreover, this NOX inhibitor is currently moving from Phase I to II 
in clinical trials for patients with diabetic kidney disease (Lee et al., 2020).  
 
NOX inhibitors have also shown some efficacy in other pre-clinical models of disease. 
GKT137831 induced favourable effects in models of ischaemic retina disease and 
diabetic retinopathy (Appukuttan et al., 2018, Jiao et al., 2019), hypertensive cardiac 
remodelling and hypertrophy (Zeng et al., 2019) and liver fibrosis (Sun et al., 2017). 
VAS2870, a pan NOX inhibitor, has demonstrated vascular protective effects in 
models of pulmonary hypertension (Li et al., 2019) and Alzheimer’s disease 
(Abubaker et al., 2019). Additionally, ML090, which has preferential activity toward 
NOX5, was beneficial in models of stroke (Casas et al., 2019, Dao et al., 2020). 
Collectively, NOX inhibition seems to represent a promising therapeutic strategy with 
a wide scope of clinical applications.  
 
1.8 Obstructive sleep apnoea syndrome (OSAS)  
OSAS is a common respiratory disorder affecting at least 4% of men and 2% of women 
worldwide (Lee et al., 2008). It represents the most prevalent form of sleep 
disordered breathing (SDB) recorded in ~85% of all SDB cases (Ho and Brass, 2011). 
Predisposition to OSAS is multifactorial, however abnormal airway anatomy remains 
a central feature of this disorder, with both congenital and acquired factors affecting 
the size of the pharyngeal airway. Although OSAS can affect individuals 
indiscriminately, numerous risk factors including obesity (BMI > 30) (Romero-Corral 
et al., 2010), family history, age, hypertension  (Al Lawati et al., 2009) and smoking  
(Lin et al., 2012) have been identified. 
 
1.8.1 Pathophysiology of OSAS  
More than 20 UA muscles work harmoniously to regulate UA patency and prevent 
airway collapse. The pharynx lacks bony and cartilaginous support resulting in greater 
susceptibility to collapse (White and Younes, 2012). This is especially true during 
inspiration, as the diaphragm and accessory inspiratory muscles contract to produce 
a sub-atmospheric (negative) pressure in the UA. This results in reflex activation of 
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pharyngeal dilator muscles to ensure protection of airway patency on a breath-by-
breath basis, as well as functioning to restore airflow following pharyngeal collapse. 
However, when the negative pressure produced by the diaphragm exceeds the 
dilative force-generating capacity of the UA muscles, airway occlusion occurs. The 
resultant apnoea is described as a cessation of external breathing (airflow) for more 
than 10 seconds (Eckert et al., 2009). The severity of OSAS is clinically quantified by 
the apnoea-hypopnoea index (AHI) i.e. the number of apnoeas and hypopneas per 
hour of sleep due to recurrent collapse of the upper airway, with severe OSAS 
patients experiencing more than 30 apnoeic events per hour during sleep (Olson et 
al., 2003, Crummy et al., 2008).  
 
Upon airway collapse, a fall in PO2 and increase in PCO2 is sensed by the carotid body 
and central chemoreceptors, respectively, to produce an increased ventilatory effort. 
However, arousal from sleep is typically necessary to re-establish airway patency and 
normal ventilation, resulting in hazardous levels of daytime hypersomnolence (Ward 
et al., 2013). The repetitive collapse of the UA begets recurrent waves of hypoxia 
(with concomitant arterial oxygen desaturation) and subsequent re-oxygenation 
upon airway re-opening. This results in the hallmark feature of OSAS, chronic 
intermittent hypoxia (CIH). CIH is widely considered to be the driving force behind 
the development and maintenance of a range of morbidities reported in patients 
presenting with OSAS. The detrimental effects are likely attributable to CIH-induced 
oxidative stress, extensively shown to be produced following repeated hypoxia/re-
oxygenation cycles throughout the night cycle (Lavie, 2003).  
 
UA collapse in OSAS is likely to be multifactorial as CIH-induced mal-adaptation 
presents at multiple levels of the respiratory control system. This includes respiratory 
muscle weakness and fatigue (Clanton et al., 2001, McGuire et al., 2002a, McGuire 
et al., 2002b, McGuire et al., 2003a, Liu et al., 2005, Pae et al., 2005, Liu et al., 2009, 
Skelly et al., 2012b, Skelly et al., 2013, Shortt et al., 2014, Shortt and O'Halloran, 2014, 
McDonald et al., 2015) impaired motor control of the upper airway (O'Halloran et al., 
2002, Veasey et al., 2004, Ray et al., 2007) and discordant respiratory rhythm and 
pattern generation (Peng et al., 2003, Reeves and Gozal, 2006, Edge et al., 2012, 
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Moraes et al., 2013, Donovan et al., 2014, Souza et al., 2015, Elliot-Portal et al., 2018, 
Joseph et al., 2020). This highlights the potential for CIH-induced oxidative stress to 
exacerbate OSAS, perpetuating a vicious cycle of respiratory morbidity. OSAS is a 
highly underdiagnosed disease associated with a plethora of co-morbidities beyond 
that of the respiratory system, thus elevating its status to that of a major public 
health risk (Lavie, 2009). The range of maladies is widespread with evidence for 
neurocognitive (Al Lawati et al., 2009), metabolic (Drager et al., 2011), cardiovascular 
(Dumitrascu et al., 2013), testicular (Torres et al., 2014), hepatic (Savransky et al., 
2007), renal (Rosas, 2011) and pancreatic (Wang et al., 2013a) disorders.  
 
1.8.2 Current treatments  
At present, the gold standard treatment for severe OSAS is the application of 
continuous positive airway pressure (CPAP) during sleep, which pneumatically 
stabilises the upper airway (Becker et al., 2003). However, there is only ~50% 
compliance with this current line of treatment, as patients frequently report 
claustrophobia, facial discomfort, throat dryness, nasal and eye pain (Wolkove et al., 
2008). Oral appliances, categorised into tongue retaining devices and mandibular 
advancement devices (MADs), are commonly used and more efficacious in patients 
with a mild-to-moderate form of OSAS, but are also utilised in instances of severe 
OSAS when CPAP is poorly tolerated. These appliances aim to improve UA patency 
during sleep by enlarging the UA or by decreasing UA collapsibility (Gagnadoux et al., 
2009). Surgical treatments aimed at reducing the obstruction caused by anatomical 
features that may predispose to OSA such as the retroposition of the mandible, 
enlarged pharyngeal fat pads, enlarged soft palate, enlarged tongue, narrow 
posterior airway space, and UA hypotonia have shown some success, but may not 
represent a true clinical cure (Pavwoski and Shelgikar, 2017). Experiments utilising 
hypoglossal nerve stimulation, to protrude the tongue, thus opening the pharyngeal 
airway and ensuring patency have shown some promise (Kezirian et al., 2014). 
Hypoglossal nerve stimulation has been shown to successfully reduce the AHI index 
by 68% (Strollo et al., 2014), with this magnitude of improvement persisting for 3 
years post-treatment in patients with moderate-to-severe OSAS (Woodson et al., 
2016). However, hypoglossal nerve stimulation is not deemed a viable treatment 
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option for patients with a BMI > 32 and those with concentric retropalatal collapse 
(Strollo et al., 2014). Transcranial magnetic stimulation has also shown some early 
signs of promise as a drug-free treatment (Bradford, 2013), but this may only hold 
true for a subset of OSAS patients. Studies investigating the role of drug therapy in 
reducing the severity of OSAS by increasing UA muscle tone, ventilatory drive, 
cholinergic tone, arousal threshold or reduction in the proportion of paradoxical 
(REM) sleep remain largely inconclusive (Mason et al., 2013). Thus, the development 
of specific antioxidants which may serve as an adjunct therapy by ameliorating 
excessive levels of ROS, central to respiratory morbidity in OSAS, are of great interest.  
 
1.9 Animal models of OSAS 
1.9.1 Spontaneous models  
The English bulldog represents the first natural model of sleep disordered breathing 
(Hendricks et al., 1987). This model is characterised by abnormal upper airway 
anatomy encompassing an enlarged soft palate, narrow oropharynx and innate 
tendency to snore. The relative area of fast fibres is increased in the UA musculature 
of this model (Petrof et al., 1994), similar to observations in human OSAS patients 
(Smirne et al., 1991), consistent with airway dilator muscle fatigue. Studies examining 
this model reveal disordered ventilation, O2 desaturations to less than 90% and 
central and obstructive apnoeas during REM sleep, leading to daytime 
hypersomnolence at levels ~10 times greater than those observed in controls. The 
understanding of the effect of SDB on respiratory muscle activation was significantly 
increased arising from experiments utilising this model, which demonstrate a 
significantly reduced respiratory drive to the diaphragm (suppressed to 42% of its 
original drive) and sternohyoid (suppressed to 17% of its original drive) muscles at 
the onset of SDB during REM sleep (Hendricks et al., 1991). Serotonin (5-HT) has been 
implicated in the pathogenesis of OSAS. At high doses, ondansetron, a 5-HT 
antagonist, reduced the respiratory disturbance index (RDI) in the English bulldog 
model during REM sleep, with no observable effect on sleep efficiency or 
oxyhaemoglobin saturation (Veasey et al., 2001). Studies in extremely obese Yucatan 
miniature pigs have shown oxyhaemoglobin desaturations with concomitant 
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obstructive and central apnoeas during REM sleep, thus highlighting the central role 
of obesity as a major risk factor in the elaboration of severity of OSAS (Lonergan et 
al., 1998). Similarly, a smaller pharyngeal airway cross-sectional area during both 
inspiration and expiration and a reduction in the increase in airway area during 
inspiration has been observed in obese Zucker rats (Brennick et al., 2006). These 
mechanical abnormalities were attributed to fat infiltration in the tongue, similar to 
that observed in OSAS patients.  
 
1.9.2 Surgical models  
Animal models of OSAS can also be experimentally induced through surgical 
methods, by mechanically occluding or altering the UA. Studies utilising this model 
of OSAS have been used in a range of animals including dogs (Kimoff et al., 1997), 
baboons (White et al., 1995), pigs (Chen and Scharf, 2000) and rats (Fletcher et al., 
1992). Typically, this involves the use of tracheotomy with intermittently occluding 
endotracheal tubes. A computer controls the sequence of events which begins with 
an UA obstruction due to the valve of the tracheotomy closing at the onset of sleep. 
Once the animal is aroused from sleep, the valve opens, and the pharyngeal collapse 
is recovered. These models are highly valuable as they are widely accepted to closely 
mimic the events of OSAS in humans and enable the precise control of the frequency 
of apnoea occurrence as well as their relative severity i.e. duration. These models 
allow the analysis of a comprehensive range of factors critical for understanding the 
underlying pathology of OSAS including arousal from sleep, intrathoracic pressure, 
length of apnoeas and oxygen desaturations. However, these models are labour-
intensive, with concomitant low throughput, rendering them quite demanding for 
use in the study of OSAS. 
 
1.9.3 Intermittent hypoxia models  
IH is a central feature of OSAS and so the exposure of animals to repetitive 
intermittent cycles of hypoxia interspersed with normoxia, modelling the arterial 
hypoxaemia experienced by OSAS patients due to airway collapse, has become one 
of the most widely used models of SDB. IH is widely considered to be one of the most 
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noxious stimuli of OSAS, as well as being easily adjusted to induce varying degrees of 
severity of OSAS (Mesarwi et al., 2015).  A system to deliver hypoxic gases to rodents 
in a cyclical pattern reminiscent of the oxygen profile observed in severe OSAS was 
developed in the early 90s (Fletcher et al., 1992), resulting in rats developing 
hypertension through a mechanism reliant upon reflex sympathetic overactivity 
following IH exposure for 3 weeks during their sleep phase. IH models minimise the 
invasive aspect of surgical experimental models while also enabling a higher 
experimental throughput. IH-reoxygenation paradigms have been employed in 
humans (Tamisier et al., 2009) and more extensively in rodents (Farré et al., 2018). 
Rodents are exposed to IH during the diurnal period during sleep and are 
subsequently returned to normoxic room air for night hours during wakefulness, in 
an attempt to mimic the pattern of human exposure in OSAS.  
 
The pattern, duration and intensity of IH exposure is pivotal in determining 
phenotypical responses in the respiratory and other systems (Reeves and Gozal, 
2006, Morgan et al., 2016a). Interestingly, several experiments have demonstrated 
beneficial effects of IH. Animals exposed to acute bouts of IH become more resistant 
to damage associated with exposure to severe hypoxic paradigms (Almendros et al., 
2014). Mice treated with acute and brief episodes of IH, lasting for several hours 
and/or days with mild hypoxia (>12% FiO2) survive longer when subsequently 
exposed to severe IH, characterised by <12% FiO2. This suggests that by utilising a mild 
hypoxia paradigm, animals develop protective and adaptive mechanisms. This form 
of preconditioning is based on the principle that applying potentially deleterious 
stimuli near or just below the threshold of damage enables tissues and organs to 
become resistant to the same noxious stimuli, thus reducing or even preventing IH-
induced injury (Peng et al., 2003). Short-term exposure to IH comprising of 3-10 
cycles for 1-2 hours/day results in a form of respiratory motor plasticity, known as 
long-term facilitation (LTF) and results in an increase in the strength of respiratory 
muscle contractions and ventilation (Dale et al., 2014). Additionally, these acute 
hypoxia paradigms have been shown to upregulate hypoxia-sensitive growth/tropic 
factors within respiratory motor neurons resulting in an increased phrenic, 
hypoglossal and carotid sinus nerve discharge both in humans (Xing et al., 2013) and 
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animals (Mahamed and Mitchell, 2007). Thus, acute bouts of mild hypoxia may have 
relevance as a therapeutic strategy in certain disease states (Navarrete-Opazo and 
Mitchell, 2014).  
 
However, OSAS is a chronic condition and when IH is administered over a long period 
of time it is termed CIH. The conventional settings used for applying IH to animals 
include two major parameters: the frequency and severity of hypoxic events. When 
IH is administered over a chronic period, at a moderate-to-severe dose and at a high 
frequency, mal-adaptative outcomes tend to occur, with deleterious consequences 
for integrative body systems. Typically, animals are subjected to CIH involving the 
cyclical change of the oxygen fraction (FiO2) in the gas breathed by the animals from 
room air (FIO2 - 21%) to nadir values ranging from FIO2 of 4 to 15%, over a time period 
of days, weeks, or months, which results in a concomitant decrease in O2 saturation 
ranging from 60-80%, values comparable to humans presenting with moderate-to-
severe OSAS (Lim and Pack, 2014).  
 
These models produce different degrees of hypoxia severity, yielding dose-response 
effects (Lim et al., 2016, Gallego-Martin et al., 2017, Docio et al., 2018). Additionally, 
setting the frequency of IH allows a calibration, albeit possibly loose, to the clinical 
AHI observed in polysomnographic studies of patients with OSAS. Studies in animal 
models have utilised varying rates of hypoxic events, to mimic a wide range of AHI, 
e.g., from the high event rates in severe OSAS patients (60 events/h) to occasional 
events in patients with a mild form of the disorder (2 events/h) (Gozal et al., 2001, 
Almendros et al., 2013). There is extensive experimental and epidemiological 
evidence that the oxidative stress and inflammatory response generated at both 
systemic and tissue levels by the recurrent hypoxia-reoxygenation events over a 
longer period of time are major drivers underlying clinically-relevant morbid 
consequences of OSAS (Lavie, 2015). These include, but are not confined to, 
increased risk of cardiovascular, metabolic, neurocognitive and malignant diseases 
(Lévy et al., 2015). Evidence from experimental models for the role of CIH-induced 
mal-adaptation at multiple levels of the respiratory control is discussed in detail in 
the next section.  
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1.10 Chronic Intermittent hypoxia and the respiratory control system  
Exposure to CIH drives a pro-oxidant state resulting in aberrant plasticity at multiple 
levels of the respiratory control system, thus accounting for the devastating clinical 
consequences of OSAS. Mal-adaptive remodelling culminates in alterations to 
respiratory rhythm and pattern generation (Peng et al., 2003, Reeves and Gozal, 
2006, Edge et al., 2012, Moraes et al., 2013, Donovan et al., 2014, Souza et al., 2015, 
Elliot-Portal et al., 2018, Joseph et al., 2020), impaired motor control of the upper 
airway (O'Halloran et al., 2002, Veasey et al., 2004, Ray et al., 2007) and respiratory 
muscle weakness (Clanton et al., 2001, McGuire et al., 2002a, McGuire et al., 2002b, 
McGuire et al., 2003a, Liu et al., 2005, Pae et al., 2005, Liu et al., 2009, Skelly et al., 
2012b, Skelly et al., 2013, Shortt et al., 2014, Shortt and O'Halloran, 2014, McDonald 
et al., 2015). Therefore, specific antioxidant strategies may have application as an 
adjunctive treatment in OSAS and other respiratory conditions characterised by 
exposure to CIH.  
 
1.10.1 CIH and impaired motor control of the upper airway  
Muscles of the UA play a critical role in the maintenance of airway calibre and in the 
alleviation of obstructive events. However, in certain instances, this control is 
compromised and the airway becomes unstable (O'Halloran et al., 2002). O’Halloran 
et al. (2002) were the first to show that exposure to CIH impairs reflex control of UA 
muscle activity in vivo. Exposure to CIH significantly reduced sternohyoid EMG 
responsiveness during acute hypoxic and asphyxic challenges, with no alteration to 
diaphragm EMG responses. This selective impairment of motor drive to the UA 
muscle may perpetuate a vicious cycle of events to exacerbate the likelihood of 
further airway collapse. An assessment of the critical closing pressure of the pharynx 
(Pcrit) is considered a clinically relevant ‘gold standard’ measurement of airway 
collapsibility. 12 weeks of exposure to CIH in rats has been shown to cause a more 
positive pharyngeal pressure associated with collapse (Pcrit) (Ray et al., 2007). This 
increased collapsibility of the airway was not attributable to changes in musculature 
of the UA as measured by MHC composition. Rather, it is suggested to be due to an 
alteration in the neurological mechanisms controlling the UA, and specifically the 
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serotonergic system. Exposure to CIH has been shown to reduce the excitability of 
the hypoglossal motor nerve which innervates dilator muscles of the pharynx. 
Administration of tempol, a superoxide dismutase mimetic, ameliorated CIH-induced 
impairment (Veasey et al., 2004). However, 7 days of exposure to CIH was insufficient 
to  alter genioglossus electromyograph (EMG) responses to airway occlusion in rats 
(Edge et al., 2014).  Interestingly, the same CIH paradigm induced breathing 
instability in sleeping rats as evidenced by an increased spontaneous apnoea index 
(Edge et al., 2012). Administration of the superoxide dismutase mimetic, tempol, or 
the NOX inhibitor, apocynin, prevented the CIH-induced increase in the propensity 
for apnoea. This further highlights the role of oxidative stress, which may be NOX2-
derived, in CIH-induced respiratory plasticity.  
 
1.10.2 CIH and impaired respiratory control  
The respiratory control system has the ability to exhibit considerable plasticity, 
similar to that observed in many other neural networks. Plasticity can be defined as 
a persistent change in a neural control system based on a prior experience, which 
may involve structural and/or functional alterations (Mitchell and Johnson, 2003).  
Challenges to the respiratory control system elicit alterations which are adaptive in 
nature in order to maintain respiratory homeostasis i.e. optimal blood gas and pH 
levels. However, the determination of whether neuroplasticity presents as 
adaptative or mal-adaptive is largely based on the pattern, duration and intensity of 
the stimulus (Baker and Mitchell, 2000, Peng and Prabhakar, 2004), as well as the 
timing of the perturbation throughout life (Gozal et al., 2001). Hypoxia-induced 
plasticity, which has clinical relevance to OSAS, is one of the best studied forms of 
respiratory plasticity. Indeed, both adaptive and mal-adaptive alterations in 
respiratory control have been demonstrated following intermittent hypoxic 
exposure in humans and animal studies (Bradford et al., 2005, Mahamed and 
Mitchell, 2008).  
 
Long-term facilitation is characterised by a progressive increase in respiratory motor 
output during or following exposure to IH (Baker and Mitchell, 2000, Mahamed and 
Mitchell, 2007). Sensory and motor plasticity is well described in rodents following 
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exposure to CIH (Peng et al., 2001, Peng et al., 2003, MacFarlane and Mitchell, 2008, 
MacFarlane et al., 2009, Edge et al., 2009, Edge et al., 2012). Exposure to CIH can 
evoke sensory long-term facilitation within the carotid body (Peng et al., 2003), and 
induce facilitation of breathing or altered chemoreflex control of breathing (Reeves 
and Gozal, 2006, Skelly et al., 2012b, Morgan et al., 2016b, Elliot-Portal et al., 2018). 
Recent evidence highlights the role of NOX2 as a potential source of ROS underlying 
sensory and motor plasticity at multiple sites of the respiratory control network 
(Peng et al., 2006a, Peng et al., 2009, MacFarlane et al., 2009, Peng et al., 2011, 
MacFarlane et al., 2014, Perim et al., 2018). 
 
Ventilatory adaptation is a form of respiratory plasticity described as a persistent 
increase in normoxic ventilation following exposure to IH. This likely represents a 
chemoreflex-driven increase in sympathetic outflow and breathing that contributes 
to systemic hypertension and respiratory instability in OSAS patients (Marcus et al., 
2010). Ventilatory adaptation following exposure to CIH has been demonstrated in 
rats (Reeves and Gozal, 2006, Skelly et al., 2012b). In contrast, exposure to CIH had 
no effect on resting ventilation in guinea pigs (Lucking et al., 2018), rats (McGuire et 
al., 2003b, Edge et al., 2012, Souza et al., 2015, Joseph et al., 2020) and mice (Elliot-
Portal et al., 2018). This may be explained by variations in the intensity of the IH 
stimulus employed. Indeed, ventilatory adaptation to intermittent hypoxia (VAIH) 
has been reported in rats following 30 (Reeves and Gozal, 2006) and 21 days of 
treatment (Morgan et al., 2016a), with the duration and paradigm of IH exposure 
appearing pivotal in determining the phenotypical respiratory response. Exposure to 
CIH has been shown to result in a decrease in metabolic rate in rat models (Morgan 
et al., 2016a, Joseph et al., 2020). Morgan et al., (2016a) emphasise the importance 
of assessing metabolic rate in concert with respiratory recordings, to account for the 
decrease in metabolic rate that occurs when small mammals are acutely exposed to 
hypoxia (Frappell et al., 1992). This is an especially crucial consideration in mouse 
models, as mice exhibit greater hypometabolic effects of hypoxia than rats 
(Jochmans-Lemoine et al., 2015). A failure to report on metabolic measures can 
potentially result in an over- or under-estimation of ventilatory responsiveness 
(Morgan et al., 2016a). These observations stress the importance of incorporating 
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metabolic measures when examining ventilation in animal models of OSAS and other 
diseases characterised by respiratory disturbance such as DMD (Burns et al., 2017). 
 
Exposure to CIH has been shown to modulate respiratory chemoreflex responses to 
hypoxia and hypercapnia (Greenberg et al., 1999, Peng et al., 2003, Morgan et al., 
2016a, Elliot-Portal et al., 2018, O'Connor et al., 2019), consistent with observations 
in OSAS. The functional significance of altered responses to these acute challenges is 
divergent. Respiratory mal-adaptation may present in an apnoeic patient when an 
inability to respond to a perturbation with an appropriate ventilatory response 
results in chemoreflexes not holding the essential capability to terminate apnoeic 
events. Conversely, an ‘overshoot’ or exaggerated ventilatory response may serve to 
create respiratory instability by excessively removing CO2, thus reducing the CO2 
reserve toward the apnoeic threshold during sleep (Dempsey et al., 2010). 
Ventilatory responsiveness to hypoxia varies greatly depending on the pattern and 
duration of hypoxic exposure.  Augmented hypoxic ventilatory responses and 
concomitant oxidative stress have been observed in healthy individuals following 
exposure to CIH (Pialoux et al., 2009) and in patients with OSAS (Narkiewicz et al., 
1999). The ability for exposure to CIH to stimulate carotid body sensory facilitation is 
a well described phenomenon (Peng et al., 2001, Rey et al., 2004, Peng et al., 2006b). 
An enhancement (Reeves et al., 2003, Reeves and Gozal, 2004, Peng et al., 2006b, 
Julien et al., 2008, Morgan et al., 2016a, Elliot-Portal et al., 2018), depression (Reeves 
et al., 2006, Gonzalez-Martín et al., 2011, Olea et al., 2014, Lucking et al., 2018) or 
unchanged (Edge et al., 2009, Skelly et al., 2012b) hypoxic ventilatory response in 
intact animals has been reported across a range of species following treatment with 
a variety of IH paradigms.  
 
There is increasing interest in the role of oxidative stress in enhancing hypoxic 
chemosensitivity, but evidence surrounding the culpable source of ROS remains 
largely inconclusive. NOX subunits including p22phox, gp91phox, p47phox, and 
p67phox have been localised to type I cells of guinea pig, rat, and human carotid 
bodies (Kummer and Acker, 1995). Exposure to CIH significantly increases the mRNA 
expression of NOX1, NOX2 and NOX3 in peripheral chemoreceptors (Peng et al., 
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2009, Khan et al., 2011, Prabhakar et al., 2015). Moreover, there is ample evidence 
to suggest that CIH-induced sensory plasticity of the carotid body is NOX2-dependent 
(Peng et al., 2006a, Peng et al., 2009, Yuan et al., 2011, Nanduri et al., 2013b, Nanduri 
et al., 2015) CIH-induced increases in ventilatory responsiveness to hypoxia are 
attenuated in rats treated with apocynin, as evidenced by a reduction in VTE/VTCO2 
(Morgan et al., 2016b). This implicates ROS, which may be NOX2-derived in altered 
chemoreflex sensitivity following exposure to CIH. However, p47phox, but not 
gp91phox, knock-out alters the O2 sensing capability of the carotid body seen as a 
potentiated ventilatory and chemoreceptor response to hypoxia (Sanders et al., 
2002). This suggests that NOX subunits significantly differ in their complex regulatory 
function of respiratory control. Patch-clamp studies have demonstrated that intact 
neuroepithelial bodies (NEBs) in lung slice preparations from mice deficient in 
gp91phox, failed to respond to a hypoxic stimulus (Fu et al., 2000). This provides 
evidence indicating that the dysfunction of NOX disrupts the O2 sensing capability of 
the NEBs. Interestingly, no difference in the response to hypoxia between wild-type 
and gp91phox null mice has also been reported (Roy et al., 2000). This is attributed 
to no alteration in glomus cell functioning and a conclusion that although NOX is a 
major source of ROS, it does not function as an oxygen sensor in the carotid body. 
 
Although CO2 has a pivotal role in ventilatory control during sleep, there is a paucity 
of information examining the effects of exposure to CIH on hypercapnic sensitivity. 
Chemoreflexes are essential during sleep as a protective mechanism to stimulate 
arousal and subsequent termination of apnoeic events. Failure to do so may 
contribute to an increased propensity of apnoeic events, thus leading to an increased 
severity of OSAS. Conversely, an exaggerated response to CO2 contributes to 
ventilatory instability by reducing the CO2 reserve towards apnoeic threshold 
(Dempsey et al., 2010). An increase in the hypercapnic ventilatory response (HCVR) 
has been observed in OSAS patients, as a result of episodic hypoxia (Appelberg and 
Sundström, 1997, Khodadadeh et al., 2006). Indeed, a CIH-induced increase in the 
ventilatory response to hypercapnia has been reported in mice (Elliot-Portal et al., 
2018) and dogs (Katayama et al., 2007). Conversely, evidence supports an unaltered 
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hypercapnic ventilatory response following CIH in other rodents including guinea pigs 
(Lucking et al., 2018) and rats (Greenberg et al., 1999, Edge et al., 2012). 
 
Whilst obstructive apnoeas are the predominant apnoea type in OSAS patients due 
to collapse of the upper airway, central or spontaneous apnoeas also occur in 
patients due to a lack of ventilatory drive. This reveals a common overlap in 
obstructive and central sleep apnoea. OSAS patients receiving CPAP treatment 
regularly present with periodic breathing and central apnoeas, with some patients 
consequentially being diagnosed with complex apnoea (Morgenthaler et al., 2006). 
Complex apnoea in OSAS patients may be a result of CIH-induced remodelling in the 
central respiratory network governing respiration, serving to perpetuate the severity 
of OSAS (O'Halloran, 2016). It is well documented that exposure to CIH contributes 
to reduced respiratory stability that can manifest in rodents as increased apnoea 
index and increased variability of breathing (Edge et al., 2012, Souza et al., 2015, 
Elliot-Portal et al., 2018, Joseph et al., 2020). Exposure to CIH causes an increase in 
the propensity for central apnoea in neonatal rat pups (Julien et al., 2008), adult rats 
(Edge et al., 2012, Souza et al., 2015, Joseph et al., 2020) and mice (Elliot-Portal et 
al., 2018). Moreover, the CIH-induced increase in the frequency of spontaneous 
apnoeas in rats has been shown to be ameliorated by the administration of apocynin, 
thus implicating NOX2-derived ROS in the manifestation of increased apnoea index 
(Edge et al., 2012).  
 
A degree of breathing variability is normal and essential to enable the respiratory 
control system to be malleable enough to respond to various perturbations (Wuyts 
et al., 2011). Sighs, reportedly generated in the preBötC, hold an essential function 
in the normal respiratory cycle, by monitoring brain states, stimulating arousal and 
resetting breathing variability (Ramirez, 2014). An increase in sigh frequency during 
respiratory perturbations, such as hypoxia, stimulates an arousal, highlighting their 
critical role in survival. Failure to sigh or arouse has been implicated in sudden infant 
death syndrome (Garcia et al., 2013). However, an increase in sigh frequency can 
manifest as pathological when there is persistent and excessive breathing variability. 
In an attempt to regularise breathing variability, increased sigh generation could 
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further increase irregularity through the generation of post-sigh apnoeas. An 
increase in the frequency of post-sigh apnoeas can create conditions of IH and 
oxidative stress upon frequent sighing (Garcia et al., 2013, Ramirez et al., 2013), 
further exacerbating the severity of OSAS. Indeed, exposure to CIH has also been 
shown to increase the frequency of sighs and post-sigh apnoeas in rat models (Edge 
et al., 2012, Souza et al., 2015, Joseph et al., 2020). Additional assessments of 
respiratory stability through Poincaré plot analysis of respiratory timing in adult rats 
suggests that exposure to CIH produces an increase in short- and long-term breathing 
variability, resulting in changes in respiratory pattern (Souza et al., 2015). Conversely, 
studies in guinea pigs, which have hypoxia-insensitive carotid bodies, reveal a CIH-
induced decrease in indices of breathing variability (Lucking et al., 2018). This 
apparent dichotomy in results may relate to differences in sex, species and IH 
intensity and duration between experimental approaches, as well as actions at 
multiple sites of the respiratory control network. 
 
Respiratory neurons at multiple brainstem sites have key roles in generating 
homeostatic respiratory rhythm, with inspiratory neurons at the preBötC coming to 
the fore as key players in this process. Exposure to CIH has been shown to alter the 
electrophysiological properties of these neurons (Moraes et al., 2013) and 
respiratory circuits at the level of the preBötC, in turn affecting transmission to the 
hypoglossal motor nucleus leading to increased transmission failure to the 
hypoglossal nerve (Garcia et al., 2016). Furthermore, complete ablation of the 
preBötC increases the propensity for apnoea in sleeping rats (McKay and Feldman, 
2008). ROS are implicated in multiple forms of IH-induced plasticity, with H2O2 
capable of modulating rhythmogenesis by the preBötC (Garcia et al., 2011). Notably, 
antioxidant therapy has been shown to successfully reduce CIH-mediated 
irregularities of the network rhythm and improve transmission to the hypoglossal 
nerve (Garcia et al., 2016). Thus, exposure to CIH may promote a pro-oxidant state 
which destabilises rhythmogenesis originating from the preBötC. This may represent 
part of a central mechanism that promotes apnoea and respiratory instability. 
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1.10.3 CIH and respiratory muscle weakness  
UA dilator muscles are pivotal in the maintenance of airway patency. Impaired 
function of these striated muscles is a well-described contributor to perpetuated 
respiratory pathology in OSAS (Petrof et al., 1996, Bradford et al., 2005).  The 
structure and function of UA muscles is altered in patients with OSAS, with these 
functional deficits subsequently contributing to upper airway collapse (Sérlès et al., 
1996, Carrera et al., 1999). It was first demonstrated in the early 2000s that CIH, the 
hallmark feature of OSAS, alters respiratory muscle function. Studies examining the 
contractile function of the geniohyoid, a representative upper airway muscle, in rats 
revealed a CIH-induced increase in muscle fatigue (McGuire et al., 2002a, McGuire et 
al., 2002b, Bradford et al., 2005). A plethora of studies demonstrating CIH-induced 
muscle weakness and/or fatigue in representative UA muscles including the 
geniohyoid, genioglossus and sternohyoid, have since come to the fore (Liu et al., 
2005, Pae et al., 2005, Dunleavy et al., 2008, Liu et al., 2009, Jia and Liu, 2010, Ding 
and Liu, 2011, Skelly et al., 2012b, Wang et al., 2013b, Zhou and Liu, 2013, McDonald 
et al., 2015). Perhaps not surprisingly, outcomes are variable, with notable 
differences in the pattern and duration of the CIH employed in the studies, as well as 
differences in the sex and age used across models.  
 
CIH-induced UA muscle dysfunction has been demonstrated both in male and female 
rat pups (McDonald et al., 2015). However, there is evidence to suggest that the 
effects of exposure to CIH in adults are sex-specific, as sternohyoid muscle weakness 
has been demonstrated in male, but not female rats (Skelly et al., 2012b). If this CIH-
induced UA muscle weakness translates into an increased propensity for airway 
collapse, it may be reflective of the human condition, as male sex is an independent 
risk factor for the development of OSAS (Lin et al., 2008). Moreover, the 
administration of oestrogen prevents against CIH-induced genioglossus dysfunction 
in female rats. This highlights that female hormones may have a protective role 
against the deleterious effects of exposure to CIH on respiratory muscle function (Liu 
et al., 2009, Jia and Liu, 2010, Zhou and Liu, 2013). In addition, age-specific effects of 
exposure to CIH on respiratory muscle function have been described. The exposure 
of aged male rats to CIH revealed no effect on sternohyoid muscle force or endurance 
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(Skelly et al., 2012a). As this group have previously exhibited CIH-induced 
sternohyoid muscle weakness in adult male rats using the same CIH paradigm (Skelly 
et al., 2012b), the lack of an effect on contractile function in this instance was 
deemed a justified age effect, perhaps related to the confirmed increased glycolytic 
capacity in the upper airway muscles of aged rats. Exposure to CIH during neonatal 
development has also been shown to cause sternohyoid muscle weakness in male 
and female rats (McDonald et al., 2015). Moreover, this muscle dysfunction persists 
into young adult life following the return to normoxia, suggesting that there is a 
critical window during development where UA muscles are most susceptible to 
impairment, perhaps related to epigenetic modifications. The latter findings may 
have relevance to long-term cardiorespiratory outcomes in human infants with 
disordered breathing (e.g. apnoea of prematurity).  
 
There remains a paucity of information pertaining to the mechanisms underlying CIH-
induced UA muscle dysfunction. Shifts in the structural phenotype of UA muscles 
have been described in OSAS patients, which may underlie alterations to the 
functional output of these muscles (Sérlès et al., 1996, Ferini-Strambi et al., 1998). 
Indeed, fibre-type transitions from a slow-to-fast phenotype have been observed in 
human OSAS (Smirne et al., 1991), as well as in the English bulldog model of this 
disorder (Petrof et al., 1994). A relatively short duration of  exposure to CIH has been 
shown to be sufficient to induce a fibre-type transition to predominantly type 2b 
fibres in the geniohyoid and sternohyoid muscles, thus yielding a more fatigable 
muscle phenotype (Pae et al., 2005). While these fibre-type transitions may initially 
be adaptive in order to generate large forces necessary to maintain a patent airway 
in patients with compromised airway patency, it will eventually manifest as mal-
adaptive as UA muscles are more prone to fatigue, which likely contributes to 
recurring occlusive events. However, structural alterations to UA muscles, 
manifesting as fibre-type transitions and/or atrophy, are not obligatory for the 
development of CIH-induced muscle dysfunction. This is evident through a multitude 
of studies which report little to no alteration to UA muscle fibre-type composition or 
cross-sectional area following exposure to CIH (McGuire et al., 2002a, Skelly et al., 
2012b, McDonald et al., 2015). Succinate dehydrogenase (SDH), citrate synthase and 
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glycerol-3-phosphate (GPDH) activity, indices of oxidative and glycolytic capacity 
respectively, also remain unchanged in UA muscles following exposure to CIH (Skelly 
et al., 2012b, Skelly et al., 2012a, McDonald et al., 2015, Williams et al., 2015b). This 
provides further affirmation that some paradigms of CIH, sufficient to cause muscle 
weakness, result in no major alteration to the metabolic profile of the muscle, an 
effect that that is commonly seen following sustained hypoxia and may contribute to 
the deficits in the contractile function of muscle in this instance (O'Leary and 
O'Halloran, 2016, Lewis and O'Halloran, 2016).  
 
OSAS is widely considered to be an oxidative stress disorder with a strong link 
emerging between CIH-induced increases in ROS and impaired muscle function. A 
decrease in enzymes relating to antioxidant status including aconitase, glutathione 
reductase (GR), glutathione peroxidase (GPX), CAT and SOD have been reported in 
UA muscles following exposure to CIH (Ding and Liu, 2011, Williams et al., 2015b). 
This decrease in antioxidant capacity is suggestive of a modest oxidative stress or an 
imbalance in redox status, which may have mal-adaptive consequences for the force-
generating capacity of muscle. ROS-dependent UA muscle dysfunction occurs in the 
absence of overt oxidative stress, which is typically observed as increased protein 
oxidation or lipid peroxidation. Indeed, unaltered levels of protein thiols, carbonyls 
and 4-HNE have been reported in the UA muscles of various models of CIH (Williams 
et al., 2015b, McDonald et al., 2015), notwithstanding evidence of muscle 
dysfunction. While sustained hypoxia appears to enable the stabilisation of HIF-1α 
(Nguyen et al., 2016), fewer studies have observed HIF-1α stabilisation in skeletal 
muscle during IH. This is possibly due to transient stabilisation as a result of 
alternating periods of hypoxia followed by re-oxygenation. Indeed, exposure to CIH 
yielded no change in HIF-1α protein content in the sternohyoid muscle (Williams et 
al., 2015a).  
 
Antioxidant supplementation ameliorates or prevents UA muscle dysfunction 
following exposure to CIH in rat models (Liu et al., 2005, Dunleavy et al., 2008, Skelly 
et al., 2012b, Skelly et al., 2013). Disruption of the endogenous glutathione 
antioxidant system using buthionine sulfoxamine (BSO) results in an exacerbation of 
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CIH-induced sternohyoid muscle fatigue (Dunleavy et al. 2008). Moreover, 
administration of the glutathione precursor, NAC, throughout the exposure to CIH 
prevented muscle dysfunction, highlighting the protective effect of the glutathione 
system against excessive ROS (Dunleavy et al., 2008). Similarly, the administration of 
the superoxide scavenger, tempol, has proved efficacious in preventing CIH-induced 
sternohyoid muscle dysfunction. Interestingly, the application of tempol acutely, also 
reverses CIH-induced muscle weakness (Skelly et al., 2012b). This suggests that the 
mechanism underpinning CIH-induced UA muscle dysfunction is likely to be a subtle, 
reversible stimulus such as the redox modulation of EC coupling and thus alterations 
to muscle contractile proteins, as opposed to muscle weakness due to structural 
changes or severe oxidative damage. By extension, a recent study by the same group 
proposes that NOX2-dependent ROS may be implicated in CIH-induced UA muscle 
dysfunction. A CIH-induced increase in the protein expression of NOX2 and the 
activator subunit, p47phox, was observed in sternohyoid muscle in the absence of 
overt oxidative stress, supporting the notion that altered redox signalling is sufficient 
to drive muscle dysfunction (Williams et al., 2015b).  
 
Diaphragm muscle dysfunction has been also reported in OSAS patients (Griggs et al., 
1989, Chien et al., 2010b), and animals exposed to tracheal occlusion (Smith et al., 
2012). Conversely, there is also evidence that diaphragm dysfunction does not 
present in OSAS patients (Montserrat et al., 1997). These divergences are likely due 
to differences in the severity of OSAS in patients or varied paradigms of hypoxia 
utilised in animal models.  During inspiration, the contraction of the diaphragm plays 
an essential role in the determination of UA patency. A fine balance between the 
dilating and stabilising forces produced by UA muscles and the sub-atmospheric, 
collapsing pressure of the diaphragm ensures that UA calibre remains patent 
(Brouillette and Thach, 1979a). During OSAS, the diaphragm is under considerable 
stress, as a consequence of heavy and prolonged contractions during hypoxic 
periods. This may culminate in tissue hypoxia and disordered energy balance, 
rendering it more susceptible to further damage, stress and dysfunction  (Clanton et 
al., 2001). It has also been suggested that the diaphragm is susceptible to fatigue 
during apnoeic episodes in OSAS patients (Vincken et al., 1987). Diaphragm fatigue 
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may represent a reduction in the collapsing force during apnoeas, thereby 
functioning to offset the effect of UA muscle dysfunction on OSAS pathology. CIH-
induced muscle plasticity has been shown to extend to the diaphragm, however the 
underlying mechanisms are largely underexplored.  
 
The effects of exposure to CIH are largely reliant on the duration and intensity of 
exposure and thus, varied effects of exposure to IH on diaphragm muscle function 
have been reported (Clanton et al., 2001, McGuire et al., 2003a, Pae et al., 2005, 
Shortt et al., 2014, Giordano et al., 2015). A relatively short duration of IH (hours), 
previously shown to induce UA muscle fatigue, was insufficient to cause an alteration 
to the force-generating capacity of the diaphragm.  Similarly, this IH exposure 
resulted in no observable effect on diaphragm fibre-type composition (Pae et al., 
2005). However, 4 days of IH has been shown to cause diaphragm muscle fatigue. 
Following IH exposure, the diaphragm demonstrated significant atrophy with a 
concomitant increase in the mRNA expression of autophagy markers, LC3B, GABA(A) 
receptor-associated-protein-like 3 (GABARAPL1) and BCL2 interacting protein 3 
(BNIP3), with no alteration to the levels of MuRF1 or Atrogin-1. Additionally, a fibre-
type shift towards type-1 fibres was exhibited, suggestive of a compensatory 
metabolic adaptation associated with fatigue resistance (Giordano et al., 2015). 
Elevated diaphragm force with improved anoxic tolerance and no alteration to 
fatigue or fibre-type composition has been observed following a longer IH treatment 
(10 days) in rats. It is postulated that this paradigm of IH evokes adaptive responses 
in the diaphragm that preserve its function in anoxia (Clanton et al., 2001). These 
time- and intensity-dependent effects of IH on the contractile properties of the 
diaphragm are well demonstrated in a study by (Shortt et al., 2014). Diaphragm 
muscle contractile properties were unaltered following exposure to 1 week of IH, 
while 2 weeks was sufficient to significantly decrease diaphragm force and 
endurance. A CIH-induced increase in the density of type 2b fibres was reported 
(Shortt et al., 2013, Shortt et al., 2014), suggestive of a shift to a more fatigable 
phenotype. CIH-induced diaphragm dysfunction occurred in the absence of an 
alteration to SDH or GPDH activity (Shortt et al., 2013, Shortt et al., 2014), thus an 
alteration to metabolic enzymes is not likely to underlie the increase in diaphragm 
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muscle fatigue. Similarly, diaphragm fatigue has also been reported following 
exposure to 5 weeks of CIH with attendant increase in the proportion of type 2b 
fibres (McGuire et al., 2003a). Additionally, many patients with DMD are diagnosed 
with SDB and of particular interest, exposure to CIH has been shown to exacerbate 
respiratory muscle dysfunction in DMD by reducing diaphragm strength by a further 
30% (Farkas et al., 2007).  
 
Similar to studies in UA musculature, increased ROS production has been implicated 
in diaphragm muscle dysfunction and indeed, antioxidants have been efficacious in 
preventing diaphragm weakness and fatigue (Shortt et al., 2014). The latter study 
demonstrated that 2 weeks of exposure to CIH resulted in no alteration to levels of 
malondialdehyde or 4-HNE (markers of lipid peroxidation), however exposure to CIH 
did significantly increase DNA oxidation and the GSSG/GSH ratio, indicative of 
modest oxidative stress. Administration of tempol, apocynin and NAC each 
prevented CIH-induced diaphragm muscle fatigue, with NAC proving most efficacious 
since it also prevented CIH-induced muscle weakness, likely through increased levels 
of GSH and reduced levels of GSSG. While atrophy and fibre-type transitions have 
been described in the diaphragm following IH (Shortt et al., 2014, Giordano et al., 
2015), aberrant diaphragm function is not likely to be underpinned by these 
structural alterations as muscle contractile properties were fully recovered following 
antioxidant supplementation in the absence of amelioration or prevention of a CIH-
induced increase in the areal density of 2b muscle fibres (Shortt et al., 2014). 
Collectively, these observations suggest that, similar to the UA musculature, altered 
redox signalling may underlie alterations in the contractile function of the diaphragm 
due to the lack of an apparent overt redox signature and metabolic remodelling, 
which are seen in models of chronic sustained hypoxia (Lewis et al., 2016). 
Interestingly, inhibiting NOX2-dependent ROS production increases force and 
respiratory function in dystrophic diaphragm (Loehr et al., 2018), further highlighting 
a potential role for apocynin and NOX2 blockade in the prevention of CIH-induced 




1.11 Thesis aims and structure    
 
The overarching aim of this thesis was to examine the role of NOX2 in chronic 
intermittent hypoxia (CIH)-induced respiratory system plasticity in a mouse model of 




• To characterise the effects of exposure to CIH on respiratory muscle (sternohyoid 
and diaphragm) function in adult male mice. 
 
• To characterise the effects of exposure to CIH on respiratory control in adult male 
mice. 
 
• To examine the efficacy of the putative NOX2 inhibitor/antioxidant, apocynin, on 
respiratory muscle function and respiratory control in mice exposed to CIH. 
 
• To examine the specific role of NOX2 in CIH-induced respiratory muscle weakness 
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2.1 Ethical approval  
Procedures on live animals were performed under licence from the Government of 
Ireland Department of Health (B100/4498) in accordance with National and 
European legislation (2010/63/EU) following approval by University College Cork 
Animal Research Ethics Committee (AEEC no. 2013/035) and conform to the 
principles and regulations described by (Grundy, 2015).  
 
2.2 Chronic intermittent hypoxia animal model  
C57BL/6J male mice (9 weeks old) were purchased from Envigo, UK, and assigned to 
one of 3 groups: normoxic control (sham; n = 20), chronic intermittent hypoxia (CIH)-
exposed (CIH; n = 20) and CIH + apocynin (CIH + APO; n = 20).  Exposure to CIH 
consisted of the cycling of gas from normoxia (21% O2) for 210 seconds to hypoxia 
(5% O2 at the nadir) over 90 seconds for 8hr/day during light hours for 14 consecutive 
days as previously described (Lucking et al., 2014). CIH + APO group also received the 
NADPH oxidase 2 inhibitor, apocynin, in the drinking water (2mM) for the duration 
of the exposure to CIH. The drug solution was made up fresh and changed daily for 
the 14 days. The sham group was exposed to 21% O2 in parallel. In separate studies, 
9-week-old NOX2 null male mice (B6.129S-Cybbtm1Din/J) were purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA) and assigned to a sham (NOX2 KO sham; 
n=12) or CIH (NOX2 KO CIH; n=12) exposure. Mice were housed in standard cages 
placed in commercially designed hypoxia chambers (Oxycyler™, Biospherix, Lacona, 
NY, USA) for daily gas treatment. Ambient O2 concentration within the hypoxia 
chambers was continuously monitored and deviations from the desired O2 
concentration were automatically rectified by altering nitrogen gas flow to the 
chambers under the control of specialised software (Biospherix). Animals were 
conventionally housed in temperature- and humidity-controlled rooms, operating on 
a 12h light/ 12h dark cycle with food and water available ad libitum. Due to the 
immunocompromised nature of NOX2 null mice, these mice were housed in 
individually ventilated chambers when not undergoing exposure to CIH. Exposure to 
normoxia or CIH began at 11 weeks of age and all mice were studied the day after 14 
consecutive days of exposure. Mice were weighed daily to monitor for any 
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substantial deleterious effects of exposure to CIH on body mass. On ‘day 15’, a subset 
of mice was subject to respiratory recordings using whole-body plethysmography 
(WBP; 2.3). Mice were subsequently anaesthetised with 5% isoflurane in air and 
euthanised humanely via cervical spinal dislocation. Brainstem tissue was collected 
from these mice, snap frozen in liquid nitrogen and stored at -80°C for subsequent 
analysis of monoamine concentrations using high performance liquid 
chromatography (HPLC; 2.4). An additional subset of mice was euthanised humanely 
as previously described. Sternohyoid (representative upper airway dilator muscle) 
and diaphragm (inspiratory pump muscle) muscles were excised and used for ex vivo 
muscle function analysis (2.5) or snap frozen in liquid nitrogen and stored at -80°C 
for further tissue processing prior to gene (2.6) and protein analysis (2.7, 2.8 & 2.9).  
 
2.3 Whole-body plethysmography (WBP) 
Respiratory flow recordings were examined in awake, unrestrained and 
unanaesthetised mice during quiet rest using WBP. Mice were introduced into 
plethysmograph chambers (Model PLY4211; volume 600ml, Buxco Research 
Systems, Wilmington, NC, USA) with room air flowing through to ensure adequate O2 
and CO2 environmental conditions. Mice were allowed 60 minutes to acclimate to 
the chamber environment. Following exploration and grooming behaviours during 
this period, mice were considered settled and baseline recordings commenced. 
Multiple baseline measurements consisting of 15-minute bins were averaged to 
increase the length and power of the baseline period represented in table 3.2. 
Respiratory variables including respiratory frequency (fR), tidal volume (VT), minute 
ventilation (VTI) inspiratory time (Ti), expiratory time (Te), peak inspiratory flow (PIF) 
and peak expiratory flow (PEF) were recorded every 2 seconds for analysis offline. 
Levels of O2 and CO2 gas entering and exiting the plethysmograph chambers were 
measured on a minute-by-minute basis (O2 and CO2 analyser; AD Instruments, 
Colorado Springs, CO, USA) allowing O2 consumption (VTO2) and CO2 production 
(VTCO2) in mice to be determined (Burns et al., 2017, Burns et al., 2018). From this, 
the ventilatory equivalent for CO2 (VT I / VTCO2) and O2 (VT I/ VTO2) were calculated.  
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2.3.1 Respiratory stability 
Respiratory flow recordings for sham (n = 12), CIH (n = 12), CIH + APO (n = 12), NOX2 
KO sham (n = 12) and NOX2 KO CIH (n =12) mice during normoxia (21% O2) were 
examined for the measurement of respiratory stability and apnoea scoring. The 
breath-to-breath (BBn) and subsequent interval (BBn+1) of 200 breaths were 
analysed as previously described (Peng et al., 2011, Souza et al., 2015). Poincaré plots 
expressing BBn versus BBn+1 for 200 consecutive breaths were plotted for expiratory 
time (Te) and total breath duration (Ttot) for all groups outlined above. Short-term 
variability (SD1) and long-term variability (SD2) were calculated as indices of 
breathing variability. Respiratory flow signals were visually analysed for the 
frequency of sigh events (augmented breaths), which was defined as an increase in 
tidal volume to at least twice the amplitude observed during a eupnoeic breath. 
Additionally, the frequency and duration of spontaneous and post-sigh apnoeic 
events were determined. The criterion for apnoea was defined as a cessation in 
breathing greater than two missed breaths and the criterion for a post-sigh apnoea 
was an apnoeic event occurring within 20s following an augmented breath, as 
previously described  (Edge et al., 2012, O'Connor et al., 2019).  
 
2.3.2 Ventilatory responsiveness to chemostimulation 
Following baseline recordings, ventilatory responsiveness to chemostimulation was 
examined for all groups. A 10-minute hypoxic challenge (FiO2 = 0.1) was elicited in 
which mice were challenged with reduced levels of O2 before returning flow to room 
air for 20 minutes. Once baseline was established, a 10-minute hypercapnic (FiCO2 = 
0.05, FiO2 = 0.95) challenge was performed. Ventilatory parameters were also 
recorded every 2 seconds during hypoxic and hypercapnic challenges. These data 
were subsequently averaged and expressed on a minute-by-minute basis. Metabolic 
parameters (VTO2 and VTCO2) were recorded on a minute-by-minute basis. Peak 
ventilation for each individual animal was determined during hypoxia and 
hypercapnia and compared with the baseline normoxic period. Ventilatory 
responsiveness to hypoxia and hypercapnia was expressed as a change from baseline 
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(Δ VT I). The corresponding VTCO2 value for each peak response was then used to 
calculate Δ VT I / VTCO2. 
 
2.4 High performance liquid chromatography 
Monoamines and metabolites important in the neurochemical control of breathing, 
including 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA), were 
quantified in brainstem samples from all groups using high performance liquid 
chromatography (HPLC), as previously described (Clarke et al., 2013). Frozen samples 
were thawed in 500 µl of chilled homogenising buffer spiked with 2ng/20µl of N-
Methyl 5-HT (Sigma, UK) as internal standard, sonicated for 2 x 4 s bursts (Bandelin 
Sonoplus HD 2070) and centrifuged at 14,000 RPM for 20 mins at 8oC (MIKRO 22 R 
refrigerated centrifuge). 20 µl of supernatant was injected onto the HPLC system 
(Electrochemical Detection). The mobile phase contained 0.1M citric acid, 0.1M 
sodium dihydrogen phosphate, 0.01mM EDTA (Fisher Scientific Ireland), 5.6mM 
octane-1-sulphonic acid (Sigma) and 11% (v/v) HPLC-grade methanol (Fisher 
Scientific, Ireland), and was adjusted to pH 2.8 using 4N sodium hydroxide 
(Alkem/Reagecon). A reverse-phase column (Kinetex 2.6u C18 100 x 4.6mm, 
Phenomenex, UK) maintained at 30oC was employed in the separation (flow rate 
0.9ml/min), the glassy carbon working electrode combined with an Ag/AgCl 
reference electrode (Shimdazu) was operated a +0.8V and the chromatograms 
generated were analysed using Class-VP 5 software (Shimadzu, Corporation, Kyoto, 
Japan). Monoamines and their metabolites were identified by their characteristic 
retention times as determined by standard injections which were run at regular 
intervals during the sample analysis. The chromatograms were processed using Class 
5-VP software (Shimadzu Corporation, Kyoto, Japan). Analyte: Internal standard peak 
height ratios were measured and compared with standard injections and results 






2.5 Ex vivo muscle function analysis  
2.5.1 Muscle dissection and preparation 
Animals were euthanised as described in section 2.2 and sternohyoid and diaphragm 
muscles were excised carefully, but quickly to minimise damage. Briefly, a ventral 
incision was made from the genu of the mandible to the sternum. A closed forceps 
was delicately placed under the paired sternohyoid muscles to gently tease them 
away from the trachea. The muscles were then cut at the rostral and caudal 
boundaries and were immediately placed in a storage bath of hyperoxic (95% O2, 5% 
CO2) Krebs solution (NaCl 120mM, KCl 5mM, Ca2+ gluconate 2.5 mM, MgSO4 1.2 mM, 
NaH2PO4 1.2 mM, NaHCO3 25 mM, glucose 11.5 mM and d-tubocurarine 25 μM) to 
allow the muscles to recover from dissection at room temperature. For removal of 
the diaphragm muscle, the ventral incision was extended from the neck to the 
abdomen, inferior to the lower ribcage. By firmly gripping the central tendon and 
cutting around the rib cage, the whole diaphragm muscle was excised and 
subsequently added to the storage bath of hyperoxic Krebs solution. For functional 
analysis, muscles were cut into strips of appropriate size. The sternohyoid was cut 
longitudinally along its natural midline, separating the two paired muscles (~2mm 
each) whereas a strip of diaphragm was cut longitudinally in the direction of its 
muscle fibres (~2mm in diameter). Muscles were returned to the hyperoxic Krebs 
solution for 10-15 minutes to recover from dissection. Following this, muscles were 
suspended vertically in a water-jacketed organ bath maintained at 35oC. Using non-
elastic string, one sternohyoid muscle was attached to an immobile hook on the 
bottom and a dual-mode lever transducer on top (Aurora Scientific Inc., Canada) with 
platinum plate electrodes flanking either side of the muscle. Similarly, a strip of 
diaphragm muscle was attached with non-elastic string at the rib end to the immobile 
hook and the central tendon to the dual-mode lever transducer, with platinum plate 
electrodes flanking either side of the muscle. The bath was filled with Krebs solution 
and constantly bubbled with carbogen (95% O2, 5% CO2) to maintain a hyperoxic 
environment. Muscles were allowed an equilibration time of 15 minutes in the 
muscle bath before the experimental protocol was initiated.  
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 2.5.2 Isometric protocol  
Muscle function was examined by employing a range of protocols extensively used 
by our group (O'Leary and O'Halloran, 2016, Burns et al., 2017, Burns et al., 2018, 
O'Leary et al., 2018, Burns et al., 2019). Sternohyoid and diaphragm muscles from all 
experimental groups (sham, CIH, CIH + APO, NOX2 KO sham & NOX2 KO CIH; n = 8-
10 per group) were examined. When assessing isometric muscle contractions, the 
force transducer remained at maximum tension (>100% load). Muscle strips were 
stimulated at supramaximal voltage via the platinum plate electrodes. The optimal 
length (Lo), the length which produces the maximum twitch force, was obtained by 
stimulating the muscle supra-maximally for 1ms. The length of the muscle was 
adjusted using a micro-positioner between each of these stimulations and once the 
Lo was achieved, the muscle remained at this length for the duration of the protocol. 
The Lo (mm) encompasses the muscle between the knot attaching it to the immobile 
hook and the knot attaching it to the force transducer, therefore ensuring that only 
actively contracting muscle fibres are accounted for. A single twitch stimulation was 
applied from which twitch force and contractile kinetics including contraction time 
(CT; time to peak force) and half-relaxation time (1/2 RT; time for force to decay by 
50%) were determined. Following this, an isometric tetanic contraction was evoked 
by supramaximal stimulation at a frequency of 100Hz for 300ms to determine the 
peak tetanic force (Fmax). Specific force was calculated in N/cm2 of estimated muscle 
cross sectional area (CSA). The CSA of each strip was determined by dividing the 
muscle mass (weight in grams) by the product of muscle Lo (cm) and muscle density 
(assumed to be 1.06g/cm3). 
 
2.5.3 Isotonic protocol  
Throughout the isotonic protocol, the force transducer was set to varying degrees of 
tension (0-100% load). Initially, the force transducer was set to its minimum tension 
(0%) and the muscle was stimulated to contract against a load that equated to 0% of 
its Fmax. This load was then increased in a step-like manner (5%, 10%, 20%, 30%, 
40%, 60%, 80%, 100%) % of Fmax. A contraction was elicited at each step and 30 
seconds was allowed between each contraction to allow the muscle to fully return 
to Lo. The length of shortening was defined as the maximum distance of shortening 
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during the contraction and shortening velocity was derived from the distance of 
shortening during the first 30ms of shortening during a contraction (when velocity is 
maximal). Peak shortening length and velocity were achieved at 0% of Fmax. Peak 
specific shortening (Smax) was defined as the length of shortening per optimal length 
(L/Lo). Peak specific shortening velocity (Vmax) was defined as Lo/s. From this 
protocol, we were able to calculate the work (force x shortening) and power-
generating capacity (force x shortening velocity) of the sternohyoid muscle at each 
step. From the work-load and power-load relationships achieved through this 
protocol, peak work and peak power were extrapolated. Peak specific mechanical 
work (Wmax) was calculated as Joules/cm2 and peak specific mechanical power 





              Figure 2.1 Ex vivo muscle bath set-up. 
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2.6 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) 
2.6.1 Tissue homogenisation 
Equipment, gloves and surfaces were sprayed with RNaseZap® (Thermo Fisher 
Scientific, Ireland) to ensure a thoroughly decontaminated environment, pivotal for 
carrying out RNA preparation. Sternohyoid and diaphragm muscle samples from all 
experimental groups (sham, CIH, CIH + APO, NOX2 KO sham & NOX2 KO CIH; n = 6-9 
per group) were removed from storage at -80°C and immediately weighed. Samples 
ranging from 20-40mg were homogenised in 1ml of Tripure Isolating Reagent (Roche 
Diagnostics Ltd., West Sussex, UK) on ice for 3 x 10 second bursts. Homogenates 
remained on ice for 20 minutes with intermittent vortexing to enable cell lysis and 
maximal RNA yield from muscle tissue. RNA was then either immediately isolated 
from the homogenised samples or samples were stored at -80°C until required. 
  
2.6.2 RNA extraction  
200µl of chloroform was added to each sample and following a 5-minute incubation 
period at room temperature, samples were centrifuged for 15 minutes at 4°C at 
12,380 RPM (U-320R centrifuge, Boeckel + Co, Hamburg, Germany). Following this, 
three phases were observed, the upper aqueous phase containing RNA, the middle 
milky phase containing DNA and the lower pink phase containing proteins and lipids. 
The clear upper aqueous solution containing RNA was transferred to a fresh 
eppendorf and the lower phases were discarded. An additional chloroform step, as 
previously described, was repeated with 700µl added to the recovered supernatant. 
Following this, two clear phases were observed; the upper clear phase containing 
RNA and the lower clear phase contained nucleic acids and salts. 700µl of 
isopropanol was then added to each eppendorf containing the recovered upper RNA 
phase. Eppendorfs were inverted twice, incubated for 5 minutes at room 
temperature and centrifuged at 4°C at 12,380 RPM for 10 minutes to precipitate the 
RNA. Following this, a clear gel pellet of RNA was adhered to the side of the 
eppendorf as RNA is insoluble in isopropanol. Isopropanol was carefully poured off 
and ethanol (70%) was added to the pellet which was gently vortexed to ensure 
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thorough washing and removal of any salts and contaminants in RNA samples. 
Samples were then centrifuged at 4°C at 14,000 RPM for 10 minutes to adhere the 
pellet to the eppendorf once again. The ethanol was subsequently discarded, and the 
pellet was allowed to air dry.  The RNA pellet was then re-dissolved in 20-60µl of 
RNase free water (Sigma Aldrich, Arklow, Wicklow, Ireland), depending on the mass 
of the muscle sample. RNA was treated with a TURBO DNA-free kit where necessary 
(Life Technologies, Biosciences, Dun Laoghaire, Ireland), as per the manufacturer’s 
instructions, to ensure the complete digestion of any contaminating DNA that may 
be present within the sample. The purity and quantity of RNA was determined by 
spectrophotometry using a Nanodrop 1000 (Thermo Scientific, Wilmington, 
Delaware, USA) (Fig. 2.2; A). The 260/280 value measures protein and DNA 
contamination. The normal range for 260/280 values is between 1.8-2.0. The 
260/230 value measures ethanol and isopropanol contamination. The normal range 
for 260/230 values is 1.8-2.2. The integrity of the RNA was also assessed using an 
agarose gel electrophoresis system (E-gel, Life Technologies) in which samples were 
loaded against a DNA ladder (E-gel, Life Technologies) to visualise clear 28S and 18S 






Figure 2.2 RNA purity & integrity screening. (A) An absorbance curve from the Nanodrop 
1000 including the RNA concentration (ng/µl) of the sample being tested, 260/280 and 
260/230 ratios and a single peak at 260nm, indicating good sample purity. (B) Representative 
image of an RNA sample run on an e-gel, showing distinctly separate 28S and 18S ribosomal 
RNA bands, indicating preservation of RNA integrity following isolation. 
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2.6.3 cDNA synthesis  
RNA was reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit 
(Roche Diagnostics Ltd.). Briefly, the concentration of RNA was normalised across all 
samples, utilising concentrations (ng/µl) obtained from the nanodrop. Samples from 
all experimental groups (10µl) were then plated on a 96-well plate with an equal 
amount of master mix containing essential components (reverse transcriptase, 
random hexamer primers, anchored oligo(dT)18 primer and protector RNase 
inhibitor) for the reverse transcription of RNA to cDNA. The 96-well plate was sealed 
and placed in the LightCycler 96 (Roche Diagnostics Ltd.) and exposed to three 
incubation periods, 10 minutes at 25°C (pre-incubation), 60 minutes at 50°C 
(reaction) and 5 minutes at 85°C (inactivation). The resultant cDNA was diluted 1:10 
in RNase free water and stored at -20°C until required for further experimentation. 
A reverse transcription negative (RT negative) was also required for each sample, 
which contained 10µl of sample and 10µl of water. These were all subsequently 
tested against a PCR probe to confirm that there was no cDNA created without the 
addition of cDNA reaction mix. Thus, no non-specific PCR amplification could occur 
from the RNA alone or any traces of genomic DNA that may have been present in the 
sample. One RT negative representative of each group was used on every PCR plate 
thereafter. 
 
 2.6.4 qRT-PCR  
cDNA was amplified using Realtime ready Catalog or Custom Assays (Roche 
Diagnostics Ltd.) and Fast Start Essential DNA Probe Master (Roche Diagnostics Ltd.). 
Reactions were carried out as per the manufacturer’s instructions in 20µl (5µl cDNA 
and 15µl master mix). All reactions were carried out in duplicate along with 
appropriate positive and negative controls including reverse transcription negatives, 
RNA negatives, cDNA negatives (no template) and calibrators, as shown in Fig. 2.3. 
Once plated and sealed, the 96-well plate was placed in the LightCycler 96 (Roche 
Diagnostics Ltd.) and subjected to a pre-incubation period (1 cycle), 3 step 
amplification (45 cycles) and cooling (1 cycle). Quantification cycle (Cq) values 
obtained from experiments for our genes of interest (Table 2.1) were normalised to 
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that of a reference gene, hypoxanthine-guanine phosphoribosyltransferase-1 (hprt1). 
This allows a level of correction for any variation in the amount of RNA inputted or 
cDNA recovered following reverse transcription. Previous work in our laboratory 
(O'Leary and O'Halloran, 2016) has shown that hprt1 was considered the most stable 
reference gene when tissue type (respiratory muscles) and gas exposure (hypoxia) 
was considered. We confirm this finding by showing that hprt1 was stable across all 
experimental groups in the current study (Fig. 2.4). Relative gene expression was 
calculated using the ΔΔCT method to normalise the expression of genes of interest 
to that of the stable reference gene, hprt1, with a change in mRNA shown as a fold 
change over the controls (sham). 
 
 
Figure 2.3 PCR amplification. Representative image of a PCR amplification curve obtained 





Figure 2.4 Reference gene for qRT-PCR. Stability of hprt1 across all groups in (A) sternohyoid 
and (B) diaphragm muscle. 
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Gene name Gene Symbol Assay ID 
NOX enzymes 
  
NOX1 NOX1 310986 
NOX2 Cybb 317885 
NOX4 NOX4 300795 
p22phox Cyba 317890 
p47phox Ncf1 301105 
p67phox Ncf2 317897 
p40phox Ncf4 317894 
Rac Racgap1 310907 
Duox1 Duox1 317891 
Duox2 Duox2 317888 
Atrophy 
  
Atrogin-1 Fbxo32 317844 
MuRF-1 Trim63 317843 
Autophagy 
  
BNIP3 Bnip3 311465 
LC3B Map1lc3b 317920 
GABARAPL1 Gabarapl1 317923 
Mitophagy 
  
PINK-1 Pink1 331846 
PARK-2 Park2 317264 
Inflammation 
  
NFκB Nfkb1 300085 
Antioxidant 
  
SOD1 Sod1 310738 
SOD2 Sod2 310295 
Catalase Cat 310718 
Nrf2 Nfe2l2 313377 
Muscle differentiation 
  
Myogenin Myog 313501 
Myostatin Mstn 318626 
MyoD Myod1 313570 
MEF2C Mef2c 318629 
IGF1 Igf1 313359 
Sirtuin-1 Sirt1 310480 
Reference 
  
HPRT1 Hprt1 307879 
 
Table 2.1 Assay details for genes of interest. Real-time ready catalog and custom assays 
used for cDNA amplification.  
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2.7 Western blotting  
2.7.1 Protein extraction and quantification 
Sternohyoid and diaphragm muscles were removed from storage at -80°C and 
allowed to defrost on ice for 2 minutes. Muscles were weighed and homogenised 
with 8 x 10 second bursts using a general laboratory homogeniser (Omni-Inc., 
Kennesaw, Georgia, USA) in modified ice cold radioimmunoprecipitation assay buffer 
(RIPA buffer) containing: RIPA (25 mM Tris-HCl pH 7.6, 150 mM sodium chloride, 1% 
NP-40, 1% sodium deoxycholate, 0.1% SDS), deionised water, protease inhibitor 
cocktail (104 mM AEBSF, 80µM aprotinin, 4mM bestatin, 1.4mM E-64, 2mM 
leupeptin, 1.5mM pepstatin A) phosphatase inhibitor cocktail (200mM sodium 
fluoride, 5mM sodium orthovanadate) and 100mM PMSF (Sigma Aldrich, Arklow, 
Wicklow, Ireland) using a 10% w/v ratio. Homogenates were allowed 20 minutes lyse 
time on ice with intermittent vortexing at 4-minute intervals. Samples were 
centrifuged (U-320R centrifuge Boeckel + Co, Hamburg, Germany) for 20 minutes at 
4°C at 14,000 RPM to separate insoluble cell fractions from protein homogenates. 
The clear protein containing supernatant was recovered from each sample and 
transferred to a fresh eppendorf. The protein concentration of each sample was 
determined using a bicinchoninic acid (BCA) protein quantification assay (Pierce 
Biotechnology, Ireland). A standard curve was generated using a serial dilution of 
stock (2mg/ml) bovine serum albumin (BSA) solution. Diluted standards and samples 
(1:10) were loaded in triplicate with 200µl working reagent and incubated at 37°C 
for 30 minutes. Absorbance was measured at 562nm using a SpectraMax-M3 
spectrophotometer (Molecular Devices, Sunnyvale, California, USA) and protein 
concentrations were ascertained based on values from the standard curve. 
Homogenates were subsequently stored at -80°C until further use.  
 
2.7.2 Gel electrophoresis  
Western blot analysis was carried out on sternohyoid and diaphragm muscle 
homogenates from CIH-exposed and sham mice (n = 5-7 per group). Samples were 
diluted with deionised water, based on their protein concentration and mixed with 
an equivalent volume of SDS-PAGE loading buffer (4% SDS (sodium dodecyl sulfate), 
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200mM DTT (dithiothreitol), 20% glycerol, 100mM TRIS-CL (pH 6.8), 0.2% 
Bromophenol blue). Samples were subsequently boiled at 100°C for 5 minutes on a 
dry heating block (Techne, UK). Bio-Rad gel plates (Bio-Rad, Hertfordshire, UK) were 
set up in a clamped bracket apparatus in order to pour and set an acrylamide gel. 
10% resolving gel (deionised water, 30% acrylamide, 1.5M TRIS pH 8.8, 10% SDS, 10% 
ammonium persulfate) was prepared with 5µl of tetramethylethylenediamine 
(TEMED) added immediately before use. Isopropanol was added along the surface of 
the resolving gel to ensure a level gel and to prevent air bubbles from inhibiting 
polymerisation. This was allowed to set for ~1 hour, following which isopropanol was 
rinsed off. A 5% stacking gel (deionised water, 30% acrylamide, 1.5M TRIS pH 6.8, 
10% SDS, 10% ammonium persulfate) was made up and 5µl of TEMED was added 
immediately before use. The solution was poured on top of the resolving gel and a 
15-well comb was placed into the gel to create even spaces for the sample addition. 
Once set, the comb was carefully removed and the gel was fitted into an 
electrophoretic chamber (Bio-Rad, Hertfordshire, UK) and electrophoresis running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) was added. Specialised 
loading tips were used to add pre-stained molecular weight marker (Sigma Aldrich, 
Arklow, Wicklow, Ireland) to the first well followed by 15-20µg muscle homogenates 
into each of the wells thereafter. The chamber was connected to a power pack (Bio-
Rad, Hertfordshire, UK) and a current of 200V was applied for 50-60 minutes, 
depending on the time required to resolve proteins of interest.  
 
 
Figure 2.5 Gel electrophoresis equipment set-up. 
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2.7.3 Semi-dry transfer  
Following electrophoresis, gels were carefully removed from between glass plates 
and placed in Dunn-carbonate semi-dry transfer buffer (20% methanol, 19mM 
NaCHO3, 3mM NaCO3) on a gentle shaker (Stovall Life Science, Inc) for 10 minutes. 
Nitrocellulose membrane and filter paper were soaked in the same buffer for 15 
minutes prior to transfer. Filter paper was placed on the positive electrode plate of 
a Trans-Blot Semi Dry Transfer Cell (Bio-Rad, Hertfordshire, UK) followed by 
nitrocellulose membrane, the acrylamide gel and more filter paper. A sterile 15ml 
tube was used to gently roll out any air bubbles that might have formed at any of 
these layers. The negative electrode plate lid was placed over this sandwich 
arrangement and the unit was operated at 15V for 30 minutes. Resultant membranes 
were washed and stained with Ponceau S in 5% acetic acid to confirm the successful 
transfer of proteins and a digital image was taken to assess equal protein loading 




Figure 2.6 Protein transfer. Representative nitrocellulose membrane washed directly after 
protein transfer (left) and following Ponceau S staining (right), demonstrating successful 
protein transfer and relatively equal protein loading.  
 
2.7.4. Immunostaining  
Nitrocellulose membranes were blocked for 1 hour in TBST (20mM Tris-HCL, pH 7.6, 
150mM NaCl, 0.15% tween) containing 5% non-fat dried milk. Primary antibodies of 
interest were diluted as per the manufacturer’s instructions; anti-NOX2, anti-NOX4; 
1:10000; 1:2000 (Abcam, Cambridge, UK) in 5% bovine serum albumin (BSA) / 5% 
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non-fat dried milk. Membranes were incubated in primary antibody solutions 
overnight with gentle shaking at 4°C and rinsed with TBST 5 times at 5-minute 
intervals the next day. Membranes were then incubated with a horse radish 
peroxidase (HRP) conjugated secondary antibody (anti-mouse, 1:2000 5% non-fat 
dried milk) specific for the primary antibody of interest. Following another 5 washes 
with TBST at 5-minute intervals, enhanced chemiluminescence (ECL) solution (GE 
Healthcare, UK) was added to the surface of membranes and they were incubated 
for 5 minutes at room temperature. Membranes were exposed to photosensitive film 
and developed using an automatic film processer (AGFA CP1000). Resultant films 
were imaged and densitometric analysis was performed on both Ponceau S and 
developed film images using Image J software (NIH Image) to determine relative 
band intensities. The band intensities generated for proteins of interest were 
normalised to corresponding Ponceau S band intensities to correct for any variations 
in the quantity of protein per well, thus allowing comparative analysis of results. 



















2.8 Spectrophotometric assays 
2.8.1 Protein extraction and quantification 
Sternohyoid and diaphragm muscles were homogenised, and protein was quantified 
using the protocol previously described in section 2.7.1. 
 
2.8.2 NADPH oxidase activity 
NOX enzyme activity was assessed in sternohyoid and diaphragm muscle 
homogenates from sham and CIH-exposed mice (n = 8 per group) using a cocktail 
mixture containing: nitroblue tetrazolium (NTB, 2.2mM in water), Tris-HCL pH8 
(2.8mM) & diethylene-triamine-penta-acetic acid (1.3mM in Tris-HCL) and a fresh 
solution of NADPH (1mM). 20µl of muscle homogenate, 250µl of cocktail mixture and 
30µl of NADPH was added per well in a black 96-well plate. The plate was gently 
shaken at room temperature for 2 minutes following which absorbance was 
measured in a SpectraMax-M3 spectrophotometer (Molecular Devices, Sunnyvale, 
California, USA) at 560nm at 1 min intervals for 30 minutes. NOX activity 
corresponded to the slope of the formation of formazan blue over time. Data were 
expressed as enzymatic activity per mg of protein in the sample, previously 
determined by BCA assay, per minute.  
 
2.8.3 Citrate synthase activity  
Citrate synthase is an enzyme that catalyses the reaction between acetyl coenzyme 
A (acetyl CoA) and oxaloacetic acid to produce citric acid. It is the initial enzyme of 
the tricarboxylic acid (TCA) cycle and is commonly used as a marker of mitochondrial 
integrity. Citrate synthase activity was examined in sternohyoid and diaphragm 
muscle homogenates from sham and CIH-exposed mice (n=8 per group). The 
experimental procedure for the citrate synthase activity assay was performed in 
accordance with the manufacturer’s instructions (CS0720; Sigma-Aldrich). All assay 
solutions were warmed to 25°C in a water bath and a SpectraMax-M3 
spectrophotometer (Molecular Devices, Sunnyvale, California, USA) was set to 
412nm before beginning. 8µl of muscle homogenate was loaded per well in a black 
96 well plate. A cocktail mixture containing 178µl assay buffer, 2µl acetyl CoA 
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(30mM) & 2µl DTNB (10mM) solution) was added to the sample in each well 
following which absorbance was immediately recorded for 1.5 mins to measure the 
baseline reaction or endogenous activity levels. 10µl of oxaloacetate (OAA, 10mM) 
was then added to each well and absorbance was recorded at 10 second intervals for 
another 1.5 mins to measure total activity. Data were expressed as enzymatic activity 
per μmole per min per mg protein in the sample, previously determined by BCA 
assay.  
 
2.8.4 Thiobarbituric acid reactive substances  
Thiobarbituric acid reactive substances (TBARS) are degradation products of fats 
which are routinely used as a marker of lipid peroxidation, an indirect measurement 
of oxidative stress. Levels of TBARS were examined in sternohyoid and diaphragm 
muscle homogenates from sham and CIH-exposed mice (n=8 per group). 
Malondialdehyde (MDA) of a known concentration was used to generate a standard 
curve. Next, 50µl of thiobarbituric acid (TBA, 50 mM) was added to 50µl of muscle 
homogenate and the solution was incubated for 60 minutes at 97°C on a dry heating 
block. Samples were subsequently cooled on ice, and 75µl of methanol: 1 mM NaOH 
(91: 9) was added to the solution. Samples were then centrifuged at 3000 RPM and 
70µl of the resultant supernatant was added per well in a black 96-well plate. The 
plate was read in a SpectraMax-M3 spectrophotometer (Molecular Devices, USA) 
using 523/553 excitation/emission settings and data were compared with standards. 
Data are expressed as nM TBARS per mg of protein in the sample, previously 










2.9 Cell signalling assays  
2.9.1 Protein extraction and quantification 
Sternohyoid and diaphragm muscles were homogenised and prepared using the 
same protocol described in section 2.7.1 with some minor optimisation alterations. 
These included using a 2.5% w/v ratio of tissue to RIPA buffer, using twice the amount 
of phosphatase inhibitor and a 1:3 dilution of homogenates for the BCA assay. These 
modifications were made in order to maximise the protein yield for cell signalling 
assays discussed below.  
 
2.9.2 MAP Kinase phosphoprotein assay  
The MAP Kinase Phosphoprotein Assay quantifies the phosphoprotein content of the 
Mitogen-Activated Protein (MAP) kinases ERK1/2, p38 and JNK in a multiplex fashion. 
This assay was carried out on sternohyoid and diaphragm muscle homogenates (n = 
8 per group) from mice exposed to 2 weeks of CIH or normoxia (sham). The 
Mesoscale multiplex format assay (Mesoscale Discovery, Gaithersburg, USA) allows 
the measurement of all three of these phospho-proteins in one well. A host of 
capture antibodies against various proteins of interest are pre-coated on distinct 
spots in each well of a 96-well plate. All wells of the plate were initially blocked for 1 
hour and subsequently washed out 3 times. 25µg of sample was added per well in 
duplicate and the plate was sealed and incubated with vigorous shaking (300-1000 
RPM) at room temperature for 3 hours.  This enabled the analyte to be captured by 
the immoblilised capture antibodies on the surface of the electrodes on the bottom 
of the well. Following this, the wells were washed out again and an antibody 
detection solution containing antibodies for each protein of interest was added. 
These detection antibodies are bound to an electrochemiluminescent compound 
that acts as a tag. The detection antibody binds to the protein of interest which is 
already bound to the capture antibody on the surface of the well, thus creating a 
sandwich immunoassay. Following a 1-hour incubation the wells were washed again 
and read buffer was added to provide the correct chemical environment for 
electrochemiluminescence to occur. The plate was loaded into the MSD Sector 
Imager where a voltage is rapidly applied to the plate’s electrodes resulting in the 
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labels attached to these electrodes emitting light. This system measures the intensity 
of emitted light in order to generate a quantitative measure of the protein within the 
sample. A plate blank was used to adjust for background signal. Values are expressed 






Figure 2.7 Schematic depicting the principle of the Mesoscale 96-well plate. Schematic 
illustrating a 96 well place with 4 distinct spots for proteins of interest within each well and 
how the antibody-protein-antibody sandwich is formed and subsequently detected (Image 
adapted from www.mesoscale.com).  
 
 
2.9.3 Phospho-FOXO3a assay 
The Phospho-FOXO3a Assay is a singleplex version of the assay described above, 
quantifying phosphorylated Forkhead box O3a (FOXO3a) only. This assay was carried 
out in the same manner as described in section 2.9.2 using sternohyoid and 
diaphragm muscle homogenates (n = 8 per group) from mice exposed to 2 weeks of 
CIH or normoxia (sham). A plate blank was used to adjust for background signal. 
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Values are expressed as signal/µg of total protein, previously determined by BCA 
assay 
 
2.9.4 Total HIF-1α assay 
The HIF-1α Assay examines the total Hypoxia-Inducible Factor (HIF)-1α protein 
content in samples. This assay was carried out in the same manner as described in 
section 2.9.2 using sternohyoid and diaphragm muscle homogenates (n = 8 per 
group) from mice exposed to 2 weeks of CIH or normoxia (sham). A plate blank was 
used to adjust for background signal. Values are expressed as signal/µg of total 


















2.10 Statistical analysis 
Values are expressed as mean ± SD. Data were statistically compared using Prism 8.0 
(Graphpad Software, San Diego, CA, USA). Data were tested for normal distribution 
and equal variances. Data sets which were normally distributed and of equal variance 
were statistically compared using unpaired two-tailed Student’s t test. Welch’s 
correction was applied in the case of unequal variance. Data which were not normally 
distributed were compared using Mann Whitney non-parametric tests. P < 0.0125 
was considered statistically significant for Student’s t test and Mann Whitney test on 
the basis of the multiple comparisons that were performed. P < 0.05 was considered 
statistically significant for Student’s t test and Mann Whitney test when only one 
comparison was used.  Data for isotonic muscle measurements over a range of load 
percentages were statistically compared by repeated measures two-way ANOVA 
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Chapter 3. The role of NADPH oxidase-2 in 






























3.1 Aims and hypothesis  
 
Study aims: 
To determine the effects of exposure to CIH on ventilation and metabolism during 
baseline (normoxic) breathing in adult male mice. 
 
To investigate ventilatory responsiveness to acute physiological challenges, namely 
hypoxia and hypercapnia, to assess the effects of exposure to CIH on peripheral and 
central chemoreceptor responsiveness. 
 
To examine the effect of exposure to CIH on the propensity for apnoea and 
respiratory instability. 
 
To assess the effect of exposure to CIH on brainstem 5HT and 5HIAA concentrations.  
 
To assess the contribution of NOX2 to CIH-induced alterations in the respiratory 
control system using pharmacological and transgenic approaches.  
 
Study hypothesis: 
We hypothesised that 2 weeks of exposure to CIH would evoke mal-adaptation in 
respiratory control, which would manifest as enhanced normoxic ventilation, and 
altered chemoreflex responsiveness, together with the manifestation of respiratory 
instability and increased apnoeic index.  
 
Furthermore, we postulated that these alterations would be dependent upon NOX2 
derived ROS-dependent signalling, amenable to blockade by supplementation with 






3.2 Materials and Methods  
 
Respiratory recordings and metabolic measurements during quiet rest and in 
response to hypoxic and hypercapnic chemostimulation were assessed using whole 
body plethysmography (WBP), as described in Section 2.3.  
 
5-HT and 5-HIAA, important in the neurochemical control of breathing, were 
analysed in brainstem samples using high performance liquid chromatography 




















3.3.1 Organ and muscle mass 
Comparisons of organ and muscle mass in all experimental groups are shown in Table 
3.1. Haematocrit (Hct) was increased following exposure to CIH in wild-type (P = 
0.0247) and NOX2 KO mice (P = 0.0167), but this did not reach the threshold for 
statistical significance when correction for multiple comparisons was applied. The 
administration of the putative NOX2 inhibitor, apocynin (2mM), in the drinking water 
during exposure to CIH, significantly reduced Hct compared with CIH-exposed mice 
(P = 0.0062). A similar trend towards a decrease in spleen mass following exposure 
to CIH was observed in wild-type (P = 0.0400) and NOX2 KO mice (P = 0.0839); 
apocynin treatment significantly increased spleen mass compared with exposure to 
CIH alone (P = 0.0017). Limb muscle mass was unchanged following exposure to CIH 
in wild-type (tibialis anterior (TA); P = 0.7304, extensor digitorum longus (EDL); P = 
0.2972 , and soleus (Sol); P = 0.5435) and NOX2 KO mice (TA; P = 0.3474, EDL; P = 
0.0424, Sol; P = 0.4236). Treatment with apocynin throughout the exposure to CIH 
significantly increased limb muscle mass compared to exposure to CIH alone (TA; P = 
0.0868, EDL; P < 0.0001, Sol; P = 0.0435). Cardiac muscle mass was unaffected by 
exposure to CIH compared to sham (RV; P = 0.6306, LV; P = 0.2790, RV + LV; P = 
0.1771, RV:LV; P = 0.9711); treatment with apocynin also had no effect on cardiac 
muscle mass. LV (P = 0.0048) and total ventricular mass (RV + LV; P = 0.0075) were 
significantly increased following exposure to CIH in NOX2 KO mice. The difference 
between wet and dry lung mass, an index of pulmonary oedema, showed a trend 
towards an increase in both wild-type (P = 0.0736) and NOX2 KO mice (P = 0.0449) 
exposed to CIH compared with sham. NOX2 KO had no effect on Hct, spleen mass, 
limb muscle mass, cardiac muscle mass or measures of pulmonary oedema 








Table 3.1 Organ and muscle mass. Definition of abbreviations: Hct, haematocrit; TA, tibialis anterior; EDL, extensor digitorum longus; sol, soleus; RV, right heart ventricle; LV, left heart ventricle; 
sham, normoxia (21% O2) exposed; CIH, chronic intermittent hypoxia exposed; CIH + APO, Apocynin (2mM) given in the drinking water for the duration of CIH exposure; NOX2 KO, NADPH 
Oxidase 2 knock-out (B6.129S-Cybbtm1Din/J), sham or CIH exposed. Values are expressed as mean ± SD. Data sets which were normally distributed were statistically compared using unpaired 
two-tailed Student’s t test. Welch’s correction was applied in the case of unequal variance. Data which were not normally distributed were compared using Mann Whitney non-parametric tests. 
Bolded numbers indicate statistical significance (P < 0.0125) following correction for multiple comparisons. Relevant comparisons are denoted as follows: # APO + CIH significantly different from 
corresponding CIH values; $ NOX2 KO CIH significantly different from corresponding NOX2 KO sham values.
 Sham 
(n = 9) 
CIH 
(n = 9) 
CIH + APO 
(n = 10) 
NOX2 KO 
sham 
(n = 12) 
NOX2 KO  
CIH 
(n = 12) 
Sham vs CIH 
(P value) 
CIH vs  










Hct (%) 44.1 ± 1.0 46.9 ± 3.3 43.2 ± 2.0# 45.4 ± 2.2 47.6 ± 1.9 0.0247 0.0062# 0.0167 0.1050 
Spleen (mg/g) 2.37 ±0.57 1.92 ± 0.37 2.63 ± 0.46# 2.70 ± 0.50 2.42 ± 0.20 0.0400 0.0017# 0.0839 0.1847 
TA (mg/g) 1.47 ± 0.22 1.43 ± 0.10 1.56 ± 0.10 1.52 ± 0.21 1.60 ± 0.24 0.7304 0.0868 0.3474 0.5079 
EDL (mg/g) 0.32 ± 0.06 0.29 ± 0.05 0.42 ± 0.04# 0.36 ± 0.04 0.40 ± 0.04 0.2972 <0.0001# 0.0424 0.0411 
Sol (mg/g) 0.29 ± 0.07 0.27 ± 0.04 0.31 ± 0.05 0.30 ± 0.04 0.32 ± 0.04 0.5435 0.0435 0.4236 0.5186 
RV (mg/g) 1.16 ± 0.26 1.21 ± 0.21 1.31 ± 0.25 0.99 ± 0.13 1.06 ± 0.20 0.6306 0.3910 0.3707 0.0888 
LV (mg/g) 3.34 ± 0.35 3.50 ± 0.25 3.41 ± 0.40 3.21 ± 0.24 3.61 ± 0.35$ 0.2790 0.5483 0.0048$ 0.3584 
RV + LV (mg/g) 4.49 ± 0.40 4.71 ± 0.18 4.71 ± 0.33 4.20 ± 0.25 4.67 ± 0.46$ 0.1771 0.9991 0.0075$ 0.0655 
RV: LV 0.35 ± 0.11 0.35 ± 0.08 0.39 ± 0.11 0.31 ± 0.05 0.29 ± 0.06 0.9711 0.3479 0.4579 0.3316 
Lung (Wet – Dry) 
(mg/g) 
4.64 ± 0.34 5.14 ± 0.70 5.15 ± 0.37 4.29 ± 0.35 4.70 ± 0.44 0.0736 0.9596 0.0449 0.0342 
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3.3.2 Baseline ventilation and metabolism 
Respiratory and metabolic parameters during baseline (normoxia) are shown in Table 
3.2. Minute ventilation (V"I) during baseline (combined periods of normoxia) was 
equivalent for sham and CIH groups (P = 0.0691). The administration of the putative 
NOX2 inhibitor, apocynin (2mM), in the drinking water during exposure to CIH, 
resulted in increased VT (P = 0.0085) and V" I (P = 0.0188). V" I was significantly reduced 
in NOX2 KO sham compared with sham mice (P = 0.0018). The reduction in V" I  during 
normoxia was the result of a lower VT (P = 0.0029); fR did not differ between NOX2 
KO sham and sham groups (P = 0.3091). PIF (P = 0.9744) and PEF (P = 0.8016) were 
equivalent for sham and CIH groups. However, treatment with apocynin during 
exposure to CIH revealed an increase in both PIF (P = < 0.0001) and PEF (P < 0.0001). 
Exposure to CIH had no effect on PIF (P = 0.4580) or PEF (P = 0.9323) in NOX2 KO 
mice compared with the corresponding sham group. Additionally, PEF was reduced 
in NOX2 KO sham (P = 0.0120) compared with wild-type sham mice. Assessment of 
oxygen consumption (V"O2) and carbon dioxide production (V"CO2) revealed minimal 
differences between groups. Of note, V"O2 and V"CO2 were both increased for the CIH 
+ APO group compared to exposure to CIH alone (V"O2; P = 0.0046, V"CO2; P = 0.0001). 
The ventilatory equivalent for carbon dioxide (V" I/V"CO2) did not differ between sham 
and CIH mice (P = 0.9338), while a significant reduction in V" I/V"CO2 was evident 
following treatment with apocynin during exposure to CIH (P = 0.0064). V" I/V"CO2 was 
significantly lower in NOX2 KO sham compared with sham mice (P = 0.0050), 
indicative of hypoventilation in mice deficient in the NOX2 enzyme. Body mass (g) 
was significantly decreased following exposure to CIH compared with sham (P = 
0.0011); apocynin prevented this decrease (P = 0.0008). This well described decrease 
in body mass following exposure to CIH was also evident in NOX2 KO mice (P = 
0.0042), reminiscent of that seen in C57BL/6J (wild-type) mice. Mice lacking the 
NOX2 enzyme were significantly heavier than their wild-type control counterparts (P 
< 0.0001). Inspiratory duration (Ti), expiratory duration (Te), ventilatory equivalent 
for O2 (V" I/V"O2) and the ratio of V"CO2 to V"O2 (respiratory exchange ratio) were 





Table 3.2 Baseline breathing and metabolism measurements. Definition of abbreviations: fR, breathing frequency; VT, tidal volume; V/ I, minute ventilation; PIF, peak inspiratory flow; PEF, peak 
expiratory flow; Ti, inspiratory duration; Te, expiratory duration; V/O2, oxygen consumption; V/CO2, carbon dioxide production; V/ I/V/O2, ventilatory equivalent for oxygen; V/ I/V/CO2, ventilatory 
equivalent for carbon dioxide; V/CO2/V/O2, respiratory exchange ratio (RER); sham, normoxia (21% O2) exposed; CIH, chronic intermittent hypoxia exposed; CIH + APO, apocynin (2mM) given in 
the drinking water for the duration of CIH exposure; NOX2 KO, NADPH Oxidase 2 knock-out (B6.129S-Cybbtm1Din/J), sham- or CIH-exposed. Values are expressed as mean ± SD. Data sets which 
were normally distributed were statistically compared using unpaired two-tailed Student’s t test. Welch’s correction was applied in the case of unequal variance. Data which were not normally 
distributed were compared using Mann Whitney non-parametric tests. Bolded numbers indicate statistical significance (P < 0.0125) following correction for multiple comparisons. Relevant 
comparisons are denoted as follows: * CIH significantly different from corresponding sham values;  # APO + CIH significantly different from corresponding CIH values; $ NOX2 KO CIH significantly 
different from corresponding NOX2 KO sham values; £ NOX2 KO sham significantly different from corresponding sham values.  
 Sham 
(n = 12) 
CIH 
(n = 12) 
CIH + APO 
(n = 11-12) 
NOX2 KO sham 
(n = 12) 
NOX2 KO CIH 
(n = 12) 
Sham vs CIH 
(P value) 
CIH vs CIH + APO 
(P value) 
NOX2 KO sham 
vs NOX2 KO CIH 
(P value) 
Sham vs NOX2 
KO sham  
(P value) 
fR (bpm) 184.6 ± 12.0 182.8 ± 11.9 183.0 ± 20.5 190.7 ± 16.0 175.1 ± 18.1 0.7099 0.9780 0.0358 0.3091 
VT (ml/g) 0.0068 ±0.001 0.0073 ± 0.001 0.0084 ± 0.001# 0.0057 ± 0.001£ 0.0063 ± 0.001 0.0832 0.0085# 0.0332 0.0029£ 
V&I  (ml/min/g) 1.23 ± 0.13 1.32 ± 0.12 1.53 ± 0.25 1.05 ± 0.14£ 1.04 ± 0.15 0.0691 0.0188 >0.9999 0.0018£ 
PIF (ml/s) 2.52 ± 0.29 2.52 ± 0.30 3.24 ± 0.42# 2.60 ± 0.27 2.67 ± 0.25 0.9774 <0.0001# 0.4580 0.5550 
PEF (ml/s) 1.68 ± 0.20 1.70 ± 0.18 2.53 ± 0.29# 1.93 ± 0.24£ 1.92 ± 0.20 0.8016 <0.0001# 0.9323 0.0120£ 
Ti (ms) 116.7 ± 4.0 119.5 ± 6.9 112.9 ± 8.5 116.0 ± 6.5 117.1 ± 6.9 0.2434 0.0513 0.6904 0.7566 
Te (ms) 225.4 ± 23.1 224.8 ± 21.6 227.8 ± 34.3 216.7 ± 31.1 254.5 ± 47.1 0.9489 0.8001 0.0301 0.4455 
V&O2 (ml/min/g) 0.038 ± 0.01 0.041 ± 0.01 0.059 ± 0.02# 0.040 ± 0.01 0.038 ± 0.01 0.2195 0.0046# 0.7982 0.6976 
V&CO2 (ml/min/g) 0.031 ± 0.01 0.033 ± 0.01 0.053 ± 0.01# 0.035 ± 0.01 0.033 ± 0.01 0.3229 0.0001# 0.4568 0.1726 
V& I/V&O2 32.7 ± 5.3 32.8 ± 4.7 29.0 ± 13.9 29.3 ± 11.7 29.5 ± 8.5 0.9402 0.0512 0.7125 0.0780 
V& I/V&CO2 40.6 ± 7.4 40.9 ± 8.9 29.9 ± 8.2# 31.3 ± 7.2£ 33.8 ± 9.9 0.9338 0.0064# 0.4703 0.0050£ 
V&CO2/V&O2 0.82 ± 0.17 0.82 ± 0.19 0.94 ± 0.22 0.93 ± 0.21 0.89 ± 0.20 0.9138 0.1997 0.6563 0.1869 
Body Mass (g) 23.6 ± 1.5 21.4 ±  0.7* 23.5 ± 1.6# 28.1 ± 2.6£ 25.4 ± 0.94$ 0.0011* 0.0008# 0.0042$ <0.0001£ 
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3.3.3 Expression of sighs and apnoeas during normoxia  
Figure 3.1 shows representative respiratory flow traces illustrating a sigh and post-
sigh apnoea (A) and a spontaneous apnoea (B) in a wild-type sham mouse during 
normoxia. Analysis of sighs revealed that exposure to CIH had no effect on the 
frequency of sighs in both wild-type (P = 0.0364; Fig 3.1; C) and NOX2 KO (P = 0.2128; 
Fig 3.1; C) mice. A significant increase in the frequency of sighs was evident in NOX2 
KO sham compared with wild-type sham mice (P = 0.0066; Fig 3.1; C). No difference 
was observed in the frequency of post-sigh apnoeas following exposure to CIH in 
wild-type (P = 0.1170; Fig 3.1; D) or NOX2 KO (P = 0.3872; Fig 3.1; D) mice. Frequency 
of post-sigh apnoeas was also equivalent following NOX2 blockade via apocynin 
administration (P = 0.1230; Fig 3.1; D) and genetic NOX2 knock-out (P = 0.0522; Fig 
3.1; D). The duration of post-sigh apnoeas was significantly elevated in CIH-exposed 
compared to sham mice (P = 0.0053; Fig 3.1; E); the increase was entirely prevented 
by the administration of apocynin throughout the exposure to CIH (P = 0.0083; Fig 
3.1 E). The increase in the duration of post-sigh apnoeas following exposure to CIH 
was not observed in mice lacking the NOX2 enzyme (P = 0.1651; Fig 3.1; E).  
 
Analysis of spontaneous apnoeas revealed a significant increase in the frequency of 
spontaneous apnoeas in mice following exposure to CIH compared to the 
corresponding sham group (P < 0.0001; Fig 3.1; F); treatment with apocynin 
completely prevented the increase, with values comparable to those observed in 
sham mice (P < 0.0001; Fig 3.1; F). The frequency of spontaneous apnoeas was 
elevated following exposure to CIH in NOX2 KO mice (P = 0.0063; Fig 3.1; F), similar 
to that revealed in wild-type mice, suggesting a non-NOX2 dependent mechanism of 
action of ROS. The duration of spontaneous apnoeas was unaffected by exposure to 
CIH for both wild-type (P = 0.5125; Fig 3.1; G) and NOX2 KO (P = 0.6231; Fig 3.1; G) 
mice. Similarly, the duration of spontaneous apnoeas was not different following 
NOX2 blockade via apocynin treatment (P = 0.4007; Fig 3.1; G) and genetic NOX2 








Figure 3.1 Expression of sighs and apnoeas in awake mice during normoxia. A and B, 
representative respiratory flow traces demonstrating an augmented breath or sigh (A; grey 
shading) and post-sigh apnoea (A; grey line) and a spontaneous apnoea (B; grey shading) in 
a sham mouse during normoxia.  C, D, E, F, G, group data for sigh frequency (C), post-sigh 
apnoea frequency (D) and duration (E), and spontaneous apnoea frequency (F) and duration 
(G) occurring during normoxia for all groups. Sham, normoxia (21% O2) exposed; CIH, chronic 
intermittent hypoxia exposed; CIH + APO, apocynin (2mM) given in the drinking water for 
the duration of CIH exposure; NOX2 KO, NADPH Oxidase 2 knock-out (B6.129S-
Cybbtm1Din/J), sham- or CIH-exposed. Values are expressed as mean ± SD (n=12 per group). 
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Data sets which were normally distributed were statistically compared using unpaired two-
tailed Student’s t test. Welch’s correction was applied in the case of unequal variance. Data 
which were not normally distributed were compared using Mann Whitney non-parametric 
tests. Statistical significance was taken at P < 0.0125. Relevant comparisons are denoted as 
follows: *denotes sham vs. CIH, ** P < 0.01, **** P < 0.0001; # denotes CIH vs. CIH + APO, ## 
P < 0.01, #### P < 0.0001; £denotes sham vs. NOX2 KO sham,  ££ P < 0.01; $ denotes NOX2 KO 




3.3.4 Respiratory timing measurements during normoxia  
Figure 3.2 shows Poincaré plots of the breath-to-breath (BBn) and subsequent 
interval (BBn+1) of 200 consecutive breaths for expiratory duration (Te; A- E) and total 
breath duration (Ttot; H-L) in sham (A and H; white), CIH (B and I; black), CIH + APO (C 
and J; blue), NOX2 KO sham (D and K; pink) and NOX2 KO CIH (E and L; red). 
Assessment of the short-term (SD1) and long-term (SD2) variability of breathing 
revealed no evidence for respiratory instability for Te  following exposure to CIH in 
either wild-type (SD1; P = 0.5875, SD2; P = 0.3474; Fig 3.2; F and G, respectively) or 
NOX2 KO (SD1; P = 0.1978, SD2; P = 0.2267; Fig 3.2; F and G, respectively) mice. 
However, treatment with apocynin throughout the exposure to CIH increased 
breathing stability as indicated by significantly lower short-term (SD1; P = 0.0032; Fig 
3.2; F) and long-term (SD2; P = 0.0009; Fig 3.2; G) variability of breathing 
assessments. Similarly, SD1 and SD2 revealed no evidence for respiratory instability 
for Ttot following exposure to CIH in either wild-type (SD1; P = 0.3809, SD2; P = 0.0827; 
Fig 3.2; M and N, respectively) or NOX2 KO (SD1; P = 0.2155, SD2; P = 0.2854; Fig 3.2; 
M and N, respectively) mice. However, treatment with apocynin increased breathing 
stability as indicated by significantly lower SD1 compared to exposure to CIH alone 














Figure 3.2 Respiratory timing measurements in awake mice during normoxia. A B, C, D and 
E, Poincaré plot of breath-to-breath (BBn) and subsequent breath-to-breath (BBn+1) interval 
of expiratory duration (Te) over 200 consecutive breaths for sham (A), CIH (B), CIH + APO (C), 
NOX2 KO sham (D) and NOX2 KO CIH (E) groups. F and G, group data of short-term (F; SD1) 
and long-term (G; SD2) variability of breathing based on Te for all groups. H, I, J, K and L, 
Poincaré plots of BBn and BBn+1 of total breath duration (Ttot) over 200 consecutive breaths 
for sham (H), CIH (I), CIH + APO (J), NOX2 KO sham (K) and NOX2 KO CIH (L) groups. M and N, 
group data of short-term (M; SD1) and long-term (N; SD2) variability of breathing based on 
Ttot for all groups. Values are expressed as mean ± SD (n=12 per group). Data sets which were 
 127 
normally distributed were statistically compared using unpaired two-tailed Student’s t test. 
Welch’s correction was applied in the case of unequal variance. Data which were not 
normally distributed were compared using Mann Whitney non-parametric tests. Statistical 
significance was taken at p < 0.0125. Relevant comparisons denoted as follows;  #denotes 




3.3.5 Brainstem 5-HT and 5-HIAA concentrations  
Concentrations of 5-HT and its metabolite 5-HIAA were quantified in brainstem 
samples of mice from all groups using HPLC. These and the ratio of 5-HIAA to 5-HT 
(index of serotonergic metabolism) is shown in Figure 3.3 A-C. The concentration of 
5-HT was not different following exposure to CIH in wild-type (P = 0.3160; Fig 3.3; A) 
and NOX2 KO mice (P = 0.1431; Fig 3.3; A). Moreover, treatment with apocynin (P = 
0.1683; Fig 3.3; A) or genetic knock-out of the NOX2 enzyme alone (P = 0.0343; Fig 
3.3; A) did not significantly alter 5-HT concentration. Analysis of 5-HIAA revealed that 
its concentration was equivalent in the brainstem of both wild-type (P = 0.0560; Fig 
3.3; B) and NOX2 KO mice (P = 0.5288; Fig 3.3; B) exposed to CIH, as well as mice 
treated with apocynin during the exposure to CIH (P = 0.2930; Fig 3.3; B). A significant 
decrease in the concentration of the metabolite 5-HIAA was observed in NOX2 KO 
sham mice compared to wild-type sham mice (P = 0.0031; Fig 3.3; B). The ratio of 5-
HIAA to 5-HT, was significantly reduced in CIH-exposed mice compared to sham (P < 
0.0001; Fig 3.3; C); apocynin treatment had no effect on 5-HIAA/5-HT  (P = 0.8676; 
Fig 3.3; C). There was no difference in the ratio of 5-HIAA/5-HT between NOX2 KO 
mice exposed to CIH compared with NOX2 KO sham mice (P = 0.3333; Fig 3.3; C). 
Mice lacking the NOX2 enzyme had a significantly lower ratio of 5-HIAA/5HT within 
brainstem homogenates when compared to wild-type sham (P < 0.0001; Fig 3.3; C), 














Figure 3.3 Brainstem monoamine analysis. Definition of abbreviations: 5-HT, serotonin; 5-
HIAA, 5-hydroxyindole acetic acid. Group data for 5-HT concentration (A), 5-HIAA 
concentration (B) and 5-HIAA/5-HT ratio (C) for all groups. Sham, normoxia (21% O2) 
exposed; CIH, chronic intermittent hypoxia exposed; CIH + APO, apocynin (2mM) given in the 
drinking water for the duration of CIH exposure; NOX2 KO, NADPH Oxidase 2 knock-out 
(B6.129S-Cybbtm1Din/J), sham- or CIH-exposed. Values are expressed as mean ± SD (n=8-10 
per group). Data sets which were normally distributed were statistically compared using 
unpaired two-tailed Student’s t test. Welch’s correction was applied in the case of unequal 
variance. Data which were not normally distributed were compared using Mann Whitney 
non-parametric tests. Statistical significance was taken at p < 0.0125 to correct for multiple 
comparisons. *denotes sham vs. CIH,**** P < 0.0001; £denotes sham vs. NOX2 KO sham, ££ 







3.3.6 Ventilatory and metabolic responsiveness to hypoxia  
Figure 3.4 shows the time course of the response of a range of ventilatory and 
metabolic parameters during a 10-minute exposure to hypoxic challenge (FiO2 = 0.1; 
balance N2) for all groups. Minute ventilation increased rapidly across all groups at 
the onset of hypoxia compared to baseline ventilation values (Fig 3.4; G, H & I, 
respectively). Exposure to 2 weeks of CIH increased ventilation over the duration of 
the hypoxic challenge compared with sham (P = 0.0334; Fig 3.4; G), owing to a 
modest increase in breathing frequency (P = 0.0857; Fig 3.4; A). Apocynin treatment 
throughout the exposure to CIH did not ameliorate the increase in ventilation (P = 
0.5349; Fig 3.4; G). Similarly, exposure to CIH increased hypoxic ventilation in NOX2 
KO mice (P = 0.0032; Fig 3.4; H), owing to an increase in tidal volume (P = 0.0194; Fig 
3.4; E). No effect of NOX2 KO alone was observed on ventilation in response to 
hypoxia compared to C57BL/6J (wild-type) mice (P = 0.1699; Fig 3.4; I). V4 I/V4CO2 
increased rapidly at the onset of hypoxia compared to baseline values (Fig 3.4; M, N 
& O, respectively). However, exposure to CIH had no effect on V4 I/V4CO2 during the 
hypoxic challenge for wild type (P = 0.5221; Fig 3.4; M) or NOX2 KO mice (P = 0.7805; 
Fig 3.4; N) compared with corresponding sham exposures. Treatment with apocynin 
during exposure to CIH significantly reduced V4 I/V4CO2 during hypoxic breathing (P = 
0.0118; Fig 3.4; M) and the genetic deletion of NOX2 also reduced this parameter 
when compared to wild-type controls (P = 0.0036; Fig 3.4; O).  The respiratory 
exchange ratio (RER) initially decreased at the onset of hypoxia for all groups, with 
the exception of the CIH + APO group (Fig 3.4; P, Q & R, respectively.) RER was 
equivalent for mice exposed to CIH compared with sham mice for both wild type (P 
= 0.9083; Fig 3.4; P) and NOX2 KO groups (P = 0.6242; Fig 3.4; Q). Treatment with 
apocynin during the exposure to CIH resulted in a significantly increased RER (P = 
<0.0001; Fig 3.4; P). The change in RER during the hypoxic challenge was equivalent 












Figure 3.4 Ventilatory and metabolic responsiveness to hypoxia. Group data (mean ± SD; 
n=10-12 per group) for breathing frequency (A, B, C; fR), tidal volume (D, E, F; VT), minute 
ventilation (G, H ,I; VI), carbon dioxide production (J, K ,L; V4CO2), ventilatory equivalent for 
carbon dioxide (M, N, O; VI/VCO2) and respiratory exchange ratio (P, Q, R; VCO2/VO2) during 
baseline and 10 min of exposure to hypoxia (10% inspired oxygen; balance N2) for sham, CIH, 
CIH + APO, NOX2 KO sham and NOX2 KO CIH groups. Sham, normoxia (21% O2) exposed; CIH, 
chronic intermittent hypoxia exposed; CIH + APO, Apocynin (2mM) given in the drinking 
water for the duration of CIH exposure; NOX2 KO, NADPH Oxidase 2 knock-out (B6.129S-
Cybbtm1Din/J), sham or CIH exposed. Data were statistically compared by repeated 
measures two-way ANOVA with Bonferroni post hoc test. For repeated measures two-way 
ANOVA; CIH denotes sham vs. CIH; APO denotes CIH vs. CIH + APO for A, D, G, J, M & P. Int  
denotes the interaction between two factors for A-R. For Bonferroni post hoc test;  *denotes 
sham vs. CIH, *P < 0.05; #denotes CIH vs. CIH + APO, #P < 0.05, ## P < 0.01; $denotes NOX2 KO 
sham vs. NOX2 KO CIH, $ P < 0.05, $$ P < 0.01, $$$$ P < 0.0001; £  denotes sham vs. NOX2 KO 




3.3.7 Ventilatory and metabolic responsiveness to hypercapnia  
Fig 3.5 shows the time course of the response of a range of ventilatory and metabolic 
parameters to a 10-minute hypercapnic challenge (FiCO2 = 0.05, balance N2) for all 
groups. Ventilation increased rapidly at the onset of hypercapnia for all groups and 
remained elevated for the duration of the challenge (Fig 3.5; G, H & I). Exposure to 
CIH had no effect on hypercapnic ventilation compared to sham-exposed mice (P = 
0.3186; Fig 3.5; G); treatment with apocynin throughout the exposure to CIH also 
resulted in no difference in hypercapnic ventilation compared with exposure to CIH 
alone (P = 0.8206; Fig 3.5; G). In contrast, exposure to CIH significantly increased 
hypercapnic ventilation in NOX2 KO mice compared with NOX2 KO sham mice (P = 
0.0007; Fig 3.5; H), an effect underpinned by an increase in tidal volume (P = 0.0001; 
Fig 3.5; E). Moreover, a significant increase in ventilation was observed in NOX2 KO 
mice compared with wild-type sham mice (P = 0.0029; Fig 3.5; I). The increase in 
ventilation in NOX2 KO mice in response to hypercapnia was due to a concomitant 
increase in breathing frequency (P = 0.0015; Fig 3.5; C) and tidal volume (P = 0.0150; 
Fig 3.5; C). V4 I/V4CO2 also increased at the onset of hypercapnia compared to baseline 
values (Fig 3.5; M, N & O, respectively). However, exposure to CIH had no effect on 
V4 I/V4CO2 during the hypercapnic challenge compared to sham mice (P = 0.2043; Fig 
3.5; M); apocynin treatment had no significant effect on V4 I/V4CO2 compared with 
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exposure to CIH alone (P = 0.384; Fig 3.5; M). However, V4 I/V4CO2 was significantly 
elevated following exposure to CIH in mice lacking the NOX2 enzyme (P = 0.0352; Fig 
3.5; N). When ventilation was normalised for CO2 production, V4 I/V4CO2 was equivalent 





Figure 3.5 Ventilatory and metabolic responsiveness to hypercapnia. Group data (mean ± 
SD; n=10-12 per group) for breathing frequency (A, B, C; fR), tidal volume (D, E, F; VT), minute 
ventilation (G, H, I; VI), carbon dioxide production (J, K, L; V4CO2) and ventilatory equivalent 
for carbon dioxide (M, N, O; VI/VCO2) during baseline and 10 min of exposure to hypercapnia 
(5% inspired CO2; balance O2) for sham, CIH, CIH + APO, NOX2 KO sham and NOX2 KO CIH 
groups. Sham, normoxia (21% O2) exposed; CIH, chronic intermittent hypoxia exposed; CIH 
+ APO, apocynin (2mM) given in the drinking water for the duration of CIH exposure; NOX2 
KO, NADPH Oxidase 2 knock-out (B6.129S-Cybbtm1Din/J), sham or CIH exposed. Data were 
statistically compared by repeated measures two-way ANOVA with Bonferroni post hoc test. 
For repeated measures two-way ANOVA; CIH denotes sham vs. CIH; APO denotes CIH vs. CIH 
+ APO for A, D, G, J, & M. Int denotes the interaction between two factors for A-O. For 
Bonferroni post hoc test; #denotes CIH vs. CIH + APO, ## P < 0.01; $denotes NOX2 KO sham vs. 




3.3.8 Peak ventilatory responsiveness to hypoxia and hypercapnia  
Figure 3.6 shows grouped ventilatory and metabolic data from all groups of mice in 
response to ventilatory challenge with hypoxia (10% O2, balance N2; Fig 3.5; A and B, 
respectively) and hypercapnia (5% CO2, 95% O2; Fig 3.5; C and D, respectively) in 
order to assess chemoreceptor responsiveness. The peak hypoxic ventilatory 
response (HVR; delta V4 I) was increased following exposure to CIH compared with 
sham-exposed mice (P = 0.0341; Fig 3.6; A), although this did not meet the threshold 
for statistical significance when correction for multiple comparisons was applied. 
Apocynin treatment throughout the exposure to CIH did not affect the ventilatory 
response to hypoxia (P = 0.3989; Fig 3.6 A). Peak HVR was significantly increased in 
NOX2 KO mice exposed to CIH compared with NOX2 KO sham mice (P = 0.0003, Fig 
3.6; A). There was no difference in peak HVR in NOX2 KO mice compared with wild-
type sham mice (P = 0.4103; Fig 3.6; A). The peak response for V4 I/V4CO2 during hypoxic 
exposure is shown in Figure 3.6; B. Exposure to CIH increased the V4 I/V4CO2 peak 
response to hypoxia in both wild-type (P = 0.0633; Fig 3.6; B) and NOX2 KO mice (P = 
0.2115; Fig 3.6; B), evidenced by a notable effect size. NOX2 blockade using apocynin 
(P = 0.6811; Fig 3.6; B) or the genetic deletion of the NOX2 enzyme (P = 0.8977; Fig 
3.6; B) had no effect on the peak V4 I/V4CO2 response to hypoxia. The peak ventilatory 
response to hypercapnia (HCVR; delta V4 I) and the corresponding peak V4 I/V4CO2 
response are shown in Figure 3.6; C and D, respectively. Exposure to CIH had no 
significant effect on the peak HCVR compared with sham (P = 0.4182; Fig 3.6; C); 
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apocynin did not significantly alter the peak HCVR compared with exposure to CIH 
alone (P = 0.2661; Fig 3.6; C). Exposure to CIH resulted in a significant increase in the 
peak HVCR in mice lacking the NOX2 enzyme (P = 0.0016; Fig 3.6 C). A significant 
increase in the peak HCVR was also evident in NOX2 KO sham compared to wild-type 
sham mice (P = 0.0002; Fig 3.6 C). There was no significant difference in peak V4 I/V4CO2 
in response to acute hypercapnia following exposure to CIH in both wild-type (P = 
0.7139; Fig 3.6; D) and NOX2 KO mice (P = 0.1161; Fig 3.6; D). NOX2 blockade had no 
effect on peak V4 I/V4CO2, when examined after apocynin treatment during exposure 
to CIH (P = 0.0149; Fig 3.6; D) or after the genetic deletion of the NOX2 enzyme alone 






Figure 3.6 Peak ventilatory and metabolic responsiveness to hypoxia and hypercapnia. 
Group data for peak ventilatory responsiveness (expressed as Δ minute ventilation) to 
hypoxia (A) and hypercapnia (C) and the corresponding peak ventilatory equivalent for 
carbon dioxide (Δ V4 I/ V4CO2) to hypoxia (B) and hypercapnia (D) for sham, CIH, CIH + APO, 
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NOX2 KO sham and NOX2 KO CIH groups. Peak ventilatory responsiveness was taken as each 
individual animal’s peak response to hypoxia or hypercapnia. The corresponding V4CO2 value 
for each peak response was then used to calculate Δ V4 I / V4CO2. Values are expressed as mean 
± SD (n=10-12 per group). Sham, normoxia (21% O2)-exposed; CIH, chronic intermittent 
hypoxia-exposed; CIH + APO, Apocynin (2mM) given in the drinking water for the duration 
of CIH exposure; NOX2 KO, NADPH Oxidase 2 knock-out (B6.129S-Cybbtm1Din/J), sham- or 
CIH-exposed. Data sets which were normally distributed were statistically compared using 
unpaired two-tailed Student’s t test. Welch’s correction was applied in the case of unequal 
variance. Data which were not normally distributed were compared using Mann Whitney 
non-parametric tests. Statistical significance was taken at p < 0.0125. $ denotes NOX2 KO 
























The major findings of this study are: 
 
1) 2 weeks of exposure to CIH was not sufficient to elicit a persistent change in 
normoxic breathing in wild-type or NOX2 KO mice. 
 
2) Mice lacking the NOX2 enzyme and mice administered apocynin during exposure 
to CIH hypoventilate during normoxic breathing, evidenced by a reduction in basal 
V4 I/V4CO2. 
 
3) Exposure to CIH increased the frequency of spontaneous apnoeas by a similar 
magnitude in wild-type and NOX2 KO mice during normoxia; the increase was 
blocked by the administration of apocynin in wild-type mice throughout the exposure 
to CIH. 
 
4) Serotonergic activity, estimated by the ratio of 5-HIAA/5-HT, was reduced in NOX2 
KO mice and following exposure to CIH in wild-type mice. 
 
5) Both wild-type and NOX2 KO mice exposed to CIH display a modest increase in 
ventilatory responsiveness to hypoxia; apocynin significantly decreased the temporal 
V4 I/V4CO2 response to hypoxia. 
 
6) NOX2 KO results in a significantly decreased temporal ventilatory response to 
hypoxia; the peak ventilatory response to hypoxia remained unchanged.  
 
7) Exposure to CIH had no effect on the hypercapnic ventilatory response in wild-
type mice. NOX2 KO yields a potentiated hypercapnic ventilatory response, which 




OSAS is a highly prevalent sleep disorder, which harbours significant consequences 
for a range of integrative body systems, primarily that of cardio-respiratory control 
(Carlson et al., 1993, Leuenberger et al., 1995, Somers et al., 1995, Imadojemu et al., 
2002, Del Rio et al., 2014a, Lucking et al., 2018). CIH is the classic hallmark feature of 
OSAS as a result of repeated obstruction of the pharyngeal airway leading to 
repeated arterial oxygen desaturation (White and Younes, 2012). OSAS is widely 
considered an oxidative stress disorder (Lavie, 2003). There is a remarkable capacity 
for plasticity within the respiratory control system and there is now a growing body 
of evidence indicating hypoxia-induced respiratory plasticity. A large body of 
evidence now points to exposure to CIH as driving force maintaining aberrant 
respiratory plasticity at multiple sites of the respiratory control network, which has 
the potential to contribute to, or exacerbate the severity of, OSAS. Varying intensities 
and durations of CIH have been shown to induce respiratory muscle weakness and 
fatigue in animal models of sleep-disordered breathing (McGuire et al., 2002a, 
McGuire et al., 2002b, Liu et al., 2005, Pae et al., 2005, Dunleavy et al., 2008, Liu et 
al., 2009, Jia and Liu, 2010, Skelly et al., 2012, Wang et al., 2013, Zhou and Liu, 2013, 
McDonald et al., 2015). Moreover, exposure to CIH can lead to impaired motor 
control of the upper airway (O'Halloran et al., 2002, Veasey et al., 2004, Ray et al., 
2007), altered respiratory motor outflow (Moraes et al., 2013, Moraes and Machado, 
2015) and discordant respiratory rhythm and pattern generation culminating in 
increased apnoea index (Edge et al., 2012, Donovan et al., 2014, Zanella et al., 2014, 
Souza et al., 2015, Elliot-Portal et al., 2018). Exposure to CIH can evoke sensory long-
term facilitation within the carotid body (Peng et al., 2003), and induce facilitation of 
breathing and altered chemoreflex control of breathing (Reeves and Gozal, 2006, 
Skelly et al., 2012, Morgan et al., 2016b, Elliot-Portal et al., 2018). The precise 
mechanisms of respiratory system mal-adaptation following exposure to CIH remains 
unclear. Studies utilising pharmacological interventions now place CIH-induced ROS 
at the centre of this debate (Peng et al., 2003, Veasey et al., 2004, Dunleavy et al., 
2008, Edge et al., 2012, Skelly et al., 2012). Furthermore, recent evidence highlights 
a role for the NOX2 enzymatic complex as a potential source of ROS underlying 
sensory and motor plasticity at multiple sites of the respiratory control network 
(Peng et al., 2006a, MacFarlane et al., 2009, Peng et al., 2009, Peng et al., 2011, 
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MacFarlane et al., 2014, Perim et al., 2018). Given the clinical implication of poor 
respiratory function in OSAS, the development of therapies targeting the specific 
source of CIH-induced ROS, postulated to be NOX2, may serve as an adjunct therapy 
for this debilitating disorder.  
 
In the current study, we set out to examine the effect of exposure to CIH on 
ventilation in awake, unrestrained mice using WBP. We utilised an established rodent 
model of SDB with the CIH profile employed consisting of a 14-day treatment. Our 
CIH paradigm consisted of O2 cycling from 21% for 210 seconds to 5% at the nadir for 
90 seconds, 8 hours per day during light hours (Lucking et al., 2014). This CIH profile 
yielded 12 hypoxia-reoxygenation cycles per hour, reflective of that typically 
observed throughout the night cycle of an OSAS patient with a mild-to-moderate 
form of the disorder (Goyal and Johnson, 2017). We aimed to determine the effects 
of exposure to CIH on ventilation and metabolism during baseline (normoxic) 
breathing. It is well established that IH holds the capacity to induce plasticity at 
multiple levels of the respiratory control system, with the magnitude of this effect 
largely dependent on the time, intensity and duration of the IH stimulus (Navarrete-
Opazo and Mitchell, 2014). Ventilatory adaptation following exposure to CIH, which 
can manifest as a progressive increase in normoxic ventilation following chronic 
exposure to IH, has previously been reported in rats (Reeves and Gozal, 2006, Skelly 
et al., 2012). We also aimed to investigate ventilatory responses to acute 
physiological challenges, namely hypoxia and hypercapnia, to assess the effects of 
exposure to CIH on peripheral and central chemoreceptor responsiveness. The 
functional significance of altered responses to these acute challenges is divergent. 
Respiratory mal-adaptation may present in an apnoeic patient when an inability to 
respond to a perturbation with an appropriate ventilatory response results in 
chemoreflexes not holding the essential capability to terminate apnoeic events. 
Conversely, an ‘overshoot’ or exaggerated ventilatory response may serve to create 
respiratory instability by excessively removing CO2, thus reducing the CO2 reserve 
toward the apnoeic threshold (Dempsey et al., 2010). We also sought to examine the 
effect of exposure to CIH on the propensity for apnoea in mice. Increased propensity 
for central apnoea has been reported in patients with OSAS (Salloum et al., 2010). In 
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light of this, it has been demonstrated that exposure to CIH results in central apnoea 
in neonatal rat pups (Julien et al., 2008), adult rats (Edge et al., 2012, Souza et al., 
2015, Joseph et al., 2020) and mice (Elliot-Portal et al., 2018). Exposure to CIH has 
also been shown to increase the frequency of sighs and post-sigh apnoeas in rats 
(Edge et al., 2012, Souza et al., 2015, Joseph et al., 2020). Of interest, the 
administration of antioxidants has proven beneficial in ameliorating a range of IH-
induced respiratory anomalies, highlighting the role of ROS in CIH-induced 
respiratory morbidity (Peng et al., 2003, Edge et al., 2012). Moreover, evidence 
suggests that NOX2 may be the source of CIH-induced ROS which may act to facilitate 
some of the mechanisms which underpin the alterations in respiratory control 
outlined above (Peng et al., 2009, Edge et al., 2012, Joseph et al., 2020). We 
hypothesised that 2 weeks of exposure to CIH would result in mal-adaptation in 
respiratory control which would manifest as enhanced normoxic ventilation, altered 
reflex chemoresponsiveness, and the manifestation of respiratory instability and 
increased apnoeic index. Furthermore, we postulated that these alterations would 
be underpinned by a NOX2-derived ROS-dependent mechanism, amenable to 
blockade by supplementation with apocynin (putative NOX2 inhibitor) and NOX2 
knock-out.  
 
Ventilatory adaptation is a form of respiratory plasticity described as a persistent 
increase in normoxic ventilation following exposure to CIH. This likely represents a 
chemoreflex driven increase in breathing potentially contributing to instability and 
sympathetic nervous activity that is recognised as contributing to systemic 
hypertension in OSAS patients (Marcus et al., 2010). In our model, normoxic 
ventilation and corresponding metabolic measurements were unaffected by 2 weeks 
of exposure to CIH in both wild-type and NOX2 KO mice. This lack of a CIH-induced 
effect on resting ventilation is in agreement with previous studies in guinea pigs 
(Lucking et al., 2018), rats (McGuire et al., 2003, Edge et al., 2012, Souza et al., 2015, 
Joseph et al., 2020) and mice (Elliot-Portal et al., 2018). However, previous research 
by our group demonstrates increased normoxic ventilation in male rats following 9 
days of exposure to CIH (Skelly et al., 2012). This difference may be explained by the 
intensity of the IH stimulus, which was more severe in the latter study, as the CIH 
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profile utilised 20 hypoxia-reoxygenation cycles/hour compared with the 12 
cycles/hour employed in the current study. Indeed, ventilatory adaptation to 
intermittent hypoxia (VAIH) has also been reported in rats following 30 days (Reeves 
and Gozal, 2006) and 21 days of exposure (Morgan et al., 2016a), with both groups 
highlighting that the duration and paradigm of IH exposure appears pivotal in 
determining the phenotypical respiratory response. Thus, we suggest that we did not 
observe evidence of enhanced normoxic ventilation due to the relatively mild and 
short duration of CIH used in this study. A CIH-induced decrease in metabolic rate 
has previously reported in rat models (Morgan et al., 2016a, Joseph et al., 2020). 
However, we report no alteration to V4CO2 or V4O2 following exposure to CIH in either 
wild-type or NOX2 KO mice, consistent with previous studies in mice (Elliot-Portal et 
al., 2018). Differences in metabolic responses during normoxic breathing following 
exposure to CIH are likely due to species differences between rat and mouse models, 
as differential metabolic responses to hypoxia between small and large mammals 
have been described (Haouzi et al., 2009).  
 
Many forms of IH-induced plasticity are ROS-dependent (MacFarlane and Mitchell, 
2008), and more specifically these ROS appear to be NOX2-derived (MacFarlane et 
al., 2009, Peng et al., 2009). In the current study, we report that mice administered 
with apocynin throughout the 2-week exposure to CIH hypoventilate during 
normoxic breathing. Moreover, mice deficient in the NOX2 enzyme also 
hypoventilate during normoxia. Both of these observations are reflected by a 
significantly reduced V4 I/V4CO2, but appear to depend on different contributing 
factors. In apocynin-treated mice, there was a significant increase in metabolism that 
was only partially compensated for by increased ventilation. Ventilatory drive was 
increased in apocynin-treated mice, leading to decreased respiratory variability, but 
a relative hypoventilation persisted characterised by inadequate clearance of CO2. 
Conversely, NOX2 deletion resulted in a reduction in basal ventilation (with no 
change in metabolism), suggesting a key role for NOX2 at one or more sites of the 
respiratory control network in facilitating adequate respiratory motor outflow. It 
remains to be elucidated the precise mechanism by which NOX2 blockade leads to 
hypoventilation. This could be the result of alterations at the carotid body, central 
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pattern-generating sites and/or respiratory motor neurons, wherein ROS have been 
shown to be pivotal. Interestingly, serotonergic turnover was decreased in NOX2 KO 
mice as evidenced by a reduced 5-HIAA/5-HT ratio. 5-HT neurons contribute to the 
regulation of ventilatory control by providing tonic, excitatory drive to multiple 
components of the respiratory network (Steinbusch, 1981, Connelly et al., 1989, Voss 
et al., 1990). 5-HT neurons also appropriately adjust ventilation through changes in 
neurotransmitter release to alter the level of tonic excitatory drive, in response to 
alterations in tissue pH/CO2 (Richerson et al., 2001, Severson et al., 2003, Richerson, 
2004, Richerson et al., 2005, Corcoran et al., 2009). Studies in transgenic mice, 
deficient in 5-HT neurons, demonstrate that ventilatory output in the neonatal 
period is critically dependent on serotonergic neurons, which provide excitatory 
drive to the respiratory network (Hodges et al., 2009). This culminates in severe 
disruption to eupnoeic respiratory rhythm and leads to high postnatal mortality in 
neonates, findings which provide an insight into the mechanisms underpinning 
sudden infant death syndrome (SIDS).  Conversely, the deletion of 5-HT neurons does 
not decrease eupnoeic ventilation in adult mammals (Hodges et al., 2008). However, 
it has been suggested that divergent findings may be due to differential experimental 
approaches, and as such, the majority of the existing evidence is consistent with the 
concept that 5-HT neurons play an exclusively excitatory role at all postnatal ages 
(Hodges and Richerson, 2010). Neurotransmitter receptor activation may trigger ROS 
formation. Indeed, 5-HT receptor activation activates NOX in carotid bodies (Peng et 
al., 2006a) and phrenic motor neurons (MacFarlane et al., 2011), suggesting a 
serotonergic stimulus for NOX-dependent ROS formation which may underlie 
chemosensory and spinal respiratory plasticity. 5-HT receptors regulate NOX activity 
in the respiratory control system and ROS formation in cells is known to play a role 
in ventilatory control (MacFarlane et al., 2008). Our finding of reduced 5-HIAA/5-HT 
in NOX2 KO mice suggests that there may be changes in serotonergic modulation of 
respiratory motor function and chemoresponsiveness but this requires further 
investigation. 
 
Whilst obstructive apnoeas are the predominant apnoea type in OSAS patients due 
to collapse of the upper airway, central or spontaneous apnoeas also occur in 
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patients due to respiratory control instability. This reveals a common overlap in 
obstructive and central sleep apnoea. OSAS patients receiving CPAP treatment 
regularly present with periodic breathing and central apnoeas, with some patients 
consequentially being diagnosed with complex apnoea (Morgenthaler et al., 2006). 
Complex apnoea in OSAS patients may be a result of CIH-induced remodelling in the 
central respiratory network governing respiration, serving to perpetuate the severity 
of OSAS (O'Halloran, 2016). A key finding in the current study is that exposure to CIH 
produced a significant increase in the frequency of spontaneous apnoeas in wild-type 
mice during resting ventilation. Studies in female rats (Souza et al., 2015, Joseph et 
al., 2020), male rats (Edge et al., 2012) and male mice (Elliot-Portal et al., 2018) have 
revealed similar CIH-induced increases in apnoea index. To determine if NOX2 was a 
potential source of ROS underlying increased apnoea index, we administered 
apocynin throughout the exposure to CIH. This was efficacious in preventing the CIH-
induced increase in the frequency of spontaneous apnoeas to levels comparable to 
sham mice. This result is largely reminiscent of findings reported by (Edge et al., 
2012), where 9 days of exposure to CIH induced a similar rise in the frequency of 
spontaneous apnoeas, an effect ameliorated by the same dose of apocynin (2mM) 
used in the current study. While apocynin is commonly used as a putative NOX2 
inhibitor, evidence suggests that apocynin’s pharmacological action may be through 
more general antioxidant action (Wind et al., 2010). To examine the specificity of the 
apocynin-induced effect, we utilised NOX2 KO mice which were exposed to CIH. 
Somewhat surprisingly, we observed a near identical increase in the frequency of 
spontaneous apnoeas following exposure to CIH in mice deficient in NOX2 compared 
to wild-type controls. These data reveal a non-NOX2 dependent source of ROS in the 
mechanism underlying the development of increased apnoea index following 
exposure to CIH. Multiple regions of the respiratory control network are affected by 
ROS as a result of exposure to CIH (Mifflin et al., 2015, Semenza and Prabhakar, 
2015). Additionally, a wide range of signaling molecules including ROS, 5-HT, 
adenosine, HIF-1α and inflammatory cytokines are involved in the CIH-induced 
respiratory plasticity (Peng et al., 2006b, Pawar et al., 2009, Peng et al., 2009, Del Rio 
et al., 2011, Peng et al., 2013, Iturriaga et al., 2014, Sacramento et al., 2015, Morgan 
et al., 2016b, Moya et al., 2020). As these substances exhibit pro-oxidant properties 
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and/or are sensitive to ROS, oxidative stress may represent a common thread 
underpinning a complex mechanism that results in CIH-induced increase in apnoea 
index (Del Rio et al., 2010). The specific source of ROS warrants further 
experimentation.  
 
While we report no alteration to the frequency of sighs or post-sigh apnoeas 
following exposure to CIH, the duration of post-sigh apnoeas was increased following 
exposure to CIH, which was ameliorated by apocynin administration. This suggests 
that CIH-exposed mice develop a delayed ability to create regular respiratory cycles 
following deep breaths, characterised by sighs or post-sigh apnoeas, similar to 
previous observations in female rats (Souza et al., 2015). Furthermore, our study 
implicates a role for NOX2-derived ROS, evidenced by the absence of this effect 
following treatment with apocynin and in CIH-exposed NOX2 KO mice. The frequency 
of spontaneous apnoeas was equivalent in wild-type and NOX2 KO mice. However, 
we observed a significant increase in sigh frequency in mice lacking the NOX2 enzyme 
during normoxic breathing. Sighs are reportedly generated in the preBötC (Nagel et 
al., 2001) and interestingly, the application of the dismutated form of O2-, H2O2, 
evokes a transient depression followed by an augmentation of neuronal activity in 
this region (Garcia et al., 2011). This suggests that ROS are capable of exerting an 
inhibitory effect at this level of the respiratory control network. The increase in sigh 
frequency in NOX2 KO mice suggests that these ROS may be NOX2 derived in nature, 
as the removal of NOX2 may function to remove this inhibition, thus increasing sigh 
frequency. Our results generally support the view that ROS exert a tonic inhibition, 
yet surprisingly, NOX2 KO mice hypoventilate, which reveals the complex role of 
NOX2-derived ROS in the integrative control of breathing. 
We reasoned that there is a capacity for exposure to CIH to induce breathing 
instability, likely through alterations to the rhythm and pattern generation of 
respiration. However, assessments of respiratory stability through Poincaré plot 
analysis revealed no evidence for CIH-induced alterations to respiratory timing.  This 
is in contrast to studies in adult female rats which suggest that exposure to CIH 
produces an increase in short- and long-term breathing variability, resulting in 
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changes in respiratory pattern (Souza et al., 2015). Conversely, studies in male guinea 
pigs, with hypoxia-insensitive carotid bodies, reveal a CIH-induced decrease in 
indices of breathing variability (Lucking et al., 2018). This apparent dichotomy in 
results may relate to differences in sex, species and IH intensity and duration 
between experimental approaches. In the current study, administration of apocynin 
throughout the exposure to CIH produced a significant decrease in breathing 
variability to levels below that of controls. This effect could be mal-adaptive as it is 
well established that an optimal level of ROS is necessary for numerous homeostatic 
processes, with alterations in the levels of ROS contributing to functional deficits in 
respiratory control (MacFarlane et al., 2008). A degree of breathing variability is 
normal (Wuyts et al., 2011). Sighs hold an essential function in the normal respiratory 
cycle through monitoring brain states, stimulating arousal and resetting breathing 
variability (Ramirez, 2014). An increase in sighs during respiratory perturbations such 
as hypoxia, stimulates an arousal which highlights their critical role in survival. Failure 
to sigh or arouse has been implicated in SIDS (Garcia et al., 2013). Therefore, an 
increase in breathing stability to the extent that apocynin produced in our study, may 
represent an over-scavenging of ROS at sites pivotal for rhythmogenesis. In turn, this 
could be mal-adaptive by reducing the capacity of the respiratory control system to 
adapt to various environmental and behavioural demands. However, the 
pronounced metabolic effect of apocynin, which resulted in a reflex increase in 
ventilatory drive, albeit inadequate resulting in a relative hypoventilation, likely 
resulted in decreased variability due to elevated PaCO2. 
Respiratory neurons at multiple brainstem sites are believed to have key roles in 
generating homeostatic respiratory rhythm with inspiratory neurons at the preBötC 
coming to the fore as key players in this process. Exposure to CIH has been shown to 
alter the electrophysiological properties of these neurons (Moraes et al., 2013) and 
respiratory circuits at the level of the preBötC, in turn affecting transmission to the 
hypoglossal motor nucleus leading to increased transmission failure to the 
hypoglossal nerve (Garcia et al., 2016). Furthermore, complete ablation of the 
preBötC increases the propensity for apnoea in sleeping rats (McKay and Feldman, 
2008). ROS are implicated in multiple forms of IH-induced plasticity, with H2O2 shown 
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to be capable of modulating rhythmogenesis by the preBötC (Garcia et al., 2011). 
Furthermore, antioxidant therapy has been shown to successfully reduce CIH-
mediated irregularities of the network rhythm improving transmission to the 
hypoglossal nerve (Garcia et al., 2016). Thus, in the current study we suggest that 
exposure to CIH may promote a pro-oxidant state which destabilises rhythmogenesis 
originating from the preBötC. This may represent part of a central mechanism that 
promotes apnoea and respiratory instability. Additionally, due to the similar effect of 
exposure to CIH on measures of respiratory stability in wild-type and NOX2 KO mice, 
it appears that apocynin functions as a non-specific antioxidant at higher centres of 
respiratory control in a similar manner to that previously shown in the vascular 
system (Heumüller et al., 2008). It is also plausible to suggest that increased 
propensity for apnoea arises from altered peripheral control of breathing. A CIH-
induced enhancement of the hypoxic ventilatory response (HVR) (discussed below) 
may lead to ventilatory overshoot and in this way may destabilise breathing, 
providing the substrate for apnoea. 
Ventilatory responsiveness to hypoxia following exposure to CIH varies greatly 
depending on the pattern and duration of hypoxic exposure. A diverse range of 
observations arise as a result of an intricate system of molecular mechanisms that 
underlie plasticity in the respiratory control reflex circuits and ultimately control the 
physiology of breathing in response to oxygen desaturation. Augmented HVRs and 
concomitant oxidative stress have been observed in healthy individuals following 
exposure to CIH (Pialoux et al., 2009) and in patients with OSAS (Narkiewicz et al., 
1999). Exposure to CIH evokes carotid body sensory facilitation ex vivo and in 
anesthetised animals (Peng et al., 2001, Rey et al., 2004, Peng et al., 2006b). Carotid 
body responses to hypoxia are enhanced following exposure to CIH (Peng et al., 2001, 
Peng et al., 2003, Peng et al., 2009, Del Rio et al., 2010, Del Rio et al., 2012, Del Rio 
et al., 2014b). Nevertheless, an enhancement (Reeves et al., 2003, Reeves and Gozal, 
2004, Peng et al., 2006b, Julien et al., 2008, Morgan et al., 2016a, Elliot-Portal et al., 
2018), depression (Reeves et al., 2006, Gonzalez-Martín et al., 2011, Olea et al., 2014, 
Lucking et al., 2018) or unchanged (Edge et al., 2009, Skelly et al., 2012) HVR in intact 
animals has been reported across a range of species following treatment with a 
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variety of IH paradigms. In the current study, we report a modest CIH-induced 
increase in ventilation in wild-type mice over the time course of the hypoxia 
challenge. In a similar manner, we observed a small increase in the peak HVR 
following exposure to CIH, although this did not reach statistical significance taking 
multiple comparisons into account. The importance of assessing metabolic rate in 
concert with respiratory recordings has previously been emphasised (Morgan et al., 
2016a), to account for the decrease in metabolic rate that occurs when small 
mammals are acutely exposed to hypoxia (Frappell et al., 1992). This is an especially 
crucial consideration in mouse models, such as that employed in the current study, 
as mice exhibit a greater hypometabolic response to hypoxia than rats (Jochmans-
Lemoine et al., 2015). When ventilation is normalised for V4CO2 production, the a 
priori index of metabolic function, the true hyperventilatory response to hypoxia in 
mice is revealed (i.e. an increase in V4 I/V4CO2). Failure to report on metabolic 
measures in several previous studies, limits the capacity to determine the true 
hyperventilatory response to hypoxia (Morgan et al., 2016a). In the current study, 
analysis of the delta V4 I/V4CO2 response to hypoxia revealed an increase in CIH-
exposed mice compared with sham, which was largely unaffected by NOX2 deletion. 
Although the changes were not statistically significant, the effect size was notable 
(~100%).  
 
There is increased interest in the role of oxidative stress in facilitating hypoxic 
chemosensitivity, but evidence surrounding the culpable source of ROS remains 
largely inconclusive. NOX subunits including p22phox, gp91phox, p47phox, and 
p67phox have been localised to type I cells of guinea pig, rat, and human carotid 
bodies (Kummer and Acker, 1995). Exposure to CIH significantly increases the mRNA 
expression of NOX1, NOX2 and NOX3 in peripheral chemoreceptors (Peng et al., 
2009, Khan et al., 2011, Prabhakar et al., 2015). Moreover, there is ample evidence 
to suggest that CIH-induced sensory plasticity of the carotid body is NOX2-dependent 
(Peng et al., 2006a, Peng et al., 2009, Yuan et al., 2011, Nanduri et al., 2013, Nanduri 
et al., 2015). CIH-induced increases in ventilatory responsiveness to hypoxia are 
attenuated in rats treated with apocynin, as evidenced by a reduction in V4 I/V4CO2 
(Morgan et al., 2016b). This implicates ROS, which may be NOX2-derived (depending 
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on the specificity of apocynin), in altered chemoreflex sensitivity following exposure 
to CIH, possibly due to a reduction in nitrotyrosine production in the carotid body 
(Del Rio et al., 2010, Morgan et al., 2016b). Similarly, treatment with apocynin 
throughout the exposure to CIH significantly reduced the temporal V4 I/V4CO2 response 
to acute hypoxia in the current study, further confirming that ROS are necessary for 
hypoxic chemosensitivity. However, reminiscent of findings in wild-type mice, the 
CIH-induced increase in minute ventilation in NOX2 KO mice during exposure to 
hypoxia was ameliorated when ventilation was normalised for metabolic rate. The 
equivalent magnitudes of the peak ventilatory responses to hypoxia in both wild-type 
and NOX2 KO suggests that NOX2-derived ROS do not play a role in CIH-induced 
augmentation of the chemoreflex response to acute hypoxia. p47phox, but not 
gp91phox knock-out, alters the O2 sensing capability of the carotid body seen as a 
potentiated ventilatory and chemoreceptor response to hypoxia (Sanders et al., 
2002). This suggests that NOX subunits significantly differ in their complex regulatory 
function of respiratory control. Patch-clamp studies have demonstrated that intact 
NEBs in lung slice preparations from mice deficient in gp91phox, failed to respond to 
a hypoxic stimulus (Fu et al., 2000). The latter study provides evidence indicating that 
the dysfunction of NOX disrupts the O2 sensing capability of the NEBs. Interestingly, 
no difference in the response to hypoxia between wild-type and gp91phox mice has 
also been reported (Roy et al., 2000). This is attributed to no alteration in glomus cell 
functioning and a conclusion that although NOX is a major source of ROS, it does not 
function as an oxygen sensor in the carotid body. In our gp91phox (NOX2) knock-out 
mice, we observed a decrease in V4 I/V4CO2 over ten minutes of exposure to acute 
hypoxia. However, gp91phox knock-out had no effect on the peak hypoxic 
ventilatory response.  
 
Therefore, we conclude that exposure to CIH increases ventilatory sensitivity to 
hypoxia, which presumably is a carotid body-mediated effect (Peng et al., 2001, Peng 
et al., 2003, Peng et al., 2006b, Peng et al., 2009), but apparently not NOX2-
dependent, which was surprising, given the finding that CIH-induced carotid body 
sensory long-term facilitation and potentiated chemosensory responsiveness to 
hypoxia is NOX2-dependent (Peng et al., 2009, Morgan et al., 2016b).  Our results 
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suggest that there appear to be latent pathways, independent of NOX2 signalling, 
capable of driving enhanced hypoxic chemosensitivity in response to exposure to 
CIH. Whilst a wealth of studies have focussed on the role of the carotid bodies in 
hypoxic chemosensitivity, plasticity within other respiratory centres in the central 
nervous system (CNS) may play a role in the integrative response to hypoxia. It is 
likely that CIH-induced plasticity at the level of NTS neurons underpins enhanced 
hypoxic ventilatory drive following CIH (Moya et al., 2020). The NTS represents an 
important integrative centre in the brainstem where sensory cues relayed from 
peripheral chemoreceptors inform changes in respiratory motor output, culminating 
in altered ventilatory responses (Zoccal et al., 2014). HIF-1α deficiency has been 
shown to have a pivotal role in carotid body plasticity following exposure to hypoxia 
(Kline et al., 2002, Peng et al., 2006b). Additionally, selective HIF-1α deficiency in NTS 
neurons has been shown to prevent hypoxic sensitivity following exposure to chronic 
sustained hypoxia (Moya et al., 2020). Therefore, it is plausible to suggest a that a 
HIF-1α dependent mechanism within neurons of the NTS may underpin the increased 
HVR observed following exposure to CIH in the current study. The carotid body and 
CNS regions including the NTS, paraventricular nucleus of the hypothalamus (PVN) 
and rostral ventrolateral medulla (RVLM), which are important for the chemoreflex 
control of ventilation and sympathetic outflow, are all affected by increased ROS as 
a result of exposure to CIH (Mifflin et al., 2015, Semenza and Prabhakar, 2015). 
Additionally, it has been demonstrated that a range of signaling molecules including 
ROS, 5-HT, adenosine, HIF-1α and inflammatory cytokines are involved in the CIH-
induced chemoreflex sensitization (Peng et al., 2006b, Pawar et al., 2009, Peng et al., 
2009, Del Rio et al., 2011, Peng et al., 2013, Iturriaga et al., 2014, Sacramento et al., 
2015, Morgan et al., 2016b, Moya et al., 2020). As these substances and processes 
exhibit pro-oxidant properties and/or are sensitive to ROS, oxidative stress may 
represent a common thread linking many drivers of CIH-induced hypoxic sensitivity, 
at multiple points throughout the chemoreflex loop (Del Rio et al., 2010). This 
highlights the complexity in understanding the precise mechanisms underlying CIH-




Although CO2 has a pivotal role in ventilatory control during sleep, there is a paucity 
of information examining the effects of exposure to CIH on hypercapnic sensitivity. 
Chemoreflexes are essential during sleep as a protective mechanism to stimulate 
arousal and terminate apnoeic events. Failure to do so may contribute to an 
increased propensity of apnoeic events, thus leading to an increased severity of 
OSAS. Conversely, an exaggerated response to CO2 contributes to ventilatory 
instability by reducing the CO2 reserve towards apnoeic threshold (Dempsey et al., 
2010). An increase in the hypercapnic ventilatory response (HCVR) has been 
observed in OSAS patients, as a result of episodic hypoxia (Appelberg and Sundström, 
1997, Khodadadeh et al., 2006). Consistent with this, a CIH-induced increase in the 
ventilatory response to hypercapnia has been reported in mice (Elliot-Portal et al., 
2018) and dogs (Katayama et al., 2007). Conversely, evidence supports an unaltered 
HCVR following CIH exposure in a range of models including guinea pigs (Lucking et 
al., 2018) and rats (Greenberg et al., 1999, Edge et al., 2012). In the current study, 
we report no evidence in support of a CIH-induced augmentation to the chemoreflex 
response to hypercapnia in wild-type mice. However, mice lacking the NOX2 enzyme 
have an exaggerated response to CO2 compared with wild-type controls. This 
ventilatory response was further enhanced following exposure to CIH in NOX2 KO 
mice. The increase in ventilation during hypercapnia is somewhat surprising given 
that NOX2-deficient mice exhibit evidence of hypoventilation (reduced V4 I/V4CO2) and 
reduced excitatory input (reduced 5-HIAA/5-HT). Serotonergic neurons are thought 
to play a key role in pH/CO2 sensing, as genetic deletion of 5-HT neurons prevents 
arousal from hypercapnia (Kaur et al., 2020). Therefore, the potentiated ventilatory 
response to hypercapnia in NOX2 KO mice suggests a very powerful suppression of 
hypercapnic drive by a NOX2-dependent mechanism. An exaggerated response to 
alterations in CO2 may serve to destabilise breathing. Our results support the notion 
that NOX2-dependent ROS exert a tonic inhibition on sites important for central 
chemoreception such as the NTS, locus coeruleus and the retrotrapezoid nucleus 
(Nattie and Li, 2012), which functions to suppress hypercapnic drive. This NOX2-
dependent inhibition may have a regulatory function in generating an appropriate 
ventilatory response to a perturbation in CO2 levels, as exposure to CIH further 
exacerbates the chemoreflex response in NOX2 KO mice, whereas it was without 
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effect in wild-type animals. The mechanisms underpinning this response warrant 
further investigation.  
 
Our results reveal the capacity for 2 weeks of exposure to a mild-to-moderate 
paradigm of CIH to evoke plasticity within the respiratory control system, 
predominantly evidenced by increased sensitization to hypoxia and increased 
apnoea index. Increased ventilatory responsiveness to hypoxia has been observed in 
patients with OSAS (Narkiewicz et al., 1999) and may represent an increase in 
sympathetic tone to drive a hypertensive phenotype (Narkiewicz et al., 1998, 
Imadojemu et al., 2007), while also contributing to the development of respiratory 
instability, culminating in increased apnoea index (Peng et al., 2003). Oxidative stress 
plays a causal role in the ventilatory mal-adaptations and sympathetic nervous 
system overactivity observed in animal models of OSAS, consistent with the human 
condition (Peng et al., 2009, Peng et al., 2013). Our results implicate ROS, which are 
not NOX2-derived, in the development of CIH-induced respiratory mal-adaptation, 
as we observe what we suggest are general antioxidant effects of apocynin 
ameliorating the CIH-induced increase in the temporal ventilatory response to 
hypoxia and increased apnoea index. Our results may have implications for OSAS 
patients diagnosed with complex apnoea (Morgenthaler et al., 2006). Patients with 
complex apnoea exhibit spontaneous or central apnoeas, in addition to obstructive 
apnoeas, which may be the result of CIH-induced remodeling with the central 
respiratory network (O'Halloran, 2016), such as the PreBötC (Garcia et al., 2016). 
Therefore, respiratory system mal-adaptation following exposure to CIH may 
exacerbate OSAS severity, serving to perpetuating a vicious cycle of respiratory 
morbidity. Our results reveal that antioxidant therapies may be a useful adjunctive 
therapy for the treatment of OSAS patients. However, further experimentation is 
necessary to delineate the source of ROS, mechanism of action and specific sites 
throughout the respiratory control network at which they exert their effects in order 
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Chapter 4. NADPH oxidase-2 is necessary for 
chronic intermittent hypoxia-induced 






















4.1 Aims and hypothesis  
 
Study aims: 
To examine the effect of a 2-week exposure to CIH on the function of the sternohyoid 
(a representative upper airway dilator muscle) in adult male mice. 
 
To characterise the effect of exposure to CIH on NOX enzymes in sternohyoid muscle 
at multiple levels of regulation: mRNA, protein and activity.   
 
To examine the effect of exposure to CIH on indices of oxidative stress and 
antioxidant capacity in sternohyoid muscle.  
 
To examine the effect of exposure to CIH on the mRNA expression of redox-sensitive 
genes pivotal in the regulation of skeletal muscle form and function.  
 
To assess the contribution of NOX2 to CIH-induced alterations to upper airway 
muscle function using pharmacological and transgenic approaches.  
 
Study hypothesis: 
We hypothesised that 2 weeks of exposure to CIH would result in sternohyoid muscle 
mal-adaptation, which would manifest as muscle weakness, increased expression 
and/or activity of NOX enzymes, altered redox balance and a ROS-dependent 
alteration to the expression of genes important in skeletal muscle contractile 
performance.  
 
Furthermore, we postulated that these alterations would be underpinned by a NOX2 
derived ROS-dependent mechanism, amenable to blockade by supplementation with 





4.2 Materials and methods  
 
Sternohyoid muscle function was examined ex vivo, as described in section 2.5.  
 
The mRNA expression of NOX subunits and genes relating to the regulation of skeletal 
muscle form were assessed by qRT-PCR, as described in section 2.6.  
 
The protein expression of NOX subunits was determined by Western blot, as 
described in section 2.7.  
 
Spectrophotometric assays were used to measure levels of lipid peroxidation 
(TBARS), citrate synthase and NOX activity, as described in section 2.8.  
 
Cell signalling assays were used to examine HIF-1α and proteins involved in the 



















4.3. Results  
4.3.1 Sternohyoid muscle contractile function ex vivo 
Sternohyoid twitch kinetics (Pt, CT and ½ RT) and isotonic contractile parameters 
(Pmax, Wmax, Smax and Vmax) are shown in Table 4.1. Sternohyoid twitch force (Pt) 
was significantly depressed following 2 weeks of exposure to CIH compared to sham 
mice (P = 0.0067; Table 4.1); administration of apocynin (2mM) in the drinking water 
throughout the exposure to CIH completely prevented this decrease in twitch force 
(P = 0.0004; Table 4.1). Exposure to CIH had no effect on Pt in NOX2 KO mice 
compared to NOX2 KO sham mice (P = 0.3063; Table 4.1).  NOX2 KO significantly 
increased Pt compared to wild-type sham mice (P = 0.0004; Table 4.1). Twitch 
contraction time (CT) and half-relaxation time (½ RT) were unaffected by exposure 
to CIH in both wild-type (sham vs. CIH; CT, P = 0.7466; ½ RT, P = 0.2463; Table 4.1) 
and NOX2 KO mice (NOX2 KO sham vs. NOX2 KO CIH; CT, P = 0.2891; ½ RT, P = 0.1371; 
Table 4.1). Similarly, the administration of apocynin during the exposure to CIH (CIH 
vs. CIH + APO; CT, P = 0.2891; ½ RT, P = 0.1371; Table 4.1) or NOX2 KO (sham vs. NOX2 





(n = 8) 
CIH 
(n = 8) 
CIH + APO 
(n = 9) 
NOX2 KO 
Sham 
(n = 8) 
NOX2 KO CIH 
(n = 10) 
Sham vs CIH 
(P value) 













) 1.61 ± 0.39 1.12 ± 0.26* 1.67 ± 0.26# 2.53 ± 0.46£ 2.81 ± 0.62 0.0067* 0.0004# 0.3063 0.0004£ 
CT (ms) 9.83 ± 1.03 10.17 ± 2.83 10.56 ± 1.72 10.94 ± 1.32 11.50 ± 0.85 0.7466 0.7292 0.2891 0.0723 
½ RT (ms) 1.47 ± 0.22 1.43 ± 0.10 1.56 ± 0.10 1.52 ± 0.21 1.60 ± 0.24 0.2463 0.3058 0.1371 0.0772 
Wmax (J/cm2) 0.44 ± 0.17 0.25 ± 0.06 0.64 ± 0.24# 0.93 ± 0.33£ 1.03 ± 0.38 0.0157 0.0009# 0.5877 0.0024£ 
Pmax (W/cm2) 6.56 ± 2.61 4.36 ± 0.98 7.64 ± 2.28# 11.98 ± 3.01£ 14.07 ± 5.01 0.0527 0.0023# 0.3149 0.0018£ 
Smax (L/Lo) 0.28 ± 0.12 0.23 ± 0.10 0.27 ± 0.05 0.25 ± 0.05 0.30 ± 0.06 0.3760 0.3468 0.0897 0.5789 
Vmax (L0/s) 4.07 ± 1.71 3.64 ± 1.59 4.01 ± 0.97 4.49 ± 0.70 5.35 ± 1.02 0.3823 0.3704 0.0598 0.5367 
 
Table 4.1 Ex vivo sternohyoid muscle contractile parameters. Definition of abbreviations: Pt, isometric twitch force; CT, contraction time; 1⁄2 RT, half-relaxation time; Wmax, 
maximum mechanical work; Pmax, maximum mechanical power; Smax, maximum shortening; Vmax, maximum shortening velocity; Lo, optimum length. Values are expressed 
as mean ± SD. Data sets which were normally distributed and of equal variance were statistically compared using unpaired two-tailed Student’s t test. Welch’s correction 
was applied in the case of unequal variance. Data which were not normally distributed were compared using Mann Whitney non-parametric tests. Bolded numbers highlight 
statistical significance (P < 0.0125). Relevant comparisons are denoted as follows: * CIH significantly different from corresponding sham values; # APO + CIH significantly 
different from corresponding CIH values;
 £ NOX2 KO sham significantly different from corresponding sham values.
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Figure 4.1 shows representative original traces for sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) tetanic contractions (A). 2 weeks 
of exposure to CIH significantly decreased the force-generating capacity of the 
sternohyoid compared to sham mice (P  < 0.0001; Fig 4.1; B). Exposure to CIH resulted 
in a ~45% decrease in peak specific force of the sternohyoid compared to sham mice. 
Apocynin administration throughout the exposure to CIH successfully ameliorated 
CIH-induced muscle weakness (P < 0.0001; Fig 4.1; B). Moreover, there was no 
difference in the peak tetanic force produced by NOX2 KO mice exposed to CIH 
compared to NOX2 KO sham controls (P = 0.1147; Fig 4.1; B), revealing a specific role 
for NOX2 in CIH-induced sternohyoid muscle weakness. Tetanic force was increased 
by ~31% in NOX2 KO sham mice compared to wild-type sham mice, but this increase 
did not reach the threshold for statistical significance when correction for multiple 















Figure 4.1 Ex vivo sternohyoid muscle peak tetanic force. A) Original traces of ex vivo 
sternohyoid muscle tetanic contractions for sham (grey), CIH (black), CIH + APO (blue), NOX2 
KO Sham (pink) and NOX2 KO CIH (red) preparations. B) Group data for sternohyoid muscle 
tetanic force, normalised for muscle CSA, in sham (n = 8), CIH (n = 8), CIH + APO (n = 9), NOX2 
KO sham (n = 8) and NOX2 KO CIH (n = 10) mice. Tetanic force was measured following 
stimulation at 100 Hz ex vivo. Values are expressed as mean ± SD. Data sets which were 
normally distributed and of equal variance were statistically compared using unpaired two-
tailed Student’s t test. Statistical significance was taken at P < 0.0125.   Relevant comparisons 
are denoted as follows: * CIH vs. sham, **** P < 0.0001;  # APO + CIH vs. CIH, ###  P <  0.001. 
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Figure 4.2 shows original traces of ex vivo sternohyoid muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 4.2; B, C and D show the sternohyoid 
power-load relationship. This is the power generated by the sternohyoid over a range 
of incremental loads on the muscle between 0-100% of the peak force-generating 
capacity (Fmax), determined at the beginning of the protocol. Exposure to CIH 
significantly decreased the power-generating capacity of the sternohyoid muscle 
over a range of loads compared to sham mice (P < 0.0001; repeated measures two-
way ANOVA; Fig 4.2; B). Post-hoc analysis revealed a statistically significant decrease 
in the power-generating capacity of the sternohyoid following exposure to CIH at 
30% (*P < 0.05) and 40% (**P < 0.01) of its peak force-generating capacity when 
compared to sham mice (Fig 4.2; B). The administration of apocynin throughout the 
exposure to CIH prevented the CIH-induced decrease in the power-generating 
capacity of the sternohyoid over a range of loads compared to mice exposed to CIH 
alone (P < 0.0001; Fig 4.2; B). Post-hoc analysis revealed a statistically significant 
increase in the power-generating capacity of the sternohyoid following treatment 
with apocynin throughout exposure to CIH at 20% - 80% of the peak force-generating 
capacity compared to CIH-exposed mice (Fig 4.2; B). Peak power (Pmax) was 
measured and typically occurred between 30 and 40% load. Exposure to CIH reduced 
Pmax compared to sham mice, although this did not reach the threshold for 
statistical significance (P = 0.0527; Table 4.1); Apocynin treatment throughout 
exposure to CIH significantly prevented this decrease (P = 0.0023; Table 4.1). 
Exposure to CIH had no effect on the power-generating capacity of the sternohyoid 
in NOX2 KO mice over the range of loads examined when compared to NOX2 KO 
sham controls (P = 0.0575; Fig 4.2; C). Similarly, Pmax was unaffected by exposure to 
CIH in NOX2 KO mice (P = 0.3149; Table 4.1).  Genetic knock-out of NOX2 significantly 
increased the power-generating capacity of the sternohyoid over the range of loads 
examined compared to wild-type sham mice (P < 0.0001; Fig 4.2; D). Post-hoc analysis 
revealed a statistically significant increase in the power generated by the sternohyoid 
from NOX2 KO sham mice at 20%-80% load compared to wild-type sham mice (Fig 
4.2; D). Pmax was also significantly increased in NOX2 KO sham mice compared to 






Figure 4.2: Sternohyoid muscle power–load relationship. A, original traces of ex vivo 
sternohyoid muscle maximum unloaded shortening for Sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO Sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data for 
sternohyoid power shown as power per unit CSA (Watts/cm2) as a function of the load on 
the muscle expressed as a percentage of peak tetanic force for Sham (n = 8), CIH (n = 8), CIH 
+ APO (n = 9), NOX2 KO Sham (n = 8) and NOX2 KO CIH (n = 10) mice. Data are shown as 
mean ± SD and were statistically compared by repeated measures two-way ANOVA with 
Bonferroni’s post hoc test. Relevant comparisons are denoted as follows: *denotes sham vs. 
CIH, *P < 0.05, **P < 0.01;  #denotes CIH vs. CIH + APO, #P < 0.05, ##P < 0.01; £  denotes Sham 
vs. NOX2 KO Sham,  £ P < 0.05, ££ P < 0.01, ££££ P < 0.0001. 
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Figure 4.3 shows original traces of ex vivo sternohyoid muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 4.3; B, C and D show the sternohyoid 
work-load relationship. This is the work produced by the sternohyoid over a range of 
incremental loads on the muscle between 0-100% of the peak force-generating 
capacity (Fmax), determined at the beginning of the protocol. Exposure to CIH 
significantly decreased the work produced by the sternohyoid muscle over a range 
of loads compared to sham mice (P < 0.0001; repeated measures two-way ANOVA; 
Fig 4.3; B). Post-hoc analysis revealed a statistically significant decrease in the power-
generating capacity of the sternohyoid following exposure to CIH at 20% (*P < 0.05), 
30% (***P < 0.001) and 40% (**P < 0.01) of the peak force-generating capacity 
compared to sham mice (Fig 4.3; B). The administration of apocynin throughout the 
exposure to CIH prevented the CIH-induced decrease in the work produced by the 
sternohyoid over a range of loads compared to mice exposed to CIH alone (P < 
0.0001; Fig 4.3; B). Post-hoc analysis revealed a statistically significant increase in 
work produced by the sternohyoid following treatment with apocynin throughout 
CIH exposure at 20% (# P < 0.05), 30% (# P < 0.05), and 40% (# P < 0.05) of the peak 
force-generating capacity compared to CIH-exposed mice (Fig 4.3; B). Peak work 
(Wmax) was measured and typically occurred between 30% and 40% load. Wmax 
was reduced following 2 weeks of exposure to CIH compared to sham mice, but this 
did not meet the threshold for statistical significance (P = 0.0157; Table 4.1); 
apocynin administration completely prevented the CIH-induced decrease in Wmax 
(P = 0.0009; Table 4.3). Exposure to CIH had no effect on the work produced by the 
sternohyoid in NOX2 KO mice over the range of loads examined compared to NOX2 
KO sham controls (P = 0.2417; Fig 4.3; C). Similarly, Wmax was unaffected by 
exposure to CIH in NOX2 KO mice (P = 0.5877; Table 4.1). Genetic knock-out of NOX2 
significantly increased the work produced by the sternohyoid over the range of loads 
examined compared to wild-type sham mice (P < 0.0001; Fig 4.3 D). Post-hoc analysis 
revealed a statistically significant increase in the work generated by the sternohyoid 
from NOX2 KO sham mice at 30%-80% load compared to wild-type sham mice (Fig 
4.3; D). Wmax was also significantly increased in mice lacking the NOX2 enzyme 






Figure 4.3 Sternohyoid muscle work–load relationship. A, original traces of ex vivo 
sternohyoid muscle maximum unloaded shortening for sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data for 
sternohyoid work (mean ± SD) shown as work per unit CSA (Joules/cm2) as a function of the 
load on the muscle expressed as a percentage of peak tetanic force for sham (n = 8), CIH (n 
= 8), CIH + APO (n = 9), NOX2 KO sham (n = 8) and NOX2 KO CIH (n = 10) mice. Data were 
statistically compared by repeated measures two-way ANOVA with Bonferroni’s post hoc 
test. Relevant comparisons are denoted as follows: *denotes sham vs. CIH, *P < 0.05, **P < 
0.01, ***P < 0.001;  # denotes CIH vs. CIH + APO, # P < 0.05; £ denotes sham vs. NOX2 KO sham,  
£ P < 0.05, ££ P < 0.01, £££ P < 0.001, ££££ P < 0.0001. 
 
 170 
Figure 4.4 shows original traces of ex vivo sternohyoid muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 4.4; B, C and D show the sternohyoid 
shortening-load relationship. This is the distance of shortening of the sternohyoid 
over a range of incremental loads on the muscle between 0-100% of the peak force-
generating capacity (Fmax), determined at the beginning of the protocol. 2 weeks of 
exposure to CIH had no effect on the distance of shortening of the sternohyoid 
muscle when compared to sham mice (P = 0.1429; repeated measures two-way 
ANOVA; Fig 4.4; B); apocynin treatment throughout the exposure to CIH significantly 
increased the distance of shortening of the sternohyoid over a range of loads 
examined compared with exposure to CIH alone (P = 0.0106; Fig 4.4; B). Peak 
shortening (Smax) was measured and occurred at 0% load, as expected. Smax was 
unaffected by exposure to CIH (P = 0.3760; Table 4.1) or apocynin treatment (P = 
0.3468; Table 4.1) in wild-type mice. NOX2 KO mice exposed to CIH had a significantly 
increased distance of shortening over the range of loads examined compared to 
NOX2 KO sham controls (P = 0.0116; Fig 4.4; C). Post hoc analysis revealed that NOX2 
KO CIH-exposed mice had a significantly increased distance of shortening at 0% of 
the peak force-generating capacity compared to NOX2 KO sham mice ($$ P < 0.01; Fig 
4.4; C). Smax was unchanged following exposure to CIH in NOX2 KO mice (P = 0.0897; 
Table 4.1). Genetic knock-out of NOX2 had no effect on the distance of shortening of 
the sternohyoid over the range of loads examined compared to wild-type sham mice 
(P = 0.3413; Fig 4.4; D). Similarly, Smax was not different in NOX2 KO mice compared 














Figure 4.4 Sternohyoid muscle shortening–load relationship. A, original traces of ex vivo 
sternohyoid muscle maximum unloaded shortening for Sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO Sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data for 
sternohyoid shortening (mean ± SD) shown as length per unit optimal length (L/Lo) as a 
function of the load on the muscle expressed as a percentage of peak tetanic force for Sham 
(n = 8), CIH (n = 8), CIH + APO (n = 9), NOX2 KO Sham (n = 8) and NOX2 KO CIH (n = 10) mice. 
Data were statistically compared by repeated measures two-way ANOVA with Bonferroni’s 
post hoc test. Relevant comparisons are denoted as follows: $ denotes NOX2 KO sham vs. 




Figure 4.5 shows original traces of ex vivo sternohyoid muscle maximum unloaded 
shortening velocity for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham 
(pink) and NOX2 KO CIH (red) preparations (A). Figure 4.5; B, C and D show the 
sternohyoid shortening velocity-load relationship. This is the shortening velocity of 
the sternohyoid over a range of incremental loads on the muscle between 0-100% of 
the peak force-generating capacity (Fmax), determined at the beginning of the 
protocol. 2 weeks of exposure to CIH had no effect on the shortening velocity of the 
sternohyoid muscle compared to sham mice (P = 0.9398; repeated measures two-
way ANOVA; Fig 4.5; B); apocynin treatment throughout the exposure to CIH also had 
no effect on the shortening velocity of the sternohyoid over a range of loads 
examined compared with exposure to CIH alone (P = 0.9289; Fig 4.5; B). The peak 
shortening velocity (Vmax) was measured and occurred at 0% load, as expected. 
Vmax was unaffected by exposure to CIH (P = 0.3823; Table 4.1) or treatment with 
apocynin (P = 0.3704; Table 4.1) in wild-type mice. NOX2 KO mice exposed to CIH had 
a significantly increased shortening velocity over the range of loads examined 
compared to NOX2 KO sham controls (P = 0.0005; Fig 4.5; C). Post hoc analysis 
revealed that NOX2 KO CIH mice had a significantly increased velocity of shortening 
at 0% of the peak force-generating capacity when compared to NOX2 KO sham mice 
($ P < 0.05; Fig 4.5; C). Vmax was unaffected by exposure to CIH in NOX2 KO mice (P 
= 0.0598; Table 4.1).  Genetic knock-out of NOX2 had no effect on the shortening 
velocity of the sternohyoid over the range of loads examined compared to wild-type 
sham mice (P = 0.0921; Fig 4.5; D). Similarly, Vmax was not different between NOX2 













Figure 4.5 Sternohyoid muscle shortening velocity–load relationship. A, original traces of 
ex vivo sternohyoid muscle maximum unloaded shortening for sham (grey), CIH (black), CIH 
+ APO (blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data 
for sternohyoid shortening velocity (mean ± SD) shown as optimal length per unit time (Lo/s) 
as a function of the load on the muscle expressed as a percentage of peak tetanic force for 
sham (n = 8), CIH (n = 8), CIH + APO (n = 9), NOX2 KO sham (n = 8) and NOX2 KO CIH (n = 10) 
mice. Data were statistically compared by repeated measures two-way ANOVA with 
Bonferroni’s post hoc test. Relevant comparisons are denoted as follows: $ denotes NOX2 KO 





4.3.2 Characterisation of NOX enzymes in sternohyoid muscle  
Figure 4.6 shows the mRNA expression of the most predominant muscle-specific NOX 
isoforms in naïve wild-type mouse sternohyoid muscle. The mRNA expression of 
NOX1 in the sternohyoid was significantly lower than that of both NOX4 (Fig 4.6; P = 
0.0002) and NOX2 (Fig 4.6; P = 0.0002). There was no difference in the mRNA 







Figure 4.6 mRNA expression of the predominant muscle-specific NOX isoforms in naive 
wild-type mouse sternohyoid muscle. Group data (mean ± SD, n = 6-8 per group) expressed 
as a fold difference in messenger RNA (mRNA) expression (relative to NOX4) for naïve wild-
type mouse sternohyoid muscle. Data sets, which were normally distributed and of equal 
variance, were statistically compared using unpaired two-tailed Student’s t test. Welch’s 
correction was applied in the case of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-parametric tests. € denotes NOX4 vs. 
NOX1, €€€P < 0.001; + denotes NOX2 vs. NOX1, +++P < 0.001. Definition of abbreviations: NOX4, 


































mRNA and protein expression of the NOX2 enzyme in mouse sternohyoid muscle is 
shown in Figure 4.7. There was no statistically significant difference in the mRNA 
expression of NOX2 following exposure to CIH compared with sham; apocynin 
treatment also had no effect on NOX2 mRNA levels (Fig 4.7; A). As expected, a 
significant decrease (97%) in the mRNA expression of NOX2 following NOX2 KO was 
observed compared with sham (Fig 4.7, A; P = 0.0004). Exposure to CIH had no effect 
on NOX2 mRNA expression in NOX2 KO mice (Fig 4.7; A). Western blot bands were 
detected at approximately 65kDa, corresponding to the predicted molecular weight 
(MW) of the NOX2 subunit (Fig 4.7; B). Fig. 4.7; C shows the corresponding Ponceau 
S-stained membrane, confirming relatively equal protein loading and electro-
transfer. Densitometric analysis of NOX2 band intensities, normalised by the 
intensity of the corresponding Ponceau S-stained proteins, revealed no significant 
difference in the protein expression of the NOX2 subunit in the sternohyoid of mice 














Figure 4.7 NOX2 mRNA and protein expression in 
sternohyoid muscle. A, Group data (mean ± SD, n = 6-8 per 
group) expressed as a fold change in messenger RNA 
(mRNA) expression (relative to the control (sham) group) for 
sham, CIH, CIH + APO, NOX2 KO sham and NOX2 KO CIH 
groups for A, NOX2. B, Western blot of NOX2 in 15µg of 
protein extracted from the sternohyoid of mice exposed to 
2 weeks of normoxia (sham) or CIH. C, corresponding 
Ponceau S-stained membrane used for normalisation and 
compensation for protein loading and the electro-transfer 
of proteins. D, Group data (mean ± SD, n = 5 per group) for 
normalised NOX2 expression expressed as arbitrary units 
(a.u.). This is a product of the band intensity of the 
developed blot (B) / band intensity of the corresponding 
Ponceau S image (C), as determined by densitometry. Data 
sets, which were normally distributed and of equal variance, 
were statistically compared using unpaired two-tailed 
Student’s t test. Welch’s correction was applied in the case 
of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-
parametric tests. Statistical significance was taken at P < 
0.0125 (A) or P < 0.05 (D). £ denotes sham vs. NOX2 KO sham, 
£££P < 0.001. Definition of abbreviations: MW, molecular 
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mRNA and protein expression of the NOX4 enzyme in mouse sternohyoid muscle is 
shown in Figure 4.8. There was no statistically significant difference in the mRNA 
expression of NOX4 following exposure to CIH compared with sham; apocynin 
treatment also had no effect on NOX4 mRNA levels (Fig 4.8; A). A trend towards an 
increase in the mRNA expression of NOX4 in NOX2 KO muscle was observed 
compared with sham (Fig 4.8, A; P = 0.0327). Exposure to CIH had no effect on NOX4 
mRNA expression in NOX2 KO mice (Fig 4.8; A). Western blot bands were detected 
at approximately 63kDa, corresponding to the predicted MW of the NOX4 subunit 
(Fig 4.8; B). Fig. 4.8; C shows the corresponding Ponceau S-stained membrane, 
confirming relatively equal protein loading and electro-transfer. Densitometric 
analysis of NOX4 band intensities, normalised by the intensity of the corresponding 
Ponceau S-stained proteins, revealed no significant difference in the protein 
expression of the NOX4 subunit in the sternohyoid of mice exposed to CIH compared 
to sham (Fig 4.8, D; P = 0.419).
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Figure 4.8 NOX4 mRNA and protein expression in 
sternohyoid muscle. A, Group data (mean ± SD, n = 6-8 per 
group) expressed as a fold change in messenger RNA 
(mRNA) expression (relative to the control (sham) group) for 
sham, CIH, CIH + APO, NOX2 KO sham and NOX2 KO CIH 
groups for, A, NOX4. B, Western blot of NOX4 in 15µg of 
protein extracted from the sternohyoid of mice exposed to 
2 weeks of normoxia (sham) or CIH. C, corresponding 
Ponceau S-stained membrane used for normalisation and 
compensation for protein loading and the electro-transfer 
of proteins. D, Group data (mean ± SD, n = 5 per group) for 
normalised NOX4 expression expressed as arbitrary units 
(a.u.). This is a product of the band intensity of the 
developed blot (B) / band intensity of the corresponding 
Ponceau S image (C), as determined by densitometry.  Data 
sets, which were normally distributed and of equal variance, 
were statistically compared using unpaired two-tailed 
Student’s t test. Welch’s correction was applied in the case 
of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-
parametric tests. Statistical significance was taken at P < 
0.0125 (A) or P < 0.05 (D). Definition of abbreviations: MW, 
molecular weight marker; S. sham; NOX4, NADPH oxidase 4.
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The mRNA expression of NOX catalytic and accessory subunits in sternohyoid muscle 
is show in Figure 4.9. There was no statistically significant difference in the mRNA 
expression of NOX1 (Fig 4.9; A), p22phox (Fig 4.9; B), p47phox (Fig 4.9; C), p67phox 
(Fig 4.9; D), Rac (Fig 4.9; E), DUOX1 (Fig 4.9; G) or DUOX2 (Fig 4.9; H) across all groups 
examined. 2 weeks of exposure to CIH caused a significant increase in NOX enzymatic 





Figure 4.9 mRNA expression of NOX catalytic and accessory subunits in sternohyoid 
muscle. Group data (mean ± SD, n = 6-8 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, 
NOX2 KO sham and NOX2 KO CIH groups for (A) NOX1; (B) p22phox; (C) p47phox; (D) 
p40phox; (E) p67phox; (F) Rac; (G) DUOX1 and (H) DUOX2. Group data (mean ± SD, n = 8 per 
group) for NOX enzymatic activity in sternohyoid muscle following 2 weeks of exposure to 
CIH or normoxia (sham), expressed as enzymatic activity per minute per mg protein (I). Data 
sets, which were normally distributed and of equal variance, were statistically compared 
using unpaired two-tailed Student’s t test. Welch’s correction was applied in the case of 
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unequal variance. Data, which were not normally distributed, were compared using Mann 
Whitney non-parametric tests. Statistical significance was taken at P < 0.0125 (A-H, inclusive) 
or P < 0.05 (I). Relevant comparisons are denoted as follows: * CIH vs. sham, *** P < 0.001. 















4.3.3 Molecular analysis of redox sensitive indices of sternohyoid muscle form and 
function 
 
Figure 4.10 shows the mRNA expression of genes relating to the muscle 
differentiation process in sternohyoid muscle. There were no statistically significant 
changes in the mRNA expression of Myogenin, Myostatin, MEF2C, MyoD, Sirtuin-1 or 







Figure 4.10 mRNA expression of genes related to muscle differentiation in sternohyoid 
muscle. Group data (mean ± SD, n = 6-8 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, 
NOX2 KO sham and NOX2 KO CIH groups for (A) Myogenin; (B) Myostatin; (C) MEF2C; (D) 
MyoD; (E) Sirtuin-1; and (F) IGF-1. Data sets, which were normally distributed and of equal 
variance, were statistically compared using unpaired two-tailed Student’s t test. Welch’s 
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correction was applied in the case of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-parametric tests. Statistical 
significance was taken at P < 0.0125. Definition of abbreviations: MyoD, muscle 
differentiation protein 1; MEF2C, myocyte-specific enhancer factor 2C; IGF-1, insulin-like 
growth factor 1.  
 
 
Figure 4.11 shows the mRNA expression of genes relating to antioxidant status in 
sternohyoid muscle. There were no statistically significant differences in the mRNA 
expression of SOD1, SOD2, Catalase or NRF2 across all groups examined (Fig 4.11; A, 
B, C, & D, respectively). SOD1 and SOD2, pivotal endogenous antioxidants, displayed 
a trend towards a decrease in mRNA expression in NOX2 KO sham sternohyoid 
compared to sham (P = 0.0478; Fig 4.11, A & P = 0.0452; Fig 4.11, B, respectively), 






Figure 4.11 mRNA expression of genes related to antioxidant capacity in sternohyoid 
muscle. Group data (mean ± SD, n = 6-8 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, 
NOX2 KO sham and NOX2 KO CIH groups for (A) SOD1; (B) SOD2; (C) Catalase; and (D) NRF2. 
Data sets, which were normally distributed and of equal variance, were statistically 
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compared using unpaired two-tailed Student’s t test. Welch’s correction was applied in the 
case of unequal variance. Data, which were not normally distributed, were compared using 
Mann Whitney non-parametric tests. Statistical significance was taken at P < 0.0125. 
Definition of abbreviations: SOD1, superoxide dismutase 1; SOD2, superoxide dismutase 2; 
NRF2, nuclear factor erythroid 2-related factor 2. 
 
 
Figure 4.12 shows a range of indices relating to mitochondrial capacity in sternohyoid 
muscle. There was no significant difference in the mRNA expression of genes relating 
to mitophagy, PINK1 and PARK2, across all groups examined (Fig 4.12; A & B, 
respectively). Both PINK1 and PARK2 displayed non-significant trends toward an 
increase in mRNA expression following treatment with apocynin throughout the 
exposure to CIH, compared with exposure to CIH alone (P = 0.0947; Fig 4.12; A, P = 
0.0225; Fig 4.12; B, respectively). Citrate synthase activity, commonly used as a 
quantitative enzyme marker for the presence of intact mitochondria, and hence 






Figure 4.12 Indices relating to mitochondrial integrity in sternohyoid muscle. Group data 
(mean ± SD, n = 6-8 per group) expressed as fold changes in messenger RNA (mRNA) 
expression (relative to the control (sham) group) for Sham, CIH, CIH + APO, NOX2 KO Sham 
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and NOX2 KO CIH groups for A, PINK1; and B, PARK2. C, Citrate synthase activity following 2 
weeks of exposure to CIH (mean ± SD, n = 8 per group). Data sets, which were normally 
distributed and of equal variance, were statistically compared using unpaired two-tailed 
Student’s t test. Welch’s correction was applied in the case of unequal variance. Data, which 
were not normally distributed, were compared using Mann Whitney non-parametric tests. 
Statistical significance was taken at P < 0.0125 (Fig _ A & B) or P < 0.05 (Fig _C). Definition of 
abbreviations: PINK1, PTEN-induced kinase 1; PARK2, parkin.  
 
Figure 4.13 shows a range of measures relating to inflammation and redox balance 
in sternohyoid muscle. There was no statistically significant difference in the mRNA 
expression of the inflammatory transcription factor, NF-κB, across all groups 
examined (Fig 4.13; A). However, there was a non-significant increase in the mRNA 
expression of NF-κB following the administration of apocynin throughout the 
exposure to CIH, compared with exposure to CIH exposure (P = 0.0939; Fig 4.13; A). 
TBARS are formed as a by-product of lipid peroxidation and thus, are commonly used 
as an indirect measure of oxidative stress. Levels of TBARS in sternohyoid muscle 
were unchanged following 2 weeks of exposure to CIH compared to sham, although 
a trend toward an increase was observed (P = 0.0962; Fig 4.13; B). HIF-1α is 
considered a master transcriptional regulator during periods of hypoxia and 
mediates adaptive responses to oxidative stress. Protein expression of HIF-1α was 
unaltered following 2 weeks of exposure to CIH in sternohyoid muscle compared with 








Figure 4.13 Inflammatory mediators and indirect measures of redox imbalance in 
sternohyoid muscle. Group data (mean ± SD, n = 6-8 per group) expressed as a fold change 
in messenger RNA (mRNA) expression (relative to the control (sham) group) for Sham, CIH, 
CIH + APO, NOX2 KO Sham and NOX2 KO CIH groups for A, NF-κB. B, TBARS and C, HIF-1α 
protein content in sternohyoid muscle following 2 weeks of exposure to CIH (mean ± SD, n = 
8 per group). Data sets, which were normally distributed and of equal variance, were 
statistically compared using unpaired two-tailed Student’s t test. Welch’s correction was 
applied in the case of unequal variance. Data, which were not normally distributed, were 
compared using Mann Whitney non-parametric tests. Statistical significance was taken at P 
< 0.0125 (Fig _ A) or P < 0.05 (Fig _B & C). Definition of abbreviations: NF-κB, nuclear factor 
kappa-light-chain-enhancer of activated B cells; TBARS, thiobarbituric acid reactive 
substances; HIF1α, hypoxia-inducible factor 1-alpha.  
 
Figure 4.14 shows the mRNA expression of genes relating to autophagy and atrophy 
in sternohyoid muscle. The mRNA expression of the autophagy-related gene, BNIP3, 
was significantly reduced in sternohyoid muscle following NOX2 KO compared to 
wild-type mice (P = 0.0040; Fig 4.14; A); there was no difference in the mRNA 
expression of BNIP3 across all other groups. There were no statistically significant 
differences in the mRNA expression of the atrophy-related gene, MuRF1 (Fig 4.14; 
E), across all groups. However non-significant trends towards a decreased mRNA 
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expression of MuRF1 were observed following exposure to CIH in wild-type mice 
(sham vs. CIH, P = 0.0150, Fig 4.14; E) and following NOX2 KO (sham vs. NOX2 KO 
sham, P = 0.127, Fig 4.14; E). The mRNA expression of GABARAPL1 (Fig 4.14; B), LC3B 





Figure 4.14 mRNA expression of genes relating to autophagy and atrophy in sternohyoid 
muscle. Group data (mean ± SD, n = 6-8 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, 
NOX2 KO sham and NOX2 KO CIH groups for (A) BNIP3; (B) GABARAPL1; (C) LC3B; (D) Atrogin-
1; and (E) MuRF1. Data sets, which were normally distributed and of equal variance, were 
statistically compared using unpaired two-tailed Student’s t test. Welch’s correction was 
applied in the case of unequal variance. Data, which were not normally distributed, were 
compared using Mann Whitney non-parametric tests. Statistical significance was taken at P 
< 0.0125. £ denotes sham vs. NOX2 KO sham, ££P < 0.01. Definition of abbreviations: BNIP3, 
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bcl-2 nineteen-kilodalton interacting protein 3; GABARAPL1, gamma-aminobutyric acid 
receptor-associated protein-like 1; LC3B, microtubule-associated proteins 1A/1B light chain 
3B; MuRF1, muscle RING finger 1.  
 
Figure 4.15 shows the phosphoprotein content of key proteins involved in protein 
synthesis and degradation signalling pathways in sternohyoid muscle. There was no 
alteration to the phosphoprotein content of Phospho-FOXO3a following 2 weeks of 
exposure to CIH compared with sham (Fig 4.15; A). Similarly, exposure to CIH resulted 
in no difference in the phosphoprotein content of components of the mitogen 
activated protein kinase (MAPK) pathway including Phospho-JNK, Phospho-p38 or 






Figure 4.15 Phosphoprotein content relating to protein synthesis and degradation 
signalling in sternohyoid muscle. A, Phospho-FOXO3a; B, Phospho-JNK; C, Phospho-p38 
protein content and D, sternohyoid phospho-ERK 1/2 (mean ± SD, n = 8 per group) from mice 
exposed to 2 weeks of CIH or normoxia (sham). Values are expressed as signal/μg of total 
protein (adjusted for background signal). Data sets, which were normally distributed and of 
equal variance, were statistically compared using unpaired two-tailed Student’s t test. 
Welch’s correction was applied in the case of unequal variance. Statistical significance was 
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taken at P < 0.05. Definition of abbreviations: FOXO3a, forkhead box O3a; JNK, c-Jun N-

























The key findings of this study are: 
 
1) Exposure to CIH results in considerable sternohyoid muscle weakness, which is 
prevented by treatment with apocynin, and absent in NOX2 KO mice exposed to CIH. 
 
2) NOX2 KO increases the force- and power-generating capacity of the sternohyoid 
muscle compared with wild-type controls (sham). 
 
4) Exposure to CIH does not affect the mRNA or protein expression of the 
predominant NOX isoforms, NOX2 or NOX4, in skeletal muscle.  
 
6) Exposure to CIH results in no alteration to the mRNA expression of NOX1, DUOX 1 
& 2 or NOX accessory subunits in mouse sternohyoid. However, exposure to CIH 
increases NOX activity in wild-type mice, which appears to be independent of HIF-
1α.  
 
5) The mRNA expression of NOX2 is almost completely ablated in NOX2 KO mice; 
NOX2 KO increases the mRNA expression of NOX4 compared with wild-type controls 
(sham).  
 
7) Indices of redox imbalance including levels of TBARS, citrate synthase activity and 
the mRNA expression of endogenous antioxidants are unaffected by exposure to CIH 
in mouse sternohyoid muscle.  
 
 8) The mRNA expression of genes relating to the regulation of skeletal muscle form 
and function including inflammation, autophagy, atrophy, mitophagy and muscle 
differentiation are unaffected by exposure to CIH in wild-type and NOX2 KO mice. 
Similarly, treatment with apocynin or NOX2 KO alone has no effect on the gene 
expression of these indices.  
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UA dilator muscles have a central role in the maintenance of airway patency. 
Impaired function of these striated muscles is a well-described contributor to 
respiratory pathology in OSAS by increasing the susceptibility to collapse and 
triggering a vicious cycle, which perpetuates obstructive airway events (Petrof et al., 
1996, Bradford et al., 2005). The structure and function of UA muscles is altered in 
patients with OSAS, with these functional deficits subsequently contributing to upper 
airway collapse in patients with OSAS (Sérlès et al., 1996, Carrera et al., 1999). While 
the mechanisms underpinning aberrant UA muscle remodelling in OSAS are likely 
multifactorial, a wealth of research has implicated exposure to CIH as a major factor. 
CIH-induced UA muscle weakness and/or fatigue has been well described in animal 
models utilising a variety of IH paradigms (Pae et al., 2005, Liu et al., 2005, Dunleavy 
et al., 2008, Liu et al., 2009, Jia and Liu, 2010, Ding and Liu, 2011, Skelly et al., 2012b, 
Wang et al., 2013, Zhou and Liu, 2013, McDonald et al., 2015). Similarly, 2 weeks of 
exposure to CIH resulted in significant sternohyoid muscle weakness in our model, 
evidenced by a ~45% reduction in its peak force-generating capacity when compared 
with normoxic controls. This remarkable IH-induced sternohyoid weakness is far 
greater than that previously observed in rat models and in fact, is more reminiscent 
of the magnitude of UA muscle weakness observed in models utilising chronic 
sustained hypoxia (Lewis et al., 2015), associated with profound oxidative stress and 
muscle atrophy. When considering the sternohyoid and its physiological function, 
peak isometric force is arguably the most relevant parameter given that isometric 
contractions are most likely responsible for enabling the function of the sternohyoid 
in stabilising the hyoid bone and contributing to the maintenance of UA patency.  
 
Exposure to CIH significantly decreased additional parameters including peak work 
(Wmax), peak power (Pmax) and the work and power produced over the range of 
loads examined ex vivo. We assume that the reduced power-generating capacity of 
the sternohyoid over physiological loads (predominantly due to decreased force-
generating capacity) following exposure to CIH translates in vivo to a reduced 
capacity to preserve and maintain UA calibre, given that the sternohyoid is a 
recognised UA dilator muscle, and that the response is likely representative of 
changes in other important dilator muscles of the upper airway. OSAS is a neurogenic 
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phenomenon as state-dependent reductions in neural traffic to UA muscles 
predispose the occurrence of occlusions in patients with OSAS (Saboisky et al., 2012). 
However, resolving obstructive events requires forceful muscle activation to reopen 
the airway, such that weak dilator muscles may predispose to prolonged obstruction 
and perhaps increased frequency of obstructions, arising from the failure to defend 
airway calibre. Indeed, the current study demonstrates that exposure to CIH causes 
significant UA muscle weakness, which could subsequently put the intrinsically 
collapsible human airway at risk, and in particular, may put a patient with OSAS at 
risk of protracted apnoea, thus exacerbating the severity of OSAS pathology.  
 
Alterations to Ca2+ signalling may contribute to skeletal muscle dysfunction in many 
muscular disorders such as myopathies, systemic disorders like hypoxia, sepsis, 
cachexia, sarcopenia, heart failure, and dystrophy (Agrawal et al., 2018). Reduced 
contractile kinetics (CT and ½ RT) have been observed in the genioglossus (principal 
airway dilator) of male rats following exposure to CIH (Wang et al., 2013). In contrast, 
exposure to CIH had no effect on the contractile kinetics (CT or ½ RT) of the 
sternohyoid muscle in the current study. The latter observations are consistent with 
previous findings from rat models of CIH (Skelly et al., 2012b, McDonald et al., 2016). 
The divergence in these findings may be explained by varying paradigms and 
durations of exposure to CIH as altered kinetics are observed following 5 weeks of 
exposure to CIH (Wang et al., 2013), but not  the shorter duration of 2 weeks (Skelly 
et al., 2012b). The apparent lack of an alteration to contractile kinetics in the present 
study suggests that Ca2+ handling in the sternohyoid muscle, i.e. its release and re-
uptake, at the SR is unaffected by exposure to CIH, thus dysregulated SR functioning 
is unlikely to underpin CIH-induced sternohyoid weakness. Alterations to the 
distance of shortening or velocity of shortening of pharyngeal airway muscles has 
previously been suggested to be indicative of poor mechanical efficiency, culminating 
in muscle dysfunction (Attal et al., 2000, Burns et al., 2017). However, we report no 
CIH-induced alterations to either of these contractile parameters in the sternohyoid 
over the load continuum in the current study.   
 
 192 
OSAS is an oxidative stress disorder with the ROS produced as a result of recurrent 
hypoxia/reoxygenation cycles having devastating consequences for a range of 
integrative bodily systems, highlighting a therapeutic role for antioxidants (Lavie, 
2003). Antioxidant supplementation has previously been shown to ameliorate or 
prevent UA muscle dysfunction following exposure to CIH in rat models (Liu et al., 
2005, Dunleavy et al., 2008, Skelly et al., 2012b, Skelly et al., 2013). However, these 
studies have largely utilised superoxide scavengers which may over-scavenge ROS, 
resulting in an equally detrimental consequence for muscle force production as 
proposed by (Reid et al., 1992). NOX enzymes have been proposed as a source of ROS 
contributing skeletal muscle dysfunction in a range of models (Whitehead et al., 
2010, Ahn et al., 2015, Williams et al., 2015b, Liu et al., 2017, Regan et al., 2017). In 
the current study, the administration of apocynin (NOX2 inhibitor), throughout the 
exposure to CIH, entirely prevented sternohyoid muscle weakness to levels 
comparable to sham animals. This extends previous work (Liu et al., 2005, Dunleavy 
et al., 2008, Skelly et al., 2012b, Skelly et al., 2013) and implicates NOX2 as the 
specific source of ROS underpinning CIH-induced muscle weakness in our model. 
However, while commonly used as a NOX2 inhibitor, apocynin is also reported to 
function as a general antioxidant (Altenhöfer et al., 2015). To account for this and 
ensure the specificity of our findings, transgenic NOX2 KO mice were employed. We 
demonstrated that CIH-induced muscle weakness is absent in NOX2 KO mice, as 
evidenced by an absence of deficits in the peak force-generating capacity, work or 
power produced by the sternohyoid following exposure to CIH, in mice lacking the 
NOX2 enzyme. This confirms that NOX2-derived ROS are entirely responsible and 
necessary for CIH-induced sternohyoid muscle weakness. Improved UA muscle 
performance during sleep in patients with OSAS may help reduce the incidence and 
severity of occlusive events, thus we posit that insights gleaned from our 
pharmacological and transgenic approaches may have implications for the human 
condition.  
 
The homologues NOX1, 2 and 4 are the predominant NOX isoforms expressed in 
skeletal muscle cells in culture (Piao et al., 2005, Hutchinson et al., 2007, Sun et al., 
2011, Handayaningsih et al., 2011, Hori et al., 2011). The relative abundance of these 
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isoforms, based on mRNA data in C2C12 cells, demonstrates that NOX4 is the most 
highly expressed, followed by NOX2 and subsequently NOX1 (Sun et al., 2011, 
Handayaningsih et al., 2011). Consistent with this, we have confirmed the mRNA 
expression of NOX1, NOX2 and NOX4, as well as their respective accessory subunits 
(p22phox, p40phox, p47phox, p67phox, Rac), in sternohyoid muscle from wild-type 
mice. We observed no difference between the mRNA expression of NOX2 and NOX4 
in the sternohyoid, however, we report significantly lower levels of NOX1 mRNA. 
Myostatin upregulates NOX1 in C2C12 myoblasts (Sriram et al., 2011), but a further 
role for NOX1 in skeletal muscle has not yet been discerned. In the present study, we 
also demonstrate low mRNA levels of DUOX1 and DUOX2 in the sternohyoid, 
consistent with that previously reported in C2C12 muscle cells (Sandiford et al., 
2014). Aside from this recent study highlighting the potential role of DUOX1 and 
DUOX2 in myogenesis, little is known about the physiological relevance of DUOX 
enzymes in skeletal muscle. NOX2- and NOX4-dependent ROS have been strongly 
implicated in muscle dysfunction in a variety of disease states  (Spurney et al., 2008, 
Whitehead et al., 2010, Sullivan-Gunn and Lewandowski, 2013, Pal et al., 2014, 
Williams et al., 2015b, Henríquez-Olguín et al., 2015, Ahn et al., 2015, Yamada et al., 
2015). Therefore, based on these observations, in conjunction with our mRNA data, 
we suggest that NOX2 and NOX4 isoforms hold the most relevance for respiratory 
muscle pathology in our model, and perhaps human OSAS.  
 
CIH-induced increases in NOX enzyme expression and or/activity have been reported 
in a wide range of organs and tissues including, but not confined to, liver, 
cardiovascular system, brain, kidneys and the respiratory system (Zhan et al., 2005, 
Peng et al., 2006, Jun et al., 2008, Hayashi et al., 2008, Peng et al., 2009, Nisbet et al., 
2009, Hui-guo et al., 2010, Peng et al., 2011, Gao et al., 2013, Williams et al., 2015b). 
This highlights a role for NOX-dependent ROS in CIH-induced alterations to 
homeostatic control. The regulation of NOX enzymes and their associated subunits is 
highly complex with evidence for the transient and sequential activation of NOX, such 
that understanding the patterns of NOX expression, activity and isoform cross-talk is 
a challenging task (Brandes et al., 2014). Two weeks of exposure to CIH has been 
shown to increase the protein expression of NOX2, and its activator subunit, 
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p47phox, in rat sternohyoid muscle (Williams et al., 2015b), suggestive of a role for 
NOX2-dependent ROS in CIH-induced UA muscle weakness (Skelly et al., 2012b). In 
contrast to this, we observed no alteration to the mRNA or protein expression of 
NOX2 or the mRNA expression of p47phox, p22phox, p67phox, p40phox or Rac in the 
sternohyoid muscle in the current study. While transcriptional regulation of NOX2 
has been observed, NOX2 is thought to be predominantly acutely regulated by post-
translational mechanisms such as the phosphorylation of regulatory cytosolic 
subunits, thus enabling the enzyme to assemble as a fully functioning complex 
(Lambeth, 2004). Under resting conditions, NOX2 and p22phox are complexed in the 
plasma membrane with accessory subunits unbound in the cytosol. Following 
stimulation by factors such as hypoxia or mechanical stress, including that of muscle 
contraction (Loureiro et al., 2016), cytosolic subunits are phosphorylated and 
translocated to the membrane to elicit the production of NOX2-derived ROS through 
the oxidation of NADPH. NOX2 is a major source of ROS production during exercise 
in human and mouse skeletal muscle with NOX2-dependent ROS production 
representing an important signal for increasing muscle glucose uptake during 
exercise (Henríquez-Olguin et al., 2019). Species differences between rat and mouse 
models may also represent a contributing factor to the divergent observations in 
NOX2 expression following exposure to CIH. Of interest, apocynin had no effect on 
NOX2 mRNA expression in the sternohyoid. Apocynin inhibits the generation of 
superoxide by NOX by blocking migration of p47phox to the membrane, thus 
interfering with assembly of the functional NOX complex (Touyz, 2008). Therefore, 
the lack of an effect of apocynin on NOX2 mRNA expression in the current study may 
be explained by the fact that apocynin acutely inhibits NOX activity, rather than its 
transcriptional expression.  
 
NOX4 is a unique NOX isoform in that it is constitutively active, with its activity largely 
dependent upon its level of protein expression. Therefore, the ROS that NOX4 
generates are driven at the level of gene transcription rather than through acute, 
post-translational mechanisms (Serrander et al., 2007). NOX4 is suggested to 
function as pivotal O2 sensor, with a number of studies reporting an increase in NOX4 
mRNA and protein expression following exposure to hypoxia (Nisbet et al., 2009, 
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Diebold et al., 2010). NOX4-dependent ROS have been implicated in poor skeletal 
muscle function as evidenced by increased NOX4 expression in models of disease 
characterised by skeletal muscle weakness (Ahn et al., Liu et al., 2017, Regan et al., 
2017). Therefore, it is plausible that NOX4 could be implicated in CIH-induced muscle 
weakness. However, we report no alteration to the mRNA or protein expression of 
NOX4, nor to the mRNA of NOX4 accessory proteins, p22phox or Rac, in CIH-exposed 
sternohyoid muscle. This suggests that this paradigm of CIH exposure does not 
induce alterations to NOX4 at the transcriptional level.  
 
Our findings point to an exclusive role for NOX2 in CIH-induced sternohyoid muscle 
weakness. Whereas gene and protein expression of NOX2 subunits were unaffected 
by exposure to CIH, a significant CIH-induced increase in NOX activity in the 
sternohyoid was evident in our model. We suggest that this increase in NOX activity 
may represent an increase in NOX-dependent ROS based on an acute process to 
increase enzymatic assembly and thus, ROS production. This is in contrast to an 
increase in NOX-dependent ROS production that occurs as a result of a 
transcriptional increase in the abundance of NOX enzymes. We have shown that 
NOX2 and NOX4 are the predominant NOX isoforms in sternohyoid muscle, 
consistent with previous findings in skeletal muscle cells (Sun et al., 2011, 
Handayaningsih et al., 2011). We rationalise that the increase in NOX activity in the 
sternohyoid following exposure to CIH in our model is NOX2-dependent given that 1) 
NOX2 is typically acutely regulated and 2) NOX2 KO prevents CIH-induced muscle 
weakness in our model. HIF-1α has been shown to mediate NOX activation in a range 
of organs and tissues (Diebold et al., 2010, Yuan et al., 2011, Diebold et al., 2012, 
Nanduri et al., 2015, Chen et al., 2018, Wang et al., 2020a). Interestingly, exposure 
to CIH has previously been shown to increase NOX2 expression in PC12 
pheochromocytoma cells as well as mouse embryonic fibroblasts in a HIF-1α-
dependent manner (Yuan et al., 2011). In the current study, we report no alteration 
to HIF-1α protein content in the sternohyoid following exposure to CIH, consistent 
with observations in rat models (Williams et al., 2015b). Therefore, we suggest that 
NOX activity is not increased in a HIF-1α dependent manner in our mouse model. 
However, we acknowledge that our results must be interpreted with caution as the 
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NOX activity assay utilised in the current study is not specific for any one isoform of 
NOX, rather it functions to assess the rate of NADPH consumption. NAD(P)H 
consumption assays have previously been used in the assessment of NOX activity in 
skeletal muscle (Javeshghani et al., 2002, Adams et al., 2005, Ahn et al., 2015, Bowen 
et al., 2015a, Bowen et al., 2015b). However, a recent study shows that these assays 
are not specific to NOX activity and, in several tissues and cell types, the signal 
generated was unchanged with a triple NOX1, NOX2, and NOX4 knockout (Rezende 
et al., 2016). Indeed, the lack of specific NOX activity measurements has been a major 
impediment in the field, and this warrants further attention. It is also important to 
consider that our assessment of muscle was performed on ‘day 15’, at least 15 hours 
following the final exposure to IH. As such, mice were normoxic for several hours 
before assessments were made. In this way, HIF-1α may have played a significant 
role in muscle (mal)-adaptation to CIH, in the course of exposure to CIH, but levels 
were likely restored to normal during return to normoxia. Therefore, we cannot 
discount a potential role for HIF-1α-dependent signalling in CIH-induced respiratory 
muscle weakness and this would be interesting to explore. Nevertheless, other 
models have demonstrated a stabilisation of HIF-1α mRNA and protein in the 
genioglossus following a 5-week exposure to CIH (Jia and Liu, 2010, Zhou and Liu, 
2013). Indeed, it has been suggested that HIF-1α is regulated in a dose-dependent 
manner in response to IH (Martinez et al., 2019).  
 
There is evidence of increased oxidative stress in a variety of tissues across animal 
models of CIH, consistent with the observation that human OSAS is an oxidative 
stress disorder (Lavie, 2003). However, despite the clear link between NOX2-
dependent ROS and CIH-induced UA muscle weakness in our model, we report no 
evidence of concomitant overt oxidative stress in the sternohyoid following exposure 
to CIH. Oxidative stress may present due to an accumulation of ROS, a depletion of 
antioxidant defences, or a culmination of both. Skeletal muscle encompasses a 
robust antioxidant defence system, rendering it remarkably flexible in response to 
changes in the redox milieu that can occur in both health and disease (Kozakowska 
et al., 2015, Specht et al., 2021). Reduced levels of aconitase and GR activity, 
indicative of modest oxidative stress, have been demonstrated in the sternohyoid of 
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male rats following a 2 week exposure to CIH (Williams et al., 2015b). Similarly, 
reduced activity of GPX, CAT and SOD, with concomitant genioglossus fatigue, was 
observed in female rats following exposure to 5 weeks of CIH (Ding and Liu, 2011). In 
the present study, we report no alteration to the mRNA expression of the master 
cellular regulator of antioxidant response, NRF2, or the endogenous antioxidants, 
SOD1, SOD2 & catalase, in the sternohyoid following exposure to CIH. As a result, we 
suggest that any putative CIH-induced challenge to redox homeostasis does not 
manifest as a depletion of the antioxidant defence system (Ding and Liu, 2011, 
Williams et al., 2015b), nor does it evoke an adaptive response in the form of an 
increase in antioxidant enzyme expression. However, we acknowledge that our 
results only reflect changes at the transcriptional level of the antioxidant defence 
system and that CIH-induced alterations to antioxidant enzyme activity cannot be 
ruled out.  
 
ROS have been shown to oxidise lipids as a function of the severity of OSAS (Hopps 
et al., 2014). TBARS are degradation products of fats routinely used as a marker of 
lipid peroxidation, as an indirect measurement of oxidative stress. Levels of TBARS 
show a positive correlation to OSAS severity as determined by increased apnoea 
index (Kent et al., 2011). 5 weeks of exposure to CIH has been shown to increase lipid 
peroxidation, evidenced by increased MDA levels in the genioglossus of female rats 
(Ding and Liu, 2011). Conversely, 2 weeks of exposure to CIH was insufficient to alter 
levels of lipid peroxidation, determined by levels of 4-HNE, in the sternohyoid in a rat 
model of CIH (Williams et al., 2015b). Consistent with the latter study, we report that 
2 weeks of exposure to CIH had no effect on levels of TBARS in the sternohyoid and 
thus, oxidative stress in the form of lipid peroxidation appears to be absent in our 
model.  
 
Mitochondria are an important source of ROS in skeletal muscle with ROS-dependent 
alterations to mitochondrial function and/or capacity proving consequential for 
skeletal muscle function (Hood et al., 2019). 5 weeks of exposure to CIH has been 
shown to cause genioglossus muscle fatigue and increased mitochondrial ROS 
production, suggesting a role for mitochondrial ROS in decreased genioglossus 
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endurance (Ding and Liu, 2011). Indeed, mal-adaptation of skeletal muscle to periods 
of hypoxia have been demonstrated as a loss of mitochondrial content, thus a 
reduced oxidative capacity and less endurant phenotype (Gamboa and Andrade, 
2010). Given the pivotal role of O2 as an electron acceptor in the ETC, hypoxia induces 
a build-up of electrons in this cycle, leading to an increased electron leakage and 
subsequent ROS formation. This increased ROS formation exacerbates mitochondrial 
dysfunction, yielding detrimental effects for muscle contractile performance. Citrate 
synthase activity is a routinely used marker of mitochondrial integrity and aerobic 
capacity, as it is the initial enzyme of the TCA cycle. Citrate synthase activity was 
unaffected by exposure to CIH in the sternohyoid in the current study, consistent 
with unaltered citrate synthase activity previously reported in a rat model of CIH 
(Williams et al., 2015a). Similarly, other metabolic markers, including SDH and GPDH 
activity, have been shown to be unaltered in rat sternohyoid following exposure to 
CIH (Skelly et al., 2012a, Skelly et al., 2012b). 
 
Impaired mitochondria are removed or rejuvenated via autophagy (Kim et al., 2019). 
Mitochondria utilise a specialised form of autophagy, known as mitophagy, to 
protect against excessive ROS, such as that arising from exposure to CIH. 
Mitochondrial function has been shown to be essential for plasma membrane repair 
in skeletal muscle fibres, with mitochondrial ROS shown to be pivotal in facilitating 
this membrane repair (Horn et al., 2017). Inhibiting mitochondrial ROS in myofibres 
during eccentric exercise ex vivo increases myofibre damage with concomitant 
muscle force loss (Horn et al., 2017). This highlights the beneficial role of 
mitochondrial ROS in repair mechanisms in response to strain on skeletal muscle. An 
increase in key regulators of mitophagy has been observed in rat genioglossus 
following 2-3 weeks of exposure to CIH, with these markers of mitophagy 
subsequently decreasing for the remaining 2 weeks of exposure to CIH (Wang et al., 
2020b). The initial increase in mitophagy is suggested to represent a protective 
mechanism against excessive ROS, with the persistent insult by exposure to CIH 
culminating in an increase in mitochondrial impairment and decrease in mitophagy. 
Thus, disturbances to genioglossus mitophagy may relate to impaired mitochondrial 
function and decreased contractile properties in rats induced by exposure to CIH. In 
 199 
the current study, we examined the mRNA expression of the PINK1/PARK2 pathway, 
which has emerged as a principal regulator of mitochondrial degradation in a range 
of biological systems (Narendra and Youle, 2011). However, we found that exposure 
to CIH had no effect on the mRNA expression of PINK1 or PARK2 in the sternohyoid. 
Our data suggest that overt oxidative stress and subsequent mitochondrial 
dysfunction are not likely to underlie the CIH-induced alteration to sternohyoid 
muscle function observed in the current study.  
 
Initially, the lack of evidence for CIH-induced oxidative stress could be considered 
surprising given the remarkable efficacy of antioxidants (Liu et al., 2005, Dunleavy et 
al., 2008, Skelly et al., 2012b, Skelly et al., 2013) and NOX2 KO (this study), in 
preventing CIH-induced muscle weakness. It has been well described that the 
elaboration of adaptive or mal-adaptive outcomes in response to CIH is largely 
determined by the pattern, intensity and duration of hypoxic exposure.  IH models 
produce different degrees of hypoxia severity, yielding dose-dependent effects (Lim 
et al., 2016, Gallego-Martin et al., 2017, Docio et al., 2018). The CIH paradigm utilised 
in this study is sufficient to cause respiratory muscle dysfunction, hypertension 
(Lucking et al., 2014) and increased propensity for apnoea, characteristic of OSAS.  
However, it is considered quite a modest CIH exposure. Previous studies have 
suggested that short bouts of IH (15 s hypoxia; 5 min normoxia) produce higher levels 
of ROS compared with longer bouts of IH (Raghuraman et al., 2009), such as those 
used in the current study. Therefore, our paradigm may not be expected to produce 
overt oxidative stress. A study by our group has demonstrated that in addition to 
antioxidants proving efficacious in preventing CIH induced UA muscle dysfunction, 
they also hold the capacity, following acute administration, to reverse muscle 
weakness due to CIH (Skelly et al., 2012b). This finding is pivotal in our understanding 
of the mechanisms underpinning CIH-induced muscle weakness as it strongly 
suggests that exposure to CIH does not result in irreversible oxidative damage to 
muscle per se. This is consistent with the lack of evidence for increased lipid 
peroxidation or alterations to mitochondrial content and or/function in CIH-exposed 
muscle reported in the current study. Rather, we suggest that CIH-induced 
sternohyoid muscle weakness is a dynamic NOX2 derived ROS-dependent process 
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that serves to powerfully suppress muscle contractile function, independent of 
muscle damage, such that it is entirely reversible. This is important in the context of 
potential therapeutic targeting for human OSAS, recognising the considerable 
challenge of oxidative modifications contributing to muscle injury in the context of 
chronic disease. 
 
Structural alterations in the form of slow-to-fast fibre-type transitions are observed 
in the UA musculature of humans with OSAS (Smirne et al., 1991, Carrera et al., 1999) 
as well as in the English bulldog model (Petrof et al., 1994). Consistent with this, a 
range of studies have demonstrated CIH-induced fibre-type transitions in UA 
muscles, which serve to promote a more fatigable phenotype (McGuire et al., 2002a; 
Liu et al., 2009). However, the development of UA muscle dysfunction does not 
require structural remodelling in the form of atrophy and/or fibre-type transitions in 
rat models (Skelly et al., 2012b, McDonald et al., 2015). Given the magnitude of UA 
muscle weakness observed following exposure to CIH in the current study, it is 
plausible to suggest that structural alterations may underpin muscle dysfunction. 
However, we report no indication of muscle atrophy in the sternohyoid following 
exposure to CIH in the current study, as evidenced by the unchanged mRNA 
expression of key muscle-specific ubiquitin ligases; MurF-1 and Atrogin-1. Similarly, 
key cell signalling pathways pivotal in maintaining the balance between atrophy and 
hypertrophy in skeletal muscle, including MAPK and FOXO-3a, appear unaltered by 
exposure to CIH. Basal levels of autophagy are necessary for the homeostatic 
maintenance of muscle mass. However, an interplay between atrophy and 
autophagy has been demonstrated to underlie a loss of muscle mass and resultant 
weakness in skeletal muscle (Dobrowolny et al., 2008). Consistent with a lack of 
evidence for CIH-induced muscle atrophy in the sternohyoid, we also report 
unaltered mRNA levels of key autophagy markers: GABARAPL1, LC3B and BNIP3.  
 
Skeletal muscle has an exceptional capacity to regenerate and re-establish 
homeostatic contractile and metabolic properties in response to severe damage. 
However, successive rounds of muscle degeneration and regeneration can result in 
the incomplete remodelling of the ECM. This results in the generation of large 
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amounts of fibrosis and scar tissue rather than contractile tissue, thus yielding a 
muscle with a lower force-generating capacity (Smith and Barton, 2018). It has been 
demonstrated that physiological hypoxia e.g. exercise results in muscle cell 
proliferation and myogenesis, whereas pathological hypoxia, e.g. CIH, inhibits 
myogenesis (Yun et al., 2005). 5 weeks of exposure to CIH has been shown to 
decrease the expression of key MRFs, MyoD and myogenin, in the genioglossus of 
rats (Zhou and Liu, 2013). The authors suggest that exposure to CIH damaged 
genioglossus regenerative properties, which may have implications for the observed 
decrease in genioglossus fatigue resistance. In the present study, we report no 
alterations to the mRNA expression of key MRFs including MyoD, myostatin, 
myogenin, sirtuin-1 or MEF2C in the sternohyoid following exposure to CIH. These 
gene expression data, in conjunction with our functional results demonstrating that 
exposure to CIH does not affect the distance or velocity of shortening in the 
sternohyoid muscle, suggests that CIH-induced NOX2-dependent alterations to UA 
muscle performance are not likely to be underpinned by structural remodelling.  
 
In view of the collective data described above, our results are consistent with 
previous views (Williams et al., 2015b) that CIH-induced sternohyoid muscle 
weakness may be mediated by altered redox signalling, perhaps within 
microdomains of the muscle, evidently with no widespread cellular stress or 
structural alterations. All NOX2-related subunits have been identified in skeletal 
muscle (Javeshghani et al., 2002). An increase in NOX2 activity and/or expression has 
been demonstrated in isolated SRs (Xia et al., 2003), as well as in intact and isolated 
t-tubules and triads of mammalian skeletal muscle (Hidalgo et al., 2006). Similarly, 
NOX4 expression has been shown in the mitochondria (Sakellariou et al., 2013), SR 
and t-tubules of skeletal muscle (Loureiro et al., 2016). The localisation of NOX 
enzymes juxtaposed to the contractile apparatus in skeletal muscle highlights the 
possibility of their role in ROS-dependent alterations to EC coupling mechanisms. 
Studies examining the underlying mechanisms pertaining to ROS-dependent 
alterations to muscle function have largely suggested that ROS elicit complex redox 
alterations to the Ca2+ release apparatus. ROS have been shown to activate RyR1s via 
s-glutathionylation of cysteine residues producing an increase in calcium induced 
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calcium release (CICR) in the t-tubules of skeletal muscle (Hidalgo et al., 2006). It has 
also been demonstrated that thiol groups on the SR  are a critical target of oxidative 
modification by O2-, culminating in an increase in Ca2+ release, with thiol reducing 
agents successfully closing the channel (Abramson and Salamaz, 1988). In contrast, 
various studies have reported a down regulation and impaired Ca2+ channel 
functioning in skeletal muscle upon exposure to ROS  (Guerra et al., 1996). This 
apparent dichotomy may be attributed to varying levels of ROS, which are known to 
have divergent effects in skeletal muscle. NOX4 expression has been shown to be 
positively regulated by O2 tension. Interestingly, an increase in NOX4-derived H2O2 
has been shown to be coupled to an increased oxidation of cysteine residues of RyRs 
in isolated SRs, cultured myofibres and intact muscle. This produced an increase in 
Ca2+ release and enhanced muscle contraction, implicating NOX-derived ROS in 
alterations to muscle performance in response to changes in PO2 (Sun et al., 2011). 
Our functional data revealed no change in muscle contractile kinetics, suggesting no 
major redox modulation of Ca2+ handling. This suggests that muscle weakness in CIH-
induced sternohyoid may be an effect of redox modulation at the level of the 
myofilaments influencing cross-bridge cycling or Ca2+ sensitivity of the contractile 
apparatus through redox modulation of troponin (de Paula Brotto et al., 2001, 
Ottenheijm et al., 2005, Ottenheijm et al., 2006, Coirault et al., 2007, Degens et al., 
2010, Smuder et al., 2010, Pinto et al., 2011, McDonagh et al., 2014). Therefore, we 
speculate that CIH-induced NOX-dependent ROS may impair muscle force-
generating capacity without concomitant widespread oxidative damage or structural 
(fibre-type transition and/or atrophy) alterations.  
 
The specific mechanism by which NOX2-derived ROS underlie CIH-induced UA muscle 
weakness still remains elusive. It has been well described that ROS hold the capacity 
to modulate skeletal muscle performance, with the contractile apparatus of muscle 
fibres proving highly sensitive to alterations in cellular redox state (Reid et al., 1992). 
Previous studies by our group have demonstrated that incubation with a superoxide 
scavenger, tempol, yields a powerful inotropic effect on the sternohyoid muscle 
(Skelly et al., 2010, Skelly et al., 2012b). This suggests that under basal conditions, 
ROS exert a tonic inhibition on UA muscle force production. Furthermore, it is 
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suggested that NOX2 is the culpable source of these ROS as incubation of the 
sternohyoid with apocynin results in a significant increase in its force- and power-
generating capacity (Williams et al., 2015b). However, studies utilising p47phox 
deficient mice report no inotropic effect of NOX2 knockout, evidenced by an 
unaltered force-generating capacity of the diaphragm muscle compared with wild-
type controls (Ahn et al., 2015). Consistent with the former findings, we report a 
~30% increase in the peak force-generating capacity of the sternohyoid in NOX2 KO 
mice, compared with wild-type controls. Similarly, we observed a significant increase 
in the power and work produced by the sternohyoid in NOX2 KO mice across the load 
continuum examined. Our findings extend previous work (Skelly et al., 2010, Skelly 
et al., 2012b, Williams et al., 2015b) to suggest that NOX2 is an important source of 
basal ROS production in mouse sternohyoid muscle.  Our novel data highlight that 
NOX2-derived ROS are powerful inhibitors of sternohyoid force and power, and by 
extension it is therefore plausible to suggest that increased ROS associated with 
exposure to CIH directly impairs sternohyoid muscle function.  
 
We demonstrate an almost complete ablation of NOX2 mRNA in the sternohyoid of 
NOX2 KO mice. A recent study utilising commercial NOX2 KO mice showed that NOX2 
mRNA and protein expression was still detectable in various tissues using standard 
primers and antibodies (Göllner et al., 2020). Further analysis using RNA sequencing 
revealed a modified NOX2 mRNA in the KO mice that is subsequently translated to a 
truncated inactive mutant enzyme, as these KO mice displayed no considerable 
enzymatic NOX2 activity. Therefore, while we observe trace amounts of NOX2 mRNA 
in the sternohyoid of NOX2 KO mice, that is not attributable to non-specific PCR 
amplification, we suggest that this does not translate into a functional NOX2 protein 
that would contribute to significant ROS generation in our model. Additionally, we 
observed an increase in NOX4 mRNA in the sternohyoid of NOX2 KO mice. Studies in 
human pulmonary artery endothelial cells (HPAECs) demonstrate that either NOX2 
or NOX4 knockdown using siRNA results in an upregulation of the other enzyme, 
suggesting a compensatory mechanism for basal ROS production (Pendyala et al., 
2009). Indeed, a marked compensatory upregulation of NOX4 has been exhibited in 
NOX2 KO models of diabetic kidney disease (You et al., 2013) and ageing brains (Fan 
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et al., 2019). Moreover, an inhibition of NOX2 increases NOX4 expression in mdx limb 
muscle, suggesting that NOX enzymes are an important source of ROS in skeletal 
muscle (Cully and Rodney, 2020). It has been suggested that adaptations that occur 
with embryonic deficiency of a protein might affect redox balance in knockout 
animals as respiratory muscle from mice lacking the p47phox subunit exhibit a 
downregulation of the antioxidant enzymes SOD1 and CAT (Bost et al., 2015) and an 
upregulation of NOX4 protein levels (Ferreira and Laitano, 2016). Consistent with 
this, we suggest that the increase in NOX4 mRNA in the sternohyoid and a trend 
towards a decrease in the mRNA of antioxidant enzymes in NOX2 KO mice observed 
in the present study represents a compensatory mechanism to regulate a 
homeostatic redox state in the sternohyoid muscle, in the absence of NOX2. 
 
In the current model, we reveal that NOX2 is essential for CIH-induced sternohyoid 
muscle weakness. Based on our data and previous observations in rats (Williams et 
al., 2015b), CIH-induced muscle weakness occurs in the absence of overt oxidative 
stress or structural remodelling that could explain diminished muscle function. 
Additionally, we demonstrate that NOX2-derived ROS are capable of affecting 
sternohyoid muscle performance. Therefore, it is plausible to suggest that NOX2-
derived ROS may exert their effects on contractile function through actions at one or 
more sites critical for EC coupling (Geiszt et al., 1997, Kawakami and Okabe, 1998, 
Hidalgo et al., 2006, Espinosa et al., 2006, van der Poel et al., 2007, Sun et al., 2011, 
Lamb and Westerblad, 2011, Liu et al., 2012, Cully and Rodney, 2020). We speculate 
that the inotropic effects of NOX2 KO and thus, NOX2-dependent CIH-induced 
muscle weakness, may relate to redox modulation of Ca2+ sensitivity of the 
contractile filaments (Westerblad and Allen, 1991, Edwards et al., 2007, Murphy et 
al., 2008, Dutka et al., 2017).  
 
The significance of our findings is that exposure to CIH, a hallmark feature of human 
OSAS, is detrimental to the maintenance of UA patency, potentially increasing the 
risk of obstructive airway events throughout the night cycle. Therefore, exposure to 
CIH could establish a vicious cycle serving to exacerbate respiratory morbidity in 
human OSAS. Therapeutic strategies to improve UA muscle performance may 
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function as an adjunct therapy to reduce OSAS severity in human OSAS. Our data 
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5.1 Aims and hypothesis  
 
Study aims: 
To examine the effect of a 2-week exposure to CIH on diaphragm muscle function in 
adult male mice. 
 
To characterise the effect of exposure to CIH on NOX enzymes in diaphragm muscle 
at multiple levels of regulation: mRNA, protein and activity.   
 
To examine the effect of exposure to CIH on indices of oxidative stress and 
antioxidant capacity in diaphragm muscle.  
 
To examine the effect of exposure to CIH on the mRNA expression of redox-sensitive 
genes pivotal in the regulation of skeletal muscle form and function.  
 
To assess the contribution of NOX2 to CIH-induced alterations to diaphragm muscle 
function using pharmacological and transgenic approaches.  
 
Study hypothesis: 
We hypothesised that 2 weeks of exposure to CIH would result in diaphragm muscle 
mal-adaptation, which would manifest as muscle weakness, increased expression 
and/or activity of NOX enzymes, altered redox balance and a ROS-dependent 
alteration to the expression of genes important in skeletal muscle contractile 
performance.  
 
Furthermore, we postulated that these alterations would be underpinned by a NOX2-
derived ROS-dependent mechanism, amenable to blockade by supplementation with 





5.2 Materials and methods  
 
Diaphragm muscle function was examined ex vivo, as described in section 2.5.  
 
mRNA expression was assessed by qRT-PCR, as described in section 2.6.  
 
Protein expression of NOX subunits was determined by Western blot, as described in 
section 2.7.  
 
Spectrophotometric assays were used to measure the levels of lipid peroxidation 
(TBARS), and citrate synthase and NOX enzyme activities, as described in section 2.8.  
 
Cell signalling assays were used to examine key pathways involved in the regulation 




























5.3. Results  
5.3.1 Diaphragm muscle contractile function ex vivo  
Diaphragm twitch kinetics (Pt, CT and ½ RT) and isotonic contractile parameters 
(Pmax, Wmax, Smax and Vmax) are shown in Table 5.1. Diaphragm twitch force (Pt) 
was reduced following 2 weeks of exposure to CIH compared to sham mice (P = 
0.0173; Table 5.1), however this did not reach the threshold for statistical 
significance. The administration of apocynin (2mM) in the drinking water throughout 
the exposure to CIH prevented the CIH-induced decrease in twitch force (P = 0.0043; 
Table 5.1). Exposure to CIH had no effect on Pt in NOX2 KO mice exposed to CIH 
compared to NOX2 KO sham mice (P = 0.1107; Table 5.1). Similarly, genetic knock-
out of NOX2 resulted in no difference in Pt compared to wild-type sham mice (P = 
0.3106; Table 5.1). Twitch contraction time (CT) and half-relaxation time (½ RT) were 
unaffected by exposure to CIH in both wild-type (Sham vs. CIH; CT, P = 0.0.4989; ½ 
RT, P = 0.9863; Table 5.1) and NOX2 KO mice (NOX2 KO sham vs. NOX2 KO CIH; CT, P 
= 0.8502; ½ RT, P = 0.8482; Table 5.1). Similarly, the administration of apocynin 
during the exposure to CIH resulted in no significant difference in these parameters 
(CIH vs. CIH + APO; CT, P = 0.3984; ½ RT, P = 0.4109; Table 5.1). CT was significantly 
decreased in NOX2 KO sham mice compared to wild-type sham mice (P = 0.0005; 




Table 5.1 Ex vivo diaphragm muscle contractile parameters. Definition of abbreviations: Pt, isometric twitch force; CT, contraction time; 1⁄2 RT, half-relaxation time; Wmax, 
maximum mechanical work; Pmax, maximum mechanical power; Smax, maximum shortening; Vmax, maximum shortening velocity; Lo, optimum length. Values are expressed 
as mean ± SD. Data sets which were normally distributed and of equal variance were statistically compared using unpaired two-tailed Student’s t test. Welch’s correction 
was applied in the case of unequal variance. Data, which were not normally distributed, were compared using Mann Whitney non-parametric tests. Bolded numbers highlight 
statistical significance (P < 0.0125). Relevant comparisons are denoted as follows: * CIH significantly different from corresponding sham values; # APO + CIH significantly 
different from corresponding CIH values; £ NOX2 KO sham significantly different from corresponding sham values. 
 Sham 
(n = 8) 
CIH 
(n = 8) 
CIH + APO 
(n = 9) 
NOX2 KO 
sham 
(n = 9) 
NOX2 KO CIH 
(n = 9) 
Sham vs CIH 
(P value) 











Pt (N/cm2) 2.62 ± 0.89 1.63 ± 0.31 4.06 ± 1.89# 3.50 ± 2.30 5.52 ± 2.75 0.0173 0.0043# 0.1107 0.3106 
CT (ms) 15.69 ±0.96 16.69 ± 3.87 18.17 ± 3.14 12.28 ± 2.00£ 12.44 ± 1.67 0.4989 0.3984 0.8502 0.0005£ 
½ RT (ms) 19.69 ± 7.82 19.63 ± 6.39 17.50 ± 3.79 13.39 ± 5.41 12.56 ± 5.04 0.9863 0.4109 0.8482 0.0246 
Wmax (J/cm2) 1.60 ± 0.85 0.63 ± 0.21* 1.69 ± 0.84# 2.42 ± 0.67 2.16 ± 0.60 0.0006* 0.0052# 0.3923 0.0927 
Pmax (W/cm2) 12.20 ± 3.49 6.57 ± 2.35* 13.60 ± 4.55# 18.74 ± 4.61£ 15.57 ± 5.02 0.0020* 0.0014# 0.1821 0.0053£ 
Smax (L/Lo) 1.16 ± 0.26 1.21 ± 0.21 1.31 ± 0.25 0.99 ± 0.13 1.06 ± 0.20 0.1417 0.0828 0.1148 0.1343 
Vmax (L/L0) 4.78 ± 1.57 3.59 ± 1.19 4.51 ± 0.95 4.53 ± 1.40 3.98 ± 1.27 0.1304 0.0745 0.3958 0.7291 
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Figure 5.1 shows representative original traces for sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) tetanic contractions (A). 2 weeks 
of exposure to CIH significantly decreased the force-generating capacity of the 
diaphragm compared to sham mice (P = 0.0002; Fig 5.1; B). Exposure to CIH resulted 
in a ~45% decrease in peak specific force of the diaphragm compared to sham mice. 
Apocynin administration throughout the exposure to CIH successfully ameliorated 
CIH-induced muscle weakness (P = 0.0003; Fig 5.1; B). Moreover, there was no 
difference in the tetanic force produced by NOX2 KO mice exposed to CIH compared 
to NOX2 KO sham controls (P = 0.4613; Fig 5.1; B), revealing a specific role for NOX2 
in CIH-induced diaphragm muscle weakness. Tetanic force was increased by ~47% in 
NOX2 KO sham mice compared to wild-type sham mice, although this increase did 
not reach the threshold for statistical significance when corrections for multiple 







Figure 5.1 Ex vivo diaphragm muscle contractile force. A) Original traces of ex vivo 
diaphragm muscle tetanic contractions for sham (grey), CIH (black), CIH + APO (blue), NOX2 
KO sham (pink) and NOX2 KO CIH (red) preparations. B) Group data for diaphragm muscle 
tetanic force, normalised for muscle CSA, in sham (n = 8), CIH (n = 8), CIH + APO (n = 9), NOX2 
KO Sham (n = 9) and NOX2 KO CIH (n = 9) mice. Tetanic force was measured following 
stimulation at 100 Hz ex vivo. Values are expressed as mean ± SD. Data sets which were 
normally distributed and of equal variance were statistically compared using unpaired two-
tailed Student’s t test. Welch’s correction was applied in the case of unequal variance. Data, 
which were not normally distributed, were compared using Mann Whitney non-parametric 
tests. Statistical significance was taken at P < 0.0125.  Relevant comparisons are denoted as 
follows: * CIH vs. sham, *** P < 0.001;  # APO + CIH vs. CIH, ###  P <  0.001.  
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Figure 5.2 shows original traces of ex vivo diaphragm muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 5.2; B, C and D show the diaphragm 
power-load relationship. This is the power generated by the diaphragm over a range 
of incremental loads on the muscle between 0-100% of the peak force-generating 
capacity (Fmax), determined at the beginning of the protocol. Exposure to CIH 
significantly decreased the power-generating capacity of the diaphragm muscle over 
a range of loads compared to sham mice (P < 0.0001; repeated measures two-way 
ANOVA; Fig 5.2; B). Post-hoc analysis revealed a statistically significant decrease in 
the power-generating capacity of the diaphragm following exposure to CIH at 20% 
(*P < 0.05), 30% (**P < 0.01), 40% (**P < 0.01) and 60% (*P < 0.05) load compared 
to sham mice (Fig 5.2; B). The administration of apocynin throughout the exposure 
to CIH prevented the CIH-induced decrease in the power-generating capacity of the 
diaphragm over a range of loads compared to mice exposed to CIH alone (P < 0.0001; 
Fig 5.2; B). Post-hoc analysis revealed a statistically significant increase in the power-
generating capacity of the diaphragm following treatment with apocynin throughout 
the exposure to CIH at 10% - 60% load compared to CIH-exposed mice (Fig 5.2; B). 
Peak power (Pmax) was measured and typically occurred between 30% and 40% 
load. Pmax was reduced following exposure to CIH compared to sham mice (P = 
0.0020; Table 5.1); apocynin administration significantly prevented the CIH-induced 
decrease in Pmax (P = 0.0014; Table 5.1).  Exposure to CIH reduced the power-
generating capacity of the diaphragm in NOX2 KO mice over the range of loads 
examined compared to NOX2 KO sham controls (P = 0.0020; Fig 5.2; C). Pmax was 
unaffected by exposure to CIH in NOX2 KO mice (P = 0.1821; Table 5.1).  Genetic 
knock-out of NOX2 significantly increased the power-generating capacity of the 
diaphragm over the range of loads examined compared to wild-type sham mice (P = 
0.0271; Fig 5.2; D). Pmax was significantly increased in NOX2 KO sham compared with 











Figure 5.2 Diaphragm muscle power–load relationship. A, original traces of ex vivo 
diaphragm muscle maximum unloaded shortening for sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data for 
diaphragm power (mean ± SD) shown as power per unit CSA (Watts/cm2) as a function of the 
load on the muscle expressed as a percentage of peak tetanic force for sham (n = 8), CIH (n 
= 8), CIH + APO (n = 9), NOX2 KO sham (n = 9) and NOX2 KO CIH (n = 9) mice. Data were 
statistically compared by repeated measures two-way ANOVA with Bonferroni’s post hoc 
test. Relevant comparisons are denoted as follows: *denotes sham vs. CIH, *P < 0.05, **P < 
0.01;  #denotes CIH vs. CIH + APO, #P < 0.05, ####P < 0.0001.  
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Figure 5.3 shows original traces of ex vivo diaphragm muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 5.3; B, C and D show the diaphragm work-
load relationship. This is the work produced by the diaphragm over a range of 
incremental loads on the muscle between 0-100% of the peak force-generating 
capacity (Fmax), determined at the beginning of the protocol. Exposure to CIH 
significantly decreased the work produced by the diaphragm muscle over a range of 
loads compared to sham mice (P < 0.0001; repeated measures two-way ANOVA; Fig 
5.3; B). Post-hoc analysis revealed a statistically significant decrease in the power-
generating capacity of the diaphragm following exposure to CIH at 20% (*P < 0.05), 
30% (***P < 0.001) 40% (****P < 0.0001) and 60% (****P < 0.0001) load compared 
to sham mice (Fig 5.3; B). The administration of apocynin throughout the exposure 
to CIH prevented the CIH-induced decrease in the work produced by the diaphragm 
over a range of loads compared to mice exposed to CIH alone (P < 0.0001; Fig 5.3; B). 
Post-hoc analysis revealed a statistically significant increase in work produced by the 
diaphragm following treatment with apocynin throughout the exposure to CIH at 
20% - 60% load compared to CIH-exposed mice (Fig 5.3; B). Peak work (Wmax) was 
measured and typically occurred between 30% and 40% load. Exposure to CIH for 2 
weeks significantly decreased Wmax compared to sham controls (P = 0.0006; Table 
5.1); Apocynin treatment completely prevented the CIH-induced decrease in Wmax 
(P = 0.0052; Table 5.1). Exposure to CIH decreased the work produced by the 
diaphragm in NOX2 KO mice over the range of loads examined compared to NOX2 
KO sham controls (P = 0.0305; Fig 5.3; C). Wmax was unaffected by exposure to CIH 
in NOX2 KO mice (P = 0.3923; Table 5.1). Genetic knock-out of NOX2 significantly 
increased the work produced by the diaphragm over the range of loads examined 
compared to wild-type sham mice (P < 0.0001; Fig 5.; D). Post-hoc analysis revealed 
a statistically significant increase in the power generated by the diaphragm of NOX2 
KO sham mice at 20%-40% load compared to wild-type sham mice (Fig 5.3; D). NOX2 
KO had no significant effect on Wmax compared to wild-type controls (P = 0.0927; 






Figure 5.3 Diaphragm muscle work–load relationship. A, original traces of ex vivo diaphragm 
muscle maximum unloaded shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 
KO sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data for diaphragm work 
(mean ± SD) shown as work per unit CSA (Joules/cm2) as a function of the load on the muscle 
expressed as a percentage of peak tetanic force for sham (n = 8), CIH (n = 8), CIH + APO (n = 
9), NOX2 KO sham (n = 9) and NOX2 KO CIH (n = 9) mice. Data were statistically compared by 
repeated measures two-way ANOVA with Bonferroni’s post hoc test. Relevant comparisons 
are denoted as follows: *denotes sham vs. CIH, *P < 0.05, ***P < 0.001, ****P < 0.0001;  # 
denotes CIH vs. CIH + APO, ###  P < 0.001, ####  P < 0.0001; £ denotes sham vs. NOX2 KO sham,  
£ P < 0.05, ££ P < 0.01.  
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Figure 5.4 shows original traces of ex vivo diaphragm muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 5.4; B, C and D show the diaphragm 
shortening-load relationship. This is the distance of shortening of the diaphragm over 
a range of incremental loads on the muscle between 0-100% of its peak force-
generating capacity (Fmax), determined at the beginning of the protocol.  2 weeks of 
exposure to CIH significantly decreased the distance of shortening of the diaphragm 
muscle compared to sham mice (P < 0.0001; repeated measures two-way ANOVA; 
Fig 5.4; B); Apocynin treatment throughout the exposure to CIH prevented the CIH-
induced decrease in the distance of shortening of the diaphragm over a range of 
loads examined compared with mice exposed to CIH alone (P < 0.0001; Fig 5.4; B). 
Post hoc analysis revealed that apocynin treatment significantly increased the 
distance of shortening at 0% of the peak force-generating capacity compared to CIH 
exposed mice (#P < 0.05). Peak shortening (Smax) was measured and occurred at 0% 
load, as expected. Smax was not different following exposure to CIH (P = 0.1417; 
Table 5.1) or apocynin treatment (P = 0.0828; Table 5.1) in wild-type mice. There was 
no difference in the distance of shortening between NOX2 KO sham and NOX2 KO 
CIH groups over the range of loads examined (P = 0.3893; Fig 5.4; C). Similarly, Smax 
was not different following exposure to CIH in NOX2 KO mice (P = 0.1148; Table 5.1).  
Genetic knock-out of NOX2 had no effect on the distance of shortening of the 
diaphragm over the range of loads examined compared to wild-type sham mice (P = 
0.3655; Fig 5.4; D); Smax was also not different between these groups (P = 0.1343; 












Figure 5.4 Diaphragm muscle shortening–load relationship. A, original traces of ex vivo 
diaphragm muscle maximum unloaded shortening for sham (grey), CIH (black), CIH + APO 
(blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data for 
diaphragm shortening (mean ± SD) shown as length per unit optimal length (L/Lo) as a 
function of the load on the muscle expressed as a percentage of peak tetanic force for sham 
(n = 8), CIH (n = 8), CIH + APO (n = 9), NOX2 KO sham (n = 9) and NOX2 KO CIH (n = 9) mice. 
Data were statistically compared by repeated measures two-way ANOVA with Bonferroni’s 
post hoc test. Relevant comparisons are denoted as follows: # denotes CIH vs. CIH + APO, #P 
< 0.05.  
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Figure 5.5 shows original traces of ex vivo diaphragm muscle maximum unloaded 
shortening for sham (grey), CIH (black), CIH + APO (blue), NOX2 KO sham (pink) and 
NOX2 KO CIH (red) preparations (A). Figure 5.5; B, C and D show the diaphragm 
shortening velocity-load relationship. This is the shortening velocity of the diaphragm 
over a range of incremental loads on the muscle between 0-100% of the peak force-
generating capacity (Fmax), determined at the beginning of the protocol. 2 weeks of 
exposure to CIH significantly decreased the shortening velocity of the diaphragm 
muscle compared to sham mice (P = 0.0006; repeated measures two-way ANOVA; 
Fig 5.5; B). Post hoc analysis revealed that exposure to CIH significantly decreased 
the shortening velocity of the diaphragm at 0% load compared to sham mice (*P = 
0.05; Fig 5.5; B). Apocynin treatment throughout the exposure to CIH prevented the 
decrease in shortening velocity of the diaphragm over a range of loads examined 
compared to exposure to CIH alone (P = 0.0123; Fig 5.5; B). Peak shortening velocity 
(Vmax) was measured and occurred at 0% load, as expected. Vmax was unaffected 
by exposure to CIH (P = 0.1304; Table 5.1) or apocynin treatment (P = 0.0745; Table 
5.1) in wild-type mice. There was no difference in the shortening velocity between 
NOX2 KO sham and NOX2 KO CIH groups (P = 0.0754; Fig 5.5; C); Vmax was also not 
different between these groups (P = 0.3958; Table 5.1). Similarly, genetic knock-out 
of NOX2 had no effect on the shortening velocity of the diaphragm over the range of 
loads examined compared to wild-type sham mice (P = 0.0930; Fig 5.5; D); Vmax was 





















Figure 5.5 Diaphragm muscle shortening velocity–load relationship. A, original traces of ex 
vivo diaphragm muscle maximum unloaded shortening for sham (grey), CIH (black), CIH + 
APO (blue), NOX2 KO sham (pink) and NOX2 KO CIH (red) preparations. B, C, D, group data 
for diaphragm shortening velocity (mean ± SD) shown as optimal length per unit time (Lo/s) 
as a function of the load on the muscle expressed as a percentage of peak tetanic force for 
sham (n = 8), CIH (n = 8), CIH + APO (n = 9), NOX2 KO sham (n = 9) and NOX2 KO CIH (n = 9) 
mice. Data were statistically compared by repeated measures two-way ANOVA with 
Bonferroni’s post hoc test. Relevant comparisons are denoted as follows: ##denotes CIH vs. 




5.3.2 Characterisation of NOX enzymes in diaphragm muscle  
Figure 5.6 shows the mRNA expression of the most predominant muscle-specific NOX 
isoforms in naïve wild-type mouse diaphragm muscle. The mRNA expression of NOX1 
in the diaphragm was found to be significantly lower than that of both NOX4 (Fig 5.6; 
P < 0.0001) and NOX2 (Fig 5.6; P < 0.0001). There was no difference in the mRNA 






Figure 5.6 mRNA expression of the predominant muscle-specific NOX isoforms in naive 
wild-type mouse diaphragm muscle. Group data (mean ± SD, n = 8-9 per group) expressed 
as a fold difference in messenger RNA (mRNA) expression (relative to NOX4) for naïve wild-
type mouse diaphragm muscle. Data sets, which were normally distributed and of equal 
variance, were statistically compared using unpaired two-tailed Student’s t test. Welch’s 
correction was applied in the case of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-parametric tests. € denotes NOX4 vs. 
NOX1, €€€€P < 0.0001; + denotes NOX2 vs. NOX1, ++++P < 0.0001. Definition of abbreviations: 
NOX4, NADPH oxidase 4; NOX2, NADPH oxidase 2; NOX1, NADPH oxidase 1.  
 
 






























mRNA and protein expression of the NOX2 enzyme in mouse diaphragm muscle is 
shown in Figure 5.7. There was no statistically significant difference in the mRNA 
expression of NOX2 following exposure to CIH compared with sham; a trend towards 
a lower mRNA expression of NOX2 was observed following treatment with apocynin 
throughout the exposure to CIH, however this did not reach the threshold for 
statistical significance (Fig 5.7; A, P = 0.0136). Similarly, exposure to CIH had no effect 
on NOX2 mRNA expression in NOX2 KO mice (Fig 5.7; A). As expected, a significant 
decrease (97%) in the mRNA expression of NOX2 following NOX2 KO was observed, 
compared with sham (Fig 5.7; A, P = 0.0002). Western blot bands were detected at 
approximately 65kDa, corresponding to the predicted MW of the NOX2 subunit (Fig 
5.7; B). Fig 5.7; C shows the corresponding Ponceau S-stained membrane, confirming 
relatively equal protein loading and electro-transfer. Densitometric analysis of NOX2 
band intensities, normalised by the intensity of the corresponding Ponceau S-stained 
proteins, revealed no significant difference in the protein expression of the NOX2 
subunit in the diaphragm of mice exposed to CIH compared with sham (Fig 5.7; D, P 















Figure 5.7 NOX2 mRNA and protein expression in 
diaphragm muscle. A, Group data (mean ± SD, n = 8-9 per 
group) expressed as a fold change in messenger RNA 
(mRNA) expression (relative to the control (sham) group) for 
sham, CIH, CIH + APO, NOX2 KO sham and NOX2 KO CIH 
groups for A, NOX2. B, Western blot of NOX2 in 20µg of 
protein extracted from the diaphragm of mice exposed to 2 
weeks of normoxia (sham) or CIH. C, corresponding Ponceau 
S-stained membrane used for normalisation and 
compensation for protein loading and the electro-transfer 
of proteins. D, Group data (mean ± SD, n = 6 per group) for 
normalised NOX2 expression expressed as arbitrary units 
(a.u.). This is a product of the band intensity of the 
developed blot (B) / band intensity of the corresponding 
Ponceau S image (C), as determined by densitometry. Data 
sets, which were normally distributed and of equal variance, 
were statistically compared using unpaired two-tailed 
Student’s t test. Welch’s correction was applied in the case 
of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-
parametric tests. Statistical significance was taken at P < 
0.0125 (Fig 5.7; A) or P < 0.05 (Fig 5.7; D). Comparisons are 
denoted as follows: £ denotes sham vs. NOX2 KO sham, £££P 
< 0.001. Definition of abbreviations: MW, molecular weight 
marker; S. Sham; NOX2, NADPH oxidase 2.   
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mRNA and protein expression of the NOX4 enzyme in mouse diaphragm muscle is 
shown in Figure 5.8. Exposure to CIH increased the mRNA expression of NOX4 
compared with sham, although this did not reach the threshold for statistical 
significance when correction for multiple comparisons was applied (Fig 5.8; A, P = 
0.0157); apocynin treatment throughout the exposure to CIH significantly decreased 
NOX4 mRNA levels in diaphragm muscle compared with exposure to CIH alone (Fig 
5.8; A, P = 0.0040).  NOX4 mRNA expression was significantly increased in NOX2 KO 
mice following exposure to CIH, with the size of this effect similar to that observed 
in wild-type mice (Fig 5.8; A, P = 0.0040). Western blot bands were detected at 
approximately 63kDa, corresponding to the predicted MW of the NOX4 subunit (Fig 
5.8; B). Fig 5.8; C shows the corresponding Ponceau S-stained membrane, confirming 
relatively equal protein loading and electro-transfer. Densitometric analysis of NOX4 
band intensities, normalised by the intensity of the corresponding Ponceau S-stained 
proteins, revealed a significant near two-fold increase in the protein expression of 
the NOX4 subunit in the diaphragm of mice exposed to CIH compared with sham 





Figure 5.8 NOX4 mRNA and protein expression in diaphragm 
muscle. A, Group data (mean ± SD, n = 8-9 per group) expressed as 
a fold change in messenger RNA (mRNA) expression (relative to the 
control (sham) group) for sham, CIH, CIH + APO, NOX2 KO sham and 
NOX2 KO CIH groups for A, NOX4. B, Western blot of NOX4 in 20µg 
of protein extracted from the diaphragm of mice exposed to 2 weeks 
of normoxia (sham) or CIH. C, corresponding Ponceau S-stained 
membrane used for normalisation and compensation for protein 
loading and the electro-transfer of proteins. D, Group data (mean ± 
SD, n = 6 per group) for normalised NOX4 expression expressed as 
arbitrary units (a.u.). This is a product of the band intensity of the 
developed blot (B) / band intensity of the corresponding Ponceau S 
image (C), as determined by densitometry.  Data sets, which were 
normally distributed and of equal variance, were statistically 
compared using unpaired two-tailed Student’s t test. Welch’s 
correction was applied in the case of unequal variance. Data, which 
were not normally distributed, were compared using Mann Whitney 
non-parametric tests. Statistical significance was taken at P < 0.0125 
(Fig 5.8; A) or P < 0.05 (Fig 5.8; D). Comparisons are denoted as 
follows: *denotes sham vs. CIH, **P < 0.01, # denotes CIH vs. CIH + 
APO, ##  P < 0.01, $denotes CIH vs. CIH + APO, $$  P < 0.01. Definition of 
abbreviations: MW, molecular weight marker; S. Sham; NOX4, 
NADPH oxidase 4.
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The mRNA expression of NOX catalytic and accessory subunits in diaphragm muscle 
is show in Figure 5.9. A trend towards a decrease in the mRNA expression of the 
accessory subunit, p22phox, was observed following 2 weeks of exposure to CIH in 
the diaphragm, but this did not reach the threshold for statistical significance (Fig 
5.9; B, P = 0.0264); apocynin treatment throughout the exposure to CIH prevented 
the decrease in p22phox to levels equivalent to sham (Fig 5.9; B). The mRNA 
expression of p22phox was not different in NOX2 KO mice following exposure to CIH 
compared to NOX2 KO sham mice (Fig 5.9; B).  Similarly, exposure to CIH resulted in 
a decrease in the mRNA expression of the small GTPase, Rac, compared with sham 
mice (Fig 5.9; F, P = 0.0543), but this failed to reach the threshold for statistical 
significance; apocynin administration prevented the decrease in the mRNA 
expression of Rac compared to exposure to CIH alone. There was no difference in the 
mRNA expression of Rac in NOX2 KO mice following exposure to CIH compared with 
NOX2 KO sham mice (Fig 5.9; F). There was no difference in the mRNA expression of 
NOX1 (Fig 5.9; A), p47phox (Fig 5.9; C), p40phox (Fig 5.9; D), p67phox (Fig 5.9; E), 
DUOX1 (Fig 5.9; G) or DUOX2 (Fig 5.9; H) across all groups examined. 2 weeks of 
exposure to CIH had no effect on NOX activity in the diaphragm compared with sham 
























Figure 5.9 mRNA expression of NOX catalytic and accessory subunits in diaphragm muscle. 
Group data (mean ± SD, n = 8-9 per group) expressed as a fold change in messenger RNA 
(mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, NOX2 KO 
sham and NOX2 KO CIH groups for (A) NOX1; (B) p22phox; (C) p47phox; (D) p40phox; (E) 
p67phox; (F) Rac; (G) DUOX1 and (H) DUOX2. Group data (mean ± SD, n = 8 per group) for 
NOX enzymatic activity in diaphragm muscle following 2 weeks of CIH or normoxia (sham), 
expressed as enzymatic activity per minute per mg protein (I). Data sets, which were 
normally distributed and of equal variance, were statistically compared using unpaired two-
tailed Student’s t test. Welch’s correction was applied in the case of unequal variance. Data, 
which were not normally distributed, were compared using Mann Whitney non-parametric 
tests. Statistical significance was taken at P < 0.0125 (A-H, inclusive) or P < 0.05 (I). Definition 





5.3.3 Molecular analysis of redox sensitive indices of diaphragm muscle form and 
function 
 
Figure 5.10 shows the mRNA expression of genes relating to the muscle 
differentiation process in diaphragm muscle. Exposure to CIH increased the mRNA 
expression of the transcriptional activator of muscle differentiation, myogenin, but 
this did not reach the threshold for statistical significance (P = 0.0132; Fig 5.10; A); 
treatment with apocynin throughout the exposure to CIH significantly prevented the 
increase in myogenin (P < 0.0001; Fig 5.10; A). A trend towards a decrease in the 
mRNA expression of myogenin was observed in NOX2 KO sham mice when compared 
with sham (P = 0.0703; Fig 5.10; A). Exposure to CIH had no effect on the mRNA 
expression of myogenin in NOX2 KO mice. Exposure to CIH significantly increased the 
mRNA expression of the myogenesis inhibitor, myostatin (P = 0.0041; Fig 5.10; B); 
apocynin treatment throughout the exposure to CIH reduced the increase in 
myostatin compared to exposure to CIH alone, but this did not reach statistical 
significance (P = 0.0512; Fig 5.10; B). Exposure to CIH had no effect on the mRNA 
expression of myostatin in NOX2 KO mice compared with NOX2 KO sham mice. NOX2 
KO resulted in a significant increase in the mRNA expression of myostatin compared 
with wild-type sham mice (P = 0.0052; Fig 5.10; B). The mRNA expression of the 
muscle differentiation regulator, MyoD, was increased following exposure to CIH, but 
this did not meet the threshold for statistical significance (P = 0.0128; Fig 5.10; C); 
treatment with apocynin throughout the exposure to CIH prevented the increase 
compared with exposure to CIH alone (P = 0.0003; Fig 5.10; C). Exposure to CIH 
resulted in no difference in the mRNA expression of MyoD in NOX2 KO mice. A trend 
towards a decrease in the mRNA expression of MyoD was observed in mice lacking 
the NOX2 enzyme compared with wild-type controls (P = 0.0703; Fig 5.10; C). There 
was a trend towards an increase in mRNA for the transcription factor, MEF2C, 
following exposure to CIH compared with sham (P = 0.0215; Fig 5.10; D); 
administration of apocynin throughout the exposure to CIH prevented the increase 
compared with exposure to CIH alone (P = 0.0028; Fig 5.10; D). There was no 
difference in the mRNA expression of MEF2C in NOX2 KO mice exposed to CIH 
compared with NOX2 KO sham mice. A trend towards a decrease in the mRNA 
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expression of MEF2C was observed in mice lacking the NOX2 enzyme when 
compared with wild-type mice (P = 0.0253; Fig 5.10; D). Exposure to CIH increased 
the mRNA expression of sirtuin-1 compared with sham, but this did not reach 
statistical significance (P = 0.0355; Fig 5.10; E); treatment with apocynin ameliorated 
the increase compared with exposure to CIH alone (P = 0.0005; Fig 5.10; E). There 
was no difference in the mRNA expression of sirtuin-1 between NOX2 KO CIH and 





Figure 5.10 mRNA expression of genes related to muscle differentiation in diaphragm 
muscle. Group data (mean ± SD, n = 8-9 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for Sham, CIH, CIH + APO, 
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NOX2 KO Sham and NOX2 KO CIH groups for (A) Myogenin; (B) Myostatin; (C) MyoD; (D) 
MEF2C; (E) Sirtuin-1; and (F) IGF-1. Data sets, which were normally distributed and of equal 
variance, were statistically compared using unpaired two-tailed Student’s t test. Welch’s 
correction was applied in the case of unequal variance. Data, which were not normally 
distributed, were compared using Mann Whitney non-parametric tests. Statistical 
significance was taken at P < 0.0125.  Relevant comparisons are denoted as follows: *denotes 
sham vs. CIH, **P < 0.01;  # denotes CIH vs. CIH + APO, ##  P < 0.01, ####  P < 0.0001; £ denotes 
Sham vs. NOX2 KO Sham, ££ P < 0.01. Definition of abbreviations: MyoD, muscle 
differentiation protein 1; MEF2C, myocyte-specific enhancer factor 2C; IGF-1, insulin-like 
growth factor 1.  
 
Figure 5.11 shows the mRNA expression of genes relating to antioxidant status in 
diaphragm muscle. There were no statistically significant differences in the mRNA 
expression of SOD1, SOD2 or catalase across all groups examined (Fig 5.11; A, B and 
C, respectively). However, exposure to CIH significantly increased the mRNA 
expression of NRF2 (transcription factor involved in the regulation of antioxidant 
proteins) compared with sham (P = 0.0098; Fig 5.11; D); administration of apocynin 
throughout the exposure to CIH prevented the increase in NRF2 mRNA compared to 
exposure to CIH alone (P = 0.0005; Fig 5.11; D). There was no difference in the mRNA 
expression of NRF2 in NOX2 KO mice following exposure to CIH compared with sham 
controls. There was a trend towards a decrease in the mRNA expression of NRF2 in 
NOX2 KO sham mice compared with wild-type controls (sham), however this did not 
reach the threshold for statistical significance when correction for multiple 





Figure 5.11 mRNA expression of genes related to antioxidant capacity in diaphragm 
muscle. Group data (mean ± SD, n = 8-9 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, 
NOX2 KO sham and NOX2 KO CIH groups for (A) SOD1; (B) SOD2; (C) Catalase; and (D) NRF2. 
Data sets, which were normally distributed and of equal variance, were statistically 
compared using unpaired two-tailed Student’s t test. Welch’s correction was applied in the 
case of unequal variance. Data, which were not normally distributed, were compared using 
Mann Whitney non-parametric tests. Statistical significance was taken at P < 0.0125. 
Relevant comparisons are denoted as follows: *denotes sham vs. CIH, **P < 0.01;  # denotes 
CIH vs. CIH + APO,###  P < 0.001. Definition of abbreviations: SOD1, superoxide dismutase 1 ; 
SOD2, superoxide dismutase 2; NRF2, nuclear factor erythroid 2-related factor 2. 
 
 
Figure 5.12 shows a range of indices relating to mitochondrial capacity in diaphragm 
muscle. Exposure to CIH (both in wild-type and NOX2 KO mice) or treatment with 
apocynin had no effect on the mRNA expression of the mitophagy-related gene, 
PINK1, in diaphragm muscle (Fig 5.12; A). However, genetic knock-out of the NOX2 
enzyme resulted in a significant increase in the mRNA expression of PINK1 in the 
diaphragm compared to sham (P = 0.0003; Fig 5.12; A). Exposure to CIH increased 
the mRNA expression of another mitophagy-related gene, PARK2, compared with 
sham, but this did not reach the threshold for statistical significance (P = 0.0208; Fig 
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5.12; B); treatment with apocynin significantly prevented the CIH-induced increase 
in PARK2 compared with exposure to CIH alone (P = 0.0006; Fig 5.12; B). There was 
no alteration to the mRNA expression of PARK2 in NOX2 KO mice following exposure 
to CIH. Citrate synthase activity, commonly used as a quantitative enzyme marker for 
the presence of intact mitochondria, and hence aerobic capacity, was unchanged 







Figure 5.12 Indices relating to mitochondrial integrity in diaphragm muscle. Group data 
(mean ± SD, n = 8-9 per group) expressed as fold changes in messenger RNA (mRNA) 
expression (relative to the control group) for sham, CIH, CIH + APO, NOX2 KO sham and NOX2 
KO CIH groups for A, PINK1; and B, PARK2. C, citrate synthase activity following 2 weeks of 
CIH exposure (mean ± SD, n = 8 per group). Data sets, which were normally distributed and 
of equal variance, were statistically compared using unpaired two-tailed Student’s t test. 
Welch’s correction was applied in the case of unequal variance. Data, which were not 
normally distributed, were compared using Mann Whitney non-parametric tests. Statistical 
significance was taken at P < 0.0125 (Fig 5.12; A & B) or P < 0.05 (Fig 5.12; C).  Relevant 
comparisons are denoted as follows: # denotes CIH vs. CIH + APO, ###  P < 0.001; £ denotes 
sham vs. NOX2 KO sham, £££P < 0.001. Definition of abbreviations: PINK1, PTEN-induced 
kinase 1; PARK2, parkin.  
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Figure 5.13 shows a range of measures relating to inflammation and redox balance 
in diaphragm muscle. A trend towards an increase in the expression of the 
inflammatory transcription factor, NF-κB, was observed following exposure to CIH 
compared with sham (P = 0.0742; Fig 5.13; A); administration of apocynin throughout 
the exposure to CIH prevented the CIH-induced increase in NF-κB mRNA compared 
with exposure to CIH alone (P = 0.0012; Fig 5.13; A). There was no difference in the 
mRNA expression of NF-κB in NOX2 KO mice following exposure to CIH. Levels of 
TBARS (indirect measure of oxidative stress) and protein expression of HIF-1α 
(mediator of adaptive responses to oxidative stress during hypoxia) were unaltered 






Figure 5.13 Inflammatory mediators and indirect measures of redox imbalance in 
diaphragm muscle. Group data (mean ± SD, n = 8-9 per group) expressed as a fold change in 
messenger RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH 
+ APO, NOX2 KO sham and NOX2 KO CIH groups for A, NF-κB. B, TBARS and C, HIF-1α protein 
content in sternohyoid muscle following 2 weeks of CIH (mean ± SD, n = 8 per group). Data 
sets, which were normally distributed and of equal variance, were statistically compared 
using unpaired two-tailed Student’s t test. Welch’s correction was applied in the case of 
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unequal variance. Data, which were not normally distributed, were compared using Mann 
Whitney non-parametric tests. Statistical significance was taken at P < 0.0125 (Fig 5.13; A) or 
P < 0.05 (Fig 5.13; B & C).  Relevant comparisons are denoted as follows: # denotes CIH vs. 
CIH + APO, ## P < 0.01. Definition of abbreviations: NF-κB, nuclear factor kappa-light-chain-
enhancer of activated B cells; TBARS, thiobarbituric acid reactive substances; HIF-1α, 
hypoxia-inducible factor 1-alpha.  
 
 
Figure 5.14 shows the mRNA expression of genes relating to autophagy and atrophy 
in diaphragm muscle. There was a trend towards an increase in the mRNA expression 
of the autophagy-related gene, BNIP3, following exposure to CIH compared to sham 
(P = 0.0245; Fig 5.14; A); treatment with apocynin throughout the exposure to CIH 
significantly ameliorated the increase in BNIP3 (P = 0.0026; Fig 5.14; A). There was 
no difference in the mRNA expression of BNIP3 in NOX2 KO mice following exposure 
to CIH. Similarly, there was a trend towards an increase in the mRNA expression of 
another autophagy-related gene, LC3B,  following exposure to CIH compared to sham 
mice (P = 0.0263; Fig 5.14; C); treatment with apocynin significantly ameliorated the  
increase in LC3B compared to exposure to CIH alone (P = 0.0066; Fig 5.14; C). There 
was no difference in the mRNA expression of LC3B in NOX2 KO mice following 
exposure to CIH. Exposure to CIH had no effect on the mRNA expression of the 
atrophy-related gene, atrogin-1, in wild-type or NOX2 KO mice (Fig 5.14; D). 
However, treatment with apocynin throughout the exposure to CIH significantly 
decreased the mRNA expression of atrogin-1 compared to exposure to CIH alone (P 
= 0.0056; Fig 5.14; D). Exposure to CIH increased the mRNA expression of another 
atrophy related gene, MuRF1, compared to sham, but this did not reach statistical 
significance (P = 0.0371; Fig 5.14; E; apocynin administration throughout the 
exposure to CIH prevented the CIH induced increase in MuRF1 (P = 0.0050; Fig 5.14; 
E). The mRNA expression of MuRF1 was not different in NOX2 KO mice following 
exposure to CIH compared to NOX2 KO sham mice. There was no difference in the 






Fig 5.14 mRNA expression of genes relating to autophagy and atrophy in diaphragm 
muscle. Group data (mean ± SD, n = 8-9 per group) expressed as a fold change in messenger 
RNA (mRNA) expression (relative to the control (sham) group) for sham, CIH, CIH + APO, 
NOX2 KO sham and NOX2 KO CIH groups for (A) BNIP3; (B) GABARAPL1; (C) LC3B; (D) Atrogin-
1; and (E) MuRF1. Data sets, which were normally distributed and of equal variance, were 
statistically compared using unpaired two-tailed Student’s t test. Welch’s correction was 
applied in the case of unequal variance. Data, which were not normally distributed, were 
compared using Mann Whitney non-parametric tests. Statistical significance was taken at P 
< 0.0125. Relevant comparisons are denoted as follows: # denotes CIH vs. CIH + APO, ## P < 
0.01. Definition of abbreviations: BNIP3, bcl-2 nineteen-kilodalton interacting protein 3; 
GABARAPL1, gamma-aminobutyric acid receptor-associated protein-like 1; LC3B, 
microtubule-associated proteins 1A/1B light chain 3B; MuRF1, muscle RING finger 1.  
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Figure 5.15 shows the phosphoprotein content of key proteins involved in protein 
synthesis and degradation signalling pathways in diaphragm muscle. The phospho – 
JNK (P = 0.0287; Fig 5.15; B), phospho - p38 (P = 0.0007; Fig 5.15; C) and phospho - 
ERK 1/2 (P = 0.0379; Fig 5.15; D) protein content of these arms of the mitogen 
activated protein kinase (MAPK) pathway were significantly decreased in diaphragm 
muscle following 2 weeks of exposure to CIH compared to sham mice. There was no 
alteration to the phosphoprotein content of phospho-FOXO3a in the diaphragm 




Figure 5.15 Phosphoprotein content relating to protein synthesis and degradation 
signalling in diaphragm muscle. A, Phospho-FOXO3a; B, Phospho-JNK; C, Phospho-p38 
protein content and D, Phospho-ERK 1/2 (mean ± SD, n = 8 per group) from mice exposed to 
2 weeks of CIH or normoxia (sham). Values are expressed as signal/μg of total protein 
(adjusted for background signal). Data sets, which were normally distributed and of equal 
variance, were statistically compared using unpaired two-tailed Student’s t test. Welch’s 
correction was applied in the case of unequal variance. Statistical significance was taken at 
P < 0.05. Relevant comparisons are denoted as follows: * denotes sham vs. CIH, *P < 0.05, 
***P < 0.001. Definition of abbreviations: FOXO3a, forkhead box O3a; JNK, c-Jun N-terminal 
kinase; ERK 1/2, extracellular-signal-regulated kinase 1/2. 
 246 
5.3.4 Comparison of the molecular profile of sternohyoid and diaphragm muscle 
Figure 5.16 compares the mRNA expression of the most predominant NOX isoforms 
in skeletal muscle between the sternohyoid and diaphragm muscle. The mRNA 
expression of NOX2 was significantly lower in the sternohyoid compared with the 
diaphragm muscle (Fig 5.16; A; P = 0.0223). NOX4 mRNA expression was lower in the 
sternohyoid compared with diaphragm, however this did not reach the threshold for 
statistical significance (Fig 5.16; B; P = 0.0519). There was no difference in the mRNA 
expression of NOX1 in the diaphragm compared with the sternohyoid (Fig 5.16; C; P 






Figure 5.16 Comparison of the mRNA expression of the predominant muscle-specific NOX 
isoforms in naive wild-type sternohyoid and diaphragm muscle. Group data (mean ± SD, n 
= 6-9 per group) expressed as a fold change in messenger RNA (mRNA) expression (relative 
to diaphragm) for A, NOX2, B, NOX4 & C, NOX1 for sham (naïve wild-type) sternohyoid and 
diaphragm muscle. Data sets, which were normally distributed and of equal variance, were 
statistically compared using unpaired two-tailed Student’s t test. Welch’s correction was 
applied in the case of unequal variance. Data, which were not normally distributed, were 
compared using Mann Whitney non-parametric tests. Statistical significance was taken at P 
< 0.05.  § denotes diaphragm vs. sternohyoid, §P < 0.05. Definition of abbreviations: NOX4, 
NADPH oxidase 4; NOX2, NADPH oxidase 2; NOX1, NADPH oxidase 1.  
 
Figure 5.17 is a heat map summarising the sternohyoid (A) and diaphragm (B) NOX 
enzyme mRNA expression data for all genes examined. Figure 5.18 is a heat map 
summarising the sternohyoid (A) and diaphragm (B) mRNA expression data for all 




Figure 5.17 Muscle gene expression data expressed in a heat map. Heat map depicting the fold changes in mRNA expression relative to the control (sham) 
group (mean ± SD, n = 6-8 per group) for NOX enzyme catalytic and accessory subunits for sham, CIH, CIH + APO, NOX2 KO sham and NOX2 KO CIH groups in 





Figure 5.18 Muscle gene expression data expressed in a heat map. Heat map depicting the fold changes in mRNA expression relative to the control (sham) 
group (mean ± SD, n = 6-8 per group) for genes related to mitochondrial function, autophagy, antioxidant capacity, inflammation, atrophy and muscle 
differentiation for Sham, CIH, CIH + APO, NOX2 KO Sham and NOX2 KO CIH groups in A) sternohyoid and B) diaphragm muscle. Red represents an increase in 
expression. Relevant comparisons are denoted as follows: *denotes sham vs. CIH, **P < 0.01;  # denotes CIH vs. CIH + APO, ##  P < 0.01, ###  P < 0.001, ####  P < 
0.0001; £ denotes Sham vs. NOX2 KO Sham, ££ P < 0.01, £££ P < 0.001. 
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5.4. Discussion  
 
The key findings of this study are: 
 
1) Exposure to CIH results in considerable diaphragm muscle weakness, which is 
prevented by treatment with apocynin, and absent in NOX2 KO mice exposed to CIH. 
 
2) NOX2 KO increases the force-generating capacity of the diaphragm muscle 
compared with wild-type controls (sham). 
 
4) Exposure to CIH does not affect the mRNA or protein expression of NOX2 in 
diaphragm muscle. However, exposure to CIH increases the mRNA expression and 
protein expression of NOX4; NOX activity remained unchanged following exposure 
to CIH. 
 
5) Indices of oxidative stress including levels of TBARS and citrate synthase activity 
remain unchanged in diaphragm following exposure to CIH. The mRNA expression of 
NRF2 is increased following exposure to CIH in wild-type mice only.  
 
 6) The mRNA expression of genes relating to the regulation of skeletal muscle form 
and function including autophagy, atrophy, mitophagy and muscle differentiation are 
increased following exposure to CIH in wild-type mice. The increase is prevented by 
treatment with apocynin and is absent in NOX2 KO mice following exposure to CIH. 
 
7) Whilst the magnitude of muscle weakness observed in sternohyoid and diaphragm 
muscle is similar, differences in molecular responses following exposure to CIH 
highlight the possibility of muscle-specific mechanisms underpinning respiratory 




The diaphragm muscle displays remarkable adaptability and plasticity owing to its 
mixed fibre-type composition.  Diaphragm muscle dysfunction has been reported in 
OSAS patients (Griggs et al., 1989, Chien et al., 2010), and animals exposed to 
tracheal occlusion (Smith et al., 2012). Conversely, there is also evidence that 
diaphragm dysfunction does not present in OSAS patients (Montserrat et al., 1997), 
revealing considerable heterogeneity in the respiratory consequences of OSAS. A fine 
balance between the dilating and stabilizing forces produced by UA muscles and the 
sub-atmospheric collapsing pressure of the diaphragm ensures that UA calibre 
remains patent (Brouillette and Thach, 1979). During OSAS, the diaphragm is under 
considerable stress as a consequence of heavy and prolonged contractions during 
hypoxic periods. This may culminate in tissue hypoxia and disordered energy balance, 
rendering it more susceptible to further damage, stress and dysfunction  (Clanton et 
al., 2001). It has also been suggested that the diaphragm is susceptible to fatigue 
during apnoeic episodes in OSAS patients (Vincken et al., 1987). Diaphragm fatigue 
may represent a reduction in the collapsing force during apnoeas, thereby 
functioning to offset the effect of UA muscle dysfunction on OSAS pathology. 
Conversely, weakness and fatigue may also contribute to a reduced ability to 
generate large powerful manoeuvres necessary for non-ventilatory functions such as 
airway clearance and cough, which is associated with increased morbidity. CIH-
induced muscle plasticity has been shown to extend to the diaphragm, however the 
underlying mechanisms are largely underexplored.  
 
The effects of exposure to CIH are largely reliant on the duration and intensity of 
exposure and as a result of this, varied effects of IH on diaphragm muscle function 
have been reported (Clanton et al., 2001, McGuire et al., 2003, Pae et al., 2005, Shortt 
et al., 2014, Giordano et al., 2015). In the current study, 2 weeks of exposure to CIH 
significantly reduced the peak force-generating capacity of the diaphragm by ~45% 
compared with sham controls. This is consistent with diaphragm dysfunction 
observed following 2 weeks (Shortt et al., 2014) and 5 weeks (McGuire et al., 2003) 
of exposure to CIH in rat models. Of note, the degree of diaphragm weakness 
observed in the current study is greater than that previously reported in rat models 
following a 2-week exposure to CIH (Shortt et al., 2014) and in fact, is more 
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reminiscent of diaphragm weakness observed following 6 weeks of exposure to 
chronic sustained hypoxia (Lewis et al., 2016), associated with profound oxidative 
stress. Additional measures, including peak work (Wmax), peak power (Pmax) and 
the work and power produced over the range of loads examined ex vivo, were 
significantly reduced following 2 weeks of exposure to CIH in the diaphragm. We 
posit that if the reduced power-generating capacity of the diaphragm over 
physiological loads following exposure to CIH (predominantly due to decreased 
force-generating capacity) translates in vivo, then it would have implications for 
human OSAS, and diseases characterised by exposure to CIH.  
 
Alterations to Ca2+ signalling may contribute to skeletal muscle dysfunction in many 
muscular disorders such as myopathies, systemic disorders like hypoxia, sepsis, 
cachexia, sarcopenia, heart failure, and dystrophy (Agrawal et al., 2018). Similar to 
our observations in the sternohyoid (Chapter 4), exposure to CIH had no effect on 
the contractile kinetics (CT and ½ RT) of the diaphragm when compared with sham 
controls. This is consistent with a number of other studies examining diaphragm 
contractile kinetics in rat models following exposure to varying durations and 
paradigms of exposure to CIH (McGuire et al., 2003, McDonald et al., 2016). This 
finding suggests that Ca2+ handling in the diaphragm muscle, i.e. its release and re-
uptake, at the SR is unaffected by exposure to CIH, thus dysregulated SR functioning 
is unlikely to underpin CIH-induced diaphragm weakness. Alterations to the distance 
of shortening or velocity of shortening of respiratory muscles has previously been 
suggested to be indicative of poor mechanical efficiency, culminating in muscle 
dysfunction (Attal et al., 2000, Burns et al., 2017). Exposure to CIH results in a 
decrease in both the distance and velocity of shortening of the diaphragm muscle 
across a range of physiological loads in the current study. A decrease in these 
parameters is suggestive of an increased load on the muscle, thereby contributing to 
a reduced capacity to contract and produce optimal force. We suggest that the 
reduction in the shortening of the diaphragm observed may have implications in the 
mechanism underlying CIH-induced diaphragm muscle dysfunction, due to a reduced 
capacity to contract optimally.  
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OSAS is an oxidative stress disorder with the ROS produced as a result of recurrent 
hypoxia/reoxygenation cycles having devasting consequences for a range of 
integrative bodily systems, highlighting a therapeutic role for antioxidants (Lavie, 
2003). Similar to studies in UA musculature (Liu et al., 2005, Dunleavy et al., 2008, 
Skelly et al., 2012, Skelly et al., 2013) increased ROS production has been implicated 
in diaphragm muscle dysfunction and indeed, antioxidants have been efficacious in 
preventing diaphragm weakness and fatigue (Shortt et al., 2014). Administration of 
tempol, apocynin and NAC each prevented CIH-induced diaphragm muscle fatigue, 
with NAC proving most efficacious since it also prevented CIH-induced muscle 
weakness. In the current study, the administration of the NOX2 inhibitor, apocynin, 
throughout the exposure to CIH, entirely prevented diaphragm muscle weakness, 
restoring force to levels comparable to controls (sham). Apocynin prevented CIH-
induced decreases in diaphragm work and power produced across a range of 
physiological loads, and also prevented CIH-induced decreases in diaphragm 
shortening kinetics. These findings are consistent with previous studies, which 
demonstrate that apocynin successfully ameliorates diaphragmatic contractile 
dysfunction (Supinski et al., 1999, McClung et al., 2009, Shortt et al., 2014). 
Moreover, we confirmed these results utilising transgenic NOX2 KO mice, which 
suggests a key role for NOX2-derived ROS in CIH-induced diaphragm dysfunction. The 
pronounced CIH-induced diaphragm muscle weakness observed in wild-type mice 
was entirely absent in NOX2 KO mice, confirming a specific obligatory role for NOX2-
derived ROS. Our data are consistent with other studies in mouse models of DMD 
(Loehr et al., 2018) and CHF (Ahn et al., 2015), which implicate a fundamental role 
for NOX2 in disease-related diaphragm dysfunction. Our results may have 
implications for human OSAS. Additionally, our results may have relevance to other 
disorders characterised by oxidative stress and diaphragm muscle weakness.  
 
It has been well described that ROS hold the capacity to modulate skeletal muscle 
performance, with the contractile apparatus of muscle fibres proving highly sensitive 
to alterations in cellular redox state (Reid et al., 1992). Previous studies suggest that 
under basal conditions, ROS exert a tonic inhibition on UA muscle force production 
(Skelly et al., 2010, Skelly et al., 2012, Williams et al., 2015). Consistent with this, we 
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have demonstrated that NOX2 is a culpable source of these ROS in sternohyoid 
muscle (Chapter 4). Similarly, we demonstrate that NOX2 knock-out results in a ~47% 
increase in the peak force-generating capacity of the diaphragm compared to wild-
type sham mice. This reveals for the first time that the powerful inhibition of NOX2-
dependent ROS on muscle force under basal conditions extends to the diaphragm 
muscle. The power and work produced by the diaphragm over the load continuum 
examined was increased following NOX2 KO, with no alteration to diaphragm 
shortening kinetics, indicative of no structural changes which may underlie the 
increase in force observed. However, reduced contractile kinetics (CT & ½ RT) were 
observed following NOX2 KO, suggesting an increase in Ca2+ release and re-uptake, 
which may have implications in the mechanism underpinning the increased force-
generating capacity of the diaphragm in NOX2 KO mice. An increase in myoplasmic 
Ca2+or an increase in the sensitivity of myofibrillar proteins to Ca2+ in the absence of 
NOX2 may underlie, or contribute to, the increased force-generating capacity of the 
diaphragm observed following NOX2 KO. In contrast to our findings, force production 
has been shown to be normal in the diaphragm of p47phox KO mice, suggesting that 
NOX2-derived ROS do not exert a tonic inhibition on muscle force under basal 
conditions (Ahn et al., 2015, Bost et al., 2015). The varied muscle phenotypes 
between these models may be due to the differential contribution of NOX2 subunits 
to ROS generation, as we utilise a gp91phox KO model in the current study. The 
phosphorylation of p47phox is largely considered essential in the production of 
NOX2-dependent ROS and as such, we would expect to observe the same inotropic 
effect in the diaphragm following p47phox or gp91phox KO, if NOX2-derived ROS 
underlies this effect. However, p47phox, but not gp91phox knock-out, has been 
shown to alter the O2 sensing capability of the carotid body, exemplified as a 
potentiated ventilatory and chemoreceptor response to hypoxia (Sanders et al., 
2002). This highlights that NOX subunits may differ in their complex regulatory 
function and contribution to NOX2-dependent ROS within the respiratory system, 
and therefore this may also extend to the muscles of respiration. 
  
The homologues NOX1, 2 and 4 are the predominant NOX isoforms expressed in 
skeletal muscle cells in culture (Piao et al., 2005, Sun et al., 2011, Hutchinson et al., 
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2007, Handayaningsih et al., 2011, Hori et al., 2011). The relative abundance of these 
isoforms, based on mRNA data in C2C12 cells, demonstrates that NOX4 is the most 
highly expressed, followed by NOX2 and subsequently NOX1 (Sun et al., 2011, 
Handayaningsih et al., 2011). Consistent with this, we have confirmed the mRNA 
expression of NOX1, 2 and 4, as well as their respective accessory subunits (p22phox, 
p40phox, p47phox, p67phox, Rac), in diaphragm muscle from wild-type mice. Similar 
to the sternohyoid (Chapter 4), we observed no difference between the mRNA 
expression of NOX2 and NOX4 in the diaphragm, however we report significantly 
lower levels of NOX1 mRNA. In the present study, we also demonstrate low mRNA 
levels of DUOX1 and DUOX2 in the diaphragm, consistent with that previously 
reported in C2C12 muscle cells (Sandiford et al., 2014). NOX2- and NOX4-dependent 
ROS have been strongly implicated in muscle dysfunction in a variety of disease states  
(Spurney et al., 2008, Whitehead et al., 2010, Sullivan-Gunn and Lewandowski, 2013, 
Pal et al., 2014, Williams et al., 2015, Henríquez-Olguín et al., 2015, Ahn et al., 2015, 
Yamada et al., 2015). Therefore, based on these observations in conjunction with our 
mRNA data, we suggest that NOX2 and NOX4 isoforms hold the most relevance for 
respiratory muscle pathology in our model.  
 
CIH-induced increases in NOX enzyme expression and/or activity have been reported 
in a range of organs and tissues (Zhan et al., 2005, Peng et al., 2006, Jun et al., 2008, 
Hayashi et al., 2008, Nisbet et al., 2009, Peng et al., 2009, Hui-guo et al., 2010, Peng 
et al., 2011, Gao et al., 2013, Williams et al., 2015). This highlights a role for NOX-
dependent ROS in CIH-induced alterations to homeostatic control. We observed no 
alteration to the mRNA or protein expression of NOX2 in the diaphragm muscle 
following exposure to CIH in the current study. While transcriptional regulation of 
NOX2 has been observed, NOX2 is thought to be predominantly acutely regulated by 
post-translational mechanisms such as the phosphorylation of regulatory cytosolic 
subunits, thus enabling the enzyme to assemble as a fully functioning complex 
(Lambeth, 2004). Under resting conditions, NOX2 and p22phox are complexed in the 
plasma membrane with accessory subunits unbound in the cytosol. Following 
stimulation by factors such as hypoxia or mechanical stress, including that of muscle 
contraction (Loureiro et al., 2016), cytosolic subunits are phosphorylated and 
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translocated to the membrane to elicit the production of NOX2-derived ROS through 
the oxidation of NADPH. Increases in NOX2 and its accessory subunits have been 
implicated in diaphragm muscle dysfunction in DMD (Loehr et al., 2018) and CHF 
(Ahn et al., 2015), evidenced by NOX2 pharmacological blockade and genetic KO 
ameliorating diaphragm weakness in these models. The pattern, duration and 
intensity of IH is pivotal in determining a phenotypical response and therefore we 
suggest that the paradigm of CIH used in this study was not sufficient to induce a 
transcriptional change in NOX2, but rather may induce an increase in NOX2 assembly 
and thus, enzymatic activity.  
 
Interestingly, we observed an increase in NOX4 mRNA in the diaphragm of both wild-
type and NOX2 KO mice following exposure to CIH. The protein expression of NOX4 
was also nearly doubled following exposure to CIH in the diaphragm of wild-type 
mice. NOX4 is a unique NOX isoform in that it is constitutively active, with its activity 
largely dependent on its level of protein expression. Therefore, the ROS that NOX4 
generates are inducible at the level of gene transcription rather than through acute, 
post-translational mechanisms (Serrander et al., 2007). NOX4 has been suggested to 
function as pivotal O2 sensor, with a number of studies reporting an increase in NOX4 
mRNA and protein expression following exposure to hypoxia (Nisbet et al., 2009, 
Diebold et al., 2010). Thus, we suggest that our results are consistent with these 
observations based on the transcriptional activation of NOX4 by exposure to CIH in 
the diaphragm. A decrease in the NOX4 accessory subunits, p22phox and Rac, was 
observed in the diaphragm of wild-type mice following exposure to CIH. Similar to 
NOX2, NOX4 requires an association with p22phox to generate ROS, with the mRNA 
expression of this subunit significantly decreased in the diaphragm following 
exposure to CIH.  While the contribution of Rac to the function of NOX4 is unsettled 
in the literature, its inhibition has been shown to prevent NOX4-derived H2O2 
production (Gorin et al., 2003, Meng et al., 2008). Negative feedback mechanisms to 
prevent against damage through excessive NOX4-derived ROS have previously been 
demonstrated (Kovac et al., 2015, Matsushima et al., 2016). Rac-induced superoxide 
production through NOX is connected to a negative feedback loop whereby Rac 
turnover is accelerated through its increased degradation by the ubiquitin-
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proteasome system (Kovacic et al., 2001). This negative feedback loop is thought to 
represent a switch-off mechanism for the Rac-induced activation of NOX, which 
controls excessive ROS production in the cell. Therefore, we suggest that the 
decrease in Rac, and by extension p22phox, observed in the CIH-exposed diaphragm 
may represent a protective mechanism against NOX4-induced oxidative damage, 
based on the upregulation of NOX4 mRNA and protein following exposure to CIH. 
NOX4-dependent ROS have been implicated in poor skeletal muscle function as 
evidenced by increased NOX4 expression in  models of disease characterised by 
skeletal muscle weakness (Ahn et al., Liu et al., 2017, Regan et al., 2017) and CIH-
induced NOX4 expression has also been demonstrated in lung tissue (Nisbet et al., 
2009). Therefore, we speculate that our data highlights a role for CIH-induced NOX4 
derived ROS in diaphragm muscle dysfunction.   
 
It remains to be elucidated as to how diaphragm muscle weakness is prevented 
following exposure to CIH in NOX2 KO mice, given the apparent lack of an alteration 
to NOX2 expression and activity, and the concomitant increase in the abundance of 
NOX4. Cross-talk between NOX4- and NOX2-dependent ROS has been demonstrated 
in skeletal muscle, whereby NOX4-derived ROS induce RyR Ca2+ leakage, with the 
increase in  Ca2+ in the junctional space serving to exacerbate NOX2-derived ROS, 
which otherwise have little effect on RyR function (Cully and Rodney, 2020). The 
cumulative effect of this cascade is proposed to manifest as a disruption to 
downstream cellular processes that contribute to reduced muscle performance. We 
suggest that NOX4-derived ROS may function through a similar sequential 
mechanism to contribute to diaphragm muscle weakness through the end effector, 
NOX2.  We observe an increase in NOX4 mRNA in NOX2 KO mice following exposure 
to CIH, reminiscent of that observed in wild-type mice following exposure to CIH. We 
suggest that diaphragm muscle weakness is absent in NOX2 KO mice following 
exposure to CIH because the cumulative production of ROS necessary for muscle 
weakness, possibly due to cross-talk between NOX4 and NOX2, is absent in NOX2 KO 
mice. Surprisingly, we observed no CIH-induced increase in NOX enzyme activity in 
the light of a significant increase in NOX4 expression and our hypothesis that NOX2-
dependent CIH-induced diaphragm dysfunction is based on the acute regulation of 
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NOX2, and the observation of increased NOX2 activity in CIH-induced sternohyoid 
(Chapter 4). We suggest that this may relate to the NOX activity assay utilised in the 
current study. NAD(P)H consumption assays have previously been used in the 
assessment of NOX activity in skeletal muscle (Javeshghani et al., 2002, Adams et al., 
2005, Ahn et al., 2015, Bowen et al., 2015a, Bowen et al., 2015b). However, a recent 
study shows that these assays are not specific to NOX activity and, in several tissues 
and cell types, the signal generated was unchanged with a triple NOX1, NOX2, and 
NOX4 knock-out (Rezende et al., 2016). While all NOX enzymes utilise NADPH as an 
electron donor to reduce O2 to produce ROS, reports suggest that NOX4 
preferentially utilises NADH as an electron donor and so the  assay employed in this 
study may not be suitable to detect changes in NOX4 activity (Shiose et al., 2001). 
Additionally, NOX activity has been shown in microdomains of skeletal muscle (Cully 
and Rodney, 2020), therefore the analysis of NOX activity in whole diaphragm muscle 
homogenates used in the current study may not have been adequately sensitive to 
detect changes in NOX activity in this instance.  
 
There is evidence of increased oxidative stress in a variety of tissues across animal 
models of CIH, consistent with the observation that human OSAS is an oxidative 
stress disorder (Lavie, 2003). However, despite NOX-dependent ROS evidently 
underpinning CIH-induced diaphragm muscle weakness in our model, we report no 
evidence of concomitant overt oxidative stress in the diaphragm following exposure 
to CIH. Oxidative stress may present due to an accumulation of ROS, a depletion of 
antioxidant defences, or a culmination of both. Skeletal muscle encompasses a 
robust antioxidant defence system, rendering it remarkably flexible in response to 
changes in the redox milieu that can occur both in health and disease (Kozakowska 
et al., 2015). A reduction in the GSSG/GSH ratio, indicative of modest oxidative stress 
due to the depletion in levels of the endogenous antioxidant GSH, has been reported 
following exposure to CIH in rat diaphragm muscle (Shortt et al., 2014). CIH-induced 
diaphragm muscle weakness and a restoration of the GSH system to homeostatic 
levels was demonstrated following the administration of NAC throughout the 
exposure to CIH, highlighting the pivotal role of redox homeostasis in muscle 
contractile function (Shortt et al., 2014). NRF2 is a transcription factor pivotal in 
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controlling the expression of genes whose protein products are responsible for the 
elimination of reactive oxidants by enhancing cellular antioxidant capacity (Nguyen 
et al., 2009). The mRNA expression of NRF2 is significantly increased in the diaphragm 
following exposure to CIH, with the increase ameliorated in mice administered 
apocynin and NOX2 KO. This suggests that the production of NOX2-derived ROS 
following exposure to CIH disrupts redox balance in the diaphragm, with the increase 
in NRF2 potentially representing an adaptive mechanism to up-regulate antioxidant 
defences and protect against oxidative injury. Indeed, CIH-induced increases in NRF2 
have been observed in renal and cardiac tissue (Sun et al., 2012, Zhou et al., 2017). 
Surprisingly, we did not observe a subsequent increase in the predominant 
antioxidants in skeletal muscle; SOD1, SOD2 or catalase. The effects of IH on 
diaphragm muscle function are time-dependent (Shortt et al., 2014) and therefore it 
is plausible to suggest that accompanying IH-induced alterations to cell signalling 
pathways are also transient and complex and warrant further attention. NOX2-
derived ROS have previously been shown to activate NRF2 (Chandran et al., 2018). 
Moreover, combinational antioxidant therapy inhibiting NOX2, while concomitantly 
activating NRF2, has been utilised in a model of traumatic brain injury (Chandran et 
al., 2018).  We suggest that the CIH-induced NOX2-dependent increase in the mRNA 
expression of NRF2 may point to an early adaptive response, ultimately serving to 
increase antioxidant status in the diaphragm as a defence against CIH-induced NOX2-
derived ROS.  The specificity of the NRF2 response further highlights that a redox 
signature underpins respiratory muscle dysfunction following exposure to CIH. 
 
ROS have been shown to oxidise lipids as a function of the severity of OSAS (Hopps 
et al., 2014). TBARS are degradation products of fats routinely used as a marker of 
lipid peroxidation, as an indirect measurement of oxidative stress. Levels of TBARS 
show a positive correlation to OSAS severity as determined by increased apnoea 
index (Kent et al., 2011). We report no evidence of lipid peroxidation in the 
diaphragm following exposure to CIH, as evidenced by unchanged levels of TBARS. 
This is consistent with previous observations in rat models that report unaltered 
levels of MDA and 4-HNE in the diaphragm following a 2-week exposure to CIH 
(Shortt et al., 2014). We suggest that the relatively moderate paradigm of CIH utilised 
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in the current study was not sufficient to cause oxidative stress, in the form of lipid 
peroxidation, similar to our observations in the sternohyoid muscle (Chapter 4).   
 
Mitochondria are an important source of ROS in skeletal muscle with ROS-dependent 
alterations to mitochondrial function and/or capacity proving consequential for 
skeletal muscle function (Hood et al., 2019). Mal-adaptation of skeletal muscle to 
periods of hypoxia have been demonstrated as a loss of mitochondrial content, thus 
a reduced oxidative capacity and less endurant phenotype (Gamboa and Andrade, 
2010). Citrate synthase activity is a routinely used marker of mitochondrial integrity 
and thus, aerobic capacity as it is the initial enzyme of the tricarboxylic acid (TCA) 
cycle. Citrate synthase activity has been shown to be reduced following 10 days of 
intermittent hypoxia in rat diaphragm, suggestive of shift away from mitochondrial 
respiration towards glycolysis (Clanton et al., 2001). In contrast, we observed no 
alteration to citrate synthase activity in the CIH-exposed diaphragm, which may 
relate to differences in the intensity of IH used between these studies. Similarly, 
other metabolic markers, including SDH and GPDH activity, have been shown to be 
unaltered in rat diaphragm following exposure to CIH (Shortt et al., 2013, Shortt et 
al., 2014), indicating that alterations to skeletal muscle metabolism are not likely to 
underlie the altered contractile function of the diaphragm following exposure to CIH. 
Mitochondria utilise a specialised form of autophagy, known as mitophagy, to 
protect against excessive ROS. Given the pivotal role of O2 as an electron acceptor in 
the ETC, hypoxia induces a build-up of electrons in this cycle, leading to an increased 
electron leakage and subsequent ROS formation. The increased ROS formation 
exacerbates mitochondrial dysfunction, yielding detrimental effects for muscle 
contractile performance. Additionally, mitochondrial function has been shown to be 
essential for plasma membrane repair in skeletal muscle fibres, with mitochondrial 
ROS shown to be pivotal in facilitating this membrane repair (Horn et al., 2017). 
Inhibiting mitochondrial ROS in myofibres during eccentric exercise ex vivo increases 
myofibre damage with concomitant muscle force loss (Horn et al., 2017). This 
highlights the beneficial role of mitochondrial ROS in repair mechanisms in response 
to strain on skeletal muscle.  In the current study, we examined the mRNA expression 
of the PINK1/PARK2 pathway which has emerged as a principal regulator of 
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mitochondrial degradation in a range of biological systems (Narendra and Youle, 
2011). PARK2 mRNA expression was increased in the diaphragm following exposure 
to CIH, with apocynin treatment and NOX2 KO each efficacious in preventing the 
increase. An increase in mitophagy as a protective mechanism has previously been 
demonstrated in platelets, cardiomyocytes and models of cerebral ischaemia (Lee et 
al., 2016, Tang et al., 2016, Nah et al., 2017, Tan et al., 2019). On the contrary, an 
over-activation of mitophagy due to a persistent stimulus may result in the 
degradation of essential mitochondrial machinery, which would similarly have 
unfavourable consequences for skeletal muscle function (Borgia et al., 2017, Sato et 
al., 2018). Cross-talk between NOX and the mitochondria has been demonstrated, as 
NOX-derived ROS increase mitochondrial ROS (Dikalov, 2011, Kim et al., 2017). If the 
CIH-induced increase in PARK2 mRNA observed in the current study translates to an 
increase in mitophagy, it may represent a protective mechanism against excessive 
NOX2-derived ROS-induced mitochondrial stress, which would otherwise have 
detrimental effects on skeletal muscle performance. However, further 
experimentation to measure mitophagic flux and/or dynamics is necessary to 
confirm the implications of the observed CIH-induced increase in PARK2 mRNA. 
However, since citrate synthase activity was unchanged, it is likely that the 
mitochondrial density in CIH-exposed diaphragm is normal. 
 
Structural alterations in the form of muscle atrophy are unaltered following a 2-week 
exposure to CIH in the diaphragm in rat models, however, an increase in type 2B 
fibres has been observed suggestive of a switch towards a more fatigable muscle 
phenotype (Shortt et al., 2013, Shortt et al., 2014). In contrast, 4 days of IH has been 
shown to result in a fibre-type switch towards type-1 fibres, representing a 
compensatory metabolic switch associated with fatigue resistance (Giordano et al., 
2015). Divergent responses between these studies may be due to the duration of IH 
with resultant adaptive and mal-adaptive responses in fibre-type transitions.  In the 
current study, we observed a trend towards a pro-atrophic (atrogin-1 & MuRF1) and 
pro-autophagic (LC3B, GABARAPL1 & BNIP3) response in the diaphragm following 
exposure to CIH at the mRNA level, which was ameliorated by treatment with 
apocynin and was absent in mice lacking the NOX2 enzyme. This is consistent with 
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studies reporting an increase in the mRNA of autophagy markers (LC3B, GABARAPL1 
& BNIP3) with concomitant diaphragm atrophy following 4 days of IH exposure 
(Giordano et al., 2015). Indeed, an interplay between atrophy and autophagy has 
been demonstrated to underlie a loss of muscle mass and resultant weakness in 
skeletal muscle (Dobrowolny et al., 2008). Additionally, a decrease in phospho-JNK 
and phospho-p38 observed in the diaphragm following exposure to CIH in the current 
study is suggestive of decreased protein synthesis, perhaps via the mTOR pathway. 
An increase in NOX4 expression with concomitant skeletal muscle atrophy has been 
demonstrated in rat models of SCI (Liu et al., 2017). Similarly, the deletion of NOX2 
has been shown to prevent Ang-II induced skeletal muscle atrophy (Kadoguchi et al.). 
Consistent with these observations, our results suggest that NOX2-derived ROS may 
promote diaphragm muscle atrophy following exposure to CIH, which may 
subsequently decrease muscle mass and contribute to a reduced force-generating 
capacity of the diaphragm.  
 
Studies have shown that physiological hypoxia tends to result in muscle cell 
proliferation and myogenesis, whereas pathological hypoxia is largely mal-adaptive 
and inhibits myogenesis (Yun et al., 2005). Indeed, the intensity of the hypoxic 
stimulus appears to be paramount in determining the myogenic response 
(Sakushima et al., 2020). Skeletal muscle has a large capacity to regenerate and re-
establish homeostatic contractile and metabolic properties in response to severe 
damage. NOX2 has been shown to stimulate muscle differentiation, with the increase 
prevented by treatment with DPI and apocynin in C2C12 myoblasts (Piao et al., 2005). 
Consistent with this, we observed an increase in the mRNA of key MRFs (Myogenin, 
MyoD & MEF2C) in the diaphragm following exposure to CIH, with the increase 
absent following treatment with apocynin and NOX2 KO. Successive rounds of 
muscle degeneration and regeneration can result in the incomplete remodelling of 
the ECM. This leads to the generation of large amounts of fibrosis and scar tissue 
rather than contractile tissue, thus yielding a muscle with a lower force-generating 
capacity (Smith and Barton, 2018). CIH-induced fibrosis has been reported in a range 
of organs and tissues (Didier et al., Kang et al., 2017, Kang et al., 2018, Wang et al., 
2018, Zhang et al., 2019). Earlier, we reported a modest decrease in the shortening 
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velocity and distance of shortening in the diaphragm following exposure to CIH, 
which is not present following apocynin treatment or NOX2 KO. Therefore, it is 
plausible to suggest that CIH-induced fibrosis, as a result of dysregulated myogenesis, 
may inhibit its optimal contraction. However, we also report a concomitant increase 
in the negative regulator of myogenesis, myostatin, suggestive of increased 
myogenesis being a regulated and adaptive response to muscle damage elicited by 
exposure to CIH. Further work is warranted to assess the effects of these changes at 
the mRNA level on the structure of the diaphragm to delineate whether this 
myogenic signal translates to a structural alteration in the diaphragm muscle and if 
so, whether this culminates as adaptive or mal-adaptive, and whether NOX2 is 
obligatory for the outcome.  
 
We demonstrate that NOX2-derived ROS underlie CIH-induced diaphragm muscle 
weakness. A complex interplay between increased NOX4 and NOX2 expression 
and/or activity appears to culminate in a sufficient level of ROS necessary to induce 
diaphragm muscle weakness. Oxidative stress per se is absent in the diaphragm 
following the paradigm of exposure to CIH utilised in the current study. However, an 
increase in the antioxidant defence system may represent an early adaptive response 
to protect against excessive NOX2-derived ROS, perhaps indicative of a modest (and 
localised) disruption to redox balance. NOX2-derived ROS appear to underlie CIH-
induced increases in the mRNA expression of genes relating to mitophagy, 
autophagy, atrophy and myogenesis. We acknowledge that these changes are 
determined only at the level of transcription and a comprehensive understanding of 
whether these alterations represent adaptive or mal-adaptive responses for muscle 
structure, and thus function, following exposure to CIH remains to be elucidated. 
Additionally, these processes do not appear to be HIF-1α-dependent. As previously 
mentioned in Chapter 4, mice were normoxic for several hours following the last 
exposure to CIH. Therefore, HIF-1α-dependent signalling may have a role in CIH-
induced respiratory muscle remodelling, but it may not be obligatory in the 
persistent expression of respiratory muscle weakness. We also speculate that NOX-
derived ROS may also affect muscle contractile performance through alterations to 
Ca2+ sensitivity of myofilaments influencing cross-bridge cycling or through 
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alterations to Ca2+ sensitivity of the contractile apparatus through redox modulation 
of troponin (de Paula Brotto et al., 2001, Ottenheijm et al., 2005, Ottenheijm et al., 
2006, Coirault et al., 2007, Degens et al., 2010, Smuder et al., 2010, Pinto et al., 2011, 
McDonagh et al., 2014). Alternatively, or concurrently, NOX-derived ROS may elicit 
their effects through downstream signalling processes that regulate the structure 
and hence functional capacity of skeletal muscle.  
 
We have demonstrated that CIH-induced muscle weakness is entirely prevented by 
NOX2 KO in sternohyoid (Chapter 4) and diaphragm muscle. However, the 
mechanisms underpinning respiratory muscle weakness are likely to be muscle fibre-
type specific, as evidenced by varied molecular responses to exposure to CIH 
between respiratory muscles revealed in the current study. Skeletal muscles are 
made up of heterogeneous fibre types that display distinct metabolic and contractile 
properties corresponding to the specific function of that muscle. Skeletal muscle 
fibres have different properties with respect to force, shortening velocity, time of 
relaxation, fatigability, and metabolic capacities. Skeletal muscle has a remarkable 
ability to modify its size and adjust its metabolic and contractile properties to a 
variety of stimuli including endogenous and exogenous stimuli, including mechanical 
stress and neuronal activity (i.e. contractile activity) as well as environmental stimuli 
(i.e. hypoxia) (Flück, 2006). Consistent with this, the specialisation of respiratory 
muscles appears to derive from the characteristics of the fibres from which they are 
composed. The diaphragm encompasses a mixture of all 4 myosin isoform subtypes. 
Type 1 and type 2a (oxidative) fibres support the diaphragm’s primary function as an 
inspiratory pump muscle through the preservation of a high degree of endurance. 
Additionally, the diaphragm exhibits a large force reserve capacity owing to type 
2x/2b (glycolytic) fibres. These fibres generate large amounts of force to facilitate 
non-respiratory functions such as airway clearance manoeuvres (Gransee et al., 
2012). The sternohyoid is structurally composed of mainly type 2b fibres, enabling 
large force generation, which is essential in the negative pressure reflex activation of 
UA muscles to defend airway patency and associated functions in swallowing. 
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Diaphragm muscle remodelling and dysfunction presents in several diseases 
characterised by respiratory disturbances. Sarcopenia, an age-related disorder of 
skeletal muscle, is associated with a loss of muscle mass and function (Fielding et al., 
2011). In murine models, the diaphragm muscle of older mice exhibit a ~35% 
decrease in force compared with younger mice, with a concomitant reduction in the 
size of the type 2x and/or 2b fibres (Greising et al., 2013, Greising et al., 2015). This 
is expected to impact on the ability of the diaphragm to perform non-ventilatory 
function, such as airway clearance. Cancer associated muscle dysfunction is a major 
syndrome, with the spectrum ranging from muscle weakness in the absence of 
weight loss to profound muscle wasting and cachexia (Fearon et al., 2013). Persistent 
oxidative stress (Giordano et al., 2003), atrophy and resultant muscle weakness of 
the diaphragm (Roberts et al., 2013) are associated with respiratory failure, a major 
cause of death in cancer patients. Indeed, animal models demonstrate a 30% 
reduction in respiratory muscle force production, atrophy and dysfunction across all 
fibre types, culminating in significantly impaired ventilation (Roberts et al., 2013). 
CHF causes diaphragm muscle weakness and fatigue that contributes to dyspnoea 
and limited physical capacity in patients (Empinado et al., 2014). Studies in mouse 
models of CHF display a 35% reduction in the force-generating capacity of the 
diaphragm, with an attendant increase in oxidative stress markers (Ahn et al., 2015), 
highlighting that diaphragm abnormalities contribute to the pathophysiology of CHF. 
Patients with COPD display reduced maximal inspiratory and expiratory pressures 
and the endurance of respiratory muscles is often reduced. Respiratory muscle 
dysfunction in COPD patients imposes ventilatory constraints, which may serve to 
perpetuate respiratory failure already present in patients. Animal models utilising 
chronic sustained hypoxia to mimic COPD display diaphragm weakness evidenced by 
a 35% reduction in the force-generating capacity (Lewis et al., 2016).  Structural 
alterations in the form of type 2B fibre atrophy, oxidative stress and increased 
proteolysis are features of diaphragm muscle in COPD patients and animal models of 
the disease (Barreiro and Gea, 2015). Respiratory failure is a leading cause of 
mortality in patients with DMD. Profound diaphragm muscle weakness 
demonstrated by a 50% reduction in the force generated  by  mdx mice has previously 
been demonstrated (Burns et al., 2019). Dystrophic diaphragm muscle weakness is 
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associated with fibre remodelling, fibrosis, inflammation and oxidative stress 
resulting in a severe mechanical disadvantage. Therefore, the respiratory muscle 
weakness we observed in the current study following a relatively modest exposure 
to CIH is quite remarkable when compared to other models that display severe 
respiratory deficits with lesser or similar magnitudes of weakness. Our model 
exemplifies the powerful inhibitory effect of NOX-2 derived ROS in suppressing 
muscle function, in the absence of overt oxidative stress. OSAS is a common disorder 
and it presents as a co-morbidity in many other respiratory conditions such as COPD 
and DMD. Our study draws focus to the potential role of exposure to CIH on 
diaphragm dysfunction in a range of disorders. Moreover, our study reveals NOX2 as 
a potential target in the treatment of diaphragm dysfunction. 
 
NOX expression has previously been shown to be higher in oxidative fibres compared 
with glycolytic fibres in limb muscle, with differences in the expression of NOX in fibre 
types possibly relating to the contractile characteristics of each fibre  (Loureiro et al., 
2016). It has been suggested that NOX enzymes have a role in skeletal muscle 
contraction through alterations to EC coupling and that higher NOX activity in 
muscles with a high density of oxidative fibres could be related to higher intracellular 
Ca2+ availability during contractions, crucial for sustaining muscle contractions for 
longer periods of time, which is characteristic of slow-twitch fibres (Loureiro et al., 
2016). Consistent with this, we show a greater mRNA expression of NOX enzymes 
(NOX2 & NOX4) in the diaphragm compared with the sternohyoid muscle. However, 
we report higher NOX activity in the sternohyoid muscle compared with the 
diaphragm. This discrepancy may be due to the differential regulation of NOX 
isoforms (i.e. regulated transcriptionally or post translationally), the muscle-specific 
regulation and contribution of NOX-derived ROS to cellular processes, or perhaps 
may relate to the NOX activity assay we utilised. While NOX2 is essential for CIH-
induced muscle weakness in both the sternohyoid and diaphragm muscle, we 
observed a CIH-induced increase in NOX4 in the diaphragm only. Owing to its 
oxidative phenotype, the diaphragm encompasses a greater density of mitochondria 
than the sternohyoid and indeed, NOX4 contains a mitochondria localisation 
sequence in its n-terminal and as such has been identified in the mitochondria of 
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cardiac (Ago et al., 2010) and skeletal muscle (Sakellariou et al., 2013). Moreover, a 
sequential pathway whereby NOX4-derived H2O2 activate NOX2 which then evokes 
an increase in mitochondrial ROS has been demonstrated in endothelial cells (Kim et 
al., 2017). This may represent a feed-forward mechanism of ROS-induced ROS 
release orchestrated by NOX2 and NOX4. This increase in ROS may subsequently 
affect downstream signalling pathways important in the form and function of skeletal 
muscle. Therefore, it is plausible to suggest that this may explain, in part, the NOX2-
dependent CIH-induced increase in the mRNA expression of genes relating to 
atrophy, mitophagy, autophagy and muscle differentiation in the diaphragm 
compared with the sternohyoid. Additionally, oxidative and glycolytic fibres differ in 
their contractile response, in that increased tension during contraction reaches a 
peak and declines faster in glycolytic than in oxidative fibres (Polla et al., 2004), 
determined by Ca2+ release and re-uptake at the SR, the sensitivity of the myofibrils 
to Ca2+, and the rate at which myosin forms cross bridges with actin. The density of 
Ca2+ release units and Ca2+ pumps are higher in fast fibres than in slow fibres 
(Franzini-Armstrong et al., 1999) and different specific isoforms of SERCA are 
expressed in slow and in fast fibres (Lytton et al., 1992). Therefore, glycolytic fibres 
may be more susceptible to alterations to these elements of muscle contractile 
performance which would alter the capacity to produce fast, forceful manoeuvres 
such as those produced by the sternohyoid in the maintenance of airway patency. 
Similarly, this is also applicable to glycolytic fibres of the diaphragm, which are pivotal 
in high force-dependent manoeuvres.  
 
The significance of our findings is that exposure to CIH, a hallmark feature of human 
OSAS, is detrimental to the function of the diaphragm, potentially affecting 
ventilatory and non-ventilatory performance of the respiratory system. Combined 
with upper airway muscle dysfunction (Chapter 4), exposure to CIH could establish a 
vicious cycle serving to exacerbate respiratory morbidity in human OSAS. 
Therapeutic strategies to improve diaphragm muscle performance, through NOX2 
blockade, may function as an adjunctive therapy to reduce disease burden in human 
OSAS. Our results may also have relevance to other diseases characterised by 
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6.1 Limitations  
6.1.1 Animal model of OSAS  
When conducting any scientific experiment, it must be acknowledged that certain 
limitations exist. Possibly the most important limitation in the current study is the 
use of a mouse model to research the human condition, OSAS. OSAS is a multi-
factorial and complex disease (Casale et al., 2009). We acknowledge the fact that no 
animal model of a disorder can fully recapitulate the human scenario and so similar 
to other models, we chose to focus on a subset of events characteristic of the 
disorder, with resultant limitations. Like many others, we utilised IH as a central 
feature of OSAS in our mouse model due to previous evidence supporting its central 
role in driving pathology throughout the respiratory system (Edge et al., 2012, Shortt 
et al., 2014, Skelly et al., 2012, Peng et al., 2001, Peng et al., 2003, Morgan et al., 
2016a, Morgan et al., 2016b) as well as in a wide range of other organs and tissues 
(Dumitrascu et al., 2013, Al Lawati et al., 2009, Drager et al., 2011b, Torres et al., 
2014a, Wang et al., 2013b, Wang et al., 2018, Savransky et al., 2007, Rosas, 2011). 
This implicates IH in the exacerbation of OSAS severity as well as in the development 
of multiple co-morbidities of OSAS. It must be appreciated that other risk factors for 
the development of OSAS, such as obesity (Romero-Corral et al., 2010), genetic 
predisposition, or smoking (Lin et al., 2012)  are not represented in this model.   
 
The cyclical sinusoidal pattern of IH in our model does not aim to model the IH 
pattern experienced by OSAS patients, but more specifically, it models the 
intermittent cycling of hypoxia-reoxygenation and arterial oxygen desaturations, 
thus allowing us to examine the effects of IH on multiple levels of the respiratory 
system. We acknowledge that IH is only one aspect of the disorder as concomitant 
airway collapse with mechanical trauma and hypercapnia are also experienced by 
OSAS patients throughout the night cycle. While hypercapnia is a key ventilatory 
stimulant, data from models of intermittent hypercapnic hypoxia (asphyxia) have 
highlighted that IH appears to be the dominant injurious feature of the model 
(O'Halloran et al., 2002, McGuire et al., 2003, McGuire et al., 2002b). Another 
important point worth noting is the duration of IH chosen. The effects of CIH are 
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largely time-, intensity-, duration- i.e. pattern-dependent with alterations in any of 
these factors significantly affecting the experimental outcome. While 2 weeks seems 
like a relatively short period of time, considering that OSAS patients are subject to 
apnoeic events over a much longer period of time, exposure to CIH for 2 weeks has 
been shown to be sufficient to result in a number of hallmark features of OSAS 
including respiratory muscle weakness, increased apnoea index, hypertension and 
markers of oxidative stress (Shortt et al., 2014, Lucking et al., 2014, Skelly et al., 2012, 
Edge et al., 2012). We reasoned that this paradigm of CIH, while modest, represents 
an early time point where we could delineate key mechanisms underpinning the 
development of respiratory mal-adaptation. Nevertheless, a temporal study of 
exposure to CIH would be extremely interesting to gain a better understanding of the 
time frames wherein adaptive and mal-adaptive responses occur. 
 
6.1.2 Strain difference between wild-type and NOX2 null mice  
The specific role of NOX2 in CIH-induced respiratory system mal-adaptation was 
examined in the current study by utilising NOX2 null mice. NOX2 null male mice 
(B6.129S-Cybbtm1Din/J) were purchased from the Jackson Laboratory (Bar Harbor, ME, 
USA) for this purpose. The appropriate control for these mice, as suggested by the 
Jackson Laboratory, are C57BL/6J male mice. Indeed, C57BL/6J mice have previously 
been used as a control for this particular NOX2 null model (You et al., 2013, Costford 
et al., 2014, Aydin et al., 2017). Thus, male C57BL/6J controls were purchased from 
Envigo, UK and used in the current study. However, we acknowledge that there are 
strain differences between the wild-type and NOX2 null mice employed.  NOX2 null 
mice (B6.129S-Cybbtm1Din/J) were produced by backcrossing the disrupted 129S strain 
to the C57BL/6J strain, compared to wild-type, C57BL/6J mice. This difference in the 
genetic background may have implications in differential physiological and 
neurochemical phenotypes between groups. We acknowledge this as a potential 
limitation in the current study and as a result, cautiously compare differences 
between wild-type and NOX2 null groups. 
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6.1.3 Whole body plethysmography  
We studied breathing, without the confounding effects of anaesthesia, in awake and 
unrestrained mice by means of WBP. WBP is an attractive experimental approach, 
especially for extended periods of recording that were applied throughout our 
studies. However, we are aware that calculations using WBP are based on a number 
of assumptions for the volume-based parameters (tidal volume), notably chamber 
temperature and humidity and animal airway temperature (Mortola and Frappell, 
1998, Stephenson and Gucciardi, 2002). Chamber temperature was measured and 
remained at ~21°C. However, body temperature was not measured, but rather 
assumed to be 37.5 °C for all groups examined for the calculation of tidal volume. We 
address this as a limitation as the decrease in ventilation in NOX2 KO mice compared 
with wild-type controls in the current study was as a result of a lower tidal volume. 
While we acknowledge that errors based on this assumption of body temperature 
may have contributed to differences between NOX2 KO mice and wild-type mice, we 
also note that basal CO2 production was not different between groups, strongly 
suggestive of an unaltered metabolic rate, which suggests no difference in core 
temperature.  
 
6.1.4 Ex vivo muscle function tests  
Sternohyoid and diaphragm muscle contractile properties were examined ex vivo 
under hyperoxic conditions in a water-jacketed muscle bath maintained at 35°C. This 
was to allow for assessment of intrinsic muscle performance under these conditions 
which maintained muscle viability for the duration of muscle function tests. 
However, these conditions are not physiological, and it is noteworthy that muscle 
performance in this situation may not be the same as it would be in vivo. While these 
experiments are certainly valuable for assessing a muscle’s intrinsic contractile 
activity, they do not account for a muscle’s activity in the presence of its natural 
support system (other upper airway muscles and intercostal muscles) and 
innervation systems (hypoglossal and phrenic nerves) that would be present in situ. 
Future experiments to assess UA and diaphragm muscle function in vivo would be of 
great interest and is discussed in more detail below.  
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6.1.5 Measurement of NOX activity   
The lack of a specific measurement for NOX activity has proven to be a significant 
challenge in the field. Lucigenin-enhanced chemiluminescence is an approach that 
has routinely been used for the measurement of NOX activity. Lucigenin, which is a 
fluorescent chloride indicator, reacts with superoxide to produce light. The lucigenin 
signal stimulated by addition of NAD(P)H to the reaction buffer is considered a 
measurement of NOX-derived superoxide. A conceptually similar approach involves 
the utilisation of NAD(P)H consumption by muscle homogenates. Lucigenin and 
NAD(P)H consumption assays have been used in the assessment of NOX activity in 
skeletal muscle (Javeshghani et al., 2002, Ahn et al., 2015, Adams et al., 2005, Bowen 
et al., 2015a, Bowen et al., 2015b). However, a recent study shows that these assays 
are not specific to NOX activity and in several tissues and cell types, the signal 
generated was unchanged in a triple NOX1, NOX2, and NOX4 knock-out (Rezende et 
al., 2016). We used a NADPH consumption assay in the current study and therefore, 
we acknowledge the limitations of this approach. In the light of findings by (Rezende 
et al., 2016), we cautiously report that the increase in NOX activity in the sternohyoid 
muscle following exposure to CIH is specific to NOX. Similarly, we acknowledge the 
discrepancy in the findings of an increase in the mRNA and protein expression of 
NOX4 in the diaphragm failing to translate to increased NOX activity. 
 
While we used NADPH as a substrate for NOX in the assay in the current study, it has 
been shown that a range of other systems in skeletal muscle utilise NADPH as a 
substrate (Maghzal et al., 2012).  Therefore, we cannot rule out that the signal 
generated may be related to biological factors other than NOX. While NADPH is 
considered the primary substrate for NOX in non-muscle cells (Bedard and Krause, 
2007), the use of NADH as a substrate appears to elicit a three-to-five fold higher 
NOX activity than NADPH in adult skeletal muscle (Javeshghani et al., 2002). 
Additionally, some studies report that it is specifically NOX4 that preferentially uses 
NADH as an electron donor (Shiose et al., 2001), which may provide insight into why 
we observed no increase in NOX activity in the diaphragm muscle following exposure 
to CIH. Nevertheless, NADH consumption assays face the same issues with 
deciphering signal specificity between NOX and other biological factors.  We and 
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others (Loureiro et al., 2016)  have shown that NOX expression appears to be fibre-
type specific. Moreover, NOX enzyme expression and/or activity has been shown to 
be localised to microdomains within skeletal muscle (Cully and Rodney, 2020). Taking 
these findings into consideration, it is reasonable to suggest that a NOX activity assay 
performed on a muscle homogenate may not have had the sensitivity to detect NOX 
activation in different sub-cellular compartments of skeletal muscle. Additionally, the 
signal may be diluted in whole muscle homogenates by areas of muscle in which NOX 
activity is unchanged.  
 
Phosphorylation of p47phox is reportedly necessary for NOX2 activation and as such, 
immunoprecipitation and immunoblot to determine levels of serine phosphorylation 
of p47phox has been utilised as a surrogate measure of NOX2 activity in skeletal 
muscle (Ahn et al., 2015). Additionally, genetically-encoded redox probes have 
shown significant potential for the dynamic and site-specific assessment of redox 
potential (Meyer and Dick, 2010). These genetically-encoded biosensors have the 
capacity to be targeted to specific sub-cellular compartments, including the 
mitochondria, endoplasmic reticulum, and plasma membrane. Perhaps the most 
promising advancement in the search for a specific tool to measure NOX activity has 
been the development of a redox-sensitive protein (p47-roGFP) that specifically 
assesses NOX activity by linking redox-sensitive GFP (roGFP) to the NOX organiser 
protein, p47phox  (Pal et al., 2013). The authors demonstrate that this probe is 
sensitive to NOX-derived ROS and allows for real-time assessment of NOX activity in 
living cells in response to exogenously applied agents as well as physiological 
conditions associated with increased skeletal muscle activity. p47-roGFP is extremely 
advantageous as it exhibits rapid oxidation and reduction, the capacity to be directed 
to the source of ROS and subcellular microdomains where NOX enzymes reside as 
well as conferring specificity towards NOX2. Recommendations by experts in the field 
of NOX enzymes have highlighted that it would be more beneficial to measure ROS 
formation in intact tissue rather than boosting their signal with NADPH or using 
homogenates, when addressing ROS production by NOX enzymes (Rezende et al., 
2016). p47-roGFP appears to hold significant potential in this regard.  
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6.1.6 Extrapolation of molecular results 
We acknowledge that some of our results pertaining to the mechanisms 
underpinning respiratory muscle weakness are only at the mRNA level. Therefore, 
we cannot presume that changes at the transcriptional level translate directly to 
changes in protein, in turn affecting cellular function. Similarly, we cannot presume 
that further downstream signalling pathways, in terms of protein expression or 
activity, are unaltered on the basis of unchanged observations in mRNA expression. 
For example, we measure the mRNA expression of LC3B in the current study as a 
marker of autophagy. However, studies suggest that LC3B may predominantly be 
regulated at the protein level (Jia and Bonifacino, 2020). Therefore, we acknowledge 
the limitations of our mRNA data and appreciate that measuring the ratio of LC3B II/I 
may be a more appropriate indicator of autophagy induction that should be 
considered for future studies (Kadowaki and Karim, 2009).  
 
It would be inappropriate to assume that the behaviour of a single measurement at 
a single point in time is representative of an entire organelle, process or pathway as 
a whole. This highlights the necessity to examine cellular processes at all levels of 
regulation in order to gain a comprehensive insight into the molecular processes 
underlying pathological features of disease. This represents an important factor in 
the development of targeted treatments for disease, with the benefit of fewer side 
effects. Moreover, this is an especially important consideration when there is more 
than one stimulus, such as in our study, where IH, contractile activity and redox 
imbalance can each affect cellular processes.  Exposure to IH culminates in a diverse 
range of observations that arise as a result of an intricate system of molecular 
mechanisms that underlie adaptive and mal-adaptive responses to oxygen 








6.2 Future directions  
6.2.1 Examination of skeletal muscle contractile apparatus function  
Muscle force is generated by cross-bridges, formed by myosin heavy chains that 
attach to actin filaments (Huxley and Simmons, 1971). The force-generating capacity 
of single fibres is dependent upon the contractile protein content of that fibre  
(Brenner, 1988). Ca2+ sensitivity of force generation is determined by binding of Ca2+ 
to troponin C, which in turn affects cross-bridge formation, through myosin binding 
to actin. Skinned fibre studies provide an excellent model for the direct evaluation of 
contractile protein function in fibres as exposure of the skinned fibres to Ca2+ enables 
the evaluation of contractile protein function.  
 
While a loss of contractile proteins may underlie skeletal muscle weakness, 
dysfunction of the remaining myofibrillar proteins may also contribute to poor 
muscle contractile performance. Altered cross-bridge kinetics have been described 
in skinned muscle fibres following acute exposure to hypoxia (de Paula Brotto et al., 
2001, Ottenheijm et al., 2006) and in muscle biopsies of COPD patients (Ottenheijm 
et al., 2005), possibly due to alterations related to myosin and troponin. Ca2+ 
sensitisation stabilises the conformation of the troponin complex, which functions to 
trigger muscle contraction. Ca2+ sensitivity of force generation has been shown to be 
impaired in skinned muscle fibres from diaphragm muscle biopsies from COPD 
patients, possibly contributing to the reduced force generation observed 
(Ottenheijm et al., 2005).  
 
Ca2+sensitisers, such as levosimendan, have been shown to increase force generation 
in the diaphragm muscle of COPD patients by enhancing the binding of Ca2+ to 
regulatory proteins of the contractile apparatus, such as troponin C (van Hees et al., 
2009). This in turn improves the responsiveness of myofilaments to Ca2+, yielding 
greater amount of force, for the same amount of cytosolic Ca2+. Troponin activators 
have also been shown to increase muscle contractility in critically-ill patients by 
restoring Ca2+sensitivity back to control values (Russell et al., 2012). These studies 
may represent an approach to improve muscle function in diseases characterised by 
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respiratory muscle weakness.  For future studies, it would be most interesting to 
examine the Ca2+ sensitivity of myofilaments following exposure to CIH to assess 
whether hypoxia-induced alterations occur at this level of the muscle.  
 
6.2.2 Examination of redox-dependent alterations to skeletal muscle contractile 
proteins 
ROS hold the capacity to alter myofilament structure and function (Smuder et al., 
2010). Additionally, several myofibrillar proteins including troponin C (Pinto et al., 
2011), actin (Coirault et al., 2007), alpha-actinin (McDonagh et al., 2014, Smuder et 
al., 2010) and myosin heavy chains are susceptible to oxidative modifications. These 
oxidative modifications affect Ca2+ sensitivity and cross-bridge cycling (discussed 
above), potentially culminating in contractile dysfunction. Modifications of 
myofibrillar proteins have been demonstrated as s-nitrosylation (de Paula Brotto et 
al., 2001), due to hypoxia-induced ROS. The complexity of redox-dependent 
alterations can be appreciated by divergent effects of oxidative modifications, 
evidenced by an increase or decrease in the sensitivity of contractile apparatus to 
Ca2+ (Hidalgo et al., 2006, Guerra et al., 1996). Indeed, studies in mechanically 
skinned fibres have demonstrated that S-nitrosylation and S-glutathionylation exert 
opposing effects on Ca2+ sensitivity in mammalian fast-twitch muscle fibres, 
mediated by competitive actions on Cys134 of troponin I (Dutka et al., 2017).  
 
Previous studies by our group (Lewis et al., 2015, Lewis et al., 2016) have 
demonstrated a redox-dependent modulation of key proteins involved muscle 
contractile performance, following exposure to chronic sustained hypoxia. Using 2D 
redox proteomics and mass spectrometry, hypoxia-induced oxidation of metabolic 
markers and proteins at the level of cross bridge cycling were observed in weakened 
respiratory muscles (Lewis et al., 2015, Lewis et al., 2016), consistent with that of 
COPD patients. While this technique is a relatively crude measure for the presence 
of oxidative proteins, site-specific identification of the redox modification and 
quantification of site occupancy in the context of protein abundance remains a 
crucial concept for redox proteomic approaches (Cobley et al., 2019). 
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New strategies include the development of a label-free quantitative proteomic 
approach (McDonagh et al., 2014). This proteomic approach includes a differential 
cysteine labelling step to enable the simultaneous identification of up- and 
downregulated proteins between samples, in addition to the identification and 
relative quantification of the reversible oxidation state of susceptible redox cysteine 
residues. It would be extremely interesting to assess whether CIH-induced ROS act in 
a reversible manner through the transient oxidation of cysteine residues on key 
contractile proteins in respiratory muscle, especially since we observe no overt 
oxidative damage in our model and CIH-induced UA weakness has previously been 
shown to be reversible (Skelly et al., 2012). A co-assessment of the oxidation state of 
cysteine residues in key myofibrillar proteins as well as quantification of protein 
abundance would be interesting to assess in our model, as changes in redox state 
and/or changes in protein abundance have the capacity to underpin alterations to 
skeletal muscle contraction.   
 
6.2.3 Examination of respiratory muscle structure 
There is a need to assess whether structural alterations underlie, or in part contribute 
to NOX2-dependent CIH-induced respiratory muscle dysfunction and increased 
respiratory muscle force generation following NOX2 KO. We observed an increase in 
the mRNA expression of pro-autophagic, atrophic and myogenic genes in the 
diaphragm following exposure to CIH, which is prevented by treatment with 
apocynin and NOX2 KO. Further experimentation is warranted to assess whether 
these changes at the transcriptional level translate into structural alterations, which 
may hold consequences for the force-generating capacity of the muscle.  
 
While muscle fibre atrophy is most consistently observed with chronic sustained 
hypoxia (McMorrow et al., 2011, Gamboa and Andrade, 2012),  a decrease in 
myofibre size has also been observed following exposure to IH (Giordano et al., 
2015). Immunohistochemical studies examining the cross-sectional area (CSA) and 
minimal Feret’s diameter would be most interesting, to assess whether myofibre 
atrophy occurs and thus has a role in CIH-induced respiratory muscle weakness. A 
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reduction in myofibre size would be consistent with muscle weakness, as muscle 
strength is proportional to muscle area (Rospars and Meyer-Vernet, 2016).  
 
Respiratory muscle structure encompasses a high degree of sophistication as it 
comprises a variety of different fibre types, enabling different functional properties. 
Immunohistochemical studies, such as those previously employed by our group 
(Skelly et al., 2012, McDonald et al., 2015, Shortt et al., 2013, Shortt et al., 2014, 
Burns et al., 2018), to assess the proportion and area of myosin heavy chain fibre 
types (type 1, type 2a, type 2x or type 2b) would be interesting to examine to 
determine whether alterations to the composition and size of fibre types in the 
sternohyoid or diaphragm underpin changes in their contractile characteristics 
following exposure to CIH, treatment with apocynin or NOX2 KO. A slow-to-fast fibre-
type transition would suggest a more powerful, but more fatigable muscle. Whereas 
the converse, fast-to-slow fibre-type transition would yield a more endurant, but less 
powerful muscle.  
 
CIH-induced fibrosis has been reported in a range of organs and tissues (Kang et al., 
2018, Didier et al., Kang et al., 2017, Zhang et al., 2019, Wang et al., 2018). An 
assessment of muscle fibrosis, utilising Sirius Red staining, would be interesting to 
assess whether an increase in collagen infiltrate contributes to the deficits in muscle 
contractile performance following exposure to CIH, and indeed whether NOX2-
derived ROS play a role in this. We suggest this in particular, as we observed a modest 
decrease in the capacity of the diaphragm muscle to shorten which may be indicative 
of CIH-induced structural alteration, such as fibrosis.  
 
6.2.4 Examination of key structures in the respiratory control network    
In the current study, we report CIH-induced ROS dependent alterations to respiratory 
function in mice. We report a CIH-induced increase in apnoea index in wild-type mice 
that is prevented by treatment with apocynin, but not NOX2 deletion (Chapter 3). 
This implicates another source of ROS in the manifestation of increased apnoea index 
which would be most interesting to investigate further. Similarly, we observe altered 
hypoxic and hypercapnic responses following exposure to CIH among groups, both 
 287 
of which implicate ROS and/or NOX2 (Chapter 3). The carotid body and CNS regions 
including the nucleus tractus solitarius (NTS), paraventricular nucleus of the 
hypothalamus (PVN), rostral ventrolateral medulla (RVLM) and retrotrapezoid 
nucleus (RTN), which are important for the control of ventilation and sympathetic 
outflow, are all affected by increased ROS as a result of exposure to CIH (Mifflin et 
al., 2015, Semenza and Prabhakar, 2015). Additionally, it has been demonstrated that 
a range of signaling molecules including ROS, 5-HT, adenosine, HIF-1α and 
inflammatory cytokines are involved in the CIH-induced respiratory plasticity (Peng 
et al., 2006, Pawar et al., 2009, Peng et al., 2009, Del Rio et al., 2011, Peng et al., 
2013, Iturriaga et al., 2014, Sacramento et al., 2015, Morgan et al., 2016b, Moya et 
al., 2020). As these substances and processes exhibit pro-oxidant properties and/or 
are sensitive to ROS, oxidative stress may represent a common thread linking many 
drivers of CIH-induced mal-adaptation, at multiple points throughout the respiratory 
control network (Del Rio et al., 2010). Thus, a direct examination of markers of 
oxidative stress, antioxidant capacity and inflammation in structures pivotal to 
respiratory control following exposure to CIH, treatment with apocynin and NOX2 
knock-out would be most interesting in future studies to delineate the precise 
mechanisms underpinning CIH induced respiratory system mal-adaptation.  
 
6.2.5 Assessment of respiratory muscle function in vivo  
Dysfunctional UA muscles promote an unstable airway, rendering it more prone to 
collapse (Remmers et al., 1978). We and others (Liu et al., 2005, Liu et al., 2009, 
McDonald et al., 2015, Dunleavy et al., 2008, Jia and Liu, 2010, Ding and Liu, 2011, 
Wang et al., 2013c, Zhou and Liu, 2013, Skelly et al., 2012, Pae et al., 2005) have 
demonstrated that exposure to IH results in significant UA muscle weakness and/or 
fatigue. While we examined the contractile characteristics of a representative UA 
muscle (sternohyoid) ex vivo, there is a need to address the functional impact of the 
CIH-induced weakness we observed on airway stability in mice. The gold standard 
measurement of UA collapsibility during sleep is the pharyngeal critical closing 
pressure (Pcrit) (Carberry et al., 2016). Studies in rats have demonstrated that 
exposure to IH significantly elevated Pcrit under unstimulated conditions, resulting 
in a more collapsible airway (Ray et al., 2007). We acknowledge that OSAS is primarily 
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a neurogenic disorder. However, UA collapse can occur (and be exacerbated by) a 
lack of neural drive, UA muscle weakness or a culmination of both. In the current 
study, we show that CIH-induced UA muscle weakness is entirely prevented by NOX2 
KO. In the light of this, it would be extremely interesting to assess whether an IH-
induced increase in Pcrit, that may present in our model, would also be prevented by 
NOX2 KO.  
 
Similarly, there is a need to assess the functional relevance of the CIH-induced 
diaphragm weakness observed ex vivo in the current study. An assessment of 
transdiaphragmatic pressure (Pdi) during ventilatory (i.e. eupnoea) and non-
ventilatory behaviours (e.g. airway obstruction) is essential in understanding the 
implication of diaphragm muscle weakness in physiological responses (Mantilla et al., 
2010, Greising et al., 2016). While we observe a ~45% decrease in the force-
generating capacity of the diaphragm ex vivo following exposure to CIH in the current 
study, previous studies have shown that a similar magnitude of diaphragm weakness 
results in no perturbation to ventilatory behaviours, due to the large force reserve 
capacity of the diaphragm muscle (Greising et al., 2015). Indeed, there was no 
impairment in basal minute ventilation in CIH-exposed mice in the current study 
(Chapter 3). However, deficits may be revealed during high force-dependent 
manoeuvres, necessitating up to 100% of diaphragm peak force-generating capacity. 
Remarkably, peak inspiratory pressure-generating capacity is preserved during both 
ventilatory and non-ventilatory behaviours in the mdx mouse model of DMD, even 
with significant diaphragm muscle weakness (Burns et al., 2019). The latter 
observation reveals the capacity for accessory muscles to compensate for profound 
diaphragm weakness in at least some circumstances. Therefore, an assessment of 
Pdi and peak inspiratory pressure-generating capacity in vivo would be an essential 
step in determining the relevance of CIH-induced diaphragm weakness in ventilatory 
and non-ventilatory functions, and to determine the capacity for NOX2 blockade to 
prevent potentially mal-adaptive effects, similar to that observed in diaphragm 
muscle ex vivo.  
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6.2.6 Utilisation of a conditional NOX2 KO model  
The transgenic NOX2 KO mouse model we utilised in the current study was a 
conventional KO, in that the NOX2 gene was eliminated in all tissues from early 
development. However, the study of gene function in adult mice in selected cells and 
tissues has been significantly enhanced by the development of conditional gene KO 
technology developed by Tsien and colleagues in the 1990s (Tsien et al., 1996). With 
a conditional KO, gene inactivation can occur in a certain tissue type or at a specific 
time point by crossing a loxP mouse with a specific Cre transgenic line, such that the 
target gene becomes inactivated in vivo within the expression domain of Cre (Friedel 
et al., 2011). Therefore, conditional KO models have allowed researchers to target 
genes in specific tissues, thus eliminating the drawbacks and confounders of 
traditional KO processes that eliminate genes from all tissues. For example, a gene 
may be essential for the proper development of an organism before birth and during 
postnatal development, and then later in life can encompass a different function, 
which may influence an individual’s susceptibility towards a disease.  
 
NOX2-derived ROS have a central role in innate immunity (Rada and Leto, 2008). 
NOX2 deficiency results in the development of chronic granulomatous disease (CGD), 
a primary immunodeficiency characterised by life-threatening bacterial and fungal 
infections (Segal et al., 2011). While there were no observable defects in mice lacking 
the NOX2 enzyme in the current study, we cannot rule out that NOX2 blockade would 
have unfavourable consequences for the immune system in humans. In the current 
study, we demonstrate that NOX2 is necessary for CIH-induced respiratory muscle 
weakness. However, a muscle-specific conditional NOX2 KO would be most 
interesting to confirm that muscle weakness was prevented due to the absence of 
NOX2 intrinsic to the muscle, and not due to extrinsic factors such as innervation or 
blood infiltrate. Comparisons between whole-body and muscle-specific SOD1 KO 
mouse models have shown that neuromuscular integrity and redox mechanisms are 
differentially affected, which may have implications in understanding the mechanism 
driving muscle loss during ageing (Sakellariou et al., 2018). These sophisticated, 
refined experimental approaches allow for a better understanding of the 
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6.3 Conclusion and Implications  
OSAS occurs as a result of a reduction in neural outflow to the UA, resulting in 
repetitive airway collapse throughout the night cycle. However, several other factors 
may contribute to an increase in the severity of OSAS pathology. The striated muscles 
of breathing, including the diaphragm and pharyngeal dilator muscles, play a pivotal 
role in maintaining respiratory homeostasis. The negative pressure reflex activation 
of the pharyngeal dilator muscles serves to maintain UA patency on a breath-by-
breath basis and crucially, is important in re-establishing airway patency following 
obstructive events. The co-ordinated activity of the diaphragm and UA dilator 
muscles is thereby essential for the maintenance of airway patency and thus, 
effective pulmonary ventilation. Potentially mal-adaptive alterations to UA  (Sérlès 
et al., 1996, Carrera et al., 1999) and diaphragm muscles have been observed in OSAS 
patients (Griggs et al., 1989, Chien et al., 2010). Additionally, OSAS patients exhibit 
central apnoeas during CPAP treatment (Morgenthaler et al., 2006), which further  
serves to promote respiratory instability. Indeed, our results demonstrate that 
exposure to CIH for 2 weeks, mimicking mild-to-moderate OSAS, culminates in 
increased apnoea index (Chapter 3), and profound UA (Chapter 4) and diaphragm 
(Chapter 5) muscle weakness. If our study translates to the human condition, then 
each of these findings individually and moreover, combined, may contribute to 
respiratory system impairment that would ultimately serve to exacerbate the 
severity of OSAS and perpetuate a vicious cycle of events.  
 
Patients with OSAS exhibit a derangement in the oxidant-antioxidant balance with a 
shift towards the former and as such, OSAS is widely considered an oxidative stress 
disorder (Lavie, 2003). CIH-induced ROS, as a consequence of repetitive UA collapse 
and re-opening, are implicated in impaired motor control of the UA (O'Halloran et 
al., 2002, Veasey et al., 2004, Ray et al., 2007), UA and diaphragm muscle dysfunction 
(Clanton et al., 2001, McGuire et al., 2002a, McGuire et al., 2002b, McGuire et al., 
2003, Liu et al., 2005, Pae et al., 2005, Liu et al., 2009, Skelly et al., 2012, Skelly et al., 
2013, Shortt et al., 2014, Shortt and O'Halloran, 2014, McDonald et al., 2015) and 
discordant rhythm and pattern generation (Peng et al., 2003, Reeves and Gozal, 
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2006, Edge et al., 2012, Moraes et al., 2013, Donovan et al., 2014, Souza et al., 2015, 
Elliot-Portal et al., 2018, Joseph et al., 2020). Therapies to improve any of these 
deficits individually, or moreover collectively, serves to reduce instability within the 
respiratory system contributing to a lower probability of airway collapse and thus, a 
reduced severity of OSAS pathology. Beyond the respiratory system, CIH-induced 
ROS drive a wide range of maladies with evidence for neurocognitive (Al Lawati et 
al., 2009), metabolic (Drager et al., 2011a), cardiovascular (Dumitrascu et al., 2013), 
testicular (Torres et al., 2014b), hepatic (Savransky et al., 2007), renal (Rosas, 2011) 
and pancreatic (Wang et al., 2013a) disorders. This highlights the devastating 
consequences that CIH-induced ROS have for integrative body systems as a whole, 
elevating the status of OSAS to that of a major public health disorder (Lavie, 2009). 
The application of CPAP is the first line of treatment for OSAS which functions to 
mechanically stabilise the UA in OSAS patients during sleep. CPAP has been shown to 
be efficacious in reducing several cardiovascular risk factors of OSAS (Hedner et al., 
1995), but studies also suggest that this line of treatment does not entirely restore 
redox imbalance to homeostatic levels (Barceló et al., 2006, Phillips et al., 2007). 
Worryingly, the failure rate of CPAP treatment exceeds 50% (Stepnowsky and Moore, 
2003) due to poor patient compliance with frequent reports of claustrophobia, facial 
discomfort, throat dryness, nasal and eye pain (Wolkove et al., 2008). Poor 
adherence to CPAP treatment may in part explain why the full benefits of this 
treatment are often not observed in OSAS patients and therefore, there is an urgent 
need for the development of new therapeutic strategies.  
 
Interestingly, antioxidants have already shown efficacy as an adjunct therapy in the 
treatment of OSAS. Treatment of OSAS patients with the antioxidants, vitamin E and 
C, reduced lipid peroxidation and restored glutathione levels to levels similar to 
healthy controls, demonstrating their efficacy in preventing OSAS-associated 
oxidative stress (Singh et al., 2009). Moreover, this combinational antioxidant 
treatment improved SDB, indicated by a reduction in apnoea index, as well as 
decreasing excessive day-time sleepiness, the most common symptom of OSAS 
which has a hugely negative impact on quality of life in OSAS patients (Singh et al., 
2009). Similarly, the administration of NAC to OSAS patients decreased lipid 
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peroxidation and increased levels of glutathione (Sadasivam et al., 2011). OSAS 
patients treated with NAC display significant improvements in sleep and respiratory 
parameters observed as reduced apnoea index, apnoea related-arousals, oxygen 
desaturations per hour and Epworth sleepiness score (Sadasivam et al., 2011). 
Additionally, snore characteristics were significantly decreased following NAC 
treatment, indicative of a reduction in airway narrowing and turbulent airflow in 
OSAS patients. It is suggested that long-term treatment with NAC may serve to 
reduce patient dependency on CPAP therapy (Sadasivam et al., 2011). Oral 
carbocysteine treatment has also been shown to improve the Epworth sleepiness 
score, apnoea index and time and percentage of oxygen desaturation, all of which 
are indicative of a less severe OSAS phenotype (Wu et al., 2016). Similar to the 
antioxidants above, carbocysteine reduced markers of oxidative stress in OSAS 
patients, demonstrated  as decreased levels of MDA and increased levels of SOD (Wu 
et al., 2016). While CPAP treatment resulted in much of the same beneficial effects 
as carbocysteine, patient compliance was significantly higher in OSAS patients 
treated with carbocysteine compared with CPAP (Wu et al., 2016). This highlights 
that antioxidant treatment is a promising approach for the treatment of OSAS 
patients who cannot tolerate CPAP. Additionally, long term treatment with 
antioxidants may subsequently reduce patient dependency on CPAP treatment.  
 
Although, exposure to CIH was not associated with overt oxidative stress in our 
model, we conclude that ROS, potentially derived from NOX2, are pivotal to CIH-
induced respiratory mal-adaptation. We demonstrate that treatment with apocynin 
entirely prevents the CIH-induced increase in apnoea index (independent of NOX2) 
in our murine model of OSAS (Chapter 3), implicating ROS in the manifestation of 
respiratory instability following exposure to CIH. Additionally, treatment with 
apocynin and NOX2 KO entirely prevents the profound CIH-induced UA (Chapter 4) 
and diaphragm (Chapter 5) muscles weakness observed in our model, confirming 
that NOX2-derived ROS are entirely necessary for respiratory muscle dysfunction 
following exposure to CIH. If our pre-clinical study translates to the human condition, 
antioxidants targeting NOX2 (or possibly NOX4) may hold therapeutic potential in 
reducing the severity of OSAS pathology, in a similar manner to that observed in the 
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antioxidant studies in OSAS patients (Wu et al., 2016, Singh et al., 2009, Sadasivam 
et al., 2011). NOX2 blockade may represent a specific therapeutic target for 
improving UA and diaphragm muscle function in OSAS, thereby contributing to a 
reduction in respiratory perturbations. 
 
Targeting NOX2 is particularly complex as it holds a pivotal role in host defence, yet 
it is also implicated in the pathogenesis of a wide range of diseases including 
cardiovascular disease (Liu et al., 2011, Nisbet et al., 2009), DMD (Pal et al., 2014) , 
COPD (Lagente et al., 2008), Cystic Fibrosis (Hayes et al., 2011), CHF (Ahn et al., 2015), 
Alzheimer’s disease (Park et al., 2005),  PD (Wu et al., 2003), ALS (Wu et al., 2006), 
traumatic brain injury (Dohi et al., 2010) and schizophrenia (Sorce et al., 2010) to 
name a few. Research has primarily focused on NOX4 and NOX1, due to concerns 
about the immunosuppressive effects of NOX2 blockade. Nevertheless, NOX2 clearly 
contributes to the pathogenesis of many diseases, and its inhibition is predicted to 
provide a novel therapeutic approach in the context of diseases characterised by 
oxidative stress. The World Health Organisation (WHO) has recently recognised NOX 
inhibitors as a new therapeutic class, which hold significant potential for the 
treatment of fibrotic, inflammatory, neurodegenerative and oncological disorders. 
GKT137831 (setanaxib or GKT-831), claimed to be a NOX1/4 dual inhibitor, was the 
first NOX inhibitor to reach the clinical trial stage (Wiesel et al., 2012).  Phase II clinical 
trials using GKT137831 are ongoing for the treatment of idiopathic pulmonary 
fibrosis and kidney disease in patients with type 1 diabetes. Ewha-18278 (APX-115) 
has been shown to inhibit NOX1, NOX2, and NOX4 in pre-clinical studies (Cha et al., 
2017). Moreover, this NOX inhibitor is currently moving from Phase I to II in clinical 
trials for patients with diabetic kidney disease (Lee et al., 2020). Studies 
demonstrating the efficacy of specific NOX2 blockade with minimal side effects are 
necessary to encourage future development of NOX2 inhibitors. In addition to the 
multitude of integrative systems that have previously been shown to succumb to the 
mal-adaptive tendencies of NOX2-derived ROS, our results reveal that respiratory 
muscle weakness in a murine model of OSAS is also NOX2-dependent. We suggest 
that this may have relevance for respiratory morbidity in the human condition of 
OSAS and potentially other disorders characterised by skeletal muscle weakness.  
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Overall, our study demonstrates that exposure to CIH, a fundamental feature of 
OSAS, is capable of inducing mal-adaptation within the respiratory control system 
through an increase in the incidence of central apnoeas and the development of 
severe respiratory muscle weakness. CPAP is the gold standard treatment for OSAS 
patients, beneficial in alleviating and preventing obstructive events. However, if 
reconfiguration throughout the respiratory control network has already occurred as 
a result of repetitive exposure to IH during obstructive events, OSAS patients are also 
susceptible to central apnoeic events during CPAP treatment. Indeed, many OSAS 
patients present with complex apnoea, suggesting that CIH-induced ROS drive an 
underlying central pathology which accelerates the progression of the severity of 
OSAS (i.e. mild-to-moderate-to-severe). If complex apnoea is CIH-dependent, then 
early treatment strategies are warranted to prevent these perturbations to 
respiratory control. Our results suggest a therapeutic role for antioxidant strategies 
that may intervene before long-lasting modifications ensue and CIH-induced 
increases in apnoea index develop. Moreover, a culmination of the profound UA and 
diaphragm muscle weakness observed following exposure to CIH in the current study 
is likely to increase the probability of airway collapse and impede the re-
establishment of airway calibre following obstruction, potentially exacerbating 
existing respiratory morbidity in OSAS patients, perpetuating a vicious cycle of 
events. Our results suggest that CIH-induced respiratory muscle weakness is entirely 
amenable to NOX2 blockade, highlighting specific therapeutic potential in human 
OSAS and other diseases characterised by skeletal muscle weakness. Our study in a 
murine model of OSAS offers further evidence to support the use of antioxidants as 
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